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Thesis summary 
Risk of postpartum psychosis (PP) is high in bipolar disorder (BD), however, factors influencing 
this risk are poorly understood. In particular, whether adverse childhood experiences (ACEs), 
anxiety disorders and a range of within-pregnancy factors increase risk of PP in BD is yet to be 
examined. Of within-pregnancy factors that have been investigated, most have been assessed 
retrospectively. Prospective studies examining risk of PP in BD are scarce. The main aims of this 
thesis were to a) examine the relationship between ACEs, anxiety disorders and the lifetime 
occurrence of PP in BD and b) investigate potential within-pregnancy risk factors for PP in BD 
using a prospective follow-up design.  
 
ACEs, anxiety disorders and lifetime occurrence of PP were assessed via semi-structured 
interview and self-report questionnaires in 504 parous women with DSM-IV BD-I. Within-
pregnancy potential risk factors (including medication, sleep, obstetric and psychosocial factors) 
were assessed prospectively in 103 pregnant women with DSM-5 BD (n=84 BD-I/SA-BD; n=19 
BD-II/BD-NOS) via semi-structured interview in late pregnancy (baseline); perinatal 
psychopathology was assessed via interview at 12-weeks postpartum. All data were 
supplemented by clinician questionnaires and/or psychiatric case-notes.  
 
Neither history of ACEs (p-values of 0.06-0.95) nor anxiety disorders (of any type; p=0.47, 
phobias; p=0.23, panic; p=0.53) were significantly associated with the lifetime occurrence of PP. 
21% women in the prospective sample experienced PP within 6 weeks of delivery. In unadjusted 
analyses, an episode of mania/affective psychosis during pregnancy (p=0.001; OR 11.67, 95% CI 
2.61-52.21) and loss of at least one complete night of sleep across labour/delivery (p=<0.01; OR 
5.35, 95% CI 1.50-19.11) significantly increased risk of PP. After adjusting for known lifetime 
correlates of PP, mania/affective psychosis in pregnancy remained a significant predictor of PP 
(p=<0.01; OR 16.49, 95% CI 2.76-98.48). Further adjustment revealed prophylactic mood 
stabilising medication in the postpartum period had little influence in moderating risk of PP 
(p=0.61; OR 0.67 95% CI 0.14-3.16). No significant associations were found between within-
pregnancy psychosocial or psychological factors and PP.  
 
This prospective study demonstrated that risk of PP is high in women with BD, despite use of 
prophylactic mood stabilising medication. History of ACEs or anxiety disorders did not influence 
lifetime risk of PP. Mania/affective psychosis with onset during pregnancy significantly increased 
risk of PP, over and above associations with known lifetime risk factors. Sleep loss associated 
with labour may act as a final common pathway in the triggering of PP. If replicated, these 
findings have clinical implications for managing risk of PP in women with BD. The role of 
neurobiological and medication related factors in the pathophysiology of PP requires further 
investigation in larger samples.  
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Overview of thesis 
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Chapter 1 Overview of thesis 
The relationship between childbirth and mood disorders has long been recognised. 
Episodes of depression are common among new mothers, affecting 10-15% of women 
in the general population. More rarely, postpartum psychoses occur, affecting 1-2 in 
every 1000 deliveries. Postpartum psychosis (PP) is a life-threatening psychiatric 
emergency, typically presenting as acute mania or affective psychosis within the first 
few weeks of childbirth. The consequences of these episodes can be especially 
devastating for the mother, her baby and wider family. Though the nosological status of 
PP remains controversial, evidence indicates these episodes to be manifestations of 
bipolar disorder (BD) triggered by childbirth. Longitudinal studies demonstrate that in a 
high proportion of cases, PP marks the onset of BD. Moreover, women with BD are also 
at particularly high risk of PP. Nevertheless, the factors that influence risk of PP within 
this diagnostic group are poorly understood.  
Research in this area is important for the development of National Health Services 
within the UK (National Institute for Health and Clinical Excellence 2014; NHS England 
2019b). Additional funding of £239 million pounds is being invested in perinatal 
psychiatric services over the next five years (NHS England 2019a, 2019b), ensuring more 
women with moderate to severe mental illness will have access to the specialist care 
they urgently need. High quality research data that contributes to risk prediction in PP is 
required to inform evidence-based practices within these services (National Institute for 
Health and Clinical Excellence 2014). 
Accordingly, the aim of this thesis was to identify factors involved in the aetiology and 
triggering of PP in women with BD. This work was conducted in the context of Bipolar 
Disorder Research Network (BDRN); a large ongoing programme of research to 
investigate genetic and non-genetic determinants of BD and related mood disorders. 
For many years, a key focus of BDRN has been to examine the pathogenesis of PP. 
Investigations were conducted in two samples of women recruited to BDRN:  
 
Retrospective sample: Using retrospective data collected as part of BDRN, I 
examined whether lifetime anxiety disorders and adverse childhood experiences 
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(ACEs) were associated with the lifetime occurrence of PP in a large sample of 
parous women with BD.  
 
Prospective sample: To further build on knowledge from previous literature (and 
also findings obtained from investigations conducted within the retrospective 
sample), I aimed to investigate the role that within-pregnancy factors play in the 
occurrence of PP, over and above that of known lifetime correlates of PP. These 
investigations were conducted using a prospective follow-up design in a sample 
of pregnant women with BD (The BDRN Pregnancy Study). 
 
An overview of the layout of this thesis is provided below: 
 
 Chapter 2 reviews the existing literature on PP to date, providing further 
context for this thesis and identifying areas of further research. In this chapter, 
I discuss the relationship of childbirth to mood disorders and explore issues 
regarding the nosology of the postpartum period, postpartum mood disorders 
and PP. The specificity of PP to BD will be discussed, followed by a review of 
the literature examining aetiological and triggering factors of PP. This chapter 
concludes with a detailed description of the aims of this thesis.  
 
 Chapter 3 describes the BDRN retrospective dataset in which the association 
between ACEs, lifetime comorbid anxiety disorders and the lifetime occurrence 
of PP was examined. Methods of recruitment, assessment and analysis are 
detailed, following which the results of these investigations are presented and 
discussed (Aim 1). 
 
 Chapter 4 provides an introduction to the second part of this thesis, reviewing 
literature that has reported on risk of perinatal recurrence of BD using a 
prospective follow-up methodology. This chapter concludes with a summary of 
the specific aims of The BDRN Pregnancy Study (discussed further in Chapters 
5-7). 
 
  4 
Chapter 1 Overview of thesis 
 
 Chapter 5 describes the design and methods used in the recruitment and 
assessment of women with BD in The BDRN Pregnancy Study. 
 
 Chapter 6 presents the first set of results of The BDRN Pregnancy Study in 
which I describe and discuss psychotropic medication use and psychiatric 
outcomes across the perinatal period in the sample of women recruited to this 
study (Aim 2). 
 
 Chapter 7 describes and discusses results of investigations examining the 
influence of a range of within-pregnancy factors on risk of PP in women 
recruited to the BDRN Pregnancy Study (Aim 3). 
 
 Chapter 8 summarises the main findings of this thesis. The limitations and 
potential implications for clinical practice will be discussed, concluding with 
suggestions for further research.  
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2.1 Overview of chapter 
This chapter establishes the context for this thesis by providing a review of literature 
that has examined potential aetiological and triggering factors of PP. While the primary 
aim of this review was to identify areas for further research, I also aimed to gain a 
thorough understanding of key issues that have methodological implications for future 
studies of PP. These issues concerned the nosological status of PP, presenting questions 
such as i) which populations of women should be included in future studies of this 
disorder? and ii) how should the concept of PP be defined? This review therefore 
discusses a broad range of related research areas and for this reason, a systematic 
review was not conducted. Nevertheless, a systematic approach was adopted for the 
literature search which is described further in Table 2.1. 
 
  
 
 
Relevant literature identified in the search was subsequently collated and summarised 
within this chapter. First, to define the concept of PP, I describe the relationship 
between childbirth and affective disorders and provide an overview of postpartum 
mood disorders. The nosological status of PP and its relationship to BD will be 
Table 2.1: Methods of literature search 
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discussed, followed by a review of the literature that has investigated aetiological and 
triggering factors of PP. The final section of this chapter will describe the aims of this 
thesis.   
 
2.2 Childbirth as a trigger of affective illness 
The postpartum period has long been recognised as a time of high risk for affective 
illness in new mothers, with cases being described as early as 400 BC by the ancient 
Greeks (Klompenhouwer 1992). As cited by Klompenhouwer (1992), Hippocrates was 
the first to document the onset of severe affective illness in a woman during the first 
postpartum week, characterised by symptoms of restlessness, severe insomnia and 
delirium. Esquirol and Marcé were the first to conduct systematic studies of women 
with postpartum psychiatric illness, finding that although symptoms of depression 
occurred frequently, psychotic symptoms, extreme mood lability (periods of elation and 
dysphoria) and perplexity were especially common features of illness in women 
admitted for psychiatric treatment soon following delivery (Jansson 1964; 
Klompenhouwer 1992).  
 
The temporal relationship between childbirth and affective illness has since been 
confirmed in epidemiological studies. Compared with pregnancy, or any other time in a 
woman’s life, incidence rates of affective episodes are found to be significantly elevated 
in the postpartum period (Kendell, Chalmers and Platz 1987; Kendell et al. 1976; Langan 
Martin et al. 2016; Munk-Olsen et al. 2006; Terp et al. 1999). This level of risk remains 
elevated for up to 2 years following childbirth (Kendell, Chalmers and Platz 1987; 
Langan Martin et al. 2016), with the first 3 postpartum months being a time of peak 
incidence (Kendell et al. 1976; Langan Martin et al. 2016; Munk-Olsen et al. 2006; Nott 
1982; Terp and Mortensen 1998). Episodes of non-psychotic depression represent a 
high proportion of postpartum psychiatric cases (Kendell, Chalmers and Platz 1987; 
Langan Martin et al. 2016), however, the relative risk of admission is particularly 
increased for psychotic illnesses compared to prior to or during pregnancy (Kendell et 
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al. 1976; Langan Martin et al. 2016; Munk-Olsen et al. 2006; Nott 1982; Terp and 
Mortensen 1998). In a UK population study, admissions (per week) for psychotic 
illnesses were up to 11 times more frequent within the first two postpartum weeks 
compared to the two-year period prior to pregnancy, and more than 17 times more 
frequent postpartum compared to during pregnancy (Langan Martin et al. 2016).  
 
This striking vulnerability is particularly observed among women who present with 
affective psychoses (Bågedahl-Strindlund 1986; Kendell, Chalmers and Platz 1987; 
Kendell et al. 1976; Terp and Mortensen 1998). In a general population sample, Kendell 
et al. (1987) found the risk of admission for an affective psychotic illness to be 13 times 
higher within the first 3 postpartum months compared to before pregnancy. When only 
the first postpartum month was considered, the relative risk is dramatically increased 
further, with women being approximately 22 times more likely to be admitted than 
before pregnancy. Bases on these observations, mood disorders that have onset 
following childbirth are typically classified according to a spectrum, described further in 
the following section.  
 
2.3 Spectrum of postpartum mood disorders 
Affective disturbances with postpartum onset are traditionally classified into three main 
categories: postpartum ‘baby’ blues, postnatal (non-psychotic) depression (PND) and 
PP. While not typically classified within this spectrum, postpartum ‘highs’ are also 
common among new mothers. The incidence and phenomenology of each is described 
in Table 2.2. Postpartum ‘baby blues’ and ‘highs’ are the mildest and most common 
forms of affective disturbances in new mothers, both of which are self-limiting in 
duration and do not require treatment. Consequently, neither forms of mood 
disturbance are considered clinically impairing episodes of mood disorder and as such 
are not classified within the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5, American Psychiatric Association 2013a)  or the International Classification of 
Diseases (ICD-11; World Health Organization, 2019). For this reason, the remainder of 
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this section will focus on describing PND and PP, which are traditionally classified as 
mood disorders. 
 
 
 
 
 
 
2.3.1 Postnatal non-psychotic depression 
Episodes of PND are estimated to occur in between 10-15% of women in the general 
population (Gavin et al. 2005; O’Hara and Wisner 2014; Le Strat, Dubertret and Le Foll 
2011; Watson et al. 1984). These episodes may be the first of affective illness 
experienced or can occur within the context of an existing mood disorder. Women with 
a history of affective illness are at increased risk of depression following childbirth, with 
PND occurring in up to 37% of all deliveries (Di Florio et al. 2013).   
 
Whether childbirth acts as a specific trigger for depression occurring in the postpartum 
period remains unclear. A number of large population register studies (Dean and 
Kendell 1981; Kendell et al. 1976; Munk-Olsen et al. 2006), and a controlled prospective 
study (Cooper et al. 1988) have found the relative risk of a depressive episode to be 
significantly increased in the postpartum period compared to pregnancy, while others 
have found no such difference (Heron et al. 2009; Nott 1982; Le Strat, Dubertret and Le 
Table 2.2: Incidence and phenomenology of postpartum mood disturbances 
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Foll 2011). Compared to non-postpartum control groups, episodes of depression have 
been shown to be more frequent in women who have recently given birth in some 
studies (Eberhard-Gran et al. 2002; Vesga-Lopez et al. 2008) but not in all (O’Hara et al. 
1990). It is likely that the incidence of PND has been overestimated in some cases, 
potentially including episodes with onset during pregnancy. In their large register study 
of psychiatric postpartum admissions, Dean and Kendell (1981) found that over 50% of 
episodes of PND in their sample had onset in pregnancy. Similarly, Wisner et al. (2013) 
also found that of women who screened positive for depression within 6 weeks of 
childbirth, 60% of episodes either had onset before or during pregnancy. 
 
If childbirth was a specific causal factor in the onset of depression, then episodes of 
depression which do have onset in the postpartum period would be expected to show a 
close temporal relationship to childbirth. Several studies have reported a peak in onset 
of depressive symptoms within the first four weeks following delivery (Cooper et al. 
1988; Dean and Kendell 1981; Kendell et al. 1976; Munk-Olsen et al. 2006). However, 
compared to non-parent samples or during pregnancy, the relative risk of depressive 
illness remains particularly elevated for up to 6 months postpartum (Kendell et al. 1976; 
Langan Martin et al. 2016; Munk-Olsen et al. 2006), with onset of episodes being widely 
distributed throughout this period (Dean and Kendell 1981; Di Florio et al. 2013; Kendell 
et al. 1976; Langan Martin et al. 2016; Meltzer and Kumar 1985; Munk-Olsen et al. 
2006). As will be discussed in section 2.3.4, no consensus exists on what time criterion 
should be used to define the postpartum period, yet it is reasonable to assume that 
episodes occurring more distally from the time of delivery are less likely to have a 
specific relationship with childbirth. Thus, whether childbirth plays a specific role in the 
pathophysiology of depression with onset in the postpartum period remains unclear.  
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2.3.2 Postpartum psychosis 
In contrast to episodes of PND, there is clear and consistent evidence to suggest a 
specific relationship between childbirth and PP. These episodes are described further 
within this section.  
 
2.3.2.1 Phenomenology 
As noted previously, affective symptoms are prominent features in the clinical 
presentation of PP episodes (Brockington et al. 1981; Kamperman et al. 2017; Katona 
1982; Kendell, Chalmers and Platz 1987; Klompenhouwer and van Hulst 1991; Kumar et 
al. 1995; McNeil 1986; Singh, Kaur and Mohan 1999; Videbech and Gouliaev 1995). 
Mania or hypomania (described further in section 2.4) frequently marks the onset of PP 
(Heron et al. 2008, 2007) while depressive symptoms, lability of mood and anxiety are 
also common features within these episodes (Davidson, Samspon and Davidson 2017; 
Ganjekar et al. 2013; Hays and Douglass 1984). Despite the presence of manic features, 
the prevailing mood state has been frequently observed as one of dysphoria 
(Klompenhouwer et al. 1995), contrasting with symptoms of expansive and elevated 
mood predominantly experienced in episodes of mania unrelated to childbirth.  Similar 
to psychiatric illness occurring secondary to general medical conditions, women with PP 
typically present with marked confusion and perplexity (Brockington 1996; Brockington 
et al. 1981; Ganjekar et al. 2013; Klompenhouwer et al. 1995; McNeil 1986; Videbech 
and Gouliaev 1995), suggesting this symptom may be a defining feature of severe 
affective episodes related to childbirth.  
 
As the name would suggest, psychotic symptoms frequently co-occur within the context 
of affective symptoms, and are especially prevalent in cases with early onset in the 
postpartum period (McNeil 1986; Vladimirova, Stoyanova and Milanova 2016). Almost 
every psychotic symptom has been observed to occur (Brockington 1996), though 
Schneiderian first rank symptoms (such as passivity phenomena and auditory 
hallucinations) and delusions of misrepresentation are particularly common (Hays and 
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Douglass 1984; Kadrmas, Winokur and Crowe 1979; Klompenhouwer et al. 1995; 
O’Sullivan and Dean 1991; Oosthuizen, Russouw and Roberts 1995; Pfuhlmann et al. 
1998). In episodes in which delusional ideas are present, the content typically relates to 
the child (Chandra et al. 2006; McNeil 1986). Overall, the classic presentation of PP is 
one of a ‘kaleidoscopic’ picture in which rapid changes in mood and psychotic 
symptoms may also be interspersed with brief, symptom free periods of lucidity (Di 
Florio, Smith and Jones 2013; Klompenhouwer et al. 1995; Sit, Rothschild and Wisner 
2006).  
 
PP is considered a psychiatric emergency, usually necessitating urgent treatment by 
hospital admission and pharmacological therapy. However, with treatment, recovery 
from an initial episode of PP is excellent in most women (Benvenuti et al. 1992; 
Davidson and Robertson 1985; Dean, Williams and Brockington 1989; Pfuhlmann et al. 
1999; Protheroe 1969). In contrast to psychoses unrelated to childbirth, the long term 
prognosis of PP is more favourable (Bell et al. 1994; Dean, Williams and Brockington 
1989; Katona 1982; Pfuhlmann, Stoeber and Beckmann 2002), particularly if the 
postpartum episode is the first of psychiatric illness experienced (Davidson and 
Robertson 1985; Dean, Williams and Brockington 1989; Nager et al. 2013; Polachek, 
Fung and Vigod 2016; Serretti, Olgiati and Colombo 2006; Terp et al. 1999). 
 
2.3.2.2 Prevalence 
PP is rare in the general population, estimated to affect between 1-2 in every 1000 
deliveries (Kendell, Chalmers and Platz 1987; Munk-Olsen et al. 2006; Valdimarsdóttir et 
al. 2009; Videbech and Gouliaev 1995). Notably, not only are incidence rates of PP 
reliably consistent across cultures (Kumar 1994) but episodes can also present as 
phenotypically similar (Cox 1979),  further implicating the physiology of childbirth in the 
triggering of PP.  
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2.3.2.3 Timing of onset 
The onset of symptoms of PP is extremely rapid. Psychosis presents in the majority of 
cases within the first two weeks following delivery (Dean and Kendell 1981; Heron et al. 
2007, 2008; Kendell, Chalmers and Platz 1987; Klompenhouwer et al. 1995; Kumar et al. 
1995; Munk-Olsen et al. 2006; Videbech and Gouliaev 1995). While it has previously 
been assumed that a symptom free ‘latent period’ was a unique characteristic of 
psychoses in the immediate postpartum (Robinson and Stewart 1986), this view has 
since been challenged (Heron et al. 2008, 2007; Kendell, Chalmers and Platz 1987). In a 
study of 101 episodes of PP, onset of clinically significant symptoms was retrospectively 
identified to be present on days 1-3 in over 50% of episodes and on the first postpartum 
day in 22% of cases (Heron et al. 2007). Subjective recall of initial symptoms suggest 
hypomania is particularly prevalent in the first few days following childbirth, with 
feelings of elation, reduced need for sleep, excessive energy and pressured speech 
being most commonly reported (Heron et al. 2008).  In some cases, symptoms of PP 
have also been noted to have onset during labour (Brockington 1996).  
 
2.3.3 Adverse consequences of postpartum mood disorders 
The consequences of postpartum mood episodes, but particularly of PP can be 
devastating for the mother, her baby and wider family. In the short-term, the 
relationship between the mother and her new baby is often disrupted, particularly 
when feelings of depersonalisation or delusional ideas relating to the child are present 
(Klompenhouwer et al. 1995; Mowry and Lennon 1998). The cognitive, behavioural and 
social development of infants of mothers with severe postnatal illness may also be 
impaired longer-term (Hoffman, Dunn and Njoroge 2017; Stein et al. 2014). During 
acute phases of illness, mothers often lack insight into their condition, reducing their 
ability to care for the infant appropriately and increasing the likelihood of neglect or 
accidental injury (Kumar et al. 1995; Rohde and Marneros 1993). Delusional ideation 
may provoke increased affection or protective behaviours from the mother, yet they 
can also lead to a higher prevalence of abusive behaviour, such as shouting, hitting or 
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smothering the infant (Chandra et al. 2006). While homicidal ideation is more 
frequently reported in PP compared with non-psychotic postpartum episodes (Kumar et 
al. 1995; Wisner, Peindl and Hanusa 1994), infanticide is extremely rare, estimated to 
occur in only 4% of all cases (Hatters Friedman and Sorrentino 2012). Conversely, the 
risk of self-harm is high. Compared with women outside the postpartum period, new 
mothers are up to 70 times more likely to die by suicide (Appleby, Mortensen and 
Faragher 1998), identifying suicide as a leading cause of maternal death in the UK 
(Knight 2018). 
 
2.3.3.1 Recurrence of PP  
While a small proportion of women with PP (10-15%) do not experience further 
episodes (Bell et al. 1994; Pfuhlmann et al. 1999), the majority are at high risk of 
subsequent psychiatric episodes, both related and unrelated to childbirth. Of women 
who do have further children, recurrence of psychiatric illness is estimated to follow 
between 25-60% of subsequent deliveries (Benvenuti et al. 1992; Dean, Williams and 
Brockington 1989; Pfuhlmann et al. 1999; Protheroe 1969; Robertson et al. 2005; 
Robling et al. 2000). Seemingly, some women may be particularly vulnerable to 
psychiatric illness triggered by childbirth, given that they only ever experience psychotic 
episodes in the postpartum period (Bell et al. 1994; Bergink et al. 2012; Brockington 
1996; Pfuhlmann et al. 1999). However, longitudinal studies reveal that as many as 40-
75% of PP episodes are followed by episodes of psychiatric illness unrelated to 
childbirth (Pfuhlmann et al. 1999; Robertson et al. 2005; Robling et al. 2000; Terp et al. 
1999; Videbech and Gouliaev 1995), with the index episode often marking the onset of 
a recurrent affective or psychotic disorder.  
 
2.3.4 Nosology of postpartum mood disorders 
The nosological status of postpartum mood disorders and of PP in particular remains 
controversial. As discussed, the specificity of childbirth as a trigger for non-psychotic 
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depression is ambiguous, while PP is difficult to classify given that psychotic and 
affective symptoms are both prominent features of illness. Considering these 
difficulties, the following key theories have been proposed to explain the nosological 
context of postpartum mood disorders: 
 
 Distinct entities: Postpartum mood episodes are unique illnesses, distinct from 
other functional psychiatric illnesses in terms of aetiology, phenomenology and 
prognosis. 
 
 Non-distinct entities: Postpartum mood episodes are non-distinct occurrences of 
psychiatric illnesses, initiated by a non-specific trigger in the postpartum period.  
 
 Diathesis-trigger model: Childbirth is a potent, specific trigger for psychiatric 
illness in individuals with a genetic predisposition, while the threshold for this 
triggering also differs between individuals who are susceptible. Vulnerability to 
the childbirth trigger is likely to depend on a complex interaction between 
social, psychological and biological factors.  
 
Despite continued debate, current classification systems reject the notion that 
postpartum mood episodes are distinct entities, instead recognising them as episodes 
occurring in the context of other psychiatric disorders, exacerbated by the childbirth 
trigger. Affective illnesses with postpartum onset can be coded according to the DSM-5 
using a peripartum specifier, though episodes with onset in pregnancy are not 
distinguished from those developing following childbirth. Furthermore, only episodes 
with onset within 4 weeks of delivery can be acknowledged using this specifier, a time 
period which may be too narrow for depressive episodes (Dean and Kendell 1981; Di 
Florio et al. 2013; Kendell et al. 1976; Langan Martin et al. 2016; Meltzer and Kumar 
1985; Munk-Olsen et al. 2006).  
 
In contrast, the ICD-11 includes a distinct category for psychiatric episodes occurring 
within 6 weeks of delivery (‘Mental or behavioural disorders associated with pregnancy, 
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childbirth or the puerperium’), however this should only be used when presenting 
episodes are unable to be classified within the context of other disorders. Alternatively, 
psychotic or affective episodes occurring within 6 weeks of childbirth are encouraged to 
be denoted by a postpartum specifier, indicating the presence or absence of psychotic 
features. While current practice recognises episodes of PND and PP to be 
manifestations of major psychotic or affective disorders, temporal definitions of the 
postpartum period are considered arbitrary, with a timeframe of up to one year 
following childbirth being frequently used to define the postpartum period. 
 
2.3.4.1 Nosology of postpartum psychosis 
PP is not typically recognised as a distinct disorder in current diagnostic criteria, but has 
been included in previous editions of the DSM and ICD (see Table 2.3), reflecting 
diagnostic uncertainty as to whether these episodes are most appropriately categorised 
as a psychotic disorder, affective illness or distinct entity (McGorry and Connell 1990). 
This debate is ongoing and is not discussed in detail here (see Figure 2.1 for an overview 
of relevant literature). However, the vast majority of literature provides compelling and 
consistent evidence to indicate that most episodes of PP are manifestations of BD 
triggered by childbirth (BD is described further below in section 2.4). As shown in Figure 
2.1, frequently cited evidence in support of this theory is that: 
 
 Affective symptoms, particularly manic features that also define BD are key 
characteristics of PP (Brockington et al. 1981; Kamperman et al. 2017; Katona 
1982; Kendell, Chalmers and Platz 1987; Klompenhouwer and van Hulst 1991; 
Klompenhouwer et al. 1995; Kumar et al. 1995; McNeil 1986; Singh, Kaur and 
Mohan 1999; Videbech and Gouliaev 1995). 
 
 
 
  
Chapter 2 Introduction 
17 
Table 2.3:  Clinical classification of PP according to standard diagnostic criteria 
 
 
 Women who experience PP as the first episode of psychiatric illness frequently 
have a family history of affective disorders (Benvenuti et al. 1992; Platz and 
Kendell 1988; Vladimirova, Stoyanova and Milanova 2016). 
 
 The long-term clinical course of PP is episodic rather than chronic, sharing 
greater similarities with affective disorders than schizophrenia like illnesses 
(Platz and Kendell 1988). 
 
 Over time, diagnostic conversion from PP to BD occurs in a high proportion of 
cases. This is discussed in further detail in section 2.5.1 (Benvenuti et al. 1992; 
Blackmore et al. 2013; Munk-olsen et al. 2012; Protheroe 1969; Robling et al. 
2000; Schöpf and Rust 1994a; Videbech and Gouliaev 1995).  
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Evidence for distinct entity model 
• Distinct phenomenology of PP episodes compared to 
episodes unrelated to childbirth (Agrawal, Bhatia and Malik 
1997; Ganjekar et al. 2018; Kamperman et al. 2017; Katona 1982; 
Klompenhouwer and van Hulst 1991; Klompenhouwer et al. 1995; 
McNeil 1986; Nager et al. 2013; Polachek, Fung and Vigod 2016; Terp 
and Mortensen 1998) 
 
• Non-puerperal recurrences following the index PP 
episode are diagnostically heterogeneous (Benvenuti et al. 
1992; Munk-olsen et al. 2012; Protheroe 1969) 
 
• Evidence of a ‘pure postpartum group’ of women who 
only experience psychiatric illness in relation to childbirth 
(Bergink et al. 2012; Brockington 1996, 1993; Wesseloo et al. 2016) 
Evidence against distinct entity model 
• No evidence of familiality of a ‘pure postpartum’ disorder 
(Dean and Kendell 1981; Platz and Kendell 1988) 
•  
• Frequent diagnostic conversion to BD following the index 
PP episode (Benvenuti et al. 1992; Munk-olsen et al. 2012) 
 
• Presence of affective symptoms in PP (Brockington et al. 1981; 
Kamperman et al. 2017; Katona 1982; Kendell, Chalmers and Platz 1987; 
Klompenhouwer and van Hulst 1991; Kumar et al. 1995; McNeil 1986; 
Singh, Kaur and Mohan 1999; Videbech and Gouliaev 1995). 
Evidence for PP as a psychotic spectrum disorder 
• Distinct phenomenology of PP episodes compared to episodes 
unrelated to childbirth (see left for references), including presence of 
Schneiderian first rank symptoms (Brockington 1996; Kadrmas, Winokur 
and Crowe 1979; Oosthuizen, Russouw and Roberts 1995) 
 
• Increased risk of recurrence of schizophrenia in the postpartum 
period (Langan Martin et al. 2016; Munk-Olsen et al. 2009, 2006) 
Evidence against PP as a psychotic spectrum disorder 
• Few index PP episodes diagnosed in the context of schizophrenia 
(Bågedahl-Strindlund 1986; Benvenuti et al. 1992; Dean and Kendell 1981; 
Katona 1982; Kendell, Chalmers and Platz 1987; Klompenhouwer and van Hulst 
1991; Nager et al. 2013; Schöpf and Rust 1994c; Videbech and Gouliaev 1996) 
 
• High proportion of postpartum episodes of schizophrenia have 
onset in pregnancy or later in the postpartum period (Kumar et al. 
1995; McNeil 1986; Schöpf and Rust 1994b; Terp and Mortensen 1998; Videbech 
and Gouliaev 1995) 
 
• Risk of postpartum episodes of schizophrenia comparable with 
other non-affective or non-psychotic disorders, but lower than in 
BD (Munk-Olsen et al. 2009, 2006) 
 
• Presence of affective symptoms (see left for references) 
Evidence for PP as a bipolar spectrum disorder 
• Distinct phenomenology of PP episodes compared to 
episodes unrelated to childbirth (Agrawal, Bhatia and Malik 
1997; Ganjekar et al. 2018; Kamperman et al. 2017; Katona 1982; 
Klompenhouwer and van Hulst 1991; Klompenhouwer et al. 1995; 
McNeil 1986; Nager et al. 2013; Polachek, Fung and Vigod 2016; Terp 
and Mortensen 1998) 
 
• Non-puerperal recurrences following the index PP 
episode are diagnostically heterogeneous (Benvenuti et al. 
1992; Munk-olsen et al. 2012; Protheroe 1969) 
 
• Evidence of a ‘pure postpartum group’ of women who 
only experience psychiatric illness in relation to childbirth 
(Bergink et al. 2012; Brockington 1996, 1993; Wesseloo et al. 2016) 
Evidence against PP as a bipolar spectrum disorder 
• No evidence of familiality of a ‘pure postpartum’ disorder 
(Dean and Kendell 1981; Platz and Kendell 1988) 
•  
• Frequent diagnostic conversion to BD following the index 
PP episode (Benvenuti et al. 1992; Munk-olsen et al. 2012) 
 
• Presence of affective symptoms in PP (Brockington et al. 1981; 
Kamperman et al. 2017; Katona 1982; Kendell, Chalmers and Platz 1987; 
Klompenhouwer and van Hulst 1991; Kumar et al. 1995; McNeil 1986; 
Singh, Kaur and Mohan 1999; Videbech and Gouliaev 1995). 
Figure 2.1: Nosological models of postpartum psychosis 
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 The risk of PP is highest among women with BD compared to any other 
psychiatric illness and the general population. This is discussed in further detail 
in section 2.5.2 (Kendell, Chalmers and Platz 1987; Langan Martin et al. 2016; 
Munk-Olsen et al. 2009; Viguera et al. 2011). 
 
Thus, in light of the evidence indicating PP to be a form of BD, the concept of PP is used 
within this thesis to describe episodes of mania or mixed affective states (with or 
without psychotic features) that have onset following childbirth. The relationship  
between childbirth and BD is discussed in further detail in section 2.5. First however, I 
provide a brief overview of BD.  
 
2.4 Bipolar disorder 
BD, previously known as ‘manic depression’, is a severe and episodic psychiatric illness 
characterised by periods of impairing fluctuations in mood. Episodes of depression are a 
common occurrence in BD; however, the presence of mania is the defining feature of 
this illness. Episodes of mania are typically characterised by abnormally elated or 
expansive mood, feelings of irritability, racing thoughts, a reduced need for sleep, 
reckless or disinhibited behaviour and excessive energy and activity. While these 
symptoms are also present in hypomania, they are less severe and impairing than 
mania. Psychotic features are also common within BD, with more than 50% of 
individuals estimated to experience at least one psychotic symptom throughout the 
course of their illness (Goodwin and Jamison 2007; Perälä et al. 2007). Delusions of a 
religious or grandiose nature are particularly prevalent, being most likely to occur 
during severe episodes of mania (Canuso et al. 2008; Dunayevich and Keck 2000; 
Goodwin and Jamison 2007). 
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2.4.1 Spectrum of bipolar disorders 
The phenotype of BD varies considerably between individuals (Judd et al. 2003; 
Mantere et al. 2004; Merikangas and Jin 2011) supporting the notion of a ‘mood 
disorder spectrum’ (see Figure 2.2). Distinct subtypes of BD are recognised in clinical 
practice, being categorised according to level of impairment in standardised diagnostic 
criteria. Episodes of mania are most impairing in Bipolar I disorder (BD-I), which is 
defined in DSM-5 criteria by the presence of a single manic episode lasting at least one 
week in duration, with or without psychotic features. Bipolar II (BD-II) is defined by the 
presence of at least one episode of hypomania lasting at least four days in the absence 
of psychotic features. Despite BD-I being widely considered as more impairing than BD-
II, evidence suggests that depressive episodes are more frequent in BD-II, resulting in a 
more chronic course of illness within this subtype (Choi et al. 2011; Judd et al. 2003; 
Saunders and Goodwin 2010). Presentations of impairing high mood that do not meet 
clinical criteria for BD are also recognised within the DSM-5 as those ‘not otherwise 
specified’ (BD-NOS). 
 
2.4.1.1 Schizoaffective disorder bipolar type 
Historically, BD has been considered distinct from non-affective psychoses, a paradigm 
which is still adopted in clinical practice today. The Kraepelin Dichotomy, proposed by 
Emil Kraepelin in the early 20th century, differentiated between ‘Dementia Praecox’ 
(later termed schizophrenia) and BD. This approach assumed that distinctions in the 
phenotypic characteristics of schizophrenia and BD are also likely to reflect the 
aetiological heterogeneity underlying affective and non-affective psychoses. As 
discussed in section 2.3.4.1, this view has had important implications for the 
classification and nosology of PP (Brockington 1996). This traditional method of 
classifying psychiatric illness is however being challenged, with findings from genetic 
studies providing evidence for shared genetic susceptibility to schizophrenia and BD 
(Craddock and Owen 2010; Cross-Disorder Group of the Psychiatric Genomics 
Consortium 2013).  
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Figure 2.2 Spectrum of mood disorders 
 
Schizoaffective disorders demonstrate the overlap between affective and psychotic 
illnesses. These disorders fully meet diagnostic criteria for schizophrenia, yet clinically 
impairing mood episodes are also a prominent feature of illness. Episodes of mania are 
a defining feature of schizoaffective disorder bipolar type (SA-BD), further suggesting 
shared aetiological factors with other bipolar spectrum disorders. For this reason, SA-BD 
is defined as a sub-type of BD within this thesis. 
 
2.4.2 Epidemiology and illness course of bipolar disorder 
BD is relatively common in the general population, affecting men and women equally 
(Bauer and Pfennig 2005; Di Florio and Jones 2010). Lifetime prevalence rates are 
estimated to be between 0.3 -1.5% for BD-I (Bauer and Pfennig 2005; Merikangas and 
Jin 2011; Weissman et al. 1996), 0.3-1.1% for SA-BD (Perälä et al. 2007; Scully et al. 
2004) and between 0.4-3% for BD-II disorder (Bauer and Pfennig 2005; Merikangas and 
Jin 2011). These findings are however likely to underestimate the true prevalence of BD, 
given that milder manifestations of the illness may go undetected or untreated 
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(Mantere et al. 2004). Studies assessing a wider range of bipolar spectrum disorders, 
including those of subthreshold severity have estimated that BD is more likely to affect 
between 2.4 and 6.5% of the general population (Bauer and Pfennig 2005; Merikangas 
and Jin 2011). 
 
Overall, evidence indicates few epidemiological differences in the prevalence, age at 
onset and course of BD between men and women (Azorin et al. 2012; Erol et al. 2015; 
Di Florio and Jones 2010; Nivoli et al. 2011). However, the most striking sex difference is 
observed during the perinatal period. The impact of childbirth is profoundly unique 
among women with BD, with little evidence to suggest this event acts as a course 
modifier of BD among new fathers (Kendell et al. 1976; Munk-Olsen et al. 2006).   
 
2.5 Specificity of the childbirth trigger to bipolar disorder 
As discussed in section 2.3.4.1, episodes of PP are most frequently defined as a subtype 
of BD. In this section, I discuss the literature examining the specific relationship 
between childbirth and BD.  
 
2.5.1 Childbirth as a trigger of new onset bipolar disorder 
Approximately 50-70% of women admitted for a psychotic episode following childbirth 
have no previous history of psychiatric illness (Blackmore et al. 2013; Davidson and 
Robertson 1985; Kendell, Chalmers and Platz 1987; Polachek, Fung and Vigod 2016; 
Robertson et al. 2005; Robling et al. 2000; Terp and Mortensen 1998; Valdimarsdóttir et 
al. 2009). However as shown previously, following the index episode, these women are 
at high risk of psychiatric illness unrelated to childbirth. Longitudinal follow-up studies 
of women admitted with a first episode of PP show that a considerable proportion 
subsequently develop BD (Benvenuti et al. 1992; Blackmore et al. 2013; Munk-olsen et 
al. 2012; Schöpf and Rust 1994a; Videbech and Gouliaev 1995), particularly if the index 
PP episode presented with a manic or mixed affective clinical picture (Benvenuti et al. 
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1992; Protheroe 1969; Robling et al. 2000). In a sample of 50 women who experienced 
PP as their first episode of psychiatric illness, more than 50% had a diagnosis of BD at 
follow-up after a median duration of 11 years (Videbech and Gouliaev 1995). In a similar 
study, Schöpf and Rust (1994a) reported a lower but substantial proportion of 31% of 
women (n=119) to be diagnosed with BD over a follow-up period of 22 years following 
an initial PP episode.   
 
Several studies have also suggested that first onset of depression in the postpartum 
period may be an indicator of underlying BD. Women presenting with severe depression 
in the postpartum period have been found to more frequently experience atypical 
features such as mixed affective and psychotic symptoms (Azorin et al. 2012), thus 
being more consistent with a bipolar diathesis. Diagnostic conversion from psychotic 
unipolar depression to BD is estimated to occur in 11-29% of cases (Benvenuti et al. 
1992; Bratfos and Haug 1966; Robling et al. 2000).  
 
Onset of a psychiatric illness in the postpartum period that does not meet diagnostic 
criteria for an affective or psychotic disorder may also be an early indicator of 
underlying bipolarity (Benvenuti et al. 1992). In a study of 120,378 women with a first-
time psychiatric contact for a non-bipolar related illness in the postpartum period, 3062 
later had an admission or contact with psychiatric services for BD. Those whose first 
episode of illness occurred within a month of childbirth were significantly more likely to 
convert to BD (Munk-olsen et al. 2012), particularly if the episode required admission to 
hospital or occurred within the first two postpartum weeks. Overall, approximately 14% 
of women with postpartum onset of psychiatric symptoms in the first month converted 
to BD within 15 years of initial psychiatric contact, increasing to almost 19% within 22 
years. This compared to 6.5% of women whose initial episode occurred later in the 
postpartum period and 5.4% of women for whom the index episode of psychiatric 
illness was unrelated to childbirth. 
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2.5.2 Childbirth and risk of recurrence of bipolar disorder 
While a high proportion of women with BD experience their first impairing episode of 
mood illness following childbirth, consistent evidence also indicates that women with 
pre-existing BD are especially vulnerable to recurrence in the postpartum period. Thus, 
further implicating childbirth as a unique and specific trigger of affective illness within 
this group. This is in contrast to pregnancy, for which there is little indication that 
vulnerability to recurrence of BD is increased during this period (Di Florio and Jones 
2010; Viguera et al. 2000). Viguera et al. (2000) compared risk of recurrence over time 
in pregnant and non-pregnant women with BD who had discontinued mood stabilising 
medication. Over a period of 40 weeks (consistent with the average gestation period of 
most pregnancies), women who were pregnant were no more likely to experience a 
mood episode compared to a sample of non-pregnant women, suggesting pregnancy 
itself has little influence on the course of BD. Conversely, it has been suggested that 
pregnancy may be protective for women with BD (Brockington 1996), resulting in a 
decrease in psychopathology compared to the period prior to pregnancy (Grof et al. 
2000) and a decrease in the relative risk of psychiatric admission compared to non-
mothers with BD (Munk-Olsen et al. 2006).   
 
By comparison, the risk of psychiatric admission in women with BD is significantly 
greater following childbirth compared to any other time in their lives (Munk-Olsen et al. 
2006). Though non-psychotic depression is a common form of postpartum mood 
disturbance in women with BD (Maina et al. 2014; Viguera et al. 2011), the risk of a 
psychotic episode following childbirth is strikingly elevated, compared not only to the 
general population (Jones and Craddock 2001) but also to women with a history of 
other non-psychotic or affective psychiatric illnesses (Kendell, Chalmers and Platz 1987; 
Langan Martin et al. 2016; Munk-Olsen et al. 2009; Viguera et al. 2011). In a Danish 
registry study, the influence of childbirth on risk of admission for psychotic episodes 
was examined across a range of psychiatric disorders (Munk-Olsen et al. 2009). 
Admission rates within the first postpartum month were compared with those in 
samples of non-mothers matched for psychiatric diagnosis. Compared to non-mothers, 
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admissions for a psychotic episode were 37 times more likely in the first postpartum 
month in women with BD. Comparatively, the relative risk of admission was 
considerably lower at 4.6 for schizophrenia and 3.0 for other psychiatric disorders. 
Moreover, of disorders specified, Langan Martin et al. (2016) found the majority of 
psychiatric admissions during the first six weeks following childbirth to be for BD related 
episodes (14.4%), being considerably more common than admissions for any other 
psychiatric disorder (1.4%-7.2%).  
 
Studies which have assessed postpartum recurrence in samples of women with BD are 
described in Table 2.4. A recent meta-analysis of 25 studies (including both 
retrospective and prospective studies) sought to examine postpartum recurrence in 
5105 deliveries from 3495 women with BD (Wesseloo et al. 2016). Wesseloo and 
colleagues found that 37% of all women experienced a broadly defined mood episode 
(i.e. at least one mood episode of any type) within 12 months of childbirth and 17% an 
episode of PP, with no evidence to suggest significant differences in risk between 
women with BD-I and BD-II. Notably however, few studies included in this meta-analysis 
assessed postpartum recurrence of BD using a prospective follow-up design. Of those 
that did, risk of broadly defined recurrence occurred following childbirth in 25-70% 
cases, and affective psychotic recurrence in 25-40%, though sample sizes of these 
studies were small (n=11-37). 
 
Importantly however, the findings of this meta-analysis were based on estimates of 
postpartum recurrence that varied widely across individual studies, ranging from 13% 
(Bilszta, Meyer and Buist 2010) to 75% (Maina et al. 2014). Methodological differences 
between studies are likely to account for this variation, such as differences in the 
temporal cut-off used to define the postpartum period (between 1 and 12 months), the 
diagnostic inclusion criteria used, the definition of postpartum recurrence (i.e. type and 
polarity of episode) and the design of the study (i.e. retrospective or prospective).  
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2.5.3 History of postpartum psychosis and risk of subsequent recurrence 
As in the general population, recurrence of PP after the index PP episode is high among 
women with BD, with 50-87% of women experiencing affective psychosis following a 
subsequent delivery (Bergink et al. 2012; Blackmore et al. 2013; Maina et al. 2014; 
Pfuhlmann et al. 1999; Robertson et al. 2005). Using a narrow temporal definition of the 
postpartum period (restricted to the first 2 weeks following delivery), a history of both 
BD and PP places women at significantly greater risk of PP compared to those who have 
only ever experienced mood episodes unrelated to childbirth (Dean, Williams and 
Brockington 1989). Seemingly, risk is increased even further among women who only 
ever experience affective psychosis in relation to childbirth (i.e. a pure postpartum 
group), with PP occurring significantly more frequently compared to women with a 
more classical bipolar illness in which episodes related and unrelated to childbirth occur 
(Bergink et al. 2012). To date, it remains unclear whether a postpartum onset of BD 
predisposes women to further postpartum episodes.  Though some studies indicate 
recurrence of PP to be more frequent among women with postpartum onset BD (Dean, 
Williams and Brockington 1989; Hunt and Silverstone 1995) others have reported little 
influence on subsequent risk of PP (Robertson et al. 2005).  
 
In summary, research to date suggests that most episodes of PP are manifestations of 
BD, indicating childbirth to be a potent trigger for the onset or recurrence of BD. 
Nevertheless, findings show that despite vulnerability to mania (and psychosis in some 
cases), not all women with BD experience PP (McNeil 1988d). This would indicate that 
over and above vulnerability for BD, susceptibility to the childbirth trigger also varies 
between individuals within this disorder (consistent with the diathesis stress model 
described in section 2.3.4.). Risk of PP is therefore likely to depend on a complex 
interaction between a range of aetiological and triggering factors. The literature that 
has examined factors influencing risk of PP will be reviewed in the remainder of this 
chapter. 
 
 
 
Chapter 2 Introduction 
30 
2.6 Factors influencing risk for postpartum psychosis in 
bipolar disorder 
A history of BD is consistently identified as the strongest risk factor for PP. However, 
little is known regarding the aetiological and triggering factors that may predispose 
some women within this high-risk group to be especially vulnerable to postpartum 
relapse. Limited evidence has implicated neurobiological factors related to endocrine, 
immunological and circadian functions in the mechanism of onset of PP. Nonetheless, 
findings to date are inconclusive, suggesting that other factors may also play a role in 
the pathogenesis of PP. Here, the research examining neurobiological factors of PP will 
first be discussed, followed by a review of literature investigating other potential 
triggers and protective factors of these episodes. 
 
2.6.1 Neurobiological factors 
2.6.1.1 Genetic factors 
The familial clustering of affective disorders and of childbirth related episodes in women 
with PP strongly implies a degree of shared heritability of genetic factors in the onset of 
these disorders. PP is associated with higher rates of psychiatric illness among first or 
second degree relatives than is observed in the general population (Benvenuti et al. 
1992; Robertson et al. 2005; Schöpf and Rust 1994a; Da Silva and Johnstone 1981) 
Family history of affective disorders is especially common, being present in between 40-
50% of women with PP (Benvenuti et al. 1992; McNeil 1988d; Da Silva and Johnstone 
1981). A positive family history of BD is also frequently observed in women whose initial 
PP episode met criteria for mania (Oosthuizen, Russouw and Roberts 1995; Protheroe 
1969; Schöpf and Rust 1994a). Studies examining the familial clustering of PP in BD are 
scarce, however, episodes of PP have been observed to occur in 74% of women with BD 
with a positive family history of PP in a first degree relative (20/27 cases), compared 
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with only 30% of women with BD without this family history (38/125 cases) (Jones and 
Craddock 2001).  
 
Though evidence from family history studies indicate that genetic factors are likely to 
play an important role in susceptibility to PP, specific genes are yet to be identified. 
Findings to date are limited to genetic linkage and candidate studies. In a genome wide 
scan of 54 sibling pairs with BD and at least one family member with a history of PP, 
significant linkage found was at chromosomal location 16p13 and suggestive linkage at 
8q24 (Jones et al. 2007). These locations were not identified in the genome wide scan 
of a BD sample, suggesting a specific relationship between these locations and the 
postpartum triggering of episodes of BD.  
 
The close temporal relationship of PP to childbirth strongly suggests a role for sex 
hormones in the triggering of these episodes (discussed further in the following 
section). Genes implicated in oestrogen and neurotransmitter function have therefore 
been identified as plausible targets for candidate studies. Methyl transferase like 13 
gene (METTL13) is suspected to be involved in gene transcription associated with 
oestrogen receptor sites, thus making it an ideal candidate for an association with 
postpartum mood disorders. In a sample of 759 women with broadly defined affective 
disorders, METTL13 was associated with the occurrence of severe postpartum mood 
symptoms (Mahon et al. 2009). Importantly, this gene has also been associated 
specifically with PP among a diagnostically heterogeneous sample (Thippeswamy et al. 
2017). While the relationship of the oestrogen receptor alpha gene (ESR 1) to PP has 
also been examined, no associations have been reported between polymorphisms of 
ESR 1 and broadly defined PP (Thippeswamy et al. 2017) or with PP in women with BD 
(Middle et al. 2003). 
 
Genes which interact with neurotransmitter function, particularly in cases where 
expression of the gene is likely influenced by oestrogen have also been a focus of 
research. The 5-HTTT serotonin transporter gene is one such gene whose expression is 
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known to be influenced by hormones. Coyle et al. (2000) found variations in the 5-HTTT 
gene to be significantly associated with PP in women with BD. In particular, the 
presence of the STin2.12 allele was associated with a four times increased risk of 
postpartum relapse. This effect size was further increased when analysis was restricted 
to multiparous women with a recurrent history of PP only. These findings have since 
been replicated, with associations between a number of polymorphisms of serotonergic 
genes (including 5-HTT) and PP being found in an independent sample of women with 
BD (Kumar et al. 2007). While several additional genetic locations of interest related to 
hormonal and neurotransmitter functioning have been investigated, these have not 
been associated with the occurrence of PP (Mahon et al. 2009; Pfuhlmann, Stoeber and 
Beckmann 2002; Thippeswamy et al. 2017). Genes with a known influence on 
immunological function (Weigelt et al. 2013) and regulation of circadian rhythms have 
also been indicated as potentially important in the pathogenesis of PP (Dallaspezia et al. 
2011), yet remain to be examined further.  
 
The influence of genetic factors on susceptibility to PP remains a key focus of future 
research. International collaborative efforts to conduct genome wide association 
studies (GWAS) of postpartum mood disorders and specifically of PP, are currently 
underway (https://www.momgenesfightppd.org/ and https://www.mghp3.org/). To 
achieve sufficient power, samples of up to 100,000 individuals will be required to detect 
genetic biomarkers of PP (Davies 2017). As only 1 per every 1000 deliveries in the 
general population are affected, accruing the sample size needed has thus far been 
challenging. For this reason, genetic factors will not be examined within this thesis and 
as such, are not discussed further. Nevertheless, among women who are genetically 
susceptible, the postpartum triggering of severe mood disorders is also likely to depend 
on a complex interaction with other biological and psychosocial factors (Jones and 
Craddock 2007). The influence that these other factors may have in determining risk of 
PP will be discussed in subsequent chapters of this thesis.  
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2.6.1.2 Sex hormones 
Reproductive hormones fluctuate significantly across the perinatal period, with 
progesterone and oestrogen rising steadily during pregnancy and falling abruptly 
following delivery (Vannuccini et al. 2016). The rapid withdrawal of oestrogen following 
childbirth (between a 100-1000 times below that of late pregnancy) coincides with the 
period of greatest risk for onset of affective psychosis, implicating oestrogen pathways 
in the aetiology of PP (Kumar et al. 1997; Meakin et al. 1995; Wieck et al. 1991). 
Support for this theory has been provided by several case-studies, in which levels of 
oestrogen plasma have been found to be lower than expected among women with PP 
(Ahokas, Aito and Turtiainen 2000). In a limited number of cases, episodes of PP have  
also been effectively treated with oestradiol (Sichel et al, 1995). Nonetheless 
differences in absolute hormone levels are not observed among all women with 
postpartum mood disorders (Gale and Harlow 2003; Klier et al. 2007; Skalkidou et al. 
2012), leading to the revised hypothesis that some women may be particularly sensitive 
to the fluctuations of hormones that occur in relation to childbirth (Bloch et al. 2000; 
Elder Schiller, Meltzer-Brody and Rubinow 2015). Consistent with this theory, it has 
been demonstrated that some women experience mood episodes in relation to a range 
of reproductive cycle events. Associations have been found between mood episodes 
triggered by childbirth, the premenstrual phase of the menstrual cycle and/or 
menopause in women with BD (Brockington et al. 1988; Fornaro and Perugi 2010; 
Perich et al. 2016; Robertson Blackmore et al. 2008; Slyepchenko et al. 2017).  
 
2.6.1.3 Immunological factors 
Emerging research also suggests that immune dysfunction may play a key role in the 
pathogenesis of PP. This hypothesis is plausible for several reasons. Firstly, 
immunological factors have been implicated in the aetiology of psychosis more 
generally (Bergink, Gibney and Drexhage 2014) and in BD (Piccoli de Melo et al. 2017). 
Prevalence of comorbid immune disorders are high in BD (SayuriYamagata et al. 2017), 
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while the risk of BD is also increased among individuals with autoimmune disorders 
(Benros et al. 2013). Inflammatory cytokines (responsible for cell signalling and 
promotion of systemic inflammatory response) are found to be significantly elevated 
during acute phases of bipolar related mood episodes, most consistently during 
episodes of mania (Brietzke et al. 2009; Sayana et al. 2017). Secondly, immune 
disorders such as postpartum thyroiditis, rheumatoid arthritis and multiple sclerosis are 
typically exacerbated in the postpartum period, sharing similarities with the clinical 
course of PP (Bergink et al., 2013, 2015). In some cases, PP and immune disorders have 
been known to co-occur (Ganjekar et al. 2018). 
 
Other studies which have investigated the immunological hypothesis of PP have 
provided further support for this theory. Generalised immune dysregulation has been 
observed in women with PP (Kumar et al. 2017). Furthermore, PP has been associated 
with significantly increased rates of autoimmune thyroid dysfunction, which progresses 
significantly faster to clinical thyroid disease in women admitted for PP compared to a 
postpartum control group (Bergink et al. 2011b). In this study, rates of thyroid 
dysfunction and of clinical thyroid disease remained significantly elevated at 9 months 
postpartum and were found to be independent of the effect of lithium treatment, 
which has been demonstrated to adversely affect thyroid function. More recently, 
monocyte levels and upregulation of inflammatory monocyte genes have also been 
reported in women admitted for first-onset PP compared to postpartum and non-
postpartum control groups who did not have PP (Bergink et al. 2013).   
 
2.6.2 Other triggering and protective factors 
Compared to neurobiological factors, comparatively less is known regarding other 
factors that may influence risk of PP. Identifying triggering and protective factors of PP 
(especially those that are modifiable) are important for the management of BD during 
the perinatal period, and in particular, the prevention of these episodes. Here, I review 
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the literature examining the relationship between other, non-neurobiological factors 
and PP.    
 
2.6.2.1 Sleep disruption 
Sleep loss and the disruption of circadian rhythms has long been proposed as a final 
common pathway in the aetiology of PP (Jones et al. 2014). This hypothesis is proposed 
for several reasons. First, sleep loss is both a symptom and frequently cited precipitant 
of mania unrelated to childbirth (Benedetti and Colombo 2011; Lewis et al. 2017; Lewis, 
Foster and Jones 2016). Second, reproductive hormones and neurotransmitters play a 
role in the regulation of the circadian sleep/wake cycle (Rosenwasser and Turek 2015), 
both of which are also implicated in the aetiology of mood disorders more generally and 
of PP. Third, the period from late pregnancy through the immediate postpartum is 
associated with acute sleep loss in new mothers, a time which typically coincides with 
the onset of PP. Strouse, Szuba and Baxter (1992) reported on the cases of three 
women in which mania was induced following partial sleep deprivation therapy for first 
onset of postpartum psychotic and mood symptoms. Symptoms remitted in all women 
after a period of recovery sleep, though all women required further treatment with 
mood stabilisers.  
 
Only three studies have since investigated the potential triggering of PP associated with 
sleep disruption. In the first, duration of labour and time of delivery were compared as 
proxy measures of sleep disruption during labour between 21 women admitted with PP 
and a comparison group of 21 parous women without PP recruited from the same 
hospital. These women were also matched for age, parity and year of delivery. The PP 
group comprised women meeting DSM-IV diagnostic criteria for BD, schizoaffective 
disorder (both bipolar and depressed type) and major recurrent depression (with 
psychotic features). Compared to the control group, women with PP were found to 
have experienced significantly longer labours and were more likely to give birth during 
the night time, suggesting acute sleep loss during labour may precipitate the onset of 
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PP (Sharma, Smith and Khan 2004). It is however difficult to relate these findings to PP 
within BD, given that women with major psychotic depression and schizoaffective 
disorder depressed type were also included in the PP group. Furthermore, the control 
group consisted of healthy parous women without a personal or family history of mood 
disorders, thus it is possible that differences in the length of labour and time of delivery 
reflect factors associated with the presence or absence of psychiatric disorder. 
Furthermore, sample sizes in this study were small (n=21 in each group) and no 
information was obtained regarding sleep patterns in late pregnancy. This may be 
important given that changes in sleep in late pregnancy may be indicators of more 
chronic sleep disruption prior to childbirth. 
 
Bilszta, Meyer and Buist (2010) aimed to prospectively compare sleep patterns 
throughout pregnancy and the postpartum period between women at high-risk of PP 
(defined as women with a diagnosis of BD-I or BD-II or a history of PP, n=23) and a 
control group of 15 pregnant women without any psychiatric history. Assessments 
included sleep diaries that were completed daily and self-report questionnaires 
administered at baseline, in the last two weeks of pregnancy and at weeks one, four 
and eight postpartum. The authors found no significant differences between the two 
groups in any sleep related factors across the perinatal period (such as time in bed, time 
available for sleep, time awake during the night and subjective sleep). However, given 
that so few women experienced a severe recurrence of mood disorder following 
delivery (n=3, defined as any recurrence causing impairment that required inpatient or 
outpatient clinical intervention), it was not possible to perform comparisons of sleep 
factors between women who did and did not experience a severe postpartum mood 
episode.  
 
Finally, in a large sample of women with well-defined BD-I (n=870), our research group 
(BDRN) examined whether overall vulnerability to mania triggered by sleep loss 
(indicated by a self-reported history of manic episodes triggered by sleep loss) was also 
associated with the lifetime occurrence of PP (Lewis et al. 2018). In this study, we 
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compared the lifetime occurrence of PP between women who self-reported at least 
three episodes of mania triggered by sleep loss and women who did not report this. PP 
episodes were significantly more frequent among women who report sleep loss as a 
frequent trigger of mania (36.8%), compared to women who did not (21.8%). 
Conversely, we found no association between self-reported history of depressive 
episodes triggered by sleep loss and the occurrence of PP or of PND, indicating 
specificity of the sleep loss trigger to episodes of mania and of PP. However, due to the 
retrospective nature of this study, we were not able to directly assess the role of sleep 
loss within the same perinatal period in which the episode of PP occurred. Furthermore, 
whether sleep loss was a causal factor in the triggering of mania as opposed to the 
onset of early prodromal symptoms could not be determined.  
 
Thus, based on literature to date, the role of sleep disruption occurring within the 
perinatal period (for example during late pregnancy or associated with labour) in the 
occurrence of PP remains unclear. Furthermore, these relationships are yet to be 
investigated in women with BD using a prospective methodology. 
 
2.6.2.2 Mood stabilising medication during the perinatal period 
Women who have BD face difficult decisions regarding medication use during the 
perinatal period, often in the absence of an established evidence base (Dolman, Jones 
and Howard 2016; Jones and Jones 2017). Careful consideration must be given to the 
risks and benefits of psychotropic medication use not only for the mother, but also for 
her baby and wider family. This decision-making process is influenced by a range of 
factors, such as the woman’s illness history and previous response to treatment, 
efficacy and teratogenicity of psychotropic medications, intention to breastfeed and 
crucially, risk of recurrence during the perinatal period (Dolman, Jones and Howard 
2016; National Institute for Health and Clinical Excellence 2014; Stevenson et al. 2016). 
Subsequently, many women withdraw pharmacotherapy during pregnancy, particularly 
when there are concerns of teratogenic effects on the foetus (Dolman, Jones and 
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Howard 2016; Stevenson et al. 2016). Nevertheless, few studies have examined the 
effects of medication withdrawal on course of BD during pregnancy. Available evidence 
indicates that compared to women who continue prophylactic mood stabilisers during 
pregnancy, the risk of antenatal recurrence of BD is significantly higher among women 
who discontinue medication (Stevens et al. 2019; Viguera et al. 2007). Furthermore, 
latency to illness recurrence has been found to be 11 times quicker in women with BD 
who discontinued lithium treatment rapidly during pregnancy (within two weeks) 
compared to those who withdrew lithium more gradually (over a period greater than 
two weeks; Viguera et al. 2007). 
 
In contrast to pregnancy, there is limited evidence to suggest that prophylactic mood 
stabilisers during the perinatal period moderate risk for postpartum recurrence in BD. 
Based on data obtained from only eleven studies, a recent meta-analysis found women 
who continued prophylactic mood stabilisers throughout the perinatal period were 
significantly less likely to experience a mood episode following childbirth compared to 
those did not take any medication (Wesseloo et al. 2016). The authors reported 23% of 
women who had taken prophylactic mood stabilisers during pregnancy to experience a 
postpartum recurrence, compared to 66% of women who remained medication free. 
However, these findings are predominantly based on case-reports or small 
retrospective studies of lithium. Controlled studies examining the efficacy of 
prophylactic mood stabilisers in preventing postpartum relapse in women with BD are 
rare (Cohen et al. 1995; Viguera et al. 2000; Wisner et al. 2004).  
 
Due to the focus of research on lithium, little is known regarding the prophylactic 
efficacy of antipsychotics and anticonvulsants for prevention of PP, despite these 
medications being frequently utilised for their mood stabilising properties (Galbally et 
al. 2019). Only one small study has examined prophylactic antipsychotic use during the 
perinatal period in a sample of 25 women with BD (Sharma, Smith and Mazmanian 
2006). Of 11 women who were taking prophylactic olanzapine for at least one month 
following delivery, only two subsequently experienced psychotic relapse (18.2%). In 
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comparison, more than half of those who did not take prophylactic olanzapine (but 
remained on other psychotropic medications) experienced PP (8/14, 57.1%). However, 
the small sample size of this study did not allow for statistical comparison between the 
groups.  
 
The efficacy of prophylactic lamotrigine for preventing postpartum relapse in BD has 
been compared to that of lithium in a Danish registry study (Wesseloo et al. 2017b). 
After controlling for potential confounders such as parity and other medication use, 
prophylactic lamotrigine during pregnancy was found to be no more effective at 
preventing postpartum relapse than lithium (7.3% versus 15.3%). However, the risk for 
PP was not specifically examined. Notably, postpartum recurrence was defined in this 
study as an episode of any mental disorder requiring hospitalisation within 3 months 
postpartum. It is therefore likely that episodes of illness that were managed in the 
community were not captured by this description. Also, in this study, medication use 
was defined on the basis of prescriptions only, as indicated by the register. Neither 
duration of use or adherence to prescribed medication across the perinatal period 
could be confirmed by this method. Finally, diagnosis of BD was based on case-note 
review only and not confirmed by clinical research interview.  
 
More recently, among a sample of 196 women with a history of severe affective 
disorders (primarily of BD and PP), exposure to any type of prophylactic medication in 
the third trimester of pregnancy and/or the postpartum period did not significantly 
reduce risk of mood episodes that required admission to acute care within the first 
three months of delivery (Taylor et al. 2018). Importantly however, use of prophylactic 
mood stabilisers and antipsychotics were not distinguished from prophylactic 
antidepressant use. Use of antidepressant medications (particularly without a 
concomitant mood stabiliser) has been shown to increase risk of recurrence of BD 
during the perinatal period (Viguera et al. 2007). It is therefore possible that 
antidepressant use confounded the results of this study, inflating recurrence rates 
among women who were using psychotropic medication. Furthermore, findings of 
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Taylor et al.'s study (2018) were based on health records of women who were all under 
the care of secondary psychiatric services and in some cases, specialist perinatal 
psychiatric services. Thus, their findings may be subject to confounding by indication. 
That is, women recruited from secondary and tertiary psychiatric services may be more 
likely to have a more severe form of BD illness that is potentially associated with both 
medication use and postpartum recurrence. Consequently, severity of illness may be a 
moderating factor in the relationship between medication use and postpartum 
recurrence.  
 
Considering findings to date, the efficacy of mood stabilising medications for 
prophylaxis of PP in women with BD remains ambiguous. It is however apparent that 
withdrawal of medication in the perinatal period cannot fully explain the particularly 
elevated rates of recurrence observed within this high-risk group. As discussed 
previously, Viguera et al., (2000) found that pregnant women with BD who withdraw 
mood stabilising medication are no more likely to relapse compared to a sample of non-
pregnant women who also discontinued medication. However, of women who were 
euthymic at the 40-week follow-up, recurrence between weeks 41-64 was 2.9 times 
more frequent among parous women in the postpartum period compared to women in 
the non-postpartum equivalent period.  
 
2.6.2.3 Obstetric factors 
The close temporal relationship between childbirth and the onset of PP has led to the 
suggestion that obstetric factors may also influence susceptibility to PP. Several factors 
have previously been associated with PP, including mode of delivery (Kendell et al. 
1981; McNeil 1988c; Nager et al. 2008), female sex of baby (Agrawal, Bhatia and Malik 
1990), pre-term delivery (Nager et al. 2008; Paffenbarger et al. 1961; Videbech and 
Gouliaev 1995), reduced birth weight (Videbech and Gouliaev 1995), twin birth (Munk-
Olsen and Agerbo 2015) and longer interval between pregnancies(Paffenbarger et al. 
1961). Findings are however inconsistent or without replication in independent 
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samples. The role of obstetric complications has specifically been investigated, similarly 
being shown to be associated with PP in some studies (Blackmore et al. 2006; 
Hellerstedt et al. 2013; Kendell et al. 1981; Paffenbarger et al. 1961; Paffenbarger and 
McCabe 1966; Upadhyaya, Sharma and Raval 2014), but not all (Bergink et al. 2011a; 
Kumar et al. 1995; McNeil 1988c; Meltzer-Brody et al. 2017; Nott 1982; Videbech and 
Gouliaev 1995).  
 
Thus far, primiparity is the only obstetric factor to be robustly related to the onset of 
PP, being reported in epidemiological studies (Kendell et al. 1981; Munk-Olsen, Jones 
and Laursen 2014; Nager et al. 2008), broadly defined clinical samples (Paffenbarger 
and McCabe 1966; Upadhyaya, Sharma and Raval 2014) and among women with BD 
(Blackmore et al. 2006; Di Florio et al. 2014). The effect of primiparity is strongest 
among women with BD (Munk-Olsen, Jones and Laursen 2014). Arguably, it is possible 
this association reflects a bias of women who experience PP following their first baby to 
be less likely to have further children (for fear of recurrence). However, as the 
relationship between primiparity and PP has also been demonstrated among samples of 
multiparous women, this is unlikely to explain such findings (Di Florio et al. 2014; Nager 
et al. 2008). Currently, the mechanism by which primiparity increases risk for PP is not 
well understood, given that in addition to the physiological changes that occur, first 
pregnancies may also cause greater disruption to sleep routines and require greater 
psychosocial adjustment (for example financially, changes in daily and occupational 
routine and social relationships) from subsequent pregnancies.  
 
A small number of studies have also suggested an association between pre-eclampsia 
and PP (Annagur and Kerimolglu 2013; Bergink et al. 2015b). This association is of 
interest for further research, given that pre-eclampsia and PP can present as clinically 
similar. Case reports have shown that psychotic features, mood symptoms, mutism or 
catatonia and perplexity can be features of both illnesses, suggesting potential overlap 
in the underlying aetiological mechanisms of both disorders (Brockington 1996; Joseph, 
Shebak and Greenage 2016; Ranzini et al. 1996). Furthermore, much like PP, pre-
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eclampsia has also been associated with first pregnancies (Hernández-Díaz, Toh and 
Cnattingius 2009) and immunological factors implicated in the pathophysiology of 
symptoms (Lokki, Heikkinen-Eloranta and Laivuori 2018). Nonetheless, no published 
studies, retrospective or otherwise have examined the relationship between pre-
eclampsia and PP in women with BD.  
 
In summary, based on the literature to date, it is unclear whether obstetric factors are 
associated with PP. Inconsistent findings are likely due to variation in definitions of both 
obstetric complications (e.g. severity, type and timing of occurrence) and the 
postpartum period. Findings are further limited by frequent use of retrospective 
methods of assessments, potentially leading to a detection bias of obstetric 
complications in women admitted with PP. Several studies also lacked an appropriate 
control group, comprised of ‘healthy’ parous women as opposed to women with BD 
who did not experience obstetric complications (Hellerstedt et al. 2013; Meltzer-Brody 
et al. 2017; Paffenbarger and McCabe 1966; Upadhyaya, Sharma and Raval 2014). Given 
that women with psychiatric disorders are more likely to use medications during 
pregnancy and are known to be at increased risk of obstetric complications compared 
to women without any psychiatric illness (Jablensky et al. 2005), it is possible that the 
effect of obstetric complications reflect differences between women with and without 
psychiatric disorders. Finally, despite being at greatest risk of PP, only two studies have 
specifically assessed obstetric factors in relation to postpartum recurrence in women 
with BD (Blackmore et al. 2006; Di Florio et al. 2014). 
 
2.6.2.4 Comorbid anxiety disorders 
Women are approximately twice more likely to experience anxiety disorders than men, 
with the onset of symptoms occurring in most cases before the age of 35 years (Remes 
et al. 2016). Consequently, many women are affected by anxiety disorders during their 
childbearing years, and commonly during the perinatal period (Dennis, Falah-Hassani 
and Shiri 2017). Evidence suggests that compared to pregnancy or outside the perinatal 
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period, risk of new onset or exacerbation of existing anxiety disorders may be greater in 
the postpartum period (Goodman, Watson and Stubbs 2016; Remes et al. 2016). 
Several studies have also shown that the onset of panic disorder may be delayed and 
symptoms less severe among women who are breastfeeding, compared to parous 
women who were not breastfeeding (Goodman, Watson and Stubbs 2016).  
 
The mechanism by which anxiety disorders are exacerbated or triggered by childbirth is 
not well understood, however findings suggest that similar to postpartum mood 
disorders, oestrogen and progesterone may also play an important role in the 
pathogenesis of anxiety disorders (Li and Graham 2017). In addition, the perinatal 
period is associated with unique psychological and psychosocial stressors which may 
also act to further provoke symptoms of anxiety (Huizink et al. 2017). Women 
experiencing pathological anxiety during the perinatal period are by definition likely to 
experience excessive, uncontrollable worrying and disturbances to sleep pattern, which 
may in turn have an adverse impact on mood. This may be especially the case during 
the postpartum period, when sleep is scarce and the developmental needs of the baby 
are considered a priority over the needs of the mother.  
 
The link between anxiety disorders and postpartum mood disorders has been primarily 
been examined in relation to PND. History of lifetime anxiety disorders prior to 
pregnancy has been associated with the occurrence of PND (Guintivano et al. 2018). 
Moreover, antenatal anxiety has been identified as a strong predictor of PND (Austin, 
Tully and Parker 2007; Heron et al. 2004; Skouteris et al. 2009), independent of the 
effect of antenatal depression (Austin, Tully and Parker 2007; Heron et al. 2004). 
Anxiety disorders and PND also frequently co-occur within the same period (Falah-
Hassani, Shiri and Dennis 2016; Merikangas and Jin 2011; Nakić Radoš, Tadinac and 
Herman 2018).  
 
Despite focus of research on the association between anxiety and PPD, whether 
comorbid anxiety disorders also increase risk of PP, over and above the relationship 
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with BD is yet to be investigated. Only one previous study has reported on the 
association between anxiety during pregnancy and the occurrence of broadly defined 
PP (psychosis in the postpartum period that was affective or non-affective). In this 
prospective study, 88 women with a history of psychotic disorders were followed 
through pregnancy to six months postpartum (McNeil 1988a). The authors found that 
women who experienced the onset of PP within three weeks of delivery (which were 
predominantly affective or cycloid episodes) were significantly more anxious during 
pregnancy than women who remained well. Interestingly, the same association was not 
observed in relation to episodes of PP that occurred later in the postpartum period and 
were predominantly schizophrenic-like psychoses. Thus, suggesting an association 
between anxiety during pregnancy and postpartum affective psychoses in particular. 
 
In addition to the findings of this study, a relationship between anxiety and PP within BD 
is also plausible for several other reasons. First, anxiety disorders are highly prevalent in 
individuals with BD (Vázquez, Baldessarini and Tondo 2014) and have also been 
demonstrated to adversely influence course of BD (Hawke et al. 2013; Hunt et al. 2016). 
Second, sleep disruption associated with anxiety during the perinatal period may 
increase risk of PP, given that sleep loss has also been identified as a common trigger of 
episodes of mania unrelated to childbirth. Third, symptoms of anxiety have been 
observed more frequently in postpartum manias compared to those unrelated to 
childbirth (Ganjekar et al. 2013). Fourth, hormonal factors have been implicated in both 
anxiety disorders and PP, suggesting these disorders may share underlying aetiological 
factors.  For these reasons, studies further examining the role of anxiety disorders in the 
occurrence of PP within BD is required. Such findings may provide important clues to 
the pathogenesis of both disorders. Furthermore, if related, the presence of anxiety 
disorders prior to or during pregnancy can be easily screened for and treated in clinical 
practice, thus potentially reducing risk of subsequent PP.  
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2.6.2.5 Psychosocial factors 
Much of the research to date suggests a lack of association between psychosocial 
factors and the occurrence of PP. In contrast to episodes of PND, there is little 
indication that level of social support, relationship or occupation difficulties influence 
risk of PP (Dowlatshahi and Paykel 1990). Several studies have reported being 
unmarried or single at the time of delivery as a potential risk factor for PP (Kendell, 
Chalmers and Platz 1987; Kendell et al. 1981; Nager, Johansson and Sundquist 2005; 
Terp and Mortensen 1998; Upadhyaya, Sharma and Raval 2014), though many others 
have not (Davidson and Robertson 1985; Dowlatshahi and Paykel 1990; McNeil 1987; 
Protheroe 1969; Wisner, Peindl and Hanusa 1994). Marital difficulties have been 
associated with the occurrence of PP in one study, however were indicated to most 
likely be a consequence of psychological vulnerability as opposed to being a 
precipitating factor of illness (Marks et al. 1992). Alternatively, these findings may 
reflect an increased likelihood of single mothers (or women lacking a supportive 
relationship) to be admitted with their baby during the postpartum period. 
 
Adverse life experiences have been frequently identified as predictors of PND (Buist and 
Janson 2001; Dennis and Vigod 2013; Guintivano et al. 2018; Howard et al. 2014; 
Kettunen and Hintikka 2017; Meltzer-Brody et al. 2018; Plaza et al. 2012), but have 
rarely been studied in relation to PP (Brockington et al. 1990; Dowlatshahi and Paykel 
1990; Marks et al. 1992; Meltzer-Brody et al. 2018). Brockington et al. (1990) examined 
the presence of adverse life events occurring prior to pregnancy in 33 women admitted 
to hospital with broadly defined PP (a diagnostically heterogeneous sample) and 25 
women with PND. Adverse events, defined as those objectively causing moderate to 
severe psychological impact, were found to have occurred in only 15% of women with 
PP compared to 32% of women with PND. However, the specific time period during 
which these events occurred was not clear. 
 
In a prospective study of 47 pregnant women with a history of broadly defined affective 
disorder, adverse life events occurring within the 12 months prior to childbirth were 
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found to significantly predict episodes of PND but not PP (Marks et al. 1992). Similarly, 
when compared with a control group of parous women who did not experience PP, 
adverse life events occurring within the 12 months prior to delivery or in the 
postpartum period (before the onset of PP) were no more prevalent among a sample of 
33 women admitted for psychiatric treatment of PP within the first month of delivery 
(Dowlatshahi and Paykel 1990).   
 
Adverse events occurring during childhood have also been shown to influence risk of 
PND, with exposure to an increased number of adverse childhood experiences (ACEs) 
seemingly having a cumulative effect on risk of PND (Guintivano et al. 2018; Meltzer-
Brody et al. 2018). Childhood abuse in particular may be a strong risk factor for PND 
(Buist and Janson 2001; Guintivano et al. 2018; Kettunen and Hintikka 2017; Plaza et al. 
2012). Prior to commencing this thesis, the relationship between ACEs and PP had only 
been investigated in one study, which is also described further above (Dowlatshahi and 
Paykel 1990). Dowlatshahi and Paykel (1990) compared a limited range of ACEs 
(specifically the death of a parent or sibling during childhood and separation from 
parents during childhood for two years or more) between the PP and control group. 
Compared to the control group, women with PP were not significantly more likely to 
report a history of ACEs. However, these factors were only assessed in combination 
with other aspects of personal history and other ACEs such as childhood abuse were not 
investigated. As discussed previously, the sample size of this study was small, including 
only 33 women with broadly defined PP.   
 
More recently, using data obtained from Danish national health registers (from 129,439 
childbirths), Meltzer-Brody et al. (2018) assessed whether a range of ACEs (including 
parental death, parental psychiatric illness, out of home care and parental criminality) 
experienced between the age of 0-15 years were associated with subsequent inpatient 
or outpatient contact for postpartum psychiatric illness within the first six months 
following childbirth. While the authors found out of home care during childhood and 
parental psychiatric illness to be associated with strongest risk of developing any 
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postpartum psychiatric disorder (and specifically non-psychotic PND and postpartum 
anxiety disorders), none of the ACEs assessed were independently associated with the 
occurrence of PP (broadly defined as any episode of mania, affective or non-affective 
psychosis). Again however, the relationship between childhood abuse and PP was not 
examined in this study. Overall, studies assessing psychosocial risk factors for PP in 
samples of high-risk women are limited. Furthermore, despite indications of a strong 
relationship between adverse life events (and in particular those occurring during 
childhood) and PND, the influence of these factors on risk of PP within BD is yet to be 
investigated. 
 
2.7 Summary 
In summary, a review of the literature indicates that the aetiology of PP within BD 
remains poorly understood. While neurobiological factors have been implicated in the 
pathogenesis of PP, emerging evidence suggests that a range of within-pregnancy 
factors may also be involved in the triggering of these episodes. Despite this, the 
literature thus far has been limited by substantial methodology heterogeneity between 
studies. Specifically, in regards to definitions used to define postpartum recurrence 
(both in the temporal cut off used to define the postpartum period and inclusion of 
diagnostically heterogeneous samples), the diagnostic criteria used and lack of an 
appropriate control group. Moreover, of potential risk factors that have been examined, 
findings between studies have been inconsistent (for example, those investigating the 
influence of obstetric complications or psychotropic medication use on risk of PP) or are 
based on retrospective methods of assessment. Importantly, prospective studies in this 
area are limited.  Finally, many potential risk factors for PP, such as those occurring 
within pregnancy are either unstudied or remain to be investigated. The role that 
lifetime comorbid anxiety disorders or ACEs play in the occurrence of PP in BD is yet to 
be determined.   
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2.8 Thesis aims 
To address the gaps identified within the literature and extend findings in this area, this 
thesis aims to investigate potential aetiological and triggering factors of PP in BD.  
Specifically, the three main aims of this thesis are to: 
 
1. Investigate potential relationships between history of ACEs, anxiety disorders 
and the lifetime occurrence of PP in a sample of parous women with BD 
(Chapter 3). 
 
2. Describe psychotropic medication use and psychiatric outcomes across the 
perinatal period in a sample of pregnant women with BD using a prospective 
follow-up design (further refining the phenotype of postpartum mood episodes 
for investigations of potential risk factors for PP within this sample; Chapter 6) 
 
3. Investigate a wide range of within-pregnancy potential risk factors for PP in a 
sample of pregnant women with BD using a prospective follow-up design 
(Chapter 7).  
 
In the following chapter (Chapter 3), results of investigations examining the association 
between lifetime co-morbid anxiety disorders, ACEs and the lifetime occurrence of PP 
among women with BD will be presented and discussed. First, the methods used in the 
recruitment and assessment of the sample within which these investigations were 
conducted will be described.
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3.1 Introduction 
As discussed in Chapter 2 (section 2.7, page 47) the association between adverse 
childhood experiences (ACEs), lifetime comorbid anxiety disorders and PP remains to be 
investigated. The aim of this chapter is to examine these relationships among a large 
sample of parous women with BD recruited to BDRN. In this chapter, I first describe the 
BDRN programme of research, detailing inclusion criteria, approaches to recruitment 
and the process of screening and obtaining written, informed consent from those 
recruited. This is followed by a description of the neuropsychiatric assessment of 
participants including demographic characteristics, lifetime psychopathology and 
history of ACEs. Statistical approaches used to assess the relationship between potential 
risk factors and the occurrence of PP within this sample are summarised. Finally, the 
results of these analyses are presented, followed by a detailed discussion of these 
findings in relation to the literature.  
 
3.2 Methods 
3.2.1 Bipolar Disorder Research Network (BDRN) 
BDRN is a long-standing research collaboration between the Mood Disorders Research 
Group at the University of Worcester (led by Professor Lisa Jones) and at Cardiff 
University (previously led for many years by Professor Nick Craddock and currently by 
Professor Ian Jones). While recruitment to BDRN is ongoing, more than 7000 individuals 
with BD have been recruited into the research programme. The broad aims of BDRN are 
to investigate genetic and non-genetic determinants (such as adverse life events and 
psychosocial factors) of BD and related mood disorders.  
 
This research (and all subsequent substantial amendments to the initial protocol) has 
received a favourable opinion for conduct in the National Health Service (NHS) by the 
West Midlands Multi-Centre Research Ethics Committee (MREC/97/7/01) and has 
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received local Research and Development approval in all participating health boards and 
NHS trusts nationwide.  
 
3.2.2 Recruitment: BDRN retrospective sample 
A combination of systematic and non-systematic approaches has been used for 
recruiting eligible participants to BDRN. Individuals were eligible to take part in BDRN if 
they are at least 18 years of age and have a lifetime history of BD. Individuals were not 
eligible to participate if they do not have a lifetime history of BD or the onset of BD 
occurred over the age of 65 years. Detailed descriptions of methods used to recruit 
eligible participants to BDRN are summarised below.   
 
3.2.2.1 Systematic Recruitment 
Systematically recruited participants were identified by Clinical Studies Officers (CSOs; 
researchers employed by the NHS to facilitate the identification and recruitment of 
participants to studies) or members of their psychiatric clinical team via case load 
screening in 25 NHS community mental health teams and lithium clinics nationwide. 
Eligible individuals were provided with brief information about the research either in 
person or by an information pack and asked if they would be willing to participate. Each 
information pack contained a standard study invitation letter signed by the individual’s 
lead clinician, a participant information sheet, an annual BDRN newsletter and a 
standard contact reply form. Individuals who expressed an interest in the research gave 
permission for their details to be passed on to the research team either directly by the 
CSO or clinical team, or by completing the reply form that was returned to the research 
team in a freepost envelope. 
 
Further systematic recruitment of participants was achieved by displaying posters and 
study information leaflets that advertised the research in waiting rooms of community 
mental health services and lithium clinics.  
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3.2.2.2 Non-Systematic Recruitment 
Participants have also been recruited to BDRN using a variety of non-systematic 
approaches. Non-systematic methods of recruitment predominantly involved the BDRN 
website, coverage of the study via national and local media (e.g. radio, television and 
newspapers) and national patient support charities. BDRN has worked closely with two 
charities in particular, Bipolar UK and Action on Postpartum Psychosis (APP). Specific 
methods of recruitment tailored to each charity are described below. 
 
 Bipolar UK   
Bipolar UK (www.bipolaruk.org), previously called the Manic Depression 
Fellowship (MDF) is a national charity which provides support and advice to over 
80,000 individuals and their families affected by BD. Subscribing members to 
Bipolar UK regularly receive charity updates via a biannually published magazine 
(Pendulum) and monthly e-newsletters. BDRN has been frequently advertised to 
members of Bipolar UK online, in Pendulum and at annual national conferences 
hosted by the charity. In 2010, the Bipolar UK annual conference was hosted by 
BDRN.  
 
 Action on Postpartum Psychosis  
Action on Postpartum Psychosis (APP) is a national charity specifically targeted 
to providing support and advice to women with a history of PP. The charity, 
which was established in 1996, is a collaborative project run by women who 
have experienced PP, specialist healthcare professionals and academic experts.  
APP also aims to facilitate research into PP and has collaborated closely with 
BDRN for many years. BDRN has been advertised widely to over 700 members of 
APP, including online via the charity’s website and discussion forums, in e-
newsletters and charity publications.  
 
Individuals who expressed interest in participating in BDRN were contacted via 
telephone and screened by members of the research team to confirm eligibility.  
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3.2.3 Assessments: BDRN retrospective sample 
Participants were provided with a detailed participant information sheet and written 
consent obtained by a trained member of the BDRN study team. All participants 
completed a semi-structured interview lasting approximately one and a half hours and a 
battery of self-report questionnaires. Only those assessments that are relevant for the 
analysis presented in this chapter are described in detail below. 
 
3.2.3.1 Semi-structured interview 
The majority of interview assessments took place in participants’ own homes and were 
conducted by myself (>600 interviews completed as of June 2019), or other members of 
the BDRN study team who were either research psychologists or psychiatrists trained in 
administering the assessments. If conducting an interview at a participant’s home was 
not feasible, this was arranged at an alternative location convenient for the participant 
such as the home of a relative, their workplace or a room situated in a community 
mental health centre or GP clinic. The interview included the following assessments: 
 
 Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 
The Schedules for Clinical Assessment in Neuropsychiatry (SCAN; Wing et al. 
1990) is a widely used research psychiatric assessment tool used to determine 
the presence and severity of psychopathology associated with major psychiatric 
disorders. Relevant sections of the SCAN were used to assess lifetime history of 
anxiety disorders, affective symptomatology during episodes of depression and 
mania and to elicit the lifetime presence or absence of psychotic symptoms, 
including hallucinations, delusions and experiences of thought disorder and 
replacement of will.  
 
 Lifetime Perinatal Psychiatric History 
For all parous women, information was obtained at interview regarding lifetime 
psychopathology experienced during the perinatal period (during pregnancy up 
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to six months postpartum) for all pregnancies. Participants were asked about the 
occurrence and type of the most impairing mood episode with onset during 
each perinatal period, the timing of onset, the duration of each episode and 
whether psychotic features had been present during the episode.  
 
 BDRN Childhood Life Events Questionnaire - CLEQ  
History of ACEs was assessed during the interview using a bespoke questionnaire 
developed by senior members of BDRN team for the purpose of this research 
(Childhood Life Events Questionnaire, CLEQ, see Appendix A). The CLEQ was 
administered verbally by the researcher to all participants following the SCAN 
interview once rapport had been established. Participants were asked if they 
had experienced one or more of a list of twelve ACEs before the age of 16 years. 
Due to the sensitive nature of such events, participants were not asked directly 
about experiences of childhood abuse. Instead, participants were given the 
opportunity to disclose additional events by being asked “Are there any other 
significant life events you experienced as a child?” 
 
3.2.3.2 Self-report questionnaires 
Following the interview, participants were provided with a battery of self-report 
questionnaires to be completed and returned in a freepost envelope within two weeks 
of the interview. If questionnaires were not returned within two weeks, a reminder 
letter and further questionnaire pack were sent to the participant. The questionnaires 
comprised measures assessing lifetime clinical diagnosis of a range of physical and 
psychiatric illnesses, current mood state, cognitive and personality factors and history 
of adverse life events. Only assessments included in the questionnaire pack that are 
relevant for analysis reported in this chapter are described further below: 
 
 Lifetime doctor diagnosis of psychiatric illness 
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Participants were asked to report whether they had ever received a doctor 
diagnosis of a range of psychiatric illnesses (including anxiety and specifically 
panic disorder) from a specified list by indicating yes, no or unsure (see 
Appendix B).  
 
 Adverse life events 
Adverse life events were assessed using a self-report questionnaire (Brief Life 
Events Questionnaire, BLEQ) which asked about the occurrence of severe 
adverse life events during a six-month timeframe (including the six-months prior 
to onset of impairing BD) based on a list proposed by Brugha et al. (1985). An 
open question was also added to the questionnaire that asked participants “Do 
you think there is anything that has happened to you during your life which has 
contributed to you becoming unwell (i.e. the onset of BD, see Appendix C)?”  
 
3.2.3.3 Psychiatric Case-Note Screen 
Where available, psychiatric case-notes for consenting participants were screened for 
further information (case-notes have been obtained for approximately 72% of all 
individuals with BD recruited into BDRN).  
 
3.2.4 Lifetime consensus ratings 
Psychiatric case note data were combined with information obtained at interview and 
from self-report questionnaires to produce a detailed vignette for each participant. 
Vignettes summarised participants’ lifetime and perinatal psychopathology, 
demographic and social information, lifetime substance use, obstetric history and family 
history of psychiatric illness. From these vignettes, ratings were made for all variables 
outlined in the following sections. 
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3.2.4.1 Demographic characteristics 
Ratings were made of demographic variables including age at interview, ethnicity, 
relationship status, highest educational achievement, highest level of occupation and 
method of recruitment. 
 
3.2.4.2 Adverse childhood experiences (ACEs) 
Information about ACEs obtained at interview (via the CLEQ) and from responses to the 
open question of the BLEQ (included in the battery of self-report questionnaires, see 
section 3.2.3.2) were combined with information from psychiatric case notes to code 
the presence or absence of the following ACEs occurring before the age of 16 years: a) 
death of a parent, b) death of sibling, c) death of a close friend, d) divorce and/or 
separation of parents and e) serious illness that required hospitalisation.  
 
The presence or absence of childhood abuse was rated according to the following 
categories a) any emotional abuse, b) any sexual abuse and c) any physical abuse. 
Individual abuse categories were combined to create an additional variable which coded 
the presence or absence of any childhood abuse (defined as any sexual and/or physical 
and/or emotional abuse).  
 
3.2.4.3 Lifetime psychiatric history 
 Best-estimate main lifetime DSM-IV diagnoses 
Best-estimate main lifetime psychiatric diagnoses for all participants were made 
according to standard operationalised diagnostic criteria of the DSM-IV. In cases 
where more than one lifetime diagnosis was indicated, diagnoses were rated 
hierarchically according to level of functional impairment. The diagnosis causing 
the highest level of functional impairment was rated as the main lifetime 
diagnosis.  
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 Key lifetime psychiatric features 
Ratings were made for key lifetime clinical features of psychiatric illness such as 
the age of onset of impairing BD, number of lifetime episodes of mania and 
depression and the lifetime occurrence of psychotic features.  
 
 Lifetime anxiety disorders 
Information obtained at interview (using the SCAN) and from the self-report 
questionnaire regarding lifetime history of anxiety disorders was combined to 
code the presence or absence of a lifetime history of any anxiety disorder and 
specifically of panic and generalised anxiety disorder.   
 
3.2.4.4 Lifetime perinatal psychiatric history 
 Pregnancy by pregnancy  
For all parous women (i.e. women who had given birth to at least one live child), 
collated data were used to rate the presence and type of the most impairing 
mood episode with onset within each perinatal period (defined as during 
pregnancy or within 6 months postpartum). Episodes were rated hierarchically, 
with mania/affective psychoses being rated in favour of episodes of non-
psychotic depression. In cases in which a participant had experienced episodes 
with onset during pregnancy and the postpartum period, only the postpartum 
episode was rated.  
 
 Lifetime most impairing perinatal mood episode  
To further refine ratings of perinatal mood episodes according to phenotype, 
pregnancy by pregnancy ratings were used to code the lifetime most impairing 
perinatal mood episode. Episodes were rated hierarchically as shown in Figure 
3.1. This system ensured that only the most impairing, narrowly defined episode 
was rated. For multiparous women with a lifetime history of postpartum 
mania/affective psychosis and of any other mood episode (i.e. hypomania or 
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PND), the episode of mania/affective psychosis was rated as the lifetime most 
impairing perinatal mood episode.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Definition of perinatal psychiatric outcomes 
Ratings of the worst lifetime perinatal mood episode were used to define the 
outcome variable for analysis (PP/control group) by stratifying women to the 
following two groups (samples are described further in section 3.2.5): 
 
Postpartum psychosis group (PP group): defined as parous women with a 
lifetime worst history of mania (with or without mixed features) or an episode of 
affective psychosis with onset within six weeks of delivery. To further refine this 
group, multiparous women with a lifetime history of PP who also had a lifetime 
history of PND were excluded from this analysis. As discussed in section 2.3.4 
(page 14, Chapter 2), there is currently no consensus regarding the temporal 
Figure 3.1: Rating categories of the lifetime most impairing perinatal mood episode in parous 
women in the BDRN retrospective sample 
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definition of the postpartum period, therefore a cut-off of six weeks was chosen 
to be consistent with both DSM-IV and ICD-11 definitions of the postpartum 
period. 
 
No perinatal mood episode group (No PME group): defined as parous women 
with no lifetime history of any mood episode during pregnancy or within six 
months following delivery. A broader temporal definition of the perinatal period 
(to include both pregnancy and up to six months postpartum) was selected for 
this group to ensure that participants did not experience any episodes of 
affective illness that could be considered related to childbirth.  
 
Parous women who did not meet criteria for inclusion in the PP or No PME 
groups according to the strict definitions above were excluded from analyses. 
This included women who experienced: 
 
a) Non-psychotic depression with onset within six weeks of delivery. 
b) Hypomania with onset within six weeks of delivery. 
c) Any other perinatal mood episode: including a mood episode with onset 
during pregnancy, any mood episode with onset between 6 weeks and six 
months of delivery and a mood episode with onset during the perinatal 
period that did not meet DSM criteria for impairment. 
 
3.2.4.5 Inter-rater reliability 
Senior members of the BDRN team who were trained in rating raw data according to 
clinical diagnostic criteria made all ratings. In cases of ambiguity, at least two members 
of the study team made ratings (blind to each other’s ratings) and consensus reached 
via discussion if necessary.  
 
Inter-rater reliability for consensus ratings was formally assessed for 20 cases using 
Cohen’s Kappa Coefficient. Mean kappa statistics were 0.85 for DSM–IV diagnosis, 0.97 
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for the lifetime most impairing perinatal mood episode and between 0.81 and 0.99 for 
other key categorical clinical variables. Mean intra-class correlation coefficients were 
between 0.91 and 0.97 for key continuous clinical variables. 
 
3.2.5 Sample 
Participants were 1113 unrelated, parous women with a lifetime diagnosis of BD-I (for 
whom data were also collected on ACEs and/or anxiety disorders) recruited to BDRN. 
Analyses included women with BD-I only, given that no women with BD-II had 
experienced a postpartum episode of psychotic depression (consistent with the strict 
definition of PP detailed above in section 3.2.4.4). This step was taken to control for 
potential confounding effects of diagnosis by including all BD-II women in the No PME 
group.  
 
As 98.2% (n=1093/1113) of women were of white ethnicity (due to the focus of BDRN 
on investigating genetic aetiological factors of BD), analyses were further restricted to 
this ethnic group only. This resulted in a sample of 1093 women who were eligible for 
inclusion in the current analysis. 
As shown in Figure 3.2, the lifetime worst occurrence of perinatal mood episodes 
among the 1093 parous women was as follows: 
 601 (55%) experienced a lifetime worst postpartum recurrence of mood 
disorder with onset within six weeks of delivery; PP (n=297), non-psychotic 
depression (n=283) and hypomania (n=21) 
 
 200 (18%) had a lifetime history of other perinatal mood episodes; onset of a 
mood episode during pregnancy (n=70), onset of a mood episode between six 
weeks and six months postpartum (n=110), onset of a mood episode not 
meeting DSM criteria for impairment (n=20) 
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 292 (27%) women had no lifetime history of any perinatal mood episode (during 
pregnancy or within six months postpartum, No PME group) 
 
From this sample, women were selected for inclusion if they met the following criteria: 
a) had a lifetime history of No PME or PP  
b) the onset of impairing BD occurred at 45 years or younger (to ensure that only 
women who had experienced BD during their childbearing years were included)  
 
After excluding multiparous women who had a lifetime history of both PP and PND 
(n=61) from the PP group and women with an age of onset of impairing BD ≥ 45 years 
(n=24), the final groupings for each subset of analyses were as follows: 
ACEs subset (see Figure 3.2 for flow-chart of sample selection) 
 PP group (n=208) and No PME group (n=224)  
 
Anxiety subset (see Figure 3.3 for flow-chart of sample selection) 
 PP group (n=162) and No PME group (n=165). Groups are smaller within 
this subset as information about lifetime history of anxiety disorders was 
not systematically collected for all women in the sample.   
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Figure 3.2: Flowchart of sample selection of the ACE subset from 1093 parous women with BD-I in BDRN 
retrospective dataset 
 Lifetime history of postpartum 
mood episodes <6 weeks of delivery 
n=601 (55% parous women) 
No lifetime history of 
postpartum mood episodes 
n=292 (27% parous women) 
Unrelated parous women with BD-I 
n=1093 
aOther perinatal mood 
episodes 
n=200 (18% parous women) 
ACEs subset 
No PME group  
n=224  
No ACE data 
n=44 
 
Excluded 
bAge at onset of BD ≥ 45 
n=24 
 
Excluded  
ACEs subset 
PP group  
n=208  
History of mania and non-
psychotic depression, n=61 
 Lifetime history of PP only < 
6 weeks, n=236 
Hypomania, n=21 
Non-psychotic depression, n=283 
No ACE data 
n=28 
 
Excluded  
Excluded  
Excluded  
 Lifetime history of PP < 6 
weeks, n=297 
Excluded  
BDRN: Bipolar Disorder Research Network; ACEs: Adverse childhood experiences; BD-I: Bipolar I disorder; PP: Postpartum 
psychosis (defined as an episode of mania, mixed affective state or affective psychosis within 6 weeks of delivery; No PME: No 
lifetime history of perinatal mood episodes during pregnancy or within 6 months postpartum. aThis group comprised episodes 
with onset during pregnancy, postpartum mood episodes with onset >6 weeks following delivery and episodes not meeting DSM 
impairment criteria b Age at onset defined as age at onset of impairing BD in years.   
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BDRN: Bipolar Disorder Research Network; BD-I: Bipolar I disorder; PP: Postpartum psychosis (defined as an episode of mania, 
mixed affective state or affective psychosis within 6 weeks of delivery; No PME: No lifetime history of perinatal mood episodes 
during pregnancy or within 6 months postpartum. aThis group comprised episodes with onset during pregnancy, postpartum 
mood episodes with onset >6 weeks following delivery and episodes not meeting DSM impairment criteria b Age at onset defined 
as age at onset of impairing BD in years.   
Figure 3.3: Flowchart of sample selection of the anxiety subset from 1093 parous women with BD-I in 
BDRN retrospective dataset 
 Lifetime history of postpartum 
mood episodes <6 weeks of delivery 
n=601 (55% parous women) 
No lifetime history of 
postpartum mood episodes 
n=292 (27% parous women) 
Unrelated parous women with BD-I 
n=1093 
a Other perinatal mood 
episodes 
n=200 (18% parous women) 
No anxiety data 
n=74 
 
Excluded 
bAge at onset of BD ≥ 45 
n=24 
 
Excluded  
History of mania and non-
psychotic depression, n=61 
 Lifetime history of PP only  
< 6 weeks, n=236 
Hypomania, n=21 
Non-psychotic depression, 
No anxiety data 
n=103 
 
Excluded  
Excluded  
Excluded  
 Lifetime history of PP < 6 
weeks, n=297 
Excluded  
Anxiety subset 
No PME group  
n=165 
Anxiety subset 
PP group  
n= 162 
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3.2.6 Statistical Analysis 
All data were analysed using the statistical package SPSS version 24. As continuous data 
were non-normally distributed (as indicated by the Kolmogorov–Smirnov test), non-
parametric tests were used to compare differences between groups, as summarised 
below. All tests were deemed significant at a p-value of <0.05 (two-tailed).  
 
3.2.6.1 Continuous Data    
Due to being non-normally distributed, continuous data (including age at interview, age 
at onset of impairing BD illness, average lifetime number of episodes of mania and 
depression per illness year, age at first pregnancy and number of deliveries) were 
compared between the No PME and PP groups using Mann Whitney-U tests. For this 
reason, medians, range and inter-quartile ranges are reported for each continuous 
variable within each group.  
 
3.2.6.2 Categorical Data     
Categorical data (including level of education, method of recruitment, the 
presence/absence of ACEs and lifetime history of anxiety disorders) were compared 
between the No PME and PP groups using Pearson’s Chi Square tests. For each variable, 
the number of cases and proportions within each group are reported.    
 
3.2.6.3 Logistic regression analyses 
Associations between potential risk factors and postpartum psychiatric outcome were 
further assessed in binary logistic regression models (using the enter method) with No 
PME/PP as the outcome variable. Each model was adjusted for demographic and 
lifetime clinical variables that significantly differed between groups in univariate 
analysis.  
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3.3 Results 
3.3.1 Adverse childhood life events and postpartum psychosis 
3.3.1.1 Demographics 
Table 3.1 summarises the demographic characteristics of women in the sample 
according to postpartum psychiatric outcome. Women in the PP group were 
significantly younger at interview (median 47 years vs 52 years respectively, p<0.001), 
more likely to have completed further education (defined as achieving equivalent to A-
Level qualifications or above; 73.1%, n=141/193 vs 59.2%, n=129/218 respectively, 
p=0.003) and be recruited non-systematically (75.9%, 158/207 and 62.9%, n=141/224 
respectively, p=0.003) compared with women in the No PME group.  
 
 Table 3.1: Demographic characteristics according to postpartum psychiatric outcome in the ACEs subset 
of parous women with BD-I in the BDRN retrospective sample (n=432) 
                                                                                                                                                                               
Ns differ due to unknown data. BD-I: Bipolar I disorder, No PME: No lifetime history of any perinatal mood episode, 
PP: Lifetime history of postpartum psychosis. a Further education defined as equivalent to A-Level qualification or 
above. b Pearson’s Chi-Square or Mann Whitney-U test.  
 
 
3.3.1.2 Lifetime clinical features 
As shown in Table 3.2, women in the PP group were significantly younger at age of 
illness onset (median 23 years; defined as age at first impairment due to BD illness) 
compared to women in the No PME group (27 years, p<0.001). While women in the PP 
 
 
 
Demographic 
PP 
(n=208) 
No PME 
(n=224) 
 
Test  
statistic 
 
p- valueb 
Age at interview (years) 
Median (IQR) 
Range 
 
47 (16) 
21-79 
 
52 (16) 
24-73 
 
U= 18519.000, 
 Z = -3.685 
 
 
<0.001 
 
Education  
No further education 
Further educationa 
 
52 (26.9%) 
141 (73.1%) 
 
89 (40.8%) 
129 (59.2%) 
 
χ2 (1) 8.754 
 
 
0.003 
Method of Recruitment 
Non-systematic    
                 Systematic 
                      
 
158 (75.9%) 
50 (24.1%) 
 
141 (62.9%) 
83 (37.1%) 
 
 
χ2 (1) 8.574 
 
0.003 
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group had on average experienced significantly fewer episodes of depression per illness 
year (0.21 episodes) compared to the No PME group (0.28 episodes, p=0.039), there 
was no significant difference between the PP and No PME groups in the average 
number of episodes of mania per illness year (0.25 and 0.23 episodes respectively, 
p=0.452). 
 
 
Table 3.2: Lifetime clinical characteristics according to postpartum psychiatric outcome in the ACEs 
subset of parous women with BD-I in the BDRN retrospective sample (n=432) 
 
BD-I: Bipolar I disorder, No PME: No lifetime history of any perinatal mood episode, PP: Lifetime history of 
postpartum psychosis.  bMann Whitney-U test.  
 
 
 
3.3.1.3 Lifetime perinatal characteristics 
Table 3.3 summarises lifetime perinatal characteristics of the sample within the PP and 
No PME groups. Women in the PP group were significantly older at the age of their first 
pregnancy (median 27 years) compared to women in the No PME group (median 24.5 
years, p=0.019). However, the median number of deliveries did not statistically differ 
between women in the PP (2) and No PME groups (2, p=0.561). 
 
 
 
 
 
 
Lifetime clinical characteristic 
PP 
(n=208) 
No PME 
(n=224) 
Test  
statistic 
p- valueb 
Age at illness onset (years) 
                  Median (IQR) 
                  Range 
 
23 (10) 
10-39 
 
27 (17) 
10-45 
 
U= 18092.000, 
 Z = -4.016 
 
<0.001 
 
Number of episodes of mania per 
illness year (avg.) 
Median (IQR) 
Range 
 
 
0.25 (0.32) 
0.04-3.16 
 
 
0.23 (0.34) 
0.02-10.87 
 
 
U=20701.500, 
 Z = -0.753 
 
 
 
0.452 
Number of episodes of depression per 
illness year (avg.) 
Median (IQR) 
Range 
 
 
0.21 (0.42) 
0-6.10 
 
 
0.28 (0.43) 
0-10.87 
 
 
U= 16677.500, 
 Z = -2.064 
 
 
 
0.039 
 
 
 67 
Chapter 3 ACEs, anxiety and PP 
Table 3.3: Lifetime perinatal characteristics according to postpartum psychiatric outcome in the ACEs 
subset of parous women with BD-I in the BDRN retrospective sample (n=432) 
 
 
BD-I: Bipolar I disorder, No PME: No lifetime history of any perinatal mood episode, PP: Lifetime history of 
postpartum psychosis.  bMann Whitney-U test.  
 
 
 
3.3.1.4 Adverse childhood experiences 
Figure 3.4 shows the proportion of women in the PP and No PME groups who 
experienced each non-abuse ACE. As shown in Table 3.4, unadjusted comparisons 
between the groups revealed women in the PP group were not significantly more likely 
to experience any of the following non-abuse related ACEs compared to women in the 
No PME group (proportions are presented respectively); death of a parent (7.7%, 
n=16/207 vs 9.8%, n=22/224, p=0.444, OR 0.77 95% CI 0.39-1.51), death of a sibling 
(5.3%, 11/207 vs 4.5%, n=10/224, p=0.682, OR 1.20 95% CI 0.50-2.89), death of a close 
friend (9.7%, n=20/207 vs 9.4%, n=21/224, p=0.919, OR 1.03 95% CI 0.54-1.97), divorce 
or separation of parents (17.9%, n=37/207 vs 14.4%, n=32/222, p=0.330, OR 1.29 95% 
CI 0.77-2.17) and a serious physical illness requiring hospitalisation (17.9%, n=37/207 vs 
21%, n=47/224, p=0.416, OR 0.82 95% CI 0.51-1.32). 
 
 
 
Lifetime perinatal characteristic 
PP 
(n=208) 
No PME 
(n=224) 
Test  
statistic 
p- valueb 
Age at 1st pregnancy (years) 
Median (IQR) 
                  Range 
 
27 (5) 
19-38 
 
24.5 (7) 
13-38 
 
U= 873.000, 
 Z = -2.342 
 
 
0.019 
 
Number of deliveries 
Median (IQR) 
                  Range 
 
2 (1) 
1-9 
 
2 (1) 
1-6 
 
U= 22395.000, 
 Z = -0.581 
 
 
0.561 
 
 
  
6
8
 
      
ACE: Adverse childhood experience; Bars represent 95% confidence intervals
Figure 3.4: Prevalence of each non-abuse ACE according to postpartum psychiatric outcome in the ACEs subset of parous women with BD-I in the BDRN 
retrospective sample (n=432) 
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Table 3.4: Prevalence of non-abuse ACEs according to postpartum psychiatric outcome in the ACEs 
subset of parous women with BD-I in the BDRN retrospective sample (n=432) 
 
Ns differ due to unknown data. ACEs: Adverse childhood experiences, BD-I: Bipolar I disorder, No PME: No lifetime 
history of any perinatal mood episode, PP: Lifetime history of postpartum psychosis. b Pearson’s Chi-Square  
 
Figure 3.5 shows the proportion of women in the PP and No PME groups who 
experienced any and each type of abuse during childhood.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                  ACE: Adverse childhood experience; Bars represent 95% confidence intervals     
 
 
 
Type of non-abuse ACE 
PP 
(n=208) 
No PME 
(n=224) 
 
Test  
statistic 
 
p- valueb 
Death of a parent 
Yes  
No 
 
16 (7.7) 
191 (92.3%) 
 
22 (9.8) 
202 (90.2%) 
 
χ2 (1) 0.586 
 
 
0.444 
 
Death of a sibling 
Yes 
No 
 
11 (5.3%) 
196 (94.7%) 
 
10 (4.5%) 
214 (95.5%) 
 
χ2 (1) 0.168 
 
 
0.682 
Death of a close friend 
Yes 
No                     
 
20 (9.7%) 
187 (90.3%) 
 
21 (9.4%) 
203 (90.6%) 
 
χ2 (1) 0.010 
 
0.919 
Divorce/separation of parents 
Yes 
No                    
 
37 (17.9%) 
170 (82.1%) 
 
32 (14.4%) 
190 (85.6%) 
 
χ2 (1) 0.950 
 
0.330 
Serious physical illness requiring 
hospitalisation 
Yes 
                  No 
 
 
37 (17.9%) 
170 (82.1%) 
 
 
47 (21.0%) 
177 (79.0%) 
 
 
χ2 (1) 0.662 
 
 
0.416 
Figure 3.5: Prevalence of childhood abuse according to postpartum psychiatric outcome in the ACEs subset of 
parous BD-I women in the BDRN retrospective sample (n=432) 
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Compared to the No PME group, women in the PP group were not significantly more 
likely to experience the following types of childhood abuse (see Table 3.5): any form of 
childhood abuse (defined as any emotional, physical or sexual abuse, 19.5%, n=38/195 
vs 13.6%, n=29/214, p=0.416, OR 1.54 95% CI 0.91-2.61), emotional abuse (3.4%, 
n=7/208 vs 3.6%, n=8/224, p=0.907, OR 0.94 95% CI 0.34-2.64), physical abuse (7.7%, 
n=15/195 vs 5.6%, n=12/214, p=0.396, OR 1.403 95% CI 0.64-3.08) or sexual abuse 
(13.3%, n=26/195 vs 7.9%, n=17/214, p=0.076, OR 1.78 95% CI 0.94-3.40). 
 
 
Table 3.5: Prevalence of each type of childhood abuse according to postpartum psychiatric outcome in 
the ACEs subset of parous women with BD-I in the BDRN retrospective sample (n=432) 
Ns differ due to unknown data. ACEs: Adverse childhood experiences, BD-I: Bipolar I disorder, No PME: No lifetime 
history of any perinatal mood episode, PP: Lifetime history of postpartum psychosis. b Pearson’s Chi-Square  
 
 
To examine whether a dose-response relationship existed between ACEs and the 
occurrence of PP, the median total number of ACEs was further compared between the 
PP and No PME groups. The number of ACEs did not significantly differ between the two 
groups (median of one ACE, range 0-4, p=0.561). 
 
 
 
 
Type of childhood abuse  
PP 
(n=208) 
No PME 
(n=224) 
 
Test  
statistic 
 
p- valueb 
Any abuse 
Yes  
No 
 
38 (19.5%) 
157 (80.5%) 
 
29 (13.6%) 
185 (86.4%) 
 
χ2 (1) 0.662 
 
 
0.416 
 
Emotional abuse 
Yes 
No 
 
7 (3.4%) 
201 (96.6%) 
 
8 (3.6%) 
216 (96.4%) 
 
χ2 (1) 0.014 
 
 
0.907 
Physical abuse 
Yes 
No 
                      
 
15 (7.7%) 
180 (92.3%) 
 
12 (5.6%) 
202 (94.4%) 
 
 
χ2 (1) 0.719 
 
0.396 
Sexual abuse 
Yes 
No 
                      
 
26 (13.3%) 
169 (86.6%) 
 
17 (7.9%) 
197 (92.1%) 
 
 
χ2 (1) 3.150 
 
0.076 
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3.3.1.5 Multivariate binary logistic regression models 
After controlling for clinical and demographic factors found to significantly differ 
between women in the PP and No PME groups in univariate analyses (age at interview, 
education, method of recruitment, age at illness onset, average number of episodes of 
depression per illness year and age at first pregnancy), there remained no significant 
association between history of any ACE (including each subtype of childhood abuse) and 
the occurrence of PP (see Table 3.6 for adjusted p-values and odds ratios).  
 
Table 3.6: Unadjusted and adjusted odds ratios for ACEs according to postpartum psychiatric outcome in the ACEs 
subset of parous women with BD-I in the BDRN retrospective sample (n=432) 
 
ACE: Adverse childhood experience; 95% CI: 95% confidence intervals, OR: Odds ratio, *Adjusted for age at interview, 
education, method of recruitment, age at onset of impairing BD, average number of episodes of depression per 
illness year and age at first pregnancy.  
 
 
 
 
Unadjusted 
 
Adjusted* 
 
 
ACE 
p value OR (95% CI) 
 
p value OR (95% CI) 
Death of a parent 0.444 0.77 (0.39-1.51) 
 
0.479 0.74 (0.33-1.69) 
Death of a sibling 0.682 1.20 (0.50-2.89) 
 
0.401  1.70 (0.50-5.83) 
Death of a close friend 0.919 1.03 (0.54-1.97) 
 
0.944 1.00 (0.45-2.20) 
Divorce/separation of parents 0.330 1.29 (0.77-2.17) 
 
0.094 1.76 (0.91-3.40) 
Serious illness requiring 
hospitalisation 
0.416 0.82 (0.51-1.32) 
 
0.949 1.02 (0.55-1.88) 
Any abuse 0.105 1.54 (0.91-2.62) 
 
0.168 1.60 (0.82-3.10) 
Emotional abuse 0.907 0.94 (0.34-2.64) 
 
0.485 0.62 (0.16-2.36) 
Physical abuse 0.396  1.40 (0.64-3.08) 
 
0.617 1.29 (0.48-3.49) 
Sexual abuse 0.076 1.78 (0.94-3.40) 
 
0.063 2.12 (0.96-4.67) 
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3.3.2 Lifetime anxiety disorders and postpartum psychosis 
3.3.2.1 Demographics 
Table 3.7 summarises the demographic characteristics of women in the anxiety subset 
according to postpartum psychiatric outcome. Women in the PP group were 
significantly younger at interview (median 47 years vs 51 years respectively, p<0.001) 
and more likely to have completed further education (77.5%, n=117/151 vs 61.9%, 
n=99/160 respectively, p=0.003) compared with women in the No PME group. The 
method of recruitment did not significantly differ between the PP and No PME groups 
(p=0.058). 
 
 
Table 3.7: Demographic characteristics according to postpartum psychiatric outcome in the anxiety 
subset of parous women with BD-I in the BDRN retrospective sample (n=327) 
 
 
 
Demographic 
PP 
(n=162) 
No PME 
(n=165) 
 
Test  
statistic 
 
p- valueb 
Age at interview (years) 
Median (IQR) 
Range 
 
47 (18) 
21-76 
 
51 (17) 
24-73 
 
U= 10375.500, 
 Z = -3.499 
 
 
<0.001 
 
Education  
No further education 
Further educationa 
 
34 (22.5%) 
117 (77.5%) 
 
61 (38.1%) 
99 (61.9%) 
 
χ2 (1) 8.921 
 
 
 0.003 
Method of Recruitment 
Non-systematic    
                  Systematic 
                      
 
126 (77.8%) 
36 (22.2%) 
 
113 (68.5%) 
52 (31.5%) 
 
 
χ2 (1) 3.589 
 
 0.058 
Ns differ due to unknown data. BD-I: Bipolar I disorder, No PME: No lifetime history of any perinatal mood episode, 
PP: Lifetime history of postpartum psychosis. a Further education defined as equivalent to A-Level qualification or 
above. b Mann Whitney-U or Chi-Squared test.  
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3.3.2.2 Lifetime clinical features 
As shown in Table 3.8, women in the PP group were significantly younger at the age of 
onset of BD compared with women in the No PME group (median 23 years vs 26 years 
respectively, p<0.001). The median (average) number of episodes of mania or 
depression per illness year did not significantly differ between the two groups (p=0.931 
and p=0.079 respectively). 
 
 
Table 3.8: Lifetime clinical characteristics according to postpartum psychiatric outcome in the anxiety 
subset of parous women with BD-I in the BDRN retrospective sample (n=327) 
BD-I: Bipolar I disorder, No PME: No lifetime history of any perinatal mood episode, PP: Lifetime history of 
postpartum psychosis. a Mann Whitney-U test. 
 
 
 
 
3.3.2.3 Lifetime perinatal features 
Women in the PP group were significantly older at age of first pregnancy compared to 
women in the No PME group (median age of 27 years vs 25 years, p<0.001, Table 3.9). 
The lifetime number of deliveries did not significantly differ between the two groups 
(p=0.523). 
 
 
 
 
Lifetime clinical characteristic 
PP 
(n=162) 
No PME 
(n=165) 
Test  
statistic 
p- valuea 
Age at illness onset (years) 
                  Median (IQR) 
                  Range 
 
23 (10) 
10-39 
 
26 (16.3) 
10-45 
 
U= 10629.000, 
 Z = -3.203 
 
<0.001 
Number of episodes of mania per 
illness year (avg.) 
Median (IQR) 
Range 
 
 
0.22 (0.32) 
0.04-3.16 
 
 
0.24 (0.36) 
0.03-4.18 
 
 
U=12176.000, 
 Z = -0.86 
 
 
 
0.931 
Number of episodes of depression per 
illness year (avg.) 
Median (IQR) 
Range 
 
 
0.21 (0.41) 
0-6.10 
 
 
0.30 (0.48) 
0-5.30 
 
 
U= 9381.500, 
 Z = -1.759 
 
 
 
0.079 
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Table 3.9: Lifetime perinatal characteristics according to postpartum psychiatric outcome in the anxiety 
subset of parous women with BD-I in the BDRN retrospective sample (n=327) 
BD-I: Bipolar I disorder, No PME: No lifetime history of any perinatal mood episode, PP: Lifetime history of 
postpartum psychosis. a Mann Whitney-U test. 
 
 
3.3.2.4 Lifetime anxiety disorders 
Figure 3.6 shows the proportion of women with a lifetime history of each type of 
anxiety disorder. Compared to the No PME group, women in the PP group were not 
significantly more likely to report a lifetime history of the following anxiety disorders  
 
Figure 3.6: Prevalence of lifetime anxiety disorders according to postpartum psychiatric outcome in the 
anxiety subset of parous women with BD-I in the BDRN retrospective sample (n=327) 
 
 
 
 
 
 
 
 
 
 
 
           
Bars represent 95% confidence intervals     
 
 
 
Lifetime perinatal characteristic 
PP 
(n=162) 
No PME 
(n=165) 
Test  
statistic 
p- valuea 
Age at 1st pregnancy (years) 
Median (IQR) 
                  Range 
 
27 (8) 
18-41 
 
25 (7) 
16-39 
 
U= 8430.500, 
 Z = -4.465 
 
 
<0.001 
 
Number of deliveries 
Median (IQR) 
                  Range 
 
2 (1) 
1-9 
 
2 (1) 
1-6 
 
U= 12703.000, 
 Z = -0.639 
 
 
0.523 
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(see Table 3.10): any anxiety disorder (72.8%, n=118/162 vs 66.9%, n=109/163, 
p=0.241, OR 1.33 95% CI 0.83-2.14), phobic disorder (13.3%, n=14/105 vs 10.3%, 
n=12/116, p=0.491, OR 1.33 95% CI 0.59-3.03) or panic disorder (58.8%, n=70/119 vs 
52%, n=64/123, p=0.288, OR 1.32 95% CI 0.79-2.19). 
 
 
Table 3.10: Prevalence of each type of anxiety disorder according to postpartum psychiatric outcome in 
the anxiety subset of parous women with BD-I in the BDRN retrospective sample (n=327) 
BD-I: Bipolar I disorder, No PME: No lifetime history of any perinatal mood episode, PP: Lifetime history of 
postpartum psychosis. a Pearson chi-square test 
 
 
3.3.2.5 Multivariate binary regression models  
After controlling for clinical and demographic factors found to significantly differ 
between women in the PP and No PME groups in univariate analyses (age at interview, 
education, age at onset of impairing BD and age at first pregnancy), there remained no 
significant association between history of any lifetime anxiety disorder (including 
specifically phobia and panic disorder) and the occurrence of PP (see Table 3.11 for 
adjusted and unadjusted odds ratios). 
 
 
 
 
 
Type of anxiety disorder  
PP 
(n=162) 
No PME 
(n=165) 
 
Test  
statistic 
 
p- valuea 
Any anxiety disorder 
Yes  
No 
 
118 (72.8%) 
44 (27.2%) 
 
109 (66.9%) 
54 (33.1%) 
 
χ2 (1) 1.374 
 
 
0.241 
 
Phobic disorder 
Yes 
No 
 
14 (13.3%) 
91 (86.7%) 
 
12 (10.3%) 
104 (89.7%) 
 
χ2 (1) 0.474 
 
 
0.491 
Panic disorder 
Yes 
No 
                      
 
70 (58.8%) 
49 (41.2%) 
 
64 (52.0%) 
59 (48.0%) 
 
 
χ2 (1) 1.129 
 
0.288 
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Table 3.11: Unadjusted and adjusted odds ratios for lifetime anxiety disorder according to postpartum 
psychiatric outcome in the anxiety subset of parous women with BD-I in the BDRN retrospective sample 
(n=327) 
 
95% CI: 95% confidence intervals, OR: Odds ratio, *Adjusted for age at interview, education, age at onset of impairing 
BD and age at first pregnancy.  
 
 
3.4 Discussion 
3.4.1 Adverse childhood experiences  
In this study, I examined the relationship between a range of ACEs and the lifetime 
occurrence of PP within a large sample of parous women with BD-I. Though women in 
the PP group were more likely to report a history of any childhood abuse and 
specifically childhood sexual abuse compared to women without a lifetime history of 
any perinatal mood episode, this difference was not statistically significant. 
Furthermore, I did not find significant associations between any other ACLE assessed or 
the total number of ACEs experienced and PP in this sample. Even after controlling for 
differences in demographic and clinical differences between the groups (including age 
at interview, education, recruitment method, age at illness onset, lifetime number of 
episodes of depression and age at first pregnancy) the type and number of ACEs did not 
significantly differ. These findings suggest that over and above any effect on course of 
illness of BD more generally, ACEs do not appear to increase vulnerability for PP.  
 
While research in this area is limited, the findings of the current study are consistent 
with those that have also found no significant association between ACEs and the 
 
Unadjusted 
 
Adjusted* 
 
 
Anxiety disorder 
p value OR (95% CI) 
 
p value OR (95% CI) 
Any anxiety disorder  0.241 1.33 (0.83-2.14) 
 
0.468 1.22 (0.72-2.08) 
Phobic disorder 0.491 1.33 (0.59-3.03) 
 
0.225  1.75 (0.71-4.33) 
Panic disorder 0.288 1.32 (0.79-2.19) 
 
0.532 1.20 (0.68-2.14) 
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occurrence of broadly defined PP among a small diagnostically heterogeneous clinical 
sample (Dowlatshahi and Paykel 1990) and among the general population in a recent 
Danish register study (Meltzer-Brody et al. 2018). Importantly however, in contrast to 
this study, neither Dowlatshahi and Paykel (1990) nor Meltzer-Brody et al. (2018) 
examined the role of childhood abuse or used a narrow definition of PP (restricted only 
to cases of mania or affective psychoses with onset within six weeks of delivery). 
Furthermore, this study is the first to examine the relationship between ACEs and PP 
specifically among a sample of women with BD (i.e. women with BD comprised both the 
case and control group for this analysis). 
 
The lack of an association between ACEs and the occurrence of PP is also consistent 
with the wider literature. To date, there is no clear evidence to suggest a role for 
adverse life events occurring during adulthood or within the 12 months prior to 
pregnancy in the occurrence of PP (Brockington et al. 1990; Dowlatshahi and Paykel 
1990; Marks et al. 1992). While these studies were based on small diagnostically 
heterogeneous samples (ranging from 12-88 women defined as cases of PP), considered 
together with the findings of the current study, this would suggest that life stressors in 
general, nor the timing of these events appear to influence risk of PP. Conversely, it has 
been reported that women with PP are somewhat less likely to report history of adverse 
life events at any time compared with control groups (Meltzer-Brody et al. 2018).  
 
In contrast to episodes of PP, previous studies have shown ACEs and in particular, 
childhood sexual abuse, to increase risk of PND (Dennis and Vigod 2013; Meltzer-Brody 
et al. 2018; Plaza et al. 2012), Furthermore, a dose-response relationship between the 
number of ACEs experienced and risk of PND has also been demonstrated (Meltzer-
Brody et al. 2018), a finding which has not been observed in relation to PP in the 
current study or in others (Meltzer-Brody et al. 2018).  These findings are consistent 
with previous literature suggesting that overall, biological factors may be more 
important in the aetiology of PP. As discussed in the introductory chapter to this thesis, 
evidence has implicated obstetric complications (Hellerstedt et al. 2013), primiparity (Di 
 
 78 
Chapter 3 ACEs, anxiety and PP 
Florio et al. 2014), genetic factors (Jones and Craddock 2001; Jones et al. 2007), 
immunological factors  (Bergink et al. 2013, 2015a) and sleep deprivation (Lewis et al. 
2018; Sharma 2003; Sharma, Smith and Khan 2004) in the aetiology and triggering of 
PP.  
 
3.4.2  Lifetime history of anxiety disorders  
To my knowledge, this research was the first to investigate whether lifetime 
comorbidity of anxiety disorders increases lifetime vulnerability to PP in women with 
BD. Even after controlling for significant differences in demographic and clinical factors 
between the PP and No PME group (age at interview, education, age at onset of 
impairing BD and age at first pregnancy), there remained no significant association 
between a lifetime history of any anxiety disorder or type of anxiety disorder (phobia or 
panic disorder) and the occurrence of PP in this sample. These findings are in contrast 
to those of PND, which has been frequently associated with a history of anxiety 
disorders, occurring both prior to (Guintivano et al. 2018) and during pregnancy (Austin, 
Tully and Parker 2007; Heron et al. 2004; Skouteris et al. 2009). If replicated, this might 
suggest that unlike PND, aetiological factors involved in determining lifetime risk of 
anxiety disorders may be less important in the pathogenesis of PP.  
 
Though evidence to suggest an association between lifetime history of anxiety disorders 
and PP is lacking, these findings do not preclude the possibility that anxiety disorders 
that have onset during the perinatal period increase risk of PP. However, given that 
anxiety disorders and PP were assessed on a lifetime basis within this sample, it was not 
possible to further examine the specific relationship between antenatal anxiety and risk 
of PP (within the same perinatal period). Studies examining the potential relationship 
between antenatal anxiety and PP are required for several reasons. As discussed in 
section 2.6.2.4 in the background chapter of this thesis, an association between 
antenatal anxiety and postpartum depression has been demonstrated (Austin, Kildea 
and Sullivan 2007; Heron et al. 2004, 2009). While the influence of anxiety during 
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pregnancy has been associated with broadly defined PP (of an affective and non-
affective nature (McNeil 1988), this has not been specifically examined in women with 
BD. Furthermore, given that the perinatal context is unique in terms of biological, 
psychological and psychosocial factors, the aetiology of anxiety disorders related to 
pregnancy and childbirth may be distinct from anxiety disorders with onset at other 
times. Evidence also suggests that anxiety disorders and BD can both be exacerbated 
and triggered by childbirth, therefore these disorders (or subtypes of these disorders) 
may share underlying aetiological factors that are specific to childbirth. 
 
3.4.3 Limitations 
The findings presented within this chapter are subject to several limitations. Firstly, all 
women were interviewed in adult life and data were obtained cross-sectionally. 
Retrospective assessment of potential risk factors may therefore have increased the 
likelihood of recall errors or bias, leading to over or underestimates of the presence of 
these factors. However, risk of recall bias may have been compensated for, given that 
women in this study were selected from the wider BDRN sample, and were not 
specifically recruited to assess the effects of anxiety or childhood trauma (or other 
psychological factors) on psychiatric outcomes. Thus, it is less likely these women were 
primed to report these factors at interview simply due to recruitment bias. 
 
It is also possible that ACEs in particular were underreported. During assessment, 
participants were not asked directly about their experiences of childhood abuse, but 
were instead required to voluntarily disclose any such history. Thus, women may have 
been less inclined to discuss these experiences freely at interview. Nonetheless, it has 
been demonstrated that disclosure of abuse is more likely when the word ‘abuse’ is not 
used in questions pertaining to childhood experiences (Thombs et al. 2006). Notably, 
self-completed questionnaires were also screened for any mention of childhood abuse 
that was not disclosed during the face-to-face interview. Furthermore, in an effort to 
obtain additional information and also remedy any sources of error or bias that may 
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result from a cross-sectional methodology, psychiatric case-notes were screened to 
supplement all data obtained at interview.  
 
A second limitation, is that despite the modest sample size, stratification of participants 
according to postpartum psychiatric outcome considerably reduced statistical power of 
subsequent analyses. This is possibly a reason I did not find a significant association 
between ACEs, and specifically childhood abuse and PP. Post-hoc power analysis based 
on published effect sizes in relation to PND in non-bipolar samples (Plaza et al. 2012) 
showed that the sample size in this study of 432 women (208 PP; 224 No PME) has 
>95% power to detect a significant (p<0.05) between-group difference in the frequency 
of childhood sexual abuse. However, based on the effect sizes I observed, a total 
minimum sample of 1018 women with BD would be required to achieve the 
recommended minimum of 80% power to detect a significant (p<0.05) between group 
difference in the frequency of childhood sexual abuse. Nevertheless, this study remains 
one of the largest to examine the relationship between ACEs and PP, and to my 
knowledge, the only study to examine these factors specifically within women with BD.  
The findings of this study therefore extend those of previous literature, providing 
further clues to the aetiological and triggering factors of a currently poorly understood 
disorder.  
 
Thirdly, I was only able to explore the relationship between a limited range of ACEs and 
anxiety disorders and PP. It is plausible that ACEs or specific anxiety disorders not 
measured within the BDRN sample (such as severe bullying or obsessive-compulsive 
disorder) play a more important role in increasing vulnerability for PP in women with 
BD. In an effort to address both the second and third limitation discussed here, future 
research should aim to replicate the current study in a larger sample of women with BD, 
whilst also examining a wider range of ACEs and anxiety disorders that are yet to be 
investigated. Fourthly, it is important to consider that women within this sample were 
all of UK/Eire white ethnicity and so the results may not be generalisable to other 
populations.  
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3.5 Importance of prospective studies for investigating risk of 
postpartum psychosis 
This study and much of the previous literature has focused on investigating risk factors 
for PP using a cross-sectional study design. While there are considerable benefits of this 
methodology (such as enabling recruitment of larger samples of women, increasing 
power of analyses and generalisability of findings), there are also several key limitations. 
As discussed in section 3.4.3, risk of recall error and bias is increased when using a 
retrospective methodology. Moreover, accurately identifying and characterising 
historical episodes of psychiatric illness becomes more challenging. For example, in the 
BDRN retrospective sample, milder episodes of perinatal recurrence of BD may be 
underreported compared with more severe episodes. Women with a history of less 
impairing postpartum recurrences of BD would therefore be more likely to be included 
in the No PME group, potentially introducing further heterogeneity within the sample. 
 
Arguably, the most important limitation of cross-sectional research is that is it not 
possible to establish causal relationships between potential risk factors and the 
outcome of interest. Due to this limitation, the nature of the relationship between 
several potential risk factors and PP remains inconclusive. For example, sleep disruption 
has been implicated in retrospective studies as a potential triggering factor of PP (Lewis 
et al. 2018; Sharma, Smith and Khan. 2004; see section 2.6.2.1 for full description). 
Nevertheless, based on cross-sectional data, it is not possible to infer whether sleep loss 
acted as a triggering factor for PP or occurred as an early onset symptom marking the 
prodromal phase of illness. Furthermore, our research group has shown risk of PP to be 
significantly higher among women with BD-I compared to BD-II (Di Florio et al., 2013; 
see section 2.5.2 for a full description). However, given that women with BD-II who 
experience an episode of postpartum mania subsequently meet diagnostic criteria for 
BD-I, risk of PP among women with BD-II may be currently underestimated. To establish 
the direction of potential relationships and determine causality, it is therefore crucial to 
identify the presence of potential risk factors during pregnancy and prior to the onset of 
PP.  
 
 82 
Chapter 3 ACEs, anxiety and PP 
In contrast to cross-sectional research, temporality can be determined using a 
prospective cohort-design. Prospective studies are also less vulnerable to limitations of 
recall error or bias, and as such, are considered the gold standard study design for 
observational research. Studies which aim to investigate risk of PP are prime candidates 
for use of a prospective methodology, given that the perinatal period offers a unique, 
narrowly defined timeframe during which we can reliably predict the event of 
childbirth. In particular, this method is ideal for assessing potential within-pregnancy 
risk factors for PP (such as antenatal anxiety and psychotropic medication use), that are 
yet to be investigated or have predominantly been examined retrospectively. The 
findings of such a study would further extend those of previous research, given that 
prospective identification of risk factors would provide stronger evidence of causality 
than cross-sectional methods. For these reasons, studies which investigate risk factors 
for PP among women with BD using a prospective follow-up methodology are required. 
 
3.6 Summary and conclusions 
In this chapter, I investigated the role of ACEs and of lifetime anxiety disorders in the 
occurrence of PP in parous women with BD-I. Even after controlling for differences in 
clinical and demographic factors, I found no association between ACEs, or lifetime 
history of anxiety disorders and PP in this sample. The lack of evidence for an 
association between ACEs and PP in BD is consistent with studies of PP that have been 
conducted in diagnostically heterogeneous samples. To my knowledge, this study is the 
first to examine the role of lifetime anxiety disorders in PP. These findings are in 
contrast to studies of PND, in which ACEs and anxiety disorders have been associated 
with an increased risk of these episodes. If replicated, this may provide further evidence 
for a distinct aetiology between PP and PND.  
 
To date, the majority of research (including this study) has investigated risk factors for 
PP using a cross-sectional study design. However, based on this methodology, it has not 
been possible to identify causal relationships between potential aetiological or 
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triggering factors and the occurrence of PP. Establishing temporality between potential 
risk factors and PP would have important clinical implications for individualising risk 
prediction of these episodes among women with BD. To address these limitations, 
prospective follow-up studies in this area are required. In particular, focus should be 
placed on investigating the influence of a range of within-pregnancy factors on risk of 
PP, which to date are yet to be investigated or have primarily been studied 
retrospectively.  
 
To further extend the findings of this thesis thus far, subsequent chapters will therefore 
focus on examining a range of within-pregnancy potential risk factors for PP among 
pregnant women with BD using a prospective follow-up design. Results of this analysis 
will be presented in Chapter 7. Chapter 4 will provide further context for this research 
by reviewing the existing literature that has investigated the risk of recurrence of BD 
during the perinatal period using a prospective methodology. 
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4.1 Overview of chapter 
In Chapter 3, I examined the relationship between potential risk factors (anxiety 
disorders and ACEs) and lifetime occurrence of PP in a large sample of parous women 
with BD. While the majority of literature has focused on investigating lifetime correlates 
of PP, relatively little is known about factors occurring within-pregnancy that may also 
influence risk of these episodes. Moreover, of within-pregnancy factors that have been 
examined, these have primarily been investigated using a retrospective methodology. 
As discussed, cross-sectional data are subject to several key methodological limitations, 
in particular recall bias and being unable to establish causal relationships between 
potential risk factors and the outcome of interest. To address these limitations, I argued 
the need for further research investigating risk factors for PP using a prospective follow-
up methodology. In this chapter, I provide context for a prospective follow-up study of 
pregnant women with BD that was conducted as part of this thesis (The BDRN 
Pregnancy Study, described and discussed in Chapters 5, 6 and 7). Literature examining 
the course of BD during the perinatal period using a prospective follow-up design will be 
reviewed, followed by a description of the aims of The BDRN Pregnancy Study.  
 
4.1.1 Literature search 
Consistent with the purpose of this literature review (and due to a paucity of 
prospective research in this area), a systematic review was not conducted. Methods 
used to search the literature outlined in Chapter 2 (see table 2.2; page 6) were also 
utilised here. The additional following search terms were used in combination with 
those highlighted in Chapter 2: pregnancy, prospective and longitudinal. Relevant 
literature was subsequently collated and summarised in the following sections of this 
chapter.  
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4.2 Prospective pregnancy studies of the perinatal period in 
bipolar disorder 
4.2.1 Recurrence of bipolar disorder during pregnancy 
As in retrospective research, estimates of antenatal recurrence vary widely across 
prospective studies, with new onset mood episodes reported to occur in between 
11.2% and 71% of women with BD (see Table 4.1; Abdel-Hay, El-Sawy and Badawy 
2011; Bergink et al. 2012; Rosso et al. 2016; Sharma, Sommerdyk and Campbell 2013; 
Viguera et al. 2007).  Recurrence during pregnancy was found to be highest among a 
Canadian sample of 89 women with BD-I and BD-II (Viguera et al, 2007), in which the 
onset of DSM-IV defined mood episodes were assessed at each trimester of pregnancy 
through to 12 months postpartum. The authors reported as many as 71% of women to 
experience at least one recurrence of BD during pregnancy. Incidence of antenatal 
recurrence was found to be considerably lower in a Danish sample of women with BD-I 
and BD-II (n=41), being identified in almost a quarter of all women (24.4%; Bergink et al. 
2012). Variation in findings are potentially due to methodological heterogeneity 
between the two studies. For example, though the proportion of women with BD-I and 
BD-II was similar in both studies (approximately two thirds of women with BD-I), in the 
Danish sample, a higher proportion of women remained on lithium prophylaxis 
throughout pregnancy (73.1% compared to 61.8% in Viguera et al.’s study). Moreover, 
women in the Danish sample were also followed up more frequently throughout 
pregnancy and therefore may have had increased opportunity to receive clinical 
intervention had symptoms emerged, subsequently reducing risk of clinically impairing 
recurrence. Cultural differences between studies may also have influenced findings. 
 
To date, few studies have examined antenatal recurrence in samples of women with 
BD-I and BD-II independently. As discussed in Chapter 3 (section 2.5.2), little is known 
regarding risk of perinatal recurrence (and factors influencing risk) across BD subtypes. 
This is poorly understood among women with BD-II in particular, given that  
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retrospective measurements are likely to underestimate recurrence in this group. Only 
one study has investigated perinatal recurrence in women with BD-II using a 
prospective follow-up design (Sharma, Sommerdyk and Campbell 2013). Sharma, 
Sommerdyk and Campbell (2013) assessed recurrence of mood disorder during 
pregnancy in 37 women with BD-II. 51% of women in this sample experienced an 
episode of illness, though episodes that had onset prior to 24 weeks of pregnancy were 
assessed retrospectively.  
 
In one of two prospective studies of women with BD-I, 83 Egyptian women were 
assessed at each trimester of pregnancy through to four weeks postpartum (Abdel-Hay, 
El-Sawy and Badawy 2011). Almost 34% of women were reported to experience the 
onset of a mood episode during pregnancy, though it was not clear how episodes of 
recurrence were defined in this sample. In the second study, compared to findings of 
other prospective research, incidence of antenatal recurrence was lower in a small 
Italian sample of 17 women with BD-I (Rosso et al., 2016). Following monthly 
assessments during pregnancy at routine clinical appointments (which continued to 12 
months postpartum), 11.2% of women were described as having experienced an 
episode of mood disorder during pregnancy. Notably however, all women remained on 
lithium, were considered clinically to be lithium responsive and were also receiving 
regular psychiatric monitoring throughout pregnancy. Women in this sample may 
therefore have had a form of BD that was especially well managed during pregnancy 
compared to those in other prospective studies.    
 
4.2.1.1 Phenomenology of mood episodes with onset during pregnancy 
Mood episodes with onset during pregnancy have been shown in all but one study 
(Bergink et al. 2012) to most frequently present as depression or a mixed affective state 
(Abdel-Hay, El-Sawy and Badawy 2011; Van Gent and Verhoeven 1992; Newport et al. 
2008; Sharma, Sommerdyk and Campbell 2013; Viguera et al. 2007). Van Gent and 
Verhoeven (1992) followed a sample of 15 women with DSM-III BD-I and BD-II recruited 
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from a preconception counselling service, through pregnancy to 12 months 
postpartum. The authors found that of 16 pregnancies to 11 women who were 
successfully followed up, three of four pregnancies affected by a recurrence were 
depressive in polarity, with only one episode presenting as mania. Similarly, in an 
American sample of 26 pregnant women with broadly defined BD (BD-I, BD-II and BD-
NOS), episodes of depression represented the majority of recurrences during pregnancy 
(68.4%), with 15.8% being comprised of mixed affective states, 10.5% mania and 5.3% 
hypomania (Newport et al., 2008). This pattern is also consistent to that found within 
other prospective studies (Abdel-Hay, El-Sawy and Badawy 2011; Viguera et al. 2007), in 
which episodes with onset during pregnancy were predominantly of depression 41.3-
57.1%  and 28.6-38.1% mixed affective states. In contrast, only 14.3-20.6% of episodes 
were found to be episodes of mania or hypomania. 
 
4.2.1.2 Factors influencing risk of recurrence during pregnancy 
Consistent with data from cross-sectional studies, when followed prospectively, a 
significant proportion of women with BD (between 42-54%) do not use any 
psychotropic medication during the course of their pregnancy (Driscoll et al. 2017; 
Sharma, Smith and Mazmanian 2006, respectively). Of 159 pregnant women with 
broadly defined BD (BD-I, BD-II and BD-NOS), more than a quarter of women (26%) who 
were using psychotropic medication at the start of their pregnancy subsequently 
discontinued all medication within the first trimester of pregnancy (Driscoll et al., 2017). 
The destabilising effect of medication withdrawal on mood during pregnancy has been 
investigated in several prospective studies, with evidence indicating that 
discontinuation of medication prior to or during pregnancy increases risk of antenatal 
recurrence in women with BD (Bergink et al. 2012; Van Gent and Verhoeven 1992; 
Newport et al. 2008; Viguera et al. 2007). In addition, discontinuation of psychotropic 
medication, and of mood stabilisers in particular, has also been associated with a 
reduced latency to illness onset (Newport et al. 2008; Viguera et al. 2007) and longer 
duration of episodes within-pregnancy (Viguera et al. 2007). As described in Chapter 2 
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(section 2.6.2.2), latency to illness onset has been shown to be more than four times 
shorter among women who discontinue mood stabilisers rapidly (within two weeks) 
compared to those who withdraw mood stabilisers more gradually (over a period of 
more than two weeks (Viguera et al. 2007).  
 
Other factors reported to be associated with antenatal recurrence include an earlier age 
at onset of BD, a BD-II diagnosis, a history of more frequent mood episodes per year 
(prior to pregnancy), reduced time since last episode and use of antidepressants or 
anticonvulsants compared to lithium (Viguera et al. 2007).  
 
4.2.1.3 Section summary 
Based on the literature thus far, discontinuation of mood stabilisers during pregnancy 
and markers of a more severe, preconception course of BD (such as an earlier age at 
onset and a history of more frequent mood episodes) may be useful indicators of 
recurrence of BD during pregnancy. Given that childbirth is an event associated with 
unique physiological and psychosocial changes, it is plausible that the pathophysiology 
of episodes triggered by childbirth differs from episodes occurring antenatally or 
unrelated to childbirth. As discussed in the background chapter of this thesis, 
prospective studies examining risk of postpartum recurrence of BD are crucial, given 
that the risk of mania or affective psychosis is significantly greater following delivery 
compared to any other time in a woman’s life. Studies examining postpartum 
recurrence of BD using a prospective methodology are discussed further below.  
 
4.2.2 Recurrence of bipolar disorder in the postpartum period 
Consistent with retrospective literature, the risk of recurrence of BD (within the same 
samples of women) has been shown to be higher following childbirth compared to 
pregnancy in several prospective studies (Bergink et al. 2012; Van Gent and Verhoeven 
1992; Rosso et al. 2016; Sharma, Sommerdyk and Campbell 2013), but not in all (Abdel-
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Hay, El-Sawy and Badawy 2011; Bergink et al. 2012). Overall estimates suggest that 
between 22-31.3% of women with BD experience the onset of at least one mood 
episode within the first 3 months of delivery (Abdel-Hay, El-Sawy and Badawy 2011; 
Bergink et al. 2012; Rosso et al. 2016), increasing to 70.3% of women within the first 
postpartum year (Sharma, Sommerdyk and Campbell 2013). As with estimates of 
recurrence during pregnancy, direct comparison of risk of postpartum mood disorders 
across BD subtypes is difficult, given that studies stratifying by diagnosis are limited and 
there is substantial heterogeneity in the temporal definition used to define the 
postpartum period. For example, Rosso et al. (2016) reported postpartum mood 
episodes to occur in 27.8% of women with BD-I within four weeks of delivery, compared 
with 31.3% in an independent sample of women with BD-I within the first three months 
(Abdel-Hay, El-Sawy and Badawy 2011). In their unique study of women with BD-II, 
Sharma, Sommerdyk and Campbell (2013) defined the postpartum period as the first 12 
months following childbirth, during which 70% of women were reported to experience 
a clinically impairing mood episode.  
 
4.2.2.1 Phenomenology of mood episodes with onset in the postpartum 
period 
In contrast to episodes with onset during pregnancy, reports regarding the clinical 
presentation of postpartum mood episodes have been inconsistent across literature. 
Several prospective studies have observed a predominance of episodes with manic 
features following delivery (PP, mixed episodes, hypomania; Abdel-Hay, El-Sawy and 
Badawy 2011; Bergink et al. 2012; Van Gent and Verhoeven 1992), particularly in cases 
with early onset within four weeks of delivery (Abdel-Hay, El-Sawy and Badawy 2011; 
Bergink et al. 2012). Conversely, a number of studies have reported episodes of 
postpartum depression to be especially frequent (Rosso et al. 2016; Sharma, Smith and 
Mazmanian 2006; Sharma, Sommerdyk and Campbell 2013; Wisner et al. 2004), despite 
in some cases restricting onset criterion to within 12 (Rosso et al. 2016) and 4 weeks of 
delivery (Sharma, Smith and Mazmanian 2006; Wisner et al. 2004). Nevertheless, of 
those studies which have directly compared the phenomenology of perinatal episodes 
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within the same sample of women, risk of PP and hypomania was higher within the first 
three months postpartum compared to pregnancy in all (Abdel-Hay, El-Sawy and 
Badawy 2011; Bergink et al. 2015a; Van Gent and Verhoeven 1992; Sharma, 
Sommerdyk and Campbell 2013) but one study (Rosso et al. 2016). In the study by 
Sharma, Sommerdyk and Campbell (2013), risk of hypomania in their sample of women 
with BD-II was three times higher in the postpartum period compared to during 
pregnancy. Notably, none of the women experienced an episode of mania or affective 
psychosis during the study period, supporting evidence from retrospective studies 
which indicate risk of PP to be considerably lower in women with BD-II than in BD-I. 
 
4.2.2.2 Predictors of recurrence of bipolar disorder in the postpartum 
period 
 Mood stabiliser prophylaxis of postpartum mood episodes 
Well-designed, cohort studies that have prospectively examined risk factors for 
postpartum recurrence of BD are scarce. Similar to studies discussed previously, the 
majority of research in this area has been limited to assessing the influence of 
psychotropic medication only, the findings of which have been inconsistent (Bergink et 
al. 2012; Driscoll et al. 2017; Sharma, Smith and Mazmanian 2006; Sharma, Sommerdyk 
and Campbell 2013; Wisner et al. 2004). While lack of efficacy of prophylactic mood 
stabilising medication during the postpartum period has been demonstrated by several 
studies (Driscoll et al. 2017; Sharma, Smith and Mazmanian 2006; Wisner et al. 2004), 
others have reported the opposite (Abdel-Hay, El-Sawy and Badawy 2011; Bergink et al. 
2012; Sharma, Sommerdyk and Campbell 2013).  
 
Wisner et al. (2004) investigated use of prophylactic sodium valproate for the 
prevention of postpartum mood episodes in a sample of 26 pregnant women with BD. 
The authors reported no significant effect of using this particular medication, finding 
that 70% of women who remained on sodium valproate experienced the onset of a 
mood episode within two weeks of delivery, compared to 73% of women not using this 
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medication. There was also no significant association between use of sodium valproate 
and time to onset of postpartum recurrence. In their study, Abdel-Hay, El-Sawy and 
Badawy 2011, found discontinuation of sodium valproate to significantly increase risk of 
any mood episode during the perinatal period, but not specifically of those with 
postpartum onset. 
 
These findings are further supported by those of Driscoll et al. (2017), in which 
symptoms of depression and mania during the first postpartum year (assessed by 
screening measures in 107 women with BD who completed follow-up) were found to be 
comparable between women who remained on prophylactic psychotropic medication 
and those who did not, suggesting that psychotropic medication had little influence on 
risk of postpartum psychopathology. Nonetheless, these findings may only be 
generalisable to women with a less severe form of BD, given that all symptoms of 
recurrence were noted to be mild in severity. This may be explained by 40% of the 
sample having a diagnosis of BD-II or BD-NOS, both of which by definition, typically 
present with a less severe illness course than BD-I or SA-BD. As discussed previously, 
these subtypes are also potentially less vulnerable to severe postpartum recurrence. 
Moreover, 30% of women recruited during pregnancy were subsequently lost to 
attrition at postpartum follow-up. It is therefore possible that women who did not 
participate at follow-up were those who experienced the onset of a severe mood 
episode following delivery.  
 
Driscoll et al.’s (2017) study is also limited by the use of brief symptom screening 
measures to assess the presence of perinatal psychopathology. These particular 
measures were not designed specifically for use within populations of women within 
the perinatal period, and as such can be less reliable due to the inclusion of items which 
assess somatic features of mood episodes (for example changes in sleep patterns or 
appetite) that are common in pregnant women or new mothers. The nature of these 
behavioural changes may therefore be misattributed by the participant (Ross et al. 
2003), potentially leading to an over or underestimation of psychopathology within this 
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sample. In addition, as perinatal psychopathology was not defined according to 
standard diagnostic criteria, it was also not possible to determine whether 
discontinuation of medication in early pregnancy specifically increases risk of severe 
postpartum mood episodes, and in particular of PP.  
 
In contrast to the findings outlined above, the efficacy of prophylactic mood stabilisers 
during the perinatal period has been demonstrated in other research. In a sample of 25 
pregnant women with BD, postpartum recurrence within the first month of delivery was 
strikingly less frequent among women using prophylactic olanzapine (18.2%), compared 
to those who were not using this medication (57.1%; Sharma, Smith and Mazmanian 
2006). Though this finding was not statistically significant, post-hoc analyses showed 
this study was considerably underpowered (at 23%) to detect this between group 
difference, thus highlighting the need for replication of this finding within in a larger 
sample of women with BD.  
 
Moreover, Sharma, Sommerdyk and Campbell (2013)  compared the severity of 
symptoms of mania and depression (indicated by scores from screening measures) 
between BD-II women who were not taking any psychotropic medication and women 
that were. The authors reported severity of mood symptoms to be significantly greater 
at three months postpartum among women who were not using psychotropic 
medication. Importantly however, the authors did not restrict their definition of 
psychotropic medication use to mood stabilisers only, also including women who were 
receiving antidepressant or anxiolytic monotherapy which has been shown to increase 
risk of recurrence of BD during the perinatal period (Viguera et al. 2007). 
 
Bergink et al. (2012) found that among the 41 women with BD in their sample, 
compared to those who remained on lithium, discontinuation of lithium was associated 
with a significantly increased risk of any DSM-IV mood episode within the first 
postpartum month (7.7% vs 20%). Furthermore, despite treatment and subsequent 
maintenance with mood stabilisers, antenatal recurrence was associated with a 14 
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times greater risk of postpartum recurrence, with 60% of women who experienced a 
mood episode during their pregnancy also becoming clinically unwell following delivery. 
Within the same study, the effect of lithium prophylaxis was also examined in a 
separate sample of 29 pregnant women with a history of PP only (i.e. women who had 
never experienced any episodes of mood illness unrelated to childbirth). Interestingly, 
unlike women in the BD group, none of the women with a history of PP experienced an 
episode of mood illness during pregnancy, despite all remaining medication free. At 
follow-up however, 44% of women who discontinued all medication experienced a 
mood episode postpartum, compared to none of the women who commenced lithium 
immediately following delivery. This suggests that lithium may be less effective at 
preventing postpartum mood episodes among women with BD than those with a 
history of PP only. Thus, despite phenotypic similarities between the two groups of 
women, the pathophsiology and triggering of postpartum mood episodes is potentially 
distinct across these sub-groups.  
 
 Non-medication related risk factors for postpartum recurrence 
Despite emerging evidence suggesting efficacy of mood stabilising medication for the 
prophylaxis of postpartum mood episodes, findings within the literature also suggest 
that risk of postpartum recurrence in women with BD remains high despite medication 
use. This potentially indicates that factors other than medication are also likely to 
influence risk of episodes following childbirth within women with BD. Currently, only 
one prospective study has examined medication and a range of non-medication related 
factors that may influence risk of postpartum recurrence of BD (Abdel-Hay, El-Sawy and 
Badawy, 2011). Potential risk factors investigated in this study (in addition to 
psychotropic medication use) included pre-pregnancy clinical characteristics of BD and 
obstetric complications. Though other within-pregnancy potential risk factors (such as 
social support or sleep disruption) were not explored. In this sample, risk of postpartum 
recurrence was significantly greater among women who had a younger age at onset of 
BD, experienced more frequent mood episodes during pregnancy, experienced an 
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increased number of psychiatric hospitalisations prior to pregnancy, a reduced time 
since last episode and obstetric complications during delivery. 
 
However, the findings of this study are subject to several limitations. For example, it 
was not clear how perinatal recurrence was assessed in this sample and whether 
standard diagnostic criteria were used to define episodes of recurrence. Furthermore, it 
was not clear how use of psychotropic medication use defined. Specifically, the timing 
of medication use was not specified (i.e. during pregnancy and/or postpartum) and it is 
unknown whether the medication group only included women who were using 
medication prophylactically. Finally, factors previously implicated in postpartum 
recurrence of BD (such as previous history of PP or primiparity) were not adjusted for, 
or risk factors for PP specifically assessed. 
 
4.3 Summary 
Following a review of the literature, it is evident that prospective pregnancy studies of 
the perinatal period in women with BD are lacking. Those which have been conducted 
have been limited by use of a descriptive methodology (Van Gent and Verhoeven 1992; 
Viguera et al. 2007), small unrepresentative samples (ranging from 15-83 women, with 
the exception of Driscoll et al. 2017), heterogeneity in the definition of the postpartum 
period (from 4 weeks to 12 months postpartum) and lack of standardised diagnostic 
criteria to define episodes of recurrence (Abdel-Hay, El-Sawy and Badawy 2011; Driscoll 
et al. 2017; Van Gent and Verhoeven 1992; Rosso et al. 2016). Consequently, estimates 
of perinatal recurrence vary widely between studies, with little known regarding risk of 
perinatal recurrence and specifically postpartum recurrence across BD subtypes.   
 
Furthermore, prospective studies investigating potential risk factors for postpartum 
mood disorders in BD have primarily focused on examining the influence of a limited 
range of psychotropic medications, none of which have specifically been assessed in 
relation to PP. The role that other potential risk factors, specifically those occurring 
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within the perinatal period may have in the occurrence of PP in BD therefore remains to 
be investigated. Moreover, no prospective pregnancy studies in this area have been 
conducted in a UK population of women with BD.  
 
4.4 Further aims of this thesis  
In addition to investigating potential lifetime correlates of PP (the findings of which 
were presented and discussed in Chapter 3), a further aim of this thesis was to examine 
potential within-pregnancy risk factors for PP in BD using a prospective follow-up 
design. Few within-pregnancy risk factors for PP have been examined using a 
prospective methodology, and/or within a UK population, using standardised diagnostic 
criteria or by comparison with an appropriate diagnostic control group. To address the 
gaps identified within the literature, this study (The BDRN Pregnancy Study) aimed to 
examine the influence of a wide-range of within-pregnancy factors for PP in a UK 
sample of pregnant women with well-defined BD, using a prospective follow-up design.   
 
Specifically, the current study aimed to: 
 
1. Describe psychotropic medication use and psychiatric outcomes across the 
perinatal period within the BDRN pregnancy sample (this step would allow 
further phenotypic refinement of perinatal psychiatric outcomes to effectively 
address Aim 2). 
 
2. Investigate a wide range of within-pregnancy potential risk factors for PP within 
the BDRN pregnancy sample (differences observed in the occurrence of PP 
according to the presence or absence of within-pregnancy factors would identify 
factors that potentially influence risk of these episodes). 
 
The following chapter (Chapter 5) describes the methods used within the BDRN 
Pregnancy Study, following which the results of investigations conducted to address the 
aims outlines above will be reported and discussed in Chapters 6 and 7.
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5.1 Overview of chapter 
As discussed in previous chapters of this thesis, research identifying factors influencing 
risk of PP are crucial for individualised risk prediction of these episodes within BD. 
Prospective follow-up studies allow for directional relationships between predictors and 
illness outcomes to be established and as such are considered the gold standard of 
observational research. Nevertheless, there is a paucity of prospective research 
investigating potential risk factors for PP in BD. For these reasons, risk of recurrence 
during the perinatal period was assessed using a prospective-follow up design in 106 
pregnant women with a pre-conception diagnosis of BD.  
 
This chapter focuses on the methods of recruitment and assessment utilised within this 
study. First, an outline of the study design, details of ethical approval and inclusion 
criteria are described, followed by a summary of approaches used to maximise the 
identification and recruitment of women with BD during pregnancy. Detailed 
descriptions of clinical assessments conducted across the perinatal period are also 
documented and approaches to the statistical analysis of potential risk factors for 
episodes of postpartum recurrence are presented.  
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5.2 Design 
This study utilised a prospective follow-up design. Potential risk factors for postpartum 
mood episodes were assessed at baseline during pregnancy in women with a lifetime 
history of BD. Follow-up measures were conducted at three months postpartum to 
assess the occurrence of perinatal psychopathology. The follow-up period was defined 
in accordance with the literature indicating the first three postpartum months to be the 
period of greatest risk for severe recurrence of mood episodes.  
 
Baseline assessments conducted during pregnancy consisted of: 
 A semi-structured psychiatric research interview to assess pre-conception 
lifetime history of perinatal and non-perinatal psychopathology. 
 
 An interview completed during the third trimester to assess the presence or 
absence of a range of potential risk factors for postpartum recurrence in the 
current perinatal period.   
 
Postpartum follow-up assessments included: 
 A postal questionnaire completed by the participant’s General Practitioner (GP) 
and/or psychiatrist at two months postpartum. 
 
 A semi-structured telephone interview with the participant at three months 
following their expected delivery date to assess the presence or absence of 
psychopathology within the current postpartum period.  
 
Psychiatric case-notes were also reviewed at three months postpartum to supplement 
all data gathered at each assessment. Figure 5.1 provides an overview of the study 
design. 
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Figure 5.1 Flow chart summarising the timing of assessments conducted in The BDRN Pregnancy Study 
 
5.3 Ethical approval  
This study received a favourable Multi region Research Ethics Committee (MREC) 
opinion for conduct in the NHS and received local Research and Development approval 
in 9 Health Boards and NHS Trusts nationwide (MREC 97/07/001, amendment AM04). 
Participants were provided with a Participant Information Sheet (Appendix D) and 
written consent was obtained prior to participation (Appendix E). 
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5.4 Inclusion criteria 
Women were included in the current study if they: 
a) met DSM-5 criteria for lifetime BD  
b) were at least 18 years of age 
c) were at least 12 weeks pregnant.  
 
5.5 Recruitment 
To maximise the identification and recruitment of women with BD during pregnancy, a 
combination of different recruitment methods was employed. A summary of systematic 
and non-systematic methods of recruitment is provided in this section and in Figure 5.2. 
 
5.5.1 Systematic approach 
5.5.1.1 NHS perinatal mental health services 
The majority of women were recruited to the BDRN Pregnancy Study via NHS perinatal 
psychiatric services across the UK. Figure 5.3 summarises recruitment within each 
perinatal service involved in this study. Perinatal psychiatric services were selected 
within Trusts and Health Boards in which BDRN either had existing or historical ethical 
approval or contact with clinicians interested in facilitating recruitment. In NHS Trusts 
and Health Boards in which perinatal services are available, ideally all women with a 
history of BD or PP are referred for specialist psychiatric care during pregnancy. Women 
who met the study inclusion criteria (n=64) were identified by members of the perinatal 
psychiatric team or NHS Clinical Studies Officers (CSOs) during the referral process or via 
attendance at outpatient clinic appointments. Eligible women were approached by their 
clinician or a CSO and asked if they would be interesting in receiving further information 
about the study from a member of the BDRN study team. Of those who expressed an 
interest in the study, 39 (61%) women subsequently participated.  
                                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Flow chart summarising methods of recruitment of women to The BDRN Pregnancy Study 
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5.5.1.2 Cardiff University Psychiatry Service (CUPS) 
The CUPS clinic is a free second opinion psychiatry service run jointly by Cardiff 
University and Cardiff and Vale University Health Board. Within this service Professor 
Ian Jones operates a specialist perinatal clinic for women with BD. Women seeking 
further advice while in the stages of planning a pregnancy, or during their pregnancy 
may be referred to CUPS via their psychiatric team. This service is typically utilised by 
women who do not have access to specialist perinatal psychiatric services in their local 
area. Through CUPS, Professor Ian Jones identified 14 women who were eligible for 
participation in the study and asked if they would be interested in receiving further 
information. 11 (79%) of these women subsequently participated in the study.  
Figure 5.3:  Perinatal mental health services involved in the recruitment of women to The BDRN 
Pregnancy Study 
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5.5.2 Non-systematic approach 
5.5.2.1 BDRN website 
Information about the BDRN Pregnancy Study was provided on the BDRN website 
(www.BDRN.org), along with downloadable participant information leaflets (see 
Appendix F) and contact details for the study team. Women who had received initial 
information about the study via advertisements or news broadcasts in local or national 
media were directed to the BDRN website for further information. 25 women expressed 
an interest in the study via the BDRN website, of whom 20 (80%) participated.  
 
5.5.2.2 National patient support groups 
Adverts were placed on the websites of the national patient support charities APP and 
Bipolar UK. Articles were also produced for Bipolar UK’s quarterly magazine, Pendulum, 
which was distributed to all subscribing members. Participant information leaflets were 
distributed at patient support group meetings attended by myself or other members of 
the Mood Disorders Research Group.  
 
In collaboration with Bipolar UK, Professor Ian Jones, Clare Dolman (Vice Chair of 
Bipolar UK) and I also organised a series of information workshops for women with BD 
seeking advice about pregnancy and childbirth. Workshops were organised as a session 
within the Bipolar UK annual conference held in the summer of 2015 and as a stand-
alone session in summer 2016. Women planning pregnancy or those pregnant at the 
time of the workshop were provided with information and invited to participate. 15 
women expressed an interest in the study after receiving information via their support 
group, of whom 10 (66%) participated. 
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5.5.2.3 BDRN participant newsletter 
All participants involved in the BDRN programme of research were sent an annual 
research newsletter by post, informing them of study updates and advertising current 
projects, including the BDRN Pregnancy Study. 33 women involved in BDRN responded 
to study adverts included in the newsletters, of whom 26 (79%) subsequently 
participated. 
 
5.6 Participants 
As shown in Figure 5.2, 151 women expressed an interest in participating in this study 
and were screened by telephone to confirm eligibility (see appendix G). Despite their 
initial interest, 28 women did not respond to further contact, a further 13 later declined 
to participate following the telephone screen and two women did not meet diagnostic 
inclusion criteria. An additional two women unfortunately miscarried prior to 
completing the baseline semi-structured interview. Though women were not asked to 
provide an explanation for refusal to participate in the study, reasons volunteered 
included having too many commitments during pregnancy, the short length of time to 
delivery and concerns that discussing past illness experiences may increase risk of 
recurrence in the perinatal period. The final sample comprised 106 women with BD.  
 
5.7 Procedures 
All procedures and assessments utilised within this study are described below. Figure 
5.4 provides a summary of the number and proportion of women that participated in 
each stage of assessment. 
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Figure 5.4:  Flow chart summarising data collected at each assessment in The BDRN Pregnancy Study 
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5.7.1 Baseline antenatal assessments 
5.7.1.1 Semi-structured psychiatric research interview 
Once eligibility for participation in the study was confirmed, baseline semi-structured 
research interviews (Appendix H) were conducted in participant’s homes from week 12 
of pregnancy (lasting approximately 1.5-2 hours). Interviews were arranged after the 
first trimester to ensure women were beyond the period considered highest risk of 
miscarriage. A minority of women resided in Ireland (n=3) and it was not feasible to 
conduct these interviews in person. Therefore, in these cases interviews were 
completed via telephone. In total, 106 women completed the semi-structured interview 
at baseline.  
 
The semi-structured interview was used to assess lifetime psychopathology and was 
adapted from that designed and used in the BDRN programme of research (see Chapter 
3, page 53 for a full description). The baseline assessment consisted of a modified 
version of the SCAN (Wing et al., 1990) to assess lifetime occurrence of mania and 
depression, psychotic symptoms and anxiety disorders occurring prior to the current 
pregnancy.  
 
5.7.1.2 Third trimester pregnancy interview 
To assess potential predictors of postpartum recurrence present within the current 
pregnancy, an additional interview (Appendix I) informed by previous literature was 
completed in the third trimester of pregnancy (lasting approximately 10 minutes). 
Women who were less than 24 weeks pregnant at the time of the baseline semi-
structured interview subsequently completed the pregnancy interview by telephone 
once in the third trimester. This time frame was selected to capture the presence of 
potential predictors occurring within each trimester of pregnancy.  
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The third trimester interview consisted of the following measures: 
 
 SCAN (Wing et al., 1990): Relevant sections of the SCAN were used to assess the 
presence of psychopathology during the current pregnancy.  
 
 Pregnancy Risk Questionnaire (PRQ, Austin et al. 2005): Three items extracted 
from the PRQ were used to assess participant’s subjective experience of 
pregnancy and emotional support during pregnancy. Participants were asked to 
rate their experience of pregnancy on a Likert scale ranging from one indicating 
that pregnancy was ‘not at all a positive experience’ to five ‘very much a positive 
experience’. They were also asked to rate the perceived level of emotional 
support that would be provided by their partner (if applicable) and by significant 
others following the birth of their baby. Both variables were rated on a Likert 
scale from one indicating ‘not at all emotionally supportive’ to five ‘very 
emotionally supportive’.  
 
 Brief Life Events Questionnaire (BLEQ, Brugha et al., 1985): A range of 11 
adverse life events occurring during the previous six months of pregnancy were 
assessed using a modified version of the BLEQ. An open-ended question also 
asked participants ‘In the last six months, other than being pregnant, has any 
other significant event happened in your life?’ For a more detailed description of 
the BLEQ, please refer to Chapter 3, page 56. 
 
 Pittsburgh Sleep Quality Index (PSQI, Buysse et al. 1989): A closed ended 
question extracted from the PSQI was used to assess subjective experience of 
sleep quality in the third trimester of pregnancy. The PSQI is a widely used and 
well validated self-report instrument assessing sleep quality and disturbance 
over a one-month period.  Participants were asked ‘during the last month, how 
would you rate your sleep quality overall?’ Responses were coded categorically 
as ‘very good’, ‘fairly good’, ‘fairly bad’ and ‘very bad’.  
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In addition, participants were asked a series of questions about planning of the current 
pregnancy, any psychotropic medication use during the current perinatal period (in the 
six months prior to and/or during pregnancy) and any alcohol and smoking use within 
the current pregnancy. In total, 88 (83%) women completed the third trimester 
interview.  
 
5.7.2 Follow-up postpartum assessments 
Follow-up data were gathered from multiple sources in the postpartum period to 
maximise the likelihood of obtaining postpartum psychiatric outcome data and to 
corroborate information collected antenatally. These assessments are described further 
below. 
 
5.7.2.1 Clinician questionnaires 
For women who had provided explicit written consent (n=105), a postal questionnaire 
was sent to their GP (Appendix J)/and or psychiatrist (Appendix K) at two months 
following their expected delivery date. The questionnaires asked clinicians about 
participants’ use of psychotropic medication and the occurrence of any episodes of 
psychiatric illness within the current perinatal period. Questionnaires were sent at two 
months postpartum to obtain details of any adverse outcome of the pregnancy prior to 
the participant being contacted for a follow-up telephone interview at three months 
postpartum. This step was taken to avoid causing unnecessary distress to participants 
should an adverse outcome have occurred. In total, questionnaires were completed by 
the GP and/or psychiatrist for 82 (78%) women.  
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5.7.2.2 Postpartum follow-up interview 
Participants were contacted at three months following their expected delivery date for 
a telephone interview lasting approximately 20 minutes (Appendix L). The follow-up 
interview was designed to assess perinatal psychiatric outcomes, in addition to 
potential predictors of postpartum recurrence which had occurred since completion of 
the third trimester interview.  The postpartum interview comprised the following 
measures: 
 
 SCAN (Wing et al. 1990): Relevant sections of the SCAN were administered to 
obtain information about any episodes of psychiatric illness that had occurred 
during late pregnancy and/or within three months postpartum.  
 
 Psychotropic medication use: Women were asked about any changes in 
psychotropic medication use since the third trimester interview. 
 
 Smoking and alcohol use: Women were asked about any smoking or alcohol use 
in pregnancy since the third trimester interview 
 
  BLEQ (Brugha et al., 1985): The BLEQ was re-administered at postpartum 
follow-up to assess the occurrence of any adverse life events since the third 
trimester interview.  
 
Women were also asked at postpartum follow-up about a range of other factors specific 
within the current pregnancy such as sleep loss during labour and obstetric factors 
relating to pregnancy and delivery. In total, 92 (87%) women completed the follow-up 
interview. Of those women who did not complete the postpartum telephone interview, 
13 were unable to be contacted and one woman was contacted but declined to 
participate further. 
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5.7.3  Psychiatric case-note review 
For women who provided written consent, psychiatric case-notes where available were 
reviewed at three months postpartum to supplement and corroborate all data gathered 
at each assessment (n=67/103, 65%). This period was chosen so that information could 
also be gathered about any episodes of psychiatric illness occurring with onset within 
three months postpartum.  
 
5.8 Clinical Ratings 
Data gathered at each assessment were combined with psychiatric case note 
information to produce detailed, clinical vignettes. Vignettes summarised participants’ 
lifetime and perinatal psychopathology, demographic and social information, lifetime 
substance use, obstetric history and family history of psychiatric illness. From the 
vignettes, ratings were made for demographic characteristics, key lifetime psychiatric 
features, potential within-pregnancy predictors of postpartum recurrence and perinatal 
psychiatric outcome data. A summary of each variable cluster is provided below, 
followed by detailed descriptions of all variables rated.  
 
 Demographic characteristics: Ratings were made of demographic variables 
including age at baseline interview, ethnicity, relationship status, highest 
educational achievement, highest level of occupation and method of 
recruitment.  
 
 Preconception lifetime psychiatric history: Ratings were made for key lifetime 
clinical variables for the period from illness onset to conception of the current 
pregnancy. These included DSM-5 diagnoses, illness course characteristics, 
family history of postpartum mood illness and sleep loss as a trigger of affective 
episodes. 
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 Within-pregnancy potential predictors of postpartum recurrence relating to the 
current pregnancy: Ratings were made for potential predictors of postpartum 
recurrence that were specific within the current pregnancy. Variables rated 
included psychotropic medication use during the current perinatal period, 
psychopathology in pregnancy, perceived experience of pregnancy, perceived 
emotional support, substance use in pregnancy, adverse life events in the 
perinatal period, sleep quality in pregnancy, sleep loss during delivery and 
obstetric factors relating to the current pregnancy and delivery. 
 
 Perinatal psychiatric outcomes: Ratings were made for any episodes of 
psychiatric illness with onset during pregnancy and within three months of 
delivery. 
  
Table 5.1 provides an overview of the source assessment(s) from which data regarding 
potential predictors and perinatal psychiatric outcomes were obtained. 
 
 
Methodological considerations  
To ensure reliability of clinical data, Christine Fraser (CF, a research psychologist and 
senior member of BDRN) and I made independent lifetime ratings of diagnoses, key 
lifetime clinical variables and perinatal psychiatric outcomes. CF was selected as an 
independent rater for the study, due to having considerable experience of conducting 
psychiatric assessments of participants with BD and of rating lifetime clinical data and 
psychiatric diagnoses. CF and I met regularly to review all ratings and consensus was 
agreed through discussion. In cases of doubt, ratings were discussed and agreed with 
senior members of the BDRN team (Professor Ian Jones, Professor Lisa Jones and Dr 
Katherine Gordon-Smith). 
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Table 5.1: Summary of source(s) of assessment from which all data were obtained in the BDRN 
Pregnancy Study 
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5.8.1 Demographic characteristics 
Ratings were made for the following demographic variables according to definitions 
described below: 
 
 Age at interview: age at participation in the baseline semi-structured interview. 
 
 Ethnicity: rated according to the following groups; White British/White other.  
 
 Lifetime marital status: rated as a) ever married/lived as married or b) never 
married/lived as married. 
 
 Highest educational achievement: rated as a) achieving higher education level 
qualifications (defined as Advanced Level [A-Level] qualification or equivalent 
and above) or b) no higher education level qualifications (defined as General 
Certificate of Secondary Education [GSCE] or equivalent and lower).   
 
 Highest occupational status: lifetime highest occupational status was rated 
according to The International Standard Classification of Occupations (ISCO-88, 
International Labour Organisation). Responses were coded as a) having a 
lifetime history of a professional occupation (ISCO-88 groups 1-3) or b) a lifetime 
history of a non-professional occupation(s) only (all other groups). 
 
 Method of recruitment: rated as a) systematic (defined as recruitment via NHS 
Trust/Health Boards or the CUPS clinic) or b) non-systematic (all other methods).  
 
5.8.2 Preconception lifetime psychiatric history 
Key lifetime clinical characteristics for the period prior to the current pregnancy were 
rated as detailed below.  
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5.8.2.1 Lifetime psychopathology 
Best estimate DSM-5 main diagnosis:  
Ratings of best-estimate main psychiatric diagnoses were made for all participants 
according to standard operationalised diagnostic criteria of the DSM-5. In cases where 
multiple diagnoses were indicated, these were rated hierarchically according to level of 
functional impairment. The diagnosis causing the highest level of functional impairment 
was rated as the primary diagnosis. Diagnoses discussed in subsequent chapters relating 
to this study are primary diagnoses rated according to the DSM-5. 
 
Lifetime illness course characteristics: 
 
 Age at illness onset: defined as the age at which affective symptoms first caused 
impairment in daily occupation or social functioning. 
 
 History of psychotic symptoms: rated as present or absent. Presence was 
defined as a history of experiencing at least one psychotic symptom prior to the 
current pregnancy.  
 
 Number of episodes of mania/depression: defined as the number of episodes of 
mania and depression per illness year prior to the current pregnancy (calculated 
for the period between the age of onset of impairing BD and conception of the 
current pregnancy). 
 
 Family history of postpartum mood illness: rated as a) present (defined as a 
known history of postpartum mood illness among a first degree relative) or b) 
absent (no known presence of postpartum affective illness among a first degree 
relative).  
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5.8.2.2 Lifetime history of postpartum psychosis 
Lifetime history of PP (prior to the current pregnancy) was rated as present or absent.  
PP was defined as a DSM-5 episode of mania, mixed affective state or affective 
psychosis with onset within six weeks of a previous delivery. The cut-off used to define 
the postpartum period was expanded to be consistent with both DSM-5 and ICD-10 
criteria.    
 
5.8.2.3 Sleep loss as a lifetime trigger of episodes of affective illness 
Lifetime history of an affective episode triggered by sleep loss was rated as present or 
absent. Presence was defined as having a self-reported history of at least one episode 
of affective illness triggered by sleep loss.  
 
5.8.3 Potential within-pregnancy predictors of postpartum recurrence in 
the current pregnancy 
A range of factors occurring specifically within the current pregnancy was rated as 
potential predictors of postpartum recurrence. Detailed descriptions of rating 
procedures for each of these variables is provided below. 
 
5.8.3.1 Psychotropic medication use in the current perinatal period 
Data regarding psychotropic medication use during the perinatal period were highly 
complex and subject to substantial variation between participants but also across each 
individual perinatal period.  For this reason, I developed a visual timeline tool for each 
participant as a means of graphically representing this data longitudinally and simply 
across the perinatal period (Perry et al. 2017, see Appendix M for examples of perinatal 
timelines). In combination with clinical vignettes, these timelines were used as an aid 
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from which to make ratings of psychotropic medication use during the current perinatal 
period.  
 
Given the complexity of medication data, definitions of ‘prophylactic’ and of ‘mood 
stabilising medication’ (i.e. what medications would be defined as a mood stabiliser) 
were discussed and agreed through consensus with senior members of BDRN (Prof. Lisa 
Jones, Dr Katherine Gordon-Smith, Prof. Ian Jones and Dr Marisa Casanova-Dias), two of 
whom were consultant perinatal psychiatrists (Prof. Ian Jones and Dr Marisa Casanova-
Dias). Prophylactic mood stabilising medication was subsequently defined as the use of 
any medication (during the perinatal period) intended for the purpose of mood 
stabilisation, which was commenced or continued for reasons other than treatment. 
Based on clinical and research expertise, medications included in this definition were 
lithium, anticonvulsants and antipsychotics (typical and atypical). Timelines for each 
participant were subsequently reviewed and the presence/absence of prophylactic 
mood stabilising medication in the postpartum period agreed through discussion and 
consensus according to the definition described above. Specifically, ratings were made 
for the following medication related factors: 
 
 
 Use of any psychotropic medication as a mood stabiliser: rated as present or 
absent within each of the following time periods; the six months immediately 
preceding pregnancy, each month of pregnancy and each postpartum month. 
Presence included any medication used for purposes of treatment or 
prophylaxis.  
 
 Withdrawal of mood stabilising medication: rated as present or absent in 
women who were using mood stabilising medication within the six months 
immediately preceding pregnancy. Presence was defined as the discontinuation 
of all mood stabilising medication either within the six months prior to 
pregnancy or during pregnancy, which was not recommenced at any point 
during pregnancy.  
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 Use of prophylactic mood stabilising medication in the postpartum period: rated 
as present or absent. Absence was defined as use of any other psychotropic 
medication not consistent with the definition of those that were ‘mood 
stabilising’ (as outlined in section 5.8.3.1; such as antidepressants or anxiolytics) 
or no psychotropic medication. Rating were made specifically for the use of: 
a) any prophylactic mood stabilising medication (including lithium, 
anticonvulsants, typical or atypical antipsychotics) 
b) prophylactic lithium 
c) prophylactic quetiapine 
d) prophylactic olanzapine 
 
 Timing of use of prophylactic mood stabilising medication in the postpartum 
period: rated as a) use within-pregnancy which was continued into the 
postpartum or b) postpartum use only (i.e. medication was only commenced 
following delivery).    
 
5.8.3.2 Antenatal psychopathology within the current pregnancy 
 Clinically impairing symptoms of anxiety: Ratings were made for the 
presence/absence of any DSM-5 defined clinically impairing symptoms of 
anxiety disorder and specifically, the presence/absence of panic disorder and 
generalised anxiety disorder. 
 
 DSM-5 episodes of psychiatric illness within the current pregnancy: Ratings were 
made for the presence/absence, type and timing of onset of DSM-5 psychiatric 
episodes with onset during the current pregnancy.  
 
 DSM-5 worst episode of psychiatric illness within the current pregnancy: Ratings 
of individual psychiatric episodes were used to code the ‘worst’ DSM-5 
psychiatric episode with onset during pregnancy according to a hierarchy as 
indicated below Table 5.2.  
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5.8.3.3 Psychosocial factors relating to the current pregnancy 
 Planning of pregnancy: rated as planned or unplanned 
 
 Experience of the current pregnancy: Responses to the PRQ (Austin et al. 2005, 
as described in section 5.7.1.2) were collapsed to the following categories, 
indicating the experience of pregnancy to be perceived as ‘positive’ (defined as 
scores of three to five) or ‘not positive’ (defined as scores of one or two).  
 
 Partner in the current pregnancy: rated as yes or no. 
 
 Perceived emotional support from partner during current pregnancy: Among 
women who reported a partner as being present in the current pregnancy, 
responses to the PRQ item were collapsed to the following categories, indicating 
the perceived level of emotional support from their partner during pregnancy to 
be ‘very supportive’ (defined as scores of three to five) or ‘not supportive’ 
(defined as scores of one or two).  
Table 5.2 Hierarchy of rating categories for the ‘worst’ DSM-5 episode of psychiatric 
illness with onset in pregnancy within the current perinatal period in The BDRN 
Pregnancy Study 
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 Perceived emotional support from others in the current pregnancy: responses to 
the PRQ item were collapsed to the following categories, indicating the 
perceived level of emotional support during pregnancy from people other than 
their partner to be ‘very supportive’ (defined as scores of three to five) or ‘not 
supportive’ (defined as scores of one or two).  
 
 
5.8.3.4 Smoking and alcohol use during the current pregnancy 
 Smoking during the current pregnancy: Smoking of cigarettes during the current 
pregnancy was rated as present or absent.  
  
 Alcohol use during the current pregnancy: Regular alcohol use during pregnancy 
(on a weekly basis) exceeding the NHS recommended amount of 14 units per 
week, rated as present or absent. 
 
5.8.3.5 Adverse life events in the current perinatal period 
Each specified adverse life event item assessed by the BLEQ (Brugha et al. 1985) was 
rated as present or absent during the current pregnancy. Consistent with the definition 
used by Brugha et al. (1985), only events subjectively reported as being ‘moderately 
bad’ or ‘very bad’ experiences were considered sufficiently adverse to be rated as 
present.  
 
5.8.3.6 Sleep quality and loss during the current perinatal period 
Ratings were made for the following sleep variables related to the current pregnancy 
and labour: 
 
 Sleep quality in the 3rd trimester: responses to the PSQI item assessing 
perception of sleep quality in the third trimester of the current pregnancy were 
 
 125 
Chapter 5 BDRN Pregnancy Study: Methods 
coded categorically as ‘very good/fairly good’ or ‘fairly bad/very bad’ (see 
section 5.7.1.2 for a full description of the PSQI). 
 
 Any missed sleep during labour: self-reported sleep loss of any duration during 
labour was coded as present or absent.  
 
 At least one night of missed sleep due to labour: self-reported sleep loss of at 
least one complete night was rated as present or absent 
 
 Time of delivery: To enable comparisons with previous literature (Sharma et al. 
2004) the time of delivery and length of labour (in hours) were considered proxy 
measures of sleep loss during delivery. Therefore, in accordance with the 
definition used by Sharma et al. (2004), time of delivery was categorised as 
having occurred during the day (between 7:31am and 12.29pm) or night 
(between 12.30am and 7:30am).  
 
5.8.3.7 Obstetric factors relating to the current perinatal period 
Women were asked about a wide range of obstetric factors relating to the recent 
pregnancy and delivery. Ratings were made for the following variables: 
 
Pregnancy related factors 
 IVF treatment: the use of IVF treatment to facilitate conception of the current 
pregnancy was rated as present or absent.  
 
Infant related variables 
 Infant sex  
 Breastfeeding following delivery (defined as present or absent) 
 Duration of breastfeeding (defined as weeks) 
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Obstetric complications  
 Obstetric complications during pregnancy: rated as present or absent. Obstetric 
complications were defined as any maternal or infant medical condition severe 
enough to warrant treatment as an outpatient or via hospital admission.  
 
 Pre-eclampsia: rated as present or absent. Presence was defined as symptoms 
or a diagnosis of pre-eclampsia in pregnancy that warranted treatment as an 
outpatient or via hospital admission.  
 
 Obstetric complications during delivery: rated as present or absent. 
Complications were defined according to the ICD-10 (codes 60-77) and included 
the baby being breech, in distress or involved in cord accidents during labour.  
 
 Problems identified with baby at birth: rated as present or absent. Presence was 
defined as any medical condition severe enough to warrant treatment as an 
outpatient or via hospital admission within 28 days of delivery. 
 
 
Delivery factors:  
 Maternal age at delivery 
 
 Parity: rated as number of current delivery  
 
 Pre-term delivery: rated as present or absent. Consistent with the World Health 
Organisation definition, pre-term delivery was defined as any delivery occurring 
prior to 37 weeks gestation.  
 
 Induction or augmentation of labour: rated as present or absent. Presence was 
defined as history of any method or intervention used to induce or augment 
labour in the current pregnancy.  
 
 Emergency caesarean section: rated as present or absent. 
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 Assisted delivery: rated as present or absent. Presence was defined as any 
delivery requiring the use of forceps/ventouse or caesarean section.  
 
 Duration of labour: rated in hours from the onset of contractions to time of 
birth.  
 
5.8.4 Postpartum psychiatric outcomes in the current perinatal period 
Postpartum psychiatric outcome data were obtained for 103 of 106 women (97%). 
Ratings were made for the following outcomes: 
 
 DSM-5 episodes of postpartum psychiatric illness: The presence or absence and 
type of any DSM-5 episodes of psychiatric illness with onset within three months 
of the recent delivery. Episodes with onset during pregnancy that continued 
postpartum were only rated as a recurrence during pregnancy. 
 
 DSM-5 worst episode of postpartum psychiatric illness: Ratings of individual 
psychiatric episodes were used to code the ‘worst’ DSM-5 episode experienced 
within the postpartum period. For this variable, a hierarchy was used as shown 
within Table 5.3.   
 
 Timing of onset of DSM-5 episodes of postpartum psychiatric illness: The time of 
onset of DSM-5 episodes of postpartum psychiatric illness (including the worst 
episode) were rated as the number of days and/or weeks following delivery at 
which symptoms first became impairing.  
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5.9 Statistical Analysis 
All data were analysed using the statistical package SPSS version 24. As continuous data 
were non-normally distributed (as indicated by the Kolmogorov-Smirnov test), non-
parametric tests were used to assess the relationship between within-pregnancy 
potential risk factors and postpartum psychiatric outcome. All tests were deemed 
significant at a p-value of <0.05 (two-tailed). Due to the modest sample size (thus 
reducing power) and exploratory nature of the current study, corrections were not 
made for multiple testing. For this reason, significant findings were interpreted with 
caution and emphasis placed on examining trends within the data.  
 
5.9.1 Continuous Data    
Relationships between continuous data were assessed using Mann Whitney-U tests. 
Medians, range and inter-quartile ranges are therefore reported for each continuous 
variable. 
Table 5.3: Hierarchy of rating categories for the ‘worst’ DSM-5 episode of postpartum 
psychiatric illness within the current perinatal period in the BDRN Pregnancy Study 
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5.9.2 Categorical Data     
Relationships between categorical data were assessed using Pearson’s Chi Square tests. 
In cases where 20% or more of cells within a chi-square table had a cell count lower 
than the expected five; Fisher’s exact tests were used. For each variable, the number of 
cases and proportions within each group are reported.    
 
5.9.3 Logistic Regression Analyses 
Associations between potential within-pregnancy potential risk factors and postpartum 
psychiatric outcome were further assessed in two binary logistic regression models 
(using the enter method) with No PP/PP as the outcome variable. In the first, the model 
adjusted for lifetime correlates of PP as identified within the BDRN retrospective 
sample; preconception lifetime history of PP (including women who were primiparous), 
primiparity at time of conception of the current pregnancy, family history of postpartum 
affective illness in a first degree relative and sleep loss as a self-reported lifetime trigger 
for preconception episodes of mania. In the second model, use of prophylactic mood 
stabilising medication in the postpartum period was also included to investigate 
potential moderating effects of this factor on relationships between within-pregnancy 
factors and PP. 
 
Results of investigations of potential risk factors for episodes of PP within this sample 
are described and discussed further in Chapter 7. First however, patterns of 
psychotropic medication use and psychiatric outcomes within the current perinatal 
period in 103 women in the BDRN Pregnancy Sample are reported in Chapter 6.
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The BDRN Pregnancy Study: Describing psychotropic 
medication use and psychiatric outcomes across the 
perinatal period 
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6.1 Introduction 
This chapter describes 103 pregnant women with BD recruited to the BDRN Pregnancy 
Study. Demographic, preconception clinical and within-pregnancy characteristics of the 
sample are first described. This is followed by a description of patterns of psychotropic 
medication use and psychiatric outcomes during pregnancy and within the first three 
postpartum months in all women in the sample and also according to subtype of BD. 
The final part of this chapter focuses on discussion of findings in relation to the 
literature.   
 
6.2 Sample characteristics 
6.2.1 Demographics 
Table 6.1 summarises the demographic characteristics of the sample. The median age of 
women at the time of interview (and of the current pregnancy) was 34 years (range 18-
44). Women were predominantly of white ethnicity (92.2%, n=95/103) and just over 
half were recruited to the study non-systematically (52.4%, n=54/103). Most women 
had, during their lifetime married or lived as married (98.0%, n=99/101). The majority of 
the sample were educated to a degree level qualification or higher (62.1%, n=64/103) 
and had a lifetime history of working in a professional occupation (52.4%, n=54/103). 
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Table 6.1. Demographic characteristics of the BDRN pregnancy sample (n=103) 
 
aLifetime marital status unknown for two women. IQR: Interquartile range. BDRN: Bipolar Disorder Research Network 
 
 
6.2.2 Preconception lifetime clinical characteristics 
Table 6.2 summarises the key lifetime clinical characteristics of the BDRN pregnancy 
sample prior to the current pregnancy (n=103). 78.6% (n=81/103) women met DSM-5 
criteria for a main, best-estimate lifetime diagnosis of BD-I, 16.5% (n=17/103) BD-II, 
2.9% (n=3/103) SA-BD and 1.9% (n=2/103) BD-NOS. The median age of onset BD, 
defined as age of first impairment, was 20 years (range 11-36). Women had 
experienced a median number of 0.36 episodes of mania (range 0.06-3.42) and 0.47 
episodes of depression (range 0-9.81) per preconception illness year (defined as 
episodes occurring between the onset of the first impairing episode of BD to time of 
conception of the current pregnancy). Most women had a preconception lifetime 
history of psychotic symptoms (69.9%, n=72/103).  
 
 
Demographic variable 
BDRN pregnancy sample 
(n=103) 
Age at interview/pregnancy (years) 
Median (IQR) 
Range 
 
34 (6) 
18-44 
Ethnicity 
White ethnicity 
Non-white ethnicity 
 
 
95 (92.2%) 
8 (7.8%) 
Method of recruitment 
Systematic    
                 Non-systematic   
 
54 (52.4%) 
49 (47.6%) 
Lifetime marital status a 
Married/lived as married 
                 Never married/lived as married             
 
99 (98.0%) 
2 (2.0%) 
Highest education level 
Degree level qualification or higher 
                 No degree level qualification 
 
64 (62.1%) 
39 (37.9%) 
Highest occupation level 
Professional 
                 Non-professional                 
 
54 (52.4%) 
49 (47.6%) 
 
 133 
Chapter 6 BDRN Pregnancy Study:describing the perinatal period 
Table 6.2: Preconception lifetime clinical characteristics of the BDRN pregnancy sample (n=103) 
DSM-5: Diagnostic and Statistical Manual of Mental Health Disorders (5th edition); BD-I: bipolar I disorder, BD-II: bipolar II disorder,  
SA-BD: schizoaffective disorder bipolar type, BD-NOS: bipolar disorder not otherwise specified. IQR: Interquartile range. BDRN: 
Bipolar Disorder Research Network 
 
6.2.3 Within-pregnancy characteristics 
As indicated in section 6.2.1, the median age of women at the time of the current 
pregnancy was 34 years (range 18-44). Additional within-pregnancy characteristics of 
the sample are summarised in Table 6.3. 50.5% (n=52/103) of women were 
primiparous, with the majority reporting their pregnancy as being planned (76.7%, 
n=66/86). Only 3.6% (n=3/84) of women conceived their pregnancy via IVF and nearly 
all women reported having a partner present (i.e. being involved in a relationship) 
during their current pregnancy (99.0%, n=102/103).  
 
 
 
Preconception clinical variable 
BDRN pregnancy sample 
(n=103) 
Main preconception lifetime DSM-5 diagnosis 
BD-I 
BD-II 
SA-BD 
BD-NOS 
 
81 (78.6%) 
17 (16.5%) 
3 (2.9%) 
2 (1.9%) 
Age at onset of impairment of bipolar disorder (years) 
Median (IQR) 
Range 
 
20 (10) 
11-36 
Number of episodes of mania experienced per preconception 
illness year 
Median (IQR) 
Range 
 
 
0.36 (0.39) 
0.06-3.42 
Number of episodes of depression experienced per preconception 
illness year 
Median (IQR) 
Range 
 
 
0.47 (0.66) 
0.00-9.81 
Preconception history of psychotic features 
Present 
                 Absent 
 
72 (69.9%) 
31 (30.1%) 
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Table 6.3: Within-pregnancy characteristics of the BDRN pregnancy sample (n=103) 
 
a Numbers differ due to unknown data. IQR: Interquartile range, IVF: In-vitro fertilisation. BDRN: Bipolar Disorder Research Network 
 
 
6.2.3.1 Preconception perinatal characteristics in parous women 
Among the sample of parous women (n=51), the median number of deliveries occurring 
prior to the current pregnancy was one (range 1-6, Table 6.4). 30% of women had 
experienced their first impairing episode of BD with onset during the postpartum period 
(n=15/50). 50% (n=25/50) of parous women had experienced PP following a previous 
delivery and for 10% (n=5/50), PP was the only episode of mood illness experienced (i.e. 
no history of mood episodes unrelated to childbirth). For one woman, the 
presence/absence of a previous PP episode could not be determined (due to insufficient 
information obtained at baseline interview and lack of psychiatric case-notes).  
 
 
 
 
Within-pregnancy variable 
BDRN pregnancy  
sample 
(n=103) 
Age at pregnancy (years) 
Median (IQR) 
Range 
 
34 (6) 
18-44 
Primiparous 
Yes 
No 
 
52 (50.5%) 
51 (49.5%) 
Planned pregnancy a 
Planned   
                 Unplanned 
 
66 (76.7%) 
20 (23.3%) 
Conception by IVF a 
Yes 
                 No 
 
3 (3.6%) 
81 (96.4%) 
Partner present in pregnancy  
Present 
                 Absent 
 
102 (99.0%) 
1 (1.0%) 
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Table 6.4: Preconception perinatal characteristics of parous women in the BDRN pregnancy sample 
(n=51) 
 
PP: defined as an episode of mania or affective psychosis within 6 weeks of delivery, a Numbers differ due to postpartum psychiatric 
history being unknown for one woman. IQR: Interquartile range 
 
 
 
 
6.3 Psychotropic medication use during the perinatal period  
As discussed in Chapter 5 (section 5.8.3.1), detailed data were gathered for all women 
regarding psychotropic medication use during the perinatal period. These data were 
highly complex and varied considerably between women and also within each individual 
perinatal period. Figure 6.1 is an example of a timeline showing the complexity of 
medication data gathered across a perinatal period for one woman in this study 
(Participant 42, Appendix M). The proportion of women taking medication for the 
purpose of mood stabilisation (specifically those prescribed for treatment or prophylaxis 
of manic episodes) in the six months prior to pregnancy, during each month of 
pregnancy and within each of the first three postpartum months is summarised in 
Figure 6.2. Medications used for the purposes of mood stabilisation included traditional 
mood stabilisers such as lithium and anticonvulsants, in addition to atypical and typical 
antipsychotics (see section Chapter 5, page 120 for full definition). 
 
 
Preconception perinatal variable 
 
Parous women 
(n=51) 
Parity (number of deliveries) 
Median (IQR) 
Range 
 
1 (1) 
1-6 
Onset of bipolar disorder occurred in postpartum period a 
Yes 
No 
 
15 (30.0%) 
35 (70.0%) 
History of PP within 6 weeks a 
Yes 
No 
 
25 (50.0%) 
25 (50.0%) 
PP only prior mood episode a 
Yes  
                 No 
 
5 (10.0%) 
45 (90.0%) 
 
 
1
36 
Figure 6.1: Psychotropic medication use across the perinatal period in one woman in the BDRN Pregnancy sample 
Participant 42 
 
 
1
37 
 
Figure 6.2: Proportion of women in the BDRN pregnancy sample (n=103) using any psychotropic medication for mood stabilisation during the perinatal period  
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Figure 6.3. Proportion of women in the BDRN pregnancy sample (n=103) using each type of psychotropic medication for mood stabilisation during the perinatal period 
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The majority of women were using at least one psychotropic medication as a mood 
stabiliser (with or without adjunctive therapy with antidepressants or anxiolytics) during 
the six-month period prior to pregnancy (67.6%, n=69/102), during pregnancy (61.2%, 
n=63/103) and within the first three postpartum months (73.8%, n =76/103). The 
presence/absence of use of medication for mood stabilisation in the six months prior to 
pregnancy could not be determined for one woman in the sample (due to insufficient 
information obtained at interview and a lack of relevant information in psychiatric case-
notes and clinician questionnaires). Figure 6.3 provides a breakdown of medication use 
across the perinatal period according to type/class of medication. Detailed descriptions 
of patterns of medication use during the perinatal period are provided in the following 
sections.  
 
6.3.1 Use of mood stabilising medication during pregnancy 
6.3.1.1 Continuation/withdrawal of medication for mood stabilisation 
from the period prior to pregnancy  
Of the 69 women who were taking medications for mood stabilisation in the six months 
prior to their pregnancy, 40.6% (n=28/69) continued their existing medication regime 
during pregnancy without any significant changes to this medication (i.e. no withdrawal 
of any medications used as a mood stabiliser). Almost one in five women (18.8%, 
n=13/69) withdrew at least one mood stabilising medication but continued to use an 
additional or alternative medication as a mood stabiliser during their pregnancy. In 
contrast, 39.1% (n=27/69) of women using mood stabilising medication within the six-
month period preceding pregnancy withdrew all mood stabilising medications (26.4% of 
all women in the sample); 15 women doing so prior to pregnancy and 12 during their 
pregnancy (11 during the first trimester and one during the third trimester). 
 
Among the 27 women who had discontinued all mood stabilising medication prior to 
pregnancy, 29.6% (n=8/27) subsequently recommenced medication for mood 
stabilisation during pregnancy. One woman, commenced quetiapine prophylactically 
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during the first trimester of pregnancy (Participant 88) while an additional seven 
women utilised mood stabilising medication as treatment for a recurrence of affective 
symptoms during pregnancy (Participants 4, 11, 14, 16, 39, 42 and 46).  
 
6.3.1.2 Medication for mood stabilisation during pregnancy in women 
who were not using mood stabilising medication prior to pregnancy  
A third of women (32.4%, n=33/102) were not using any mood stabilising medication in 
the six-month period prior to pregnancy, the majority of whom had a preconception 
diagnosis of BD-I or SA-BD (78.8%, n=26/33). Most women who were not using any 
mood stabilising medication prior to pregnancy did not commence any medication as a 
mood stabiliser during the remainder of their pregnancy (81.8%, n=27/33). Six women 
(18.2%, n=6/33) subsequently commenced mood stabilising medication during their 
pregnancy, four prophylactically (Participants 13, 44, 75 and 92) and one following a 
recurrence of affective illness (Participant 56). One woman commenced mood 
stabilising medication later in pregnancy (Participant 1), however, the precise time at 
which this medication was commenced (in relation to the onset of a mood episode) was 
unclear. For this reason, it was not possible to determine if medication was prescribed 
prophylactically or as treatment.  
  
6.3.1.3 Use of sodium valproate during pregnancy 
As sodium valproate is a known teratogen and is typically advised against in women of 
childbearing age (National Institute for Health and Clinical Excellence 2014), the 
proportion of women using this medication during the perinatal period was specifically 
examined in this sample. Seven women (6.9%, n=7/102) were identified as using sodium 
valproate as a mood stabiliser in the six months prior to pregnancy (Participants 14, 16, 
38, 55, 63, 81 and 82), four of whom were under the care of specialist perinatal 
psychiatric services (Participants 55, 63, 81 and 82). Three of the seven women 
reported having planned their pregnancy (two of whom were under perinatal 
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psychiatric services), subsequently discontinuing use of sodium valproate; two prior to 
conception (Participants 38 and 63) and one woman at four weeks of pregnancy 
(Participant 81). None of these women recommenced sodium valproate within the 
study period.  
 
Of the four women who did not plan their pregnancy, three (Participants 14, 16 and 82) 
discontinued sodium valproate within the first eight weeks of pregnancy (one of whom 
subsequently recommenced this medication during the second trimester of pregnancy, 
participant 82). A fourth woman continued use of sodium valproate through the 
majority of her pregnancy, discontinuing at 28 weeks of pregnancy to commence an 
alternative mood stabiliser (Participant 55).     
  
6.3.1.4 Antidepressant monotherapy during the perinatal period 
Antidepressant monotherapy is also typically advised against in BD, given the potential 
for triggering of a manic episode. Therefore, the proportion of women using 
antidepressant medications without concomitant mood stabilising medication during 
pregnancy and the postpartum period was further examined. Nine women (8.8%, 
n=9/102) reported using antidepressants without adjunctive medication for mood 
stabilisation during pregnancy, four women throughout the entire duration of their 
pregnancy (Participants 10, 34, 41 and 70) and five for a duration of least one month 
during their pregnancy (Participants 13, 42, 44, 68 and 86). Furthermore, seven women 
(Participants 10, 24, 53, 68, 71, 79 and 97) took only antidepressants in the first three 
months following delivery.  
 
6.3.2 Prophylactic mood stabilising medication in the postpartum period 
As described in section 5.8.3.1, postpartum prophylaxis was defined as the use of any 
psychotropic medication during the postpartum period intended for the purpose of 
mood stabilisation (lithium, anticonvulsants, typical or atypical antipsychotics), that was 
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commenced or continued for reasons other than treatment. It was not possible to 
determine if mood stabilising medications were commenced prophylactically or as 
treatment for two women in the sample, given that the time at which medications were 
commenced (in relation to the onset of a postpartum mood episode) could not be 
established (Participants 2 and 22). Of those for whom data were available (n=101), the 
majority of women used at least one medication prophylactically as a mood stabiliser in 
the postpartum period (64.4%, n=65/101). Most women (76.9%, n=50/65) used only 
one prophylactic mood stabilising medication (with or without the use of other 
psychotropic medications, such as antidepressants), with multiple mood stabilising 
medications being used concurrently in 23.1% (n=15/65) of women. The proportion of 
women using at least one of each class and individual medication for prophylactic mood 
stabilisation in the postpartum period is illustrated in Figure 6.4. 
 
*Numbers do not sum 65 due to polypharmacy of medications in some women.  
 
 
Figure 6.4: Medications used for prophylaxis of postpartum mood episodes in the BDRN Pregnancy sample 
(n=65) 
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Of the 65 women for whom the presence of at least one prophylactic mood stabilising 
medication could be determined, 20.0% (n=13/65) were using lithium, 83.1% (n=54/65) 
at least one atypical antipsychotic, 13.8% (n=9/65) at least one anticonvulsant and 3.1% 
(n=2/65) at least one typical antipsychotic (Figure 6.4a). In addition to lithium, 
quetiapine and olanzapine were the most commonly used medications for prophylaxis 
of mood episodes in the postpartum period (44.6%, n=29/65 and 23.1%, n=15/65 
respectively, Figure 6.4b). In most cases (78.5%, n=51/65), prophylactic mood stabilising 
medications were continued from pregnancy through the postpartum period, while 
21.5% women (n=14/65) commenced mood stabilising medication following delivery. 
Nearly all women who commenced prophylactic mood stabilising medication in the 
postpartum period did so on the day of delivery (92.9% n=13/14). The remaining 
woman (Participant 70) did not commence lamotrigine prophylactically until two weeks 
postpartum.  
 
6.4 Perinatal psychiatric outcomes  
As described earlier in this thesis (see Chapter 5, section 5.8.3.2), ratings were made for 
the presence (and type) or absence of the worst DSM-5 affective episode with onset 
during the current pregnancy and postpartum period. Figure 6.5 summarises 
proportions and frequencies of the worst DSM-5 affective episode experienced 
according to time of onset within the perinatal period. The presence/absence of at least 
one DSM-5 episode during the perinatal period could not be determined for one 
woman in the sample. In this case, there was no postpartum recurrence of BD, 
however, the definite presence/absence of a mood episode during pregnancy could not 
be established. Of the remaining sample, 59.8% (n=61/102) women experienced at least 
one episode of affective illness meeting DSM-5 diagnostic criteria with onset during the 
perinatal period. The occurrence of DSM-5 episodes during pregnancy and the 
postpartum period are described further in the following sections.  
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6.4.1 Occurrence of DSM-5 affective episodes with onset during 
pregnancy 
The presence or absence of an affective episode of illness during pregnancy could not 
be determined for 1.9% (n=2/103) of women. In both cases, insufficient information 
was obtained at interview and neither psychiatric case-notes nor clinician 
questionnaires could be obtained. As shown in Figure 6.5, 42.6% (n=43/101) of women 
experienced at least one clinically impairing affective episode with onset during 
pregnancy, of which 11.9% (n=12/101) was a worst episode of mania or affective 
psychosis, 7.9% (n=8/101) hypomania and 22.8% (n=23/101) an episode of non-
psychotic depression. 57.4% (n=58/101) of the sample did not experience recurrence of 
a DSM-5 affective episode during pregnancy. Three women who experienced an onset 
of a DSM-5 episode during pregnancy continued to remain unwell throughout the 
entire postpartum period. As shown in Figure 6.6, one woman (Participant 16) 
experienced a prolonged episode of psychotic mania with mixed affective features and 
two women episodes of non-psychotic depression (Participant 68 and 96). 
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Figure 6.5: Recurrence rates of DSM-5 mood episodes with onset during the current perinatal period in the BDRN pregnancy sample 
Total N’s differ for each period due to missing data. 
1
One women excluded as the presence/absence of at least one perinatal episode could not be determined. 
2
Two women excluded as the 
presence/absence of at least one episode during pregnancy could not be determined. *excluding cases in which an episode occurred with onset during pregnancy and continued postpartum 
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Figure 6.6: Timelines showing mood episodes with onset in pregnancy that continued postpartum in three 
women in the BDRN pregnancy sample 
Participant 16 
Participant 68 
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6.4.2 DSM-5 affective episodes with onset within three months 
postpartum 
The occurrence of the worst DSM-5 affective episode of illness with onset within three 
months of delivery is presented in Figure 6.5. Women who remained unwell in the 
postpartum period following the onset of an episode during pregnancy (n=3/103, see 
Figure 6.6) were excluded from subsequent analyses. This decision was made on the 
assumption that these women did not have an opportunity to experience the onset of a 
new episode in the postpartum period. Overall, 43.0% (n=43/100) of women 
experienced an onset of an affective episode within three months of delivery, 21.0% 
(n=21/100) were episodes of mania or affective psychosis, 8.0% (n=8/100) episodes of 
hypomania and 14.0% (n=14/100) non-psychotic depression. 57.0% (n=57/100) women 
did not experience a DSM-5 recurrence in the postpartum period. A small proportion of 
the total sample (6.0%, n=6/100) experienced the onset of more than one DSM-5 
episode of postpartum psychiatric illness within the three-month follow-up period 
(Participants 21, 65, 72, 85, 86 and 103, see Figure 6.7). 
Figure 6.6 continued. Timelines showing mood episodes with onset in pregnancy that continued in to the 
postpartum period in three women in the BDRN pregnancy sample 
 
Participant 96 
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Figure 6.7: Timelines showing onset of multiple postpartum mood episodes within the current 
perinatal period in six women in the BDRN pregnancy sample. 
Participant 21 
Participant 65 
Participant 72 
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Figure 6.7 continued: Timelines showing onset of multiple postpartum mood episodes within 
the current perinatal period in six women in the BDRN pregnancy sample 
Participant 85 
Participant 86 
Participant 103 
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As shown in Figure 6.7, all six women experienced an episode of both mania/hypomania 
and depression. Two women experienced an affective switch without a period of 
euthymia between episodes (participants 72 and 85).  
 
6.4.2.1 Timing of onset of worst postpartum affective episode 
Figure 6.8 indicates the week of onset of the worst episode of affective illness 
experienced within three months of delivery. Of psychiatric episodes with an early onset 
(i.e. within two weeks of delivery (n=27), 59.3% (n=16/27) were a manic or affective 
psychosis, 18.5% (n=5/27) hypomania and 22.2% (n=6/27) a non-psychotic depression. 
76.2% (n=16/21) of all episodes of mania/affective psychosis had onset within two 
weeks of delivery. Figure 6.8a shows a particularly marked peak in the onset of episodes 
of mania or affective psychosis within the first two postpartum weeks, compared to 
between weeks three and five postpartum. 
 
 
 
 
 
Figure 6.8: Week of onset of worst DSM-5 postpartum mood episode within the current perinatal period 
in the BDRN pregnancy sample 
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Notably, no episodes of mania or affective psychosis had an onset beyond five weeks of 
delivery within this sample. The pattern of onset of episodes of hypomania (Figure 6.8b) 
was similar to that of mania and affective psychoses, with the majority of episodes 
having onset within the first two postpartum weeks (62.5%, n=5/8). However, the 
remainder of episodes had an onset later in the postpartum period, between weeks five 
and eight following delivery (37.5%, n=3/8). In comparison, the onset of episodes of 
non-psychotic depression (Figure 6.8c) was more widely distributed across the follow-
up period, with 57.1% (n=8/14) of cases occurring after two weeks postpartum.  
 
6.4.2.2 Onset of worst DSM-5 episode within 6 weeks postpartum 
As shown in Figure 6.9, using a narrow temporal definition of the postpartum onset 
period (consistent with both DSM-5 and ICD-10 definitions), 39.0% (n=39/100) women 
experienced onset of the worst mood episode within the first six weeks of delivery. The 
worst episodes with onset within this time period were as follows; 21.0% (n=21/100) 
mania or affective psychosis, 6.0% (n=6/100) hypomania and 12.0% (n=12/100) non-
psychotic depression. Two cases of PP which had particularly early onset are described 
in Figure 6.10. 
 
Figure 6.9: Recurrence rates of DSM-5 mood episodes with onset within six weeks of delivery in the BDRN 
pregnancy sample 
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Case 77 
Participant 77 was a mother of seven children, with a history of BD-I and PP. She had a 
family history of severe, unspecified psychiatric disorder and of suicide.  
 
Her current pregnancy was unplanned, but her partner and family were described as 
supportive. She remained well in mood until 37 weeks of pregnancy, when she experienced 
some mild symptoms of hypomania that subsequently resolved around the time of delivery. 
Risperidone was taken only intermittently throughout pregnancy. 
 
Her baby was delivered via normal vaginal delivery and was healthy. Within two weeks of 
delivery, she had completely discontinued all medication and her mood subsequently began 
to fluctuate from being elated and grandiose to being tearful and concerned that there was 
something wrong with her baby. Her presentation was noted to be chaotic and her mood 
labile. She experienced paranoid delusional beliefs and delusional ideas that she was still 
pregnant. She was admitted under section for several months and was subsequently treated 
with risperidone by depot amid concerns of non-compliance. Lithium was also commenced. 
 
Case 86 
Participant 86 was a young mother of one with a previous history of PP meeting DSM 
criteria for BD-I. She had no prior history of psychiatric illness before the birth of her first 
baby. She did however have a family history of affective illness (including PND and 
suspected BD) and suicidal behaviour.  
 
Her current pregnancy was unplanned but reported to be a positive experience during 
which her partner was deemed supportive. Despite this, she unfortunately experienced a 
moderately severe episode of depression during the first trimester of her pregnancy, and 
was subsequently commenced on sertraline. She had recovered from this episode by week 
16 of pregnancy.  
 
Her baby was delivered normally at 39 weeks with no complications. She had been 
prescribed olanzapine and zopiclone to commence prophylactically immediately following 
delivery, but did not take it. On day nine postpartum, she became manic, being unable to 
sleep, instead cleaning and tidying excessively. Her mood was elated with prominent 
features of irritability, which was directed towards her husband in particular. Perplexity and 
dysphoric features were also present, with symptoms including feeling low and scared.  Her 
mood was labile, being tearful and then quickly becoming elated once more. Ideas of 
reference were reported that were grandiose in content. She was admitted under section 
for three weeks, during which time delusions of misinterpretation were prominent, 
believing that members of clinical staff were police officers in disguise and that everything 
was a test or game constructed for her benefit. She reported feeling euphoric and became 
increasingly spiritual.  
 
Participant 86 recovered from the initial episode following treatment with olanzapine, 
zopiclone and lorazepam before experiencing an episode of depression soon after (from 
weeks 6-9 postpartum). 
 
Figure 6.10: Descriptions of two cases of PP with early onset within two weeks of delivery in the BDRN 
pregnancy sample 
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6.4.3 Perinatal psychiatric outcomes according to preconception lifetime 
diagnosis 
To examine differences in perinatal psychiatric outcomes between BD subtypes, 
recurrence rates across the perinatal period are also reported separately in women with 
BD-I/SA-BD and those with BD-II/BD-NOS in the following sections. 
 
6.4.3.1 BD-I and SA-BD 
Figure 6.11 shows recurrence rates of worst DSM-5 episodes with onset across the 
perinatal period in the sample of women with BD-I and SA-BD (n=84). As described 
previously in this section (page 147), total sample sizes differ for each phase of the 
perinatal period due to unknown outcomes or exclusion of cases in which postpartum 
mood episodes had onset during pregnancy. 60.2% (n=50/83) of women with BD-I/SA-
BD experienced at least one DSM-5 episode with onset during the perinatal period; 
43.9% (n=36/82) during pregnancy, 42.7% (n=35/82) within three months and 39% 
(n=32/82) within six weeks of delivery. During pregnancy, 14.6% of women (n=12/82) 
experienced an episode of mania/affective psychosis, 6.1% (n=5/82) an episode of 
hypomania and 23.2% (n=19/82) an episode of non-psychotic depression. 
 
In the postpartum period, all episodes of PP (24.4%, n=20/82) occurred within six weeks 
of delivery. 6.1% (n=5/82) of women experienced an episode of postpartum hypomania 
within three months and 3.7% (n=3/82) within six weeks of delivery. An additional 
12.2% (n=10/82) women experienced an episode of non-psychotic depression, of which 
all but one case had onset within six weeks of delivery (90%, n=9/10).  
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Figure 6.12 Recurrence rates of worst DSM-5 mood episodes with onset during the current perinatal 
period in women with BD-II/BD-NOS in the BDRN pregnancy sample (n=19) 
Figure 6.11: Recurrence rates of worst DSM-5 mood episodes with onset during the current perinatal 
period in women with BD-I/SA-BD in the BDRN pregnancy sample (n=84) 
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6.4.3.2 BD-II and BD-NOS 
Among the sample of 19 women with BD-II and BD-NOS, 57.9% (n=11/19) experienced a 
recurrence of at least one DSM-5 mood episode during the perinatal period; 36.8% 
(n=7/19) during pregnancy, 44.4% (n=8/18) within three months and 38.9% (n=7/18) 
within six weeks of delivery (see Figure 6.12). No women with BD-II or BD-NOS 
experienced a worst episode of mania/affective psychosis during pregnancy, while 
episodes of hypomania occurred in 15.8% (n=3/19) and non-psychotic depression 
within 21.1% (n=4/19) of pregnancies.  
 
Following delivery, only one woman with a preconception diagnosis of BD-II 
experienced an episode of PP within six weeks of delivery (Participant 93, see Figure 
6.13), subsequently meeting DSM-5 criteria for a lifetime diagnosis of BD-I disorder. This 
case is also described in Figure 6.14. A further 16.7% (n=3/18) of women experienced an 
episode of hypomania postpartum (all with onset within the first six weeks) and an 
additional 22.2% (n=4/8) an episode of non-psychotic depression within three months 
of delivery. As observed in women with BD-I, nearly all episodes of non-psychotic 
depression had an onset within six weeks postpartum (75%, n=3/4).  
 
 
 
 
  
Figure 6.13: Timeline showing onset of PP within the current perinatal period in a woman with a 
preconception lifetime diagnosis of BD-II in the BDRN pregnancy sample 
Participant 93 
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6.4.3.3 Comparing risk of perinatal recurrence across diagnostic subtypes 
 Recurrence with onset during pregnancy 
As shown in Table 6.5, women in the BD-I/SA-BD group were more likely to experience 
any DSM-5 mood episode and specifically an episode of mania/affective psychosis with 
Case 93 
Participant 93 was a young mother of two children with a history of BD-II. She had a 
strong family history of affective disorders occurring both perinatally (PND) and non-
perinatally (BD). A severe episode of depression with psychotic features (but no features 
of mania) occurred following the birth of her second child, for which she required 
admission. 
 
Her current pregnancy was unplanned and while she did not experience any physical 
complications, several life stressors were present throughout pregnancy and 
contributed to pathological symptoms of antenatal anxiety. Upon learning of her 
pregnancy, she discontinued lamotrigine at 12 weeks of pregnancy, while continuing 
quetiapine throughout pregnancy which was subsequently increased at 29 weeks 
gestation. 
 
Her baby was born normally with no complications, though unfortunately experienced 
some health complications within a month of delivery, which further contributed to 
increased levels of anxiety. Sertraline was prescribed as treatment, triggering an episode 
of mania at 3 weeks postpartum. Her mood quickly became elated, with increased 
libido, excessive activity (such as cleaning obsessively) and problematic excessive 
spending also being reported. Dysphoric symptoms were also present, particularly 
feeling ‘on edge’ and paranoid that someone would harm her baby. 
 
Psychotic features further developed, including auditory and visual hallucinations that 
were congruent with dysphoric mood. Delusion beliefs included ideas of reference that 
she perceived were occurring to ‘make her more depressed’. Delusions of grandiosity, 
jealousy and misinterpretation were prominent features. Persecutory ideas centred on 
the belief that clinical members of staff who were government agents in disguise, 
attempting to harm her because ‘she was special’. Classical magical thinking was also 
observed. 
 
Participant 93 recovered following admission to psychiatric hospital at 4 weeks 
postpartum. During which time, quetiapine was increased and lithium commenced. 
 
Figure 6.14: Description of a case of PP that occurred in a woman with a preconception history 
of BD-II in the BDRN pregnancy sample  
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onset during pregnancy compared to those in the BD-II/BD-NOS group, however these 
trends did not reach statistical significance (43.9%, n=36/82 vs 36.8%, n=7/19, χ2 (1), 
n=103, 3.15, p=0.575, OR=1.34, 95% CI 0.48-3.76 and 14.6%, n=12/82 vs 0%, 0/19, 
p=0.116, OR=1.17, 95% CI 1.07-1.28 respectively). In contrast, women with BD-II/BD-
NOS were more likely to experience episodes of hypomania (15.5%, n=3/19 vs 7.3%, 
n=6/82, p=0.364, OR=0.42, 95% CI 0.10-1.86) and non-psychotic depression compared 
to women with BDI-/SA-BD (36.8%, n=7/19 vs 28%, n=23/82, p=0.450, OR=0.67, 95% CI 
0.23-1.91), though again, these findings were not statistically significant. Post-hoc 
calculations indicated power to detect between groups differences in the rates of 
recurrence during pregnancy to range between 7.7%-34.7%. 
 
 Recurrence with onset within six weeks of delivery 
The rate of recurrence of any DSM-5 mood episode with onset within six weeks of 
delivery did not significantly differ between the two groups (39.0%, n=32/82 vs 38.9%, 
n=7/18, χ2 (1), n=100, 0.000, p=0.991, OR=1.01, 95% CI 0.35-2.86). However, episodes 
of hypomania and non-psychotic depression occurred more frequently in women BD-
II/BD-NOS compared to those with BD-I/BD-NOS group (16.7%, n=3/18 vs 6.1%, n=5/82 
and 33.3%, n=6/18 vs 15.9%, n=20/82 respectively), yet neither difference was 
statistically significant (p=0.153, OR=0.33, 95% CI 0.70-1.51 and p=0.103, OR=0.38, 95% 
CI 0.12-1.18 respectively). Similarly, women in the BD-I/SA-BD group were more likely to 
experience an episode of PP (24.4%, n=20/82) compared with women in the BD-II/BD-
NOS group (5.6%, n=1/18), though this finding was also not significant (Fisher’s Exact 
Test, p=0.11, OR=5.48, 95% CI 0.69-43.84). Post-hoc power to detect between group 
differences within this set of analyses was calculated to be between 2.5% and 41.2%. 
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Table 6.5: Recurrence of mood episodes with onset during the current perinatal period according to BD subtype in the BDRN Pregnancy sample                                                                                                             
 
F Fisher’s exact test, OR (95% CI): Odds ratio (95% confidence intervals), BD-I/SA-BD: Bipolar I disorder/schizoaffective disorder, BD-II/BD-NOS: Bipolar II disorder/bipolar disorder not 
otherwise specified 
 
 
 
 
DSM-5 mood episode with onset during pregnancy 
 
BD-I/SA-BD 
(n=82) 
 
BD-II/BD-NOS 
(n=19) 
 
Test 
statistic 
 
p-valuea 
 
OR (95% CI) 
 
Post-hoc 
Power 
 
Any mood episode 
Any hypomania 
Any non-psychotic depression 
Any mania/affective psychosis 
 
 
36 (43.9%) 
6 (7.3%) 
23 (28.0%) 
12 (14.6%) 
 
7 (36.8%) 
3 (15.8%) 
7 (36.8%) 
0 (0%) 
 
χ2 (1) 3.15 
- 
- 
- 
 
0.575 
0.364F 
0.450F 
0.116F 
 
1.34 (0.48-3.76) 
0.42 (0.10-1.86) 
0.67 (0.23-1.91) 
1.17 (1.07-1.28) 
 
7.7% 
25.9% 
12.4% 
34.7% 
 
DSM-5 mood episode with onset within 6 weeks postpartum 
 
BD-I/SA-BD 
(n=82) 
 
BD-II/BD-NOS 
(n=18) 
 
Test 
statistic 
 
p-valuea 
 
OR (95% CI) 
 
Post-hoc 
Power 
 
Any mood episode 
Any hypomania 
Any non-psychotic depression 
Any mania/affective psychosis 
 
 
32 (39.0%) 
5 (6.1%) 
13 (15.9%) 
20 (24.4%) 
 
7 (38.9%) 
3 (16.7%) 
6 (33.3%) 
1 (5.6%) 
 
χ2 (1) 0.000  
- 
- 
- 
 
0.991 
0.153F 
0.103F 
0.110F 
 
1.01 (0.35-2.86) 
0.33 (0.70-1.51) 
0.38 (0.12-1.18) 
5.48 (0.67-43.84) 
 
2.5% 
36.2% 
41.2% 
39.1% 
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6.5 Summary of main findings 
The first aims of this naturalistic study were to describe patterns of psychotropic 
medication use and psychiatric outcomes during the perinatal period in a well-
characterised sample of 103 pregnant women with BD using a prospective follow-up 
design. Key findings from this chapter are summarised below.  
 
6.5.1 Use of mood stabilising medication across the perinatal period 
 Use of psychotropic mood stabilising medication varied considerably across the 
perinatal period.  
 
 26.4% of all women in the sample discontinued all mood stabilising medications 
prior to or during pregnancy.  
 
 81.8% of women who were not using any mood stabilising medication within the 
six-month period prior to pregnancy, also did not use any mood stabilising 
medication during pregnancy. 
 
 Overall, the majority of women (61.2%) used at least one mood stabilising 
medication during pregnancy, with more than two thirds of women (64.4%) 
using mood stabilising medication for prophylaxis of PP in the postpartum 
period. Atypical antipsychotics (and specifically quetiapine) were the most 
commonly used mood stabilising medications. 
 
 6.9% of women were using sodium valproate for mood stabilisation within the 
six months prior to pregnancy; of which 71% continued to use this medication 
through at least the first month of pregnancy (duration of use ranged from 4-28 
weeks of pregnancy). 8.8% of women received antidepressant monotherapy for 
at least one month during the perinatal period. 
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6.5.2 Perinatal psychiatric outcomes 
 The risk of recurrence of mood disorder during the perinatal period was high, 
with 59.8% of all women experiencing an onset of at least one DSM-5 mood 
episode during pregnancy or the postpartum period.  Risk of experiencing any 
DSM-5 mood episode with onset within the first three postpartum months was 
similar to that during pregnancy (43.0% and 42.6% respectively). 
 
 The risk of mania or affective psychosis was especially high in the postpartum 
period. More than one in five women (21%) experienced an episode of PP, 
compared to 14% who experienced PND and 8% an episode of hypomania. Risk 
of PP was almost double that of mania/affective psychosis during pregnancy 
(11.9%). In contrast, risk of hypomania following delivery was comparable with 
that of pregnancy (7.9%), while episodes of depression were considerably less 
frequent postpartum compared to pregnancy (22.8%). 
 
 All PP episodes had onset within six weeks of delivery, whereas the onset of 
episodes of hypomania and in particular, non-psychotic depression was more 
widely distributed throughout the postpartum period. Moreover, PP occurred 
within the first two postpartum weeks in 76% of cases, compared to 63% of 
episodes of hypomania and 43% of PND.  
 
 Episodes of hypomania and non-psychotic depression occurred more frequently 
during pregnancy and the postpartum period in women with BD-II/BD-NOS 
compared to women with BD-I/SA-BD. However, episodes of mania or affective 
psychosis during pregnancy and of PP were especially prevalent among women 
with BD-I and SA-BD. PP occurred following 24.4% of deliveries in women with 
BD-I/SA-BD compared to only 5.6% of those with BD-II and BD-NOS. Due to 
limitations of power, these trends were not statistically significant. 
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6.6 Discussion 
The first aim of this study was to describe patterns of medication use and psychiatric 
outcomes across the perinatal period in a sample of 103 pregnant women with BD using 
a prospective follow-up design. This prospective study is one of the largest such studies 
conducted to date and also the first to characterise the perinatal period among a UK 
sample of women with BD. I also examined perinatal psychiatric outcomes across BD 
subtypes, which has rarely been investigated using a prospective methodology. In this 
section, I discuss the results of the current study in relation to previous literature. First, 
patterns of psychotropic medication use during the perinatal period will be compared 
with findings reported in independent samples of BD. This is followed by a discussion of 
psychiatric outcomes during the perinatal period, with a subsequent focus on observed 
differences within BD subtypes. Finally, the implications for further analyses conducted 
within this thesis will be discussed.   
  
6.6.1  Patterns of psychotropic medication use across the perinatal 
period 
In this study, patterns of psychotropic medication use for mood stabilisation were found 
to be complex and highly variable across the perinatal period. The proportion of women 
using mood stabilising medications reduced during pregnancy compared with the six-
month period prior to conception (from 67.6% to 61.2%), before increasing following 
delivery to 73.8%. Nevertheless, the majority of women continued to use at least one 
medication as a mood stabiliser at some point during their pregnancy or the 
postpartum period. Specifically, almost two thirds of women (64.4%) were using at least 
one medication in the postpartum period for prophylaxis of mania or psychosis. Atypical 
antipsychotics were the most commonly prescribed psychotropic medications during 
the perinatal period. Surprisingly, sodium valproate was used as a mood stabiliser prior 
to pregnancy in 6.9% of women, with the majority (71%) continuing this medication 
through at least one month of pregnancy.  Moreover, antidepressant monotherapy was 
used for at least one month during the perinatal period in 8.8% of women. Overall, the 
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findings of this naturalistic study are likely to reflect the complex scenarios and 
decisions faced by clinicians in practice when managing BD during the perinatal period. 
The decision to continue or withdraw mood stabilising medication during or planning 
pregnancy is based on several factors, ranging from individual preferences (of both the 
clinician and the patient), teratogenicity and efficacy of medications, to the perceived 
risk of recurrence (National Institute for Health and Clinical Excellence 2014).  
 
To date, only one published study has described patterns of psychotropic medication 
use during the perinatal period in a sample of 336 women with BD (Broeks et al. 2017). 
In their Danish study, psychotropic medication use was defined as the redemption of 
prescriptions (as indicated in national case registers) from 12 months preconception to 
12 months postpartum. Similar to the pattern of psychotropic medication use observed 
in this study,  Broeks et al. (2017) found redemption of prescriptions for any 
psychotropic medication to decrease during pregnancy (to 36.6% from 54.8% in the 
three months preconception), before increasing again (to 40%) at three months 
postpartum. They observed this pattern for all psychotropic medication types, including 
those used for mood stabilisation, thus being consistent with the pattern of use of 
mood stabilising medications I observed. The overall pattern observed across both 
studies (decreased use of medication during pregnancy and subsequent increase 
postpartum) is likely to reflect women opting to withdraw medication before or during 
pregnancy due to fears of teratogenic effects on the foetus or because of plans to 
breastfeed. Some of these women may instead choose to commence prophylactic 
medication following delivery, while a proportion of women only use mood stabilising 
medication for treatment of emergent mood symptoms.  
 
Indeed, I found 26% of all women to withdraw mood stabilising medications, with 17.6% 
of women doing so during pregnancy. Broeks et al. (2017) reported a higher rate of 
withdrawal of any psychotropic medication during pregnancy (27.9%), however the 
proportion of women who withdrew mood stabilising medications prior to pregnancy 
was not stated. It is therefore reasonable to assume that the proportion of women who 
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withdrew all mood stabilising medications in Broeks et al.’s (2017) study is likely closer 
to the figure I observed within the BDRN pregnancy sample.   
 
Though the pattern of medication use across the perinatal period was similar between 
this study and that reported by Broeks et al. (2017), the proportion of women using 
medication during each phase of the perinatal period was higher in the BDRN 
pregnancy sample. For example, I found 61.2% of women to be using at least one mood 
stabilising medication during pregnancy, compared to 36.6% of women (as indicated by 
redemption of prescriptions) in Broeks et al.’s study (2017). I also found the proportion 
of women using mood stabilising medication in the postpartum period for any purpose 
(73.8%, i.e. for treatment or prophylaxis) and specifically for prophylaxis of mood 
episodes (64.4%) to be higher compared to the use of any psychotropic medication 
(40%) in the Danish population. This difference is despite both studies adopting the 
same temporal definition of the postpartum period (i.e. within the first three months).  
 
There are several potential explanations for this difference. First, in the study by Broeks 
et al. (2017), analyses were restricted to primiparous women only. If these women had 
not previously experienced a postpartum mood episode, the perceived need for 
prophylaxis of postpartum mood episodes would likely be lower than for women who 
did have such history. Due to the increased uncertainty of risk of postpartum 
recurrence, women in the Danish study may have preferred to instead withdraw 
medication and adopt a ‘wait and watch’ approach before commencing any medication.  
In contrast, as indicated in section 6.2.3 of this chapter, almost a quarter of women in 
the BDRN pregnancy sample had a prior history of PP, thus likely being considered 
particularly high risk of further postpartum recurrence (24%, n=25/103). Additionally, 
given that approximately 50% of women were recruited to the BDRN pregnancy study 
via specialist perinatal psychiatric services, it is probable that a higher proportion of 
women in this sample were advised to remain on medication during the perinatal 
period. 
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Alternatively, it is possible that the proportion of women using psychotropic mood 
stabilising medication during the perinatal period may be underestimated in Broeks et 
al.’s (2017) study compared to the rates I observed. In their study, it was not possible to 
identify from case-registers medications prescribed while receiving inpatient care. 
However, in the current study, when examining use of any mood stabilising medications 
across the perinatal period, I was able to identify medication utilised as treatment or for 
prophylaxis, providing a comprehensive picture of overall psychotropic medication use.  
 
Another factor that may have contributed to an underestimation of psychotropic 
medication use in the Danish sample is that diagnosis of BD was confirmed only by 
review of case-registers and made according to ICD criteria. As such it was not possible 
for Broeks et al. (2017) to establish the presence/absence of subtypes of BD within their 
sample. Though speculative, their sample may have comprised a higher proportion of 
women with subtypes of BD (such as BD-II or BD-NOS) for whom the risk of perinatal 
recurrence is often perceived to be lower for those with a diagnosis of BD-I or SA-BD. 
This is further suggested by the high rate of antidepressant monotherapy observed in 
their sample (50%), which is typically avoided in individuals with a history of manic 
episodes. In comparison, the vast majority of women in this study (approximately 80%) 
had a preconception diagnosis of BD-I, who by definition are considered at greater risk 
of manic episodes or psychosis than women with BD-II or BD-NOS. If this were the case, 
it could be expected that fewer women in the Danish study would have remained on 
medications for the purpose of mood stabilisation compared to within the BDRN 
pregnancy sample.  
 
Nevertheless, it is important to note that directly comparing the findings of this study 
with that of Broeks et al (2017) is difficult, given other key differences in methodology 
between the two studies. Primarily, the use of a case-register methodology in Broeks et 
al.’s (2017) study meant it was not possible for the authors to infer whether medication 
was prescribed prophylactically or as treatment for emergent symptoms. Furthermore, 
as they were only able to identify medication use by the rate of redemption of 
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prescriptions, it was unknown whether women were actually compliant with 
medications prescribed during this time period. In comparison, use of mood stabilising 
medication in this study was ascertained not only by self-report, but also by information 
from clinician questionnaires and psychiatric case-notes. Thus, the findings of this study 
are likely to offer a more reliable and representative picture of psychotropic medication 
use and specifically of prophylactic mood stabiliser use across the perinatal period in 
women with BD.     
 
6.6.1.1 Sodium valproate and antidepressant monotherapy in the 
perinatal period 
In this sample, I found 6.9% of women to have used sodium valproate for mood 
stabilisation (of any duration) within six months prior to pregnancy and a further 7.8% 
antidepressant monotherapy (for a duration of at least one month) either in the six 
months prior to pregnancy or during the perinatal period. These findings are surprising, 
given that both medication regimes are advised against in clinical practice. While the 
use of antidepressant monotherapy in this sample was considerably lower than the 50% 
of women observed in Broeks et al.’s (2017) study, as discussed previously, this likely 
reflects the high proportion of women in the BDRN pregnancy sample who had 
preconception diagnosis of BD-I and thus would have been perceived at high risk of 
mania without the use of a concomitant mood stabilising medication (Goodwin et al. 
2016).  
 
The proportion of women I found to be using sodium valproate as a mood stabiliser in 
this sample is particularly concerning. The teratogenic effects of this drug on the foetus 
have been well-documented (Andrade 2018; Macfarlane and Greenhalgh 2018). Within 
the UK, evidence based guidelines for NHS practice recommend that sodium valproate 
should not be used in any woman of childbearing age (National Institute for Health and 
Clinical Excellence 2014). This finding is therefore particularly surprising, given that 
three of seven women reported planning their pregnancy and four were receiving care 
from NHS perinatal psychiatric services. This would suggest that some women (or 
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potentially their clinicians) may not have been aware of the risks of remaining on 
sodium valproate during pregnancy. When examining the proportion of women who 
used sodium valproate specifically during their pregnancy, the rate of use in the BDRN 
pregnancy sample would decrease to 3.9% (as three women discontinued use of this 
medication prior to conception). This is comparable to the 2.3% (n=4/176) women 
observed to be using carbamazepine or sodium valproate during pregnancy in Broeks et 
al.’s study (2017), though the precise number of women using sodium valproate was 
not reported. The proportion of women in this sample who were using sodium 
valproate during pregnancy is however similar to the 5.6% of women with epilepsy who 
are also reported to use this medication during pregnancy (Petersen et al. 2017). Thus, 
this finding likely represents prescribing practices across disorders and is not necessarily 
specific to BD.  
 
6.6.1.2 Section summary 
In summary, I found the overall pattern of use of mood stabilising medications to be 
consistent with the previous literature to date. The findings further demonstrate the 
complexity of managing BD during the perinatal period, showing that many women 
undergo significant changes to their medication regime during pregnancy, often 
withdrawing their use of mood stabilising medication completely or switching to 
alternative medications. Surprisingly, a notable proportion of women also continue to 
remain on medication regimes that are advised against by clinical recommendation 
guidelines, suggesting that not all women may be aware of the risks of remaining on 
valproic acid during pregnancy or of using antidepressant monotherapy.   
 
Despite variation in patterns of medication use across the perinatal period, I found the 
majority of women to remain on mood stabilising medication, the proportion of which 
was higher than has been previously reported (Broeks et al., 2017). Due to 
methodological differences between studies, direct comparison of these findings is 
difficult. However, the high proportion of women remaining on prophylactic mood 
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stabilising medications in this study is likely to reflect women in the current sample 
being perceived at particularly high risk of postpartum recurrence, given that the 
majority met criteria for a preconception diagnosis of BD-I and a quarter had a history 
of severe postpartum mood episodes.  
 
The role of mood stabilising medications in the prevention of severe postpartum 
recurrence in women with BD is largely unknown. As discussed in the introductory 
chapter of this thesis (section 2.6.2.2), previous research in this area has been primarily 
limited to small samples of women and specifically the use of lithium. Furthermore, few 
studies assessing risk factors for postpartum recurrence have controlled for 
prophylactic mood stabiliser use. In addition to a range of within-pregnancy factors, the 
influence of mood stabiliser prophylaxis on risk of PP will therefore be examined in the 
next chapter of this thesis. 
 
6.6.2  Perinatal recurrence of mood episodes 
In this study, more than half of all women (59.8%) experienced at least one DSM-5 
affective episode during the perinatal period, defined as the onset of an episode during 
pregnancy or within three months postpartum. Overall, rates of recurrence during 
pregnancy were similar to that within the postpartum period (42.6% and 43% 
respectively). However, unlike episodes of hypomania (8%) or non-psychotic depression 
(14%), when compared with similar episodes of mania/affective psychosis during 
pregnancy (21%), episodes of PP were especially frequent following childbirth. While 
onset of all episodes of PP occurred within five weeks of delivery (peaking within the 
first two weeks), the onset of episodes of hypomania and of non-psychotic depression 
was more widely distributed across the postpartum period. Examining psychiatric 
outcomes within BD subtypes revealed perinatal episodes of hypomania and non-
psychotic depression to be more frequent among women with BD-II or BD-NOS 
compared to women with BD-I or SA-BD. In contrast, perinatal episodes of 
mania/affective psychosis were more common among women with BD-I/SA-BD.  Almost 
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a quarter of women (24.4%) with BD-I and SA-BD experienced the onset of PP, 
compared to only 5.6% of women in the BD-II and BD-NOS group. Though no difference 
in perinatal psychiatric outcomes across BD subtypes reached statistical significance.  
 
6.6.2.1 Recurrence of bipolar disorder during pregnancy 
The rate of recurrence of BD during pregnancy was high in this sample, with 42.6% of 
women experiencing the onset of at least one DSM-5 mood episode. Episodes of non-
psychotic depression were especially frequent, occurring in 22.8% of women, compared 
with 11.9% who experienced a worst episode of mania or affective psychosis and 7.9% 
an episode of hypomania. No woman with BD-II experienced the onset of an episode of 
mania or affective psychosis during pregnancy. The overall recurrence rate I observed 
during pregnancy (42.6%) is considerably higher than the rate of 10.8% reported by our 
research group in our retrospective sample of 1212 women with bipolar I and II disorder 
(Di Florio et al. 2013). This variation is however likely due to key methodlogical 
differences between the two studies. Primarily, only the worst mood episode 
experienced during each perinatal period was reported in our retrospective sample. 
Perinatal mood episodes were also rated heirarchically, with postpartum episodes rated 
in favour of those occurring during pregnancy. For example, if a woman experienced 
mania during pregnancy and the postpartum period, only the episode occurring with 
onset in the postpartum period was rated, thus likely underestimating recurrence 
during pregnancy. Another contributory factor may be the retrospective method in 
which perinatal outcomes were assessed in our cross-sectional study. This likely 
increased the possibility of recall bias, with milder forms of disorder with onset during 
pregnancy being underreported. 
 
Compared with two key studies which have also examined recurrence during pregnancy 
in women with BD, recurrence in the BDRN pregnancy sample (42.6%) was higher than 
the rate of 24.4% reported in one retrospective study (Bergink et al. 2012) but 
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considerably lower than that reported in a prospective study (70.8%, Viguera et al. 
2007). The findings of Bergink et al.’s (2012) study were based on a small sample of 41 
women, 75.6% of whom had remained on medication during pregnancy and all but one 
of whom continued to use lithium prophylactically (96.8%, n=30/31). This is in striking 
contrast to the 12% of women taking lithium during pregnancy in this study. While the 
prophylactic effect of mood stabilsing medication on periantal recurrence in BD 
requires further investigation (and will be examined in the next chapter of this thesis), 
lithium remains the gold standard treatment for maintance of BD (Lähteenvuo et al. 
2018). Thus, it is possible that women in Bergink et al’s (2012) study had a form of BD 
illness that was better managed during pregnancy than within the current study, 
reducing risk of recurrence in their sample. It is also noteworthy that I found a higher 
proportion of women in the BDRN Pregnancy Study to not use any mood stabilising 
medication at all during pregnancy (38.8%), compared to 24.4% of women in the Danish 
study (Bergink et al. 2012). Interestingly, when examining women who were not using 
prophylactic mood stabilisers in pregnancy, Bergink et al. (2012) found the recurrence 
rate during pregnancy in their sample to increase to 40.0%.  
 
In another study, Viguera et al. (2007) reported 70.8% of 89 women in their sample to 
relapse during pregnancy. This contrasts with the rate of 42.6% of women in the current 
sample, despite both studies using a prospective design and DSM criteria to assess 
psychiatric outcomes. There are a number of potential differences between the two 
studies that may explain this finding. Firstly, the vast majority of women in the sample 
studied by Viguera et al. (2007) were identified as not using any mood stabilising 
medication during pregnancy (70%), compared with only 38.8% women in this sample. 
It is therefore possible the risk of recurrence may have been greater in their study than 
in the BDRN pregnancy sample. Furthermore, clinical characteristics of women included 
in their study suggest these women may have been more vulnerable to recurrence 
during the perinatal period.  The authors reported 89.4% of women in their sample to 
have a prior history of perinatal episodes, compared to the quarter of women in the 
current study who had a history of PP. Nevertheless, this is only speculative, given that I 
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only assessed lifetime history of PP (as opposed to any perinatal episode) and thus 
could not directly compare studies. Finally, episodes of depression were especially 
frequent during pregnancy in their study, occurring in 38.2% of pregnancies compared 
to only 22.8% in this sample. This may reflect the higher proportion of women with BD-
II disorder in their sample (31.5%) compared to within this study (16.5%); women who 
have been shown to be a greater risk of depressive episodes during pregnancy 
compared to women with BD-I disorder (Di Florio et al. 2013).  
 
6.6.2.2 Recurrence of bipolar disorder in the postpartum period 
I found 43% of all women with BD to experience the onset of a mood episode within 
three months of childbirth. The high rate of postpartum recurrence reported within the 
BDRN pregnancy sample is similar to the rate of 52.6% previously observed in our 
retrospective sample (Di Florio et al. 2013). Episodes of PP were found to occur 
following 21% of all deliveries within six weeks in the current study, which is almost 
identical to the rate of 19% of deliveries affected in our retrospective sample of 671 
women with BD. Notably, the rate reported by Di Florio et al. (2013) only included the 
onset of episodes of mania or mixed affective states. If episodes of psychotic depression 
were also included in this definition (as I have reported in this study), the rate of severe 
recurrence in the retrospective sample would increase to 22.4%, which is in keeping 
with the 21% of women who experienced these episodes in the BDRN pregnancy 
sample. Importantly, in both studies, recruitment methods were similar and psychiatric 
outcomes were assessed by semi-structured clinical interviews and case-note review. 
 
The postpartum recurrence rate of 43% of any mood episode within 12 weeks of 
delivery observed in this study is also generally consistent with wider research. Based 
on data from 25 studies, a recent meta-analysis found that 37% of women with BD 
experienced a postpartum mood episode within 12 months of delivery (Wesseloo et al., 
2016). The authors also reported severe recurrence (defined as an episode of 
mania/mixed affective state or affective psychosis) to occur in 17% of all deliveries up to 
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12 months following delivery, again being comparable with findings of this study that 
more than one in five women with BD are at risk of PP.  
 
Again, it is difficult to directly compare outcomes I have reported here with the findings 
of this meta-analysis, given that the 25 studies from which their data was obtained, all 
demonstrated considerable heterogeneity in assessment, study design and the 
temporal period used to define postpartum recurrence (ranging from one month to 12 
months postpartum). When studies were grouped by these key methodological 
differences, rates of postpartum recurrence varied widely. For example, using data only 
from prospective studies of BD, 33% of women were found to have a postpartum 
recurrence within the first 12 months following delivery, which is slightly lower than 
their pooled estimate of 37% when combining all studies of BD (regardless of study 
design; Wesseloo et al. (2016). This estimate from prospective studies remains lower 
that the rate of recurrence I observed within this sample (within three months of 
delivery; 43%). This difference may be indicative of the high proportion of women in 
this study with BD-I disorder (80%) who may have been at higher risk of recurrence. In 
contrast, 63% of the combined sample in Wesselloo et al.’s (2016) study was comprised 
of women with BD-I disorder. Overall however, incidence of postpartum recurrence in 
this study (39% within six weeks and 43% within three months of delivery) is within the 
range of overall estimates of postpartum recurrence (within 12 months) reported by 
Wesseloo et al. (2016) based on all included studies of BD (29-45%) and solely using 
data from prospective studies (23-45%).  
 
6.6.2.3 Presentation of postpartum mood episodes 
Relative to episodes of PP (21%), episodes of PND and hypomania within three months 
of delivery were relatively less frequent in this sample at 14% and 8% respectively. 
Previous research has found episodes of non-psychotic depression to be the most 
frequent presentation of mood disorder in the postpartum period, with prevalence 
estimates ranging between 18-59.7% in samples of women with BD (Blehar et al. 1998; 
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Bratfos and Haug 1964; Colom et al. 2010; Di Florio et al. 2013; Maina et al. 2014; 
Viguera et al. 2011; Wisner et al. 2004). However, I found that even when accounting 
for all occurrences of PND with onset within three months of delivery (i.e. also including 
women who experienced a worst episode of mania in addition to an episode of 
depression), the prevalence of PND remained slightly lower than that of PP (20%). 
Importantly, much of the previous literature has adopted a broader onset criteria of the 
postpartum period (up to six months following delivery, Di Florio et al. 2013; Viguera et 
al. 2011; Wisner et al. 2004), likely identifying episodes of depression which typically 
have a wider distribution of onset. As the follow-up period in this study was restricted 
to the first three postpartum months, it was not possible to compare recurrence 
including episodes which may have a later onset. Furthermore, as stated previously, 
only 16.5% women in this study had a preconception diagnosis of BD-II disorder, 
compared to between 20-54.4% in previous studies (Blehar et al. 1998; Bratfos and 
Haug 1964; Colom et al. 2010; Di Florio et al. 2013; Maina et al. 2014; Viguera et al. 
2011; Wisner et al. 2004). Given that evidence suggests women with BD-II may be at 
increased risk of recurrence during the perinatal period (Di Florio et al. 2013; Viguera et 
al. 2007), findings of the current study may be more representative of course of illness 
among women with BD-I.  
 
Episodes of hypomania occurred infrequently postpartum (in 8% of all women within 
three months of delivery), which is consistent with previous research (Abdel-Hay, El-
Sawy and Badawy 2011; Di Florio et al. 2013; Viguera et al. 2011). Given that I assessed 
recurrence of illness soon after delivery, it is unlikely that episodes of hypomania were 
underreported due to recall bias. It is plausible that in some cases, milder episodes 
were difficult for women and their families to distinguish from the joy experienced 
following the birth of their baby. Postpartum highs are also a common feature in the 
first few weeks after delivery in the general population (Heron et al. 2009; Smith et al. 
2009) and can be present with additional symptoms of the baby blues. Therefore, 
briefer periods of elated or mixed mood may not have been considered episodes of 
impairing illness, but rather a common experience of emotional fluctuation associated 
 
 
Chapter 6 BDRN Pregnancy Study: describing the perinatal period 
173 
with hormonal changes in the early postpartum. The likelihood of this is however 
reduced, given that case-notes and clinician questionnaires were also used to assess 
postpartum psychiatric outcomes. 
 
6.6.2.4 Timing of onset of worst postpartum mood episode 
Of the worst postpartum mood episodes experienced within the current perinatal 
period, all episodes of PP occurred within six weeks of delivery, with the majority of 
these episodes (76.2%) having onset within the first two weeks. This was in contrast to 
episodes of hypomania and non-psychotic depression, for which the onsets were more 
widely distributed across the postpartum period. Episodes of hypomania were found to 
have onset up to 8 weeks postpartum, while episodes of non-psychotic depression 
occurred up to 12 weeks postpartum. 
 
The pattern of onset observed within the current study is consistent with previous 
literature, in which studies of clinical samples (McNeil 1986), women with BD (Heron et 
al. 2008) and large populations (Kendell, Chalmers and Platz 1987; Langan Martin et al. 
2016; Munk-Olsen et al. 2006; Nott 1982) have all demonstrated the first two 
postpartum weeks to be a period of particularly high risk for onset of episodes of PP. 
This finding has important implications for clinical practice, indicating the first few 
weeks in particular to be the primary time in which women with BD should be 
monitored for the onset of early symptoms. Furthermore, the striking excess of 
episodes of PP that were found to occur early in the postpartum period provides further 
support for the hypothesis that childbirth has a specific role in the aetiology and/or 
triggering of severe mood episodes among women with BD.  
 
6.6.2.5 Perinatal recurrence according to preconception BD subtype 
The proportion of women who experienced at least one DSM-5 mood episode within six 
weeks of delivery was almost identical among those with a preconception diagnosis of 
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BD-I/SA-BD (38.9%) and those with BD-II/BD-NOS (39.0%). However, perinatal episodes 
of hypomania and non-psychotic depression were observed more frequently among 
women with a preconception history of BD-II/BD-NOS than those with BD-I/ SA-BD. 
Conversely, women with BD-I/SA-BD were at higher risk of mania/affective psychosis 
during pregnancy (14.6% vs 0% in BD-II/BD-NOS) and of PP compared to those with BD-
II or BD-NOS (24.4% vs 5.6% respectively). While these trends did not reach statistical 
significance, post-hoc calculations revealed power of these analyses to be low, ranging 
between 2.5%-41.2%. Based on the observed effect sizes (see page 158 for summary of 
odds ratios), sample size calculations indicate up to 443 women with BD would be 
needed within each diagnostic subgroup in future studies to achieve 80% power to 
detect a between group difference in the type of perinatal recurrence. Given the strong 
possibility of type II error, these findings provide an important contribution to 
individualising risk prediction of PP. Women with BD-I may need additional monitoring 
across the perinatal period, given that these women may be at especially high risk of PP.  
 
To my knowledge, this prospective study is the first to demonstrate that women with 
BD-II/BD-NOS may be at increased risk of hypomania and non-psychotic depression 
during pregnancy compared to women with BD-I/SA-BD, and that women with BD-I/SA-
BD are at comparatively increased risk of mania/affective psychosis. Nevertheless, the 
overall trend for women with BD-I/SA-BD to be at greater risk of any mood recurrence 
during pregnancy compared to BD-II/BD-NOS is in contrast with some previous 
literature (Di Florio et al. 2015; Viguera et al. 2011, 2007). As discussed, Viguera et al. 
(2007) found a BD-II diagnosis to be associated with increased risk of at least one DSM-
IV defined recurrence during pregnancy. Similarly, in our large retrospective sample (Di 
Florio et al. 2013), the occurrence of DSM-IV episodes with onset in pregnancy was 
approximately twice as high among women with BD-II (18.4%) compared to those with 
BD-I (8.6%), though this difference was not statistically compared. One possible reason 
for discrepancies between findings may be due to the inclusion of women with SA-BD 
and BD-NOS within the current sample, groups that were not included in either 
previous study. Inclusion of women with SA-BD in the BD-I/SA-BD group may have 
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inflated risk of recurrence during pregnancy within this group, whereas inclusion of 
women with BD-NOS may have simultaneously reduced risk within the BD-II/BD-NOS 
group. Risk of antenatal recurrence is also likely underestimated in our BDRN 
retrospective sample, given that only the worst mood episode within each perinatal 
period was rated. Using a hierarchy method, postpartum onset episodes were rated in 
favour of those with onset during pregnancy.  
 
Overall, the pattern of postpartum recurrence I observed across diagnostic subtypes is 
consistent with the literature. In a recent systematic review and meta-analysis of 
postpartum recurrence, no difference was found in overall recurrence rates of any 
postpartum mood episode (within 12 months postpartum) between women with BD-I 
and BD-II (45% and 50% respectively, Wesseloo et al. 2016). Though importantly, type 
of postpartum recurrence was not statistically compared across BD subtypes. To date, 
only two large retrospective studies of women with BD have described the type and 
polarity of postpartum mood episodes occurring within diagnostic subtypes (both of 
which were included in the meta-analysis by Wesseloo et al., 2016). Consistent with the 
current study, episodes of PP occurred more frequently in our BDRN retrospective 
sample among women with BD-I disorder than those with BD-II (33% vs 9.1% 
respectively, Di Florio et al., 2013). Furthermore, postpartum episodes of hypomania 
and non-psychotic depression (within 12 months of delivery) occurred more frequently 
among women with BD-II (4% and 35.4% respectively) compared to those with BD-I 
(2.6% and 24.8% respectively).  As described earlier in this thesis (section 2.5.2), 
participants were recruited to both studies using similar methods, and diagnoses and 
psychiatric outcomes assessed in both BDRN samples according to DSM criteria using 
the same semi-structured neuropsychiatric interview (SCAN).  
 
Finally, Viguera et al. (2011) assessed psychiatric outcomes of 2232 deliveries to 1162 
women with BD (283 BD-I and 338 BD-II), also finding no difference in overall 
postpartum recurrence rates within six months of delivery between diagnostic groups 
(38% in BD-I and 34.5% in BD-II). However, when examining recurrence of severe 
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postpartum episodes, no woman in the BD-II group experienced an episode of PP, 
compared to 9.8% of women in BD-I group. Viguera et al. (2011) also found mixed 
affective states to be less frequent in the BD-II group (2.5%) compared to within the BD-
I group (6.5%), though the predominant polarity of the episodes was not specified.  
 
6.6.2.6 Section summary 
In summary, the findings of this study are consistent with previous research indicating 
that risk of recurrence is high during the perinatal period in women with BD.  
Longitudinal assessment of perinatal psychiatric outcomes indicates that the 
postpartum period and specifically, the first few weeks following delivery is a time of 
especially high risk for episodes of mania or affective psychosis. Findings from this study 
also suggest that this risk may be specifically increased among women with BD-I or SA-
BD.  
 
The close temporal relationship between PP and childbirth reinforces the hypothesis 
that factors specific to childbirth are likely more important in the occurrence of these 
episodes compared to other postpartum mood disorders. Nevertheless, factors 
influencing risk of PP (including use of pharmacotherapy) are poorly understood. 
Identifying factors that place women with BD at greatest risk of severe postpartum 
recurrence would clearly have important implications for clinical practice. Therefore, in 
order to examine this further, the next chapter of this thesis will focus on investigating 
the relationship between a range of within-pregnancy potential risk factors and the 
occurrence of narrowly defined PP in the BDRN pregnancy sample. Given observed 
heterogeneity between diagnostic subtypes, these investigations will be conducted in 
women with a preconception diagnosis of BD-I and SA-BD only (n=82, for whom the 
presence/absence of postpartum recurrence could be established).
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7.1 Introduction 
The primary aim of this study was to identify potential risk factors for PP in the sample 
of women recruited to the BDRN Pregnancy Study (described in Chapter 6). Due to 
heterogeneity between diagnostic subgroups, this chapter will focus on investigations in 
women with BD-I and SA-BD only (n=84). First, results of univariate analyses examining 
the relationship between the occurrence of PP and a range of within-pregnancy 
potential risk factors will be presented, followed by reports of findings from multivariate 
binary logistic regression analyses. I extend these analyses, reporting investigations 
assessing the specificity of potential risk factors to the occurrence of PP by also 
examining their relationship to episodes of PND. The final section of this chapter 
focuses on discussion of findings in relation to the literature and implications these may 
have for future research and clinical practice.  
 
7.2 Sample 
As stated, due to heterogeneity between BD subtypes, analyses within this chapter 
were restricted to participants with a preconception DSM-5 lifetime diagnosis of BD-I or 
SA-BD only. Of the 84 women with BD-I or SA-BD who were recruited to the BDRN 
Pregnancy Study, two women had experienced the onset of an affective episode during 
pregnancy that continued into the postpartum period. As it was not possible to 
determine if these women would have experienced an episode following childbirth had 
they been euthymic at the time of delivery, these women were excluded from all 
subsequent analysis. The final sample therefore comprised 82 women with a diagnosis 
of BD-I or SA-BD.  
 
7.3 Definition of outcomes 
The worst DSM-5 mood episode occurring within six weeks of delivery (as described in 
Chapter 6, section 6.4.3.3.2) was used to categorise outcomes within the sample 
according to the presence or absence of PP (PP or No PP respectively, defined within 
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this thesis as an episode of mania with or without mixed features or affective 
psychosis). A temporal cut-off of six weeks was used to define the postpartum period to 
be consistent with both DSM-5 and ICD-10 criteria. According to this definition, 24.4% 
(n=20/82) of women had experienced an episode of PP and 75.6% No PP (n=62/82). 
 
7.4 Results 
7.4.1 Demographic and key clinical characteristics 
Demographic and preconception key clinical characteristics of the sample according to 
the presence or absence of PP are shown in Table 7.1 and Table 7.2 respectively. As 
shown in Table 7.1, there were no significant differences between the two groups with 
regards to age at interview (p=0.820), ethnicity (p=0.591), method of recruitment 
(p=0.242), lifetime marital status (p=0.435), highest education level (p=1.000) or highest 
occupational level (p=0.890).  
 
Table 7.1: Demographic characteristics of BD-I/SA-BD women in the BDRN pregnancy sample (n=82) 
according to the presence or absence of PP 
 
Numbers differ due to unknown data. PP: postpartum psychosis, No PP: No postpartum psychosis. IQR: Interquartile range, a p-
values calculated via Mann-Whitney U test for continuous variables. p-values for categorical variables calculated by Pearson’s Chi-
Square or Fisher’s exact test. FFisher’s exact test.  
 
 
 
Demographic characteristic 
PP 
24.4% (n=20) 
 
No PP 
75.6% (n=62) 
 
Test statistica p-value 
Age at interview (years) 
Median (IQR) 
Range 
 
34 (10) 
20-44 
 
35 (6) 
23-43 
 
U= 599.000, 
 Z = -.227 
 
 0.820 
 
Ethnicity 
White ethnicity 
Non-white ethnicity 
 
18 (90.0%) 
2 (10%) 
 
59 (95.2%) 
3 (4.8%) 
 
- 
 
0.591F 
 
Method of recruitment 
Non-systematic    
                   Systematic 
 
13 (65.0%) 
7 (35.0%) 
 
31 (50.0%) 
31 (50.0%) 
 
χ2 (1) 1.368 
 
0.242 
 
Lifetime marital status 
Married/lived as married 
                  Never married/lived as married                   
 
19 (95.0%) 
1 (5.0%) 
 
60 (98.4%) 
1 (1.6%) 
 
- 
 
0.435F 
Highest education level 
Degree level qualification or higher 
                  No degree level qualification              
 
17 (85.0%) 
3 (15.0%) 
 
51 (82.3%) 
11 (17.7%) 
 
- 
 
1.000 F 
Highest occupation level 
Professional 
                  Non-professional 
 
11 (55.0%) 
9 (45.0%) 
 
33 (53.2%) 
29 (46.4%) 
 
χ2 (1) 0.019 
 
0.890 
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As shown in Table 7.2, there was no significant association between the occurrence of 
PP and age at onset of impairing BD (p=0.709) or preconception lifetime number of 
episodes of mania (p=0.434) and depression per illness year (p=0.916). Women who 
experienced PP were significantly more likely to have a preconception history of 
psychotic symptoms (95%, n=19/20) compared to women who did not experience PP 
(71%, n=44/62; p=0.032, OR 7.77 95% CI 0.97-62.49).  
 
Table 7.2: Key preconception clinical characteristics of BD-I/SA-BD women in the BDRN pregnancy sample 
(n=82) according to the presence or absence of PP 
 
BD-I: Bipolar I disorder. PP: postpartum psychosis, No PP: No postpartum psychosis. IQR: Interquartile range. a p-values calculated via 
Mann-Whitney U test for continuous variables. p-values for categorical variables calculated by Fisher’s exact test.  
 
7.4.2 Within-pregnancy potential risk factors for postpartum psychosis 
This section presents results of analyses examining the relationship between the 
following range of within-pregnancy potential risk factors and occurrence of PP; 
psychosocial factors, adverse life events, smoking and alcohol use, perinatal sleep 
factors, obstetric factors, antenatal psychopathology and prophylactic medication use 
for mood stabilisation.  
 
 
 
 
Key preconception clinical characteristics 
PP 
24.4% (n=20) 
 
No PP 
75.6% (n=62) 
 
 
Test  
statistica 
 
p-value 
 
Age at onset of impairment of BD 
            Median (IQR) 
Range 
 
21 (11) 
13-36 
 
 
20 (10) 
11-35 
 
 
U= 528.500, 
 Z = -.374 
 
 0.709 
 
Preconception lifetime number of episodes of 
mania per illness year 
Median (IQR) 
Range 
 
 
0.31 (0.33) 
0.11-2.01 
 
 
 
0.38 (0.44) 
0.05-7.37 
 
 
U= 450.000, 
 Z = -.782 
 
 
0.434 
 
Preconception lifetime number of episodes of 
depression per illness year 
Median (IQR) 
Range 
 
 
0.40 (0.93) 
0.00-1.85 
 
 
0.45 (0.35) 
0-4.34 
 
 
U= 514.000, 
 Z = -.105 
 
 
0.916 
 
Preconception lifetime history of psychotic 
symptoms 
Present 
                  Absent                   
 
 
19 (95.0%) 
1 (5.0%) 
 
 
44 (71.0%) 
18 (29%) 
 
 
- 
 
 
0.032 
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7.4.2.1 Psychosocial factors relating to pregnancy 
Table 7.3 summarises postpartum psychiatric outcomes according to the presence or 
absence of psychosocial factors specific within the current pregnancy. As shown, there 
were no significant differences between the two groups in the proportion of women 
who experienced PP with regards to the planning of pregnancy (23.5% planned, 
n=12/51 vs 40.0% unplanned, n=6/15; p=0.322, OR 2.17 95% CI 0.64-7.33) or women’s 
perceived experience of pregnancy (26.3% positive experience, n=10/38 vs 22.7% 
negative experience, n=10/44; p=0.706, OR 1.21 95% CI 0.44-3.33). Due to the small 
sample size in one of the groups, the occurrence of PP according to the 
presence/absence of a partner during pregnancy or the perceived level of emotional 
support from partner or others could not be statistically compared. 
 
Table 7.3: Occurrence of PP according to psychosocial factors specific within the current pregnancy in BD-
I/SA-BD women in the BDRN pregnancy sample (n=82) 
 
Numbers differ due to unknown data. BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: Postpartum 
psychosis; No PP: No postpartum psychosis. a p-values for categorical variables calculated by Pearson’s Chi-Square or Fisher’s exact 
test. b Statistical comparisons not performed due to small sample sizes. F Statistic calculated using Fisher’s Exact Test 
 
 
 
 
 
 
 
PP No PP 
Test  
statistica 
p- value 
Planned pregnancy 
Planned (n=51) 
                  Unplanned (n=15) 
                      
 
12 (23.5%) 
6 (40.0%) 
 
 
39 (76.5%) 
9 (60.0%) 
 
 
- 
 
0.322F 
Perceived experience of pregnancy 
Positive (n=38) 
               Not positive (n=44) 
                      
 
10 (26.3%) 
10 (22.7%) 
 
 
28 (73.7%) 
34 (77.3%) 
 
 
χ2 (1) 0.142 
 
0.706 
Partner in pregnancy b 
Present (n=81) 
                  Absent (n=1) 
                      
 
20 (24.7%) 
0 (0%) 
 
 
61 (75.3%) 
1 (100%) 
 
- 
 
- 
Perceived emotional support from partner b 
Supportive (n=66) 
                  Not supportive (n=2)       
 
18 (27.3%) 
0 (0%) 
 
48 (72.7%) 
2 (100%) 
 
- 
 
- 
Perceived emotional support from others b 
Supportive (n=68) 
                  Not supportive (n=2)               
 
19 (27.9%) 
0 (0%) 
 
49 (72.1%) 
2 (100%) 
 
- 
 
 
- 
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7.4.2.2 Adverse life events during pregnancy 
Table 7.4 summarises comparisons of the occurrence of PP according to the 
presence/absence of adverse life events experienced during pregnancy. As shown, 
episodes of PP did not occur significantly more frequently among women who reported 
the presence of any (i.e. at least one) adverse life event during their pregnancy 
compared to those who did not (28.3%, n=13/46 vs 16.7%, n=4/24 respectively; 
p=0.283, OR=1.97, 95% CI 0.56-6.88). There was also no significant association between 
the total number of adverse life events experienced during pregnancy and the 
occurrence of PP (p=0.64).  
 
The proportion of women who experienced PP did not significantly differ according to 
the presence/absence of any of the following adverse events during pregnancy: a 
serious illness or injury to themselves (50.0%, n=3/6 vs 21.0%, n=13/62; p=0.137, OR 
3.77 95% CI 0.68-20.91), a serious illness or injury to a close relative (23.1%, n=3/13 vs 
23.6%, n=13/55; p=1.000, OR 0.97, 95% CI 0.23-4.06) bereavement of a close friend or 
relative (38.5%, n=5/13 vs 20.4%, n=11/54; p=0.274, OR 2.44, 95% CI 0.67-8.96) or the 
presence of at least one other adverse life event (see page 124 for a full description of 
questionnaire item (19.4%, n=6/31 vs 29.7%, n=11/37; p=0.235, OR=0.57, 95% CI 0.18-
1.77).  
 
Due to small sample sizes across groups, the occurrence of PP could not be statistically 
compared according to the presence/absence of the breakdown of a relationship during 
pregnancy, a serious problem with friends or relatives or problems with the police 
involving a court appearance. No woman in the sample reported losing a job during 
pregnancy, experienced a financial crisis equating to three months lost wages or the 
theft or loss of a valued item.   
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Table 7.4: Occurrence of PP according to the presence or absence of adverse life events during pregnancy 
in BD-I/SA-BD women in the BDRN pregnancy sample (n=82)  
 
Numbers differ due to unknown data. BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: Postpartum 
psychosis; No PP: No postpartum psychosis. a p-values for categorical variables calculated by Pearson’s Chi-Square or Fisher’s exact 
test. b Variable formed from responses to the open-ended question ‘In the last 6 months, other than being pregnant, did any other 
significant event happen in your life?’. C Statistical comparison not performed due to small sample sizes F statistic calculated by 
Fisher’s Exact Test 
 
 
 
 
 
 
 
 
Adverse event during pregnancy 
PP No PP 
Test  
statistica 
p- value 
Any adverse life event experienced 
Present (n=46) 
                  Absent (n=24) 
 
13 (28.3%) 
4 (16.7%) 
 
33 (71.7%) 
20 (83.3%) 
 
χ2 (1) 1.153 
 
0.283 
Serious illness/injury 
Present (n=6) 
Absent (n=62) 
 
3 (50.0%) 
13 (21.0%) 
 
3 (50.0%) 
49 (79.0%) 
 
- 
 
0.137F 
Serious illness/injury to close relative 
Present (n=13) 
                  Absent (n=55) 
 
3 (23.1%) 
13 (23.6%) 
 
10 (76.9%) 
42 (76.4%) 
 
- 
 
1.00 F 
Bereavement of close friend/relative 
Present (n=13) 
                  Absent (n=54) 
 
5 (38.5%) 
11 (20.4%) 
 
8 (61.5%) 
43 (79.6%) 
 
- 
 
0.274F 
Breakdown of relationship c 
Present (n=3) 
                  Absent (n=65) 
 
0 (0%) 
16 (24.6%) 
 
3 (100%) 
49 (75.4%) 
 
- 
 
- 
Serious problem with friends/relatives c 
Present (n=2) 
                  Absent (n=68) 
 
1 (50.0%) 
15 (23.1%) 
 
1 (50.0%) 
50 (76.9%) 
 
- 
 
- 
Problems with the police involving court 
appearance c 
Present (n=1) 
                  Absent (n=67) 
 
 
0 (0%) 
16 (23.9%) 
 
 
1 (100.0%) 
51 (76.1%) 
 
 
- 
 
 
- 
Any other adverse eventb 
Present (n=31) 
                  Absent (n=37) 
 
6 (19.4%) 
11 (29.7%) 
 
25(80.6%) 
26 (70.3%) 
 
χ2 (1) 0.968 
 
0.235 
Total number of adverse life events 
experienced 
Median (IQR) 
                   Range  
 
 
1 (1) 
0-4 
 
 
1 (1) 
0-3 
 
 
U= 378.000, 
Z = -0.472 
 
 
0.637 
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7.4.2.3 Smoking and alcohol use in the current pregnancy 
The proportion of women who experienced PP did not significantly differ between 
those who reported smoking during pregnancy (22.2%, n=4/18, see Table 7.5) and those 
who did not smoke during pregnancy (25.0%, n=16/64; p=1.000, OR 0.86 95% CI 0.25-
2.98). The influence of alcohol use on risk for PP could not be examined, as no woman 
in the sample consumed more than the recommended limit of units (14 units) of 
alcohol per week during their pregnancy (specifically, no woman regularly consumed 
more than one unit of alcohol within a week). 
 
Table 7.5: Occurrence of PP according to self-reported smoking during pregnancy in BD-I/SA-BD women in 
the BDRN pregnancy sample (n=82) 
 
BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: Postpartum psychosis; No PP: No postpartum psychosis. a p-
value calculated by Fisher’s exact test 
 
7.4.2.4 Psychopathology within the current pregnancy 
The occurrence of PP was compared between women according to the presence or 
absence of a DSM-5 episode of mood illness with onset during pregnancy (see Figure 
7.1a). In addition to two women who were previously excluded from the PP/No PP 
groups (see page 178), an additional two women were excluded from this analysis as 
the occurrence of a DSM-5 episode during pregnancy could not be determined. Of the 
remaining sample (n=80), 41.2% (n=14/34) of women who experienced a clinically 
impairing episode of mood illness during pregnancy subsequently experienced PP, 
compared with 13.0% (n=6/46) of women who did not experience an affective episode 
during pregnancy. This finding was statistically significant (p=0.004; OR=4.67, 95% CI 
1.56-13.97).  
 
 
 
 
PP No PP 
Test 
Statistica 
p- value 
 
Smoking in pregnancy 
Present (n=18) 
                  Absent (n=64) 
                      
 
 
4 (22.2%) 
16 (25.0%) 
 
 
14 (77.8%) 
48 (75.0%) 
 
 
- 
 
 
1.000a 
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 Polarity of mood episode in pregnancy  
Further analyses were conducted to assess the relationship between the polarity of 
DSM-5 episode experienced in pregnancy (mania/psychosis or non-psychotic 
depression) and the occurrence of PP. The relationship between hypomania during 
pregnancy and PP was not examined, as only five women experienced the onset of 
hypomania during pregnancy. Figure 7.1b shows the proportion of women who 
experienced an episode of PP among women who experienced an episode of 
mania/affective psychosis and those who did not experience any DSM-5 mood episode 
during pregnancy. Women who experienced an episode of mania or affective psychosis 
during pregnancy were significantly more likely to experience PP compared to women 
who did not experience any DSM-5 mood episode during pregnancy (63.6%, n=7/11 and 
13%, n=6/46; p=0.001, OR=11.67, 95% CI 2.61-52.21).  
 
Episodes of PP also occurred more frequently among women who experienced episodes 
of non-psychotic depression during pregnancy (27.8%, n=5/18) compared to those who  
Figure 7.1: Occurrence of PP according to the presence/absence of a DSM-5 mood episode in 
pregnancy in BD-I /SA-BD women in the BDRN pregnancy sample (n=80).  
BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: postpartum psychosis. Bars represent 95% 
confidence intervals.  
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did not experience any DSM-5 mood episodes during pregnancy (13.0%, n=6/46, Figure 
7.1c), however this finding did not reach statistical significance (p=0.27; OR=2.56, 95% 
CI 0.67-9.81). PP occurred more frequently among women who experienced an episode 
of mania/affective psychosis during pregnancy (63.6%) compared to those who 
experienced non-psychotic depression during pregnancy (27.8%), however this 
difference was not statistically significant (p=0.119; OR=4.55, 95% CI 0.92-22.63).  
 
To investigate whether severity of BD (indicated by lifetime frequency of mood 
episodes) prior to pregnancy explained the relationship between mania during 
pregnancy and PP, the number of preconception lifetime episodes of mania and 
depression per illness year were compared between women who experienced an 
episode of mania during pregnancy and those who did not experience any mood 
episode during pregnancy. Compared to women who remained euthymic during 
pregnancy, the occurrence of mania or affective psychosis during pregnancy was 
significantly associated with a greater number of episodes of mania per illness year 
(median number 0.314 and 0.625 respectively; p=0.009) but not of depression (median 
number 0.375 and 0.555 respectively; p=0.178). 
 
 
 Anxiety during pregnancy 
As shown in Figure 7.2, the occurrence of PP did not statistically differ between those 
who experienced clinically impairing symptoms of anxiety during pregnancy (see page 
119 full definition; 27.8%, n=10/36) and those who did not (15.2%, n=5/33; p=0.204, 
OR=2.15, 95% CI 0.65-7.14). 
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7.4.2.5 Obstetric factors relating to pregnancy and labour in the current 
perinatal period 
Table 7.6 summarises the proportion of women who experienced PP according to 
obstetric factors relating to pregnancy and labour within the current perinatal period. 
No significant associations were found between any of the obstetric factors studied and 
the occurrence of PP. There was however an overall trend for PP to occur more 
frequently among women who did not experience obstetric complications during the 
perinatal period. Specifically, PP occurred more frequently among women who did not 
experience; any obstetric complication during pregnancy (29.8% vs 13.3%; p=0.100, 
OR=2.76, 95% CI 0.81-9.38), symptoms or diagnosis of pre-eclampsia (27.3% vs 7.7%; 
p=0.171, OR=4.50, 95% CI 0.55-37.14), pre-term delivery (25.7% vs 14.3%; p=0.674, 
OR=2.08, 95% CI 0.23-18.44), any obstetric complication during delivery (28.2% vs 
19.4%; p=0.375, OR=1.63, 95% CI 0.55-4.80), caesarean section (28% vs 17.9%; p=0.317, 
OR=1.79, 95% CI 0.57-5.64) and any form of assisted delivery (31.6% vs 17.5%; p=0.148, 
OR=2.18, 95% CI 0.75-6.31). However, PP occurred more frequently among women 
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Figure 7.2: Occurrence of PP according to the presence/absence of clinically impairing 
symptoms of anxiety in BD-I/SA-BD women in the BDRN pregnancy sample (n=69).   
BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: postpartum psychosis. 
Bars represent 95% confidence intervals. 
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Table 7.6. Occurrence of PP according to obstetric factors relating to pregnancy and labour in the current 
perinatal period in BD-I/SA-BD women in the BDRN pregnancy sample (n=82) 
 
Numbers differ due to unknown data. BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: Postpartum 
psychosis; No PP: No postpartum psychosis. a p-values calculated via Mann-Whitney U test for continuous variables. p-values for 
categorical variables calculated by Pearson’s Chi-Square or Fisher’s exact test. b Statistical comparisons not performed due to small 
sample sizes. cAssisted delivery defined as any delivery requiring forceps/ventouse or caesarean section F Statistic calculated by 
Fisher’s Exact Test 
 
 
 
 
 
PP No PP 
Test 
statistica 
p- value 
Pregnancy complications 
Yes (n=30) 
                  No (n=47) 
                      
 
4 (13.3%) 
14 (29.8%) 
 
 
26 (86.7%) 
33 (70.2%) 
 
χ2 (1) 2.77 
 
 
0.100 
Pre-eclampsia 
Symptoms/diagnosis (n=13) 
                  No symptoms or diagnosis (n=66) 
 
1 (7.7%) 
18 (27.3%) 
 
12 (92.3%) 
48 (72.7%) 
 
- 
 
0.171F 
Induction/augmentation of labour 
Yes (n=29) 
                  No (n=43)               
 
8 (27.6%) 
9 (20.9%) 
 
21 (72.4%) 
34 (79.1%) 
 
χ2 (1) 0.43 
 
0.514 
Length of labour (hours) 
Median (IQR) 
Range 
 
13.5 (19) 
1-48 
 
12 (17) 
2-48 
 
U= 193.00 
Z = -0.129 
 
0.898 
Pre-term delivery (<37 weeks) 
Yes (n=7) 
                  No (n=70) 
              
 
1 (14.3%) 
18 (25.7%) 
 
6 (85.7%) 
52 (74.3%) 
 
- 
 
0.674F 
Delivery complications 
Yes (n=36) 
                  No (n=39) 
                      
 
7 (19.4%) 
11 (28.2%) 
 
 
29 (80.6%) 
28 (71.8%) 
 
χ2 (1) 0.79 
 
0.375 
Caesarean Section   
Caesarean section (n=28) 
Vaginal delivery (n=50) 
 
 
5 (17.9%) 
14 (28.0%) 
 
 
23 (82.1%) 
36 (72.0%) 
 
 
χ2 (1) 1.00 
 
0.317 
Assisted delivery c 
Non-assisted delivery (n=38) 
                  Assisted delivery (n=40) 
                   
 
12 (31.6%) 
7 (17.5%) 
 
26 (68.4%) 
33 (82.5%) 
 
χ2 (1) 2.10 
 
0.148 
Age at delivery (years) 
Median (IQR) 
                  Range  
 
34 (7) 
20-44 
 
35 (6) 
19-43 
 
U= 521.000, 
Z = -0.760 
 
0.447 
Delivery number of current pregnancy 
Median (IQR) 
                   Range  
 
2 (1) 
1-7 
 
1 (1) 
1-5 
 
U= 554.500, 
Z = -0.773 
 
0.440 
Sex of baby 
Male (n=36) 
                  Female (n=41) 
                      
 
6 (16.7%) 
12 (29.3%) 
 
 
30 (83.3%) 
29 (70.7%) 
 
χ2 (1) 1.70 
 
0.192 
Problems with baby at birth 
Yes (n=24) 
                  No (n=53) 
                      
 
7 (29.2%) 
12 (22.6%) 
 
 
17 (70.8%) 
41 (77.4%) 
 
χ2 (1) 0.38 
 
0.538 
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whose babies experienced health problems at birth, though this difference was not 
significant (29.2% vs 22.6%; p=0.538, OR=1.41, 95% CI 0.41-4.19). A non-significant 
association was also observed between PP and deliveries to female babies (29.3%, 
n=12/41 compared to 16.7% of deliveries to male babies, n=6/36; p=0.192, OR=2.07, 
95% CI 0.69-6.25). 
 
 
7.4.2.6 Breastfeeding within the current postpartum period 
As indicated in Table 7.7, there was no significant association between breastfeeding 
status (18.7%, n=9/48 vs 32.1%, n=9/28; p=0.185, OR=0.49, 95% CI 0.17-1.43) or the 
duration of breastfeeding and the occurrence of PP (median 1.3 vs 6 weeks, p=0.598). 
 
 
Table 7.7: Occurrence of PP according to breastfeeding status in the current postpartum period among 
BD-I/SA-BD women in the BDRN pregnancy sample (n=76) 
 
Numbers differ due to unknown data. BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: Postpartum 
psychosis; No PP: No postpartum psychosis. a p-values calculated via Mann-Whitney U test for continuous variables. P-values for 
categorical variables calculated by Pearson’s Chi-Square. 
 
 
7.4.2.7 Sleep factors relating to pregnancy and labour in the current 
perinatal period 
Table 7.8 summarises the proportion of women who experienced PP according to sleep 
related factors within the current perinatal period. Women who reported missing at 
least one complete night of sleep due to labour and delivery (defined as at least one 
 
 
 
 
PP No PP Test statistica p- value 
Breastfed baby 
Yes (n=48) 
                  No (n=28) 
                      
 
9 (18.7%) 
9 (32.1%) 
 
 
39 (81.3%) 
19 (67.9%) 
 
χ2 (1) 1.76 
 
0.185 
Duration of breastfeeding (weeks) 
Median (IQR) 
                   Range  
 
1.3 (11) 
0.5-12 
 
6.0 (10.75) 
0.1-12 
 
U= 140.500, 
Z = -0.640 
 
0.598 
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complete night without any sleep between the onset of labour and the first night’s 
sleep) were significantly more likely to experience PP (43.3%, n=13/30) compared to 
those who did not miss a complete night’s sleep (12.5%, n=4/32; p=0.007, OR=5.35, 
95% CI 1.50-19.11).  
 
Table 7.8: Occurrence of PP according to the presence/absence of sleep factors within the current perinatal 
period in BD-I/SA-BD women in the BDRN pregnancy sample (n=82) 
 
Numbers differ due to unknown data. BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: Postpartum 
psychosis; No PP: No postpartum psychosis. a p-values for categorical variables calculated by Pearson’s Chi-Square or Fisher’s exact 
test. F Statistic calculated by Fisher’s Exact Test 
 
However, the proportion of women who experienced PP was comparable between 
those who self-reported their quality of sleep within the third trimester to be 
‘good/very good’ (30.0%, n=6/20) and ‘fairly bad/very bad’ (32.1%, n=9/28; p=0.875, 
OR=0.91, 95% CI 0.26-3.13). There was also no significant difference in the occurrence 
of PP between women who gave birth during the daytime (26.2%, n=11/42) versus the 
night time (12.5%, n=1/8; p=0.661, OR 2.48 95% CI 0.27-22.54) or between those who 
reported any sleep lost due to labour (36.8%, n=14/38) and those who did not report 
this (18.8%, n=3/16; p=0.191, OR=2.53, 95% CI 0.61-10.44). 
 
 
 
 
 
PP No PP Test Statistica p- value 
 
Sleep quality in the 3rd trimester 
Good/very good (n=20) 
                  Fairly bad/very bad (n=28) 
 
 
 
6 (30.0%) 
9 (32.1%) 
 
 
 
14 (70.0%) 
19 (67.9%) 
 
 
χ2 (1) 0.25 
 
 
0.875 
 
Day/night time delivery 
Day time delivery (n=42) 
                  Night time delivery (n=8) 
 
 
 
11(26.2%) 
1 (12.5%) 
 
 
 
31 (73.8%) 
7 (87.5%) 
 
 
- 
 
 
 
 
0.661F 
 
Any sleep loss during labour 
Yes (n=38) 
                  No (n=16) 
 
 
14 (36.8%) 
3 (18.8%) 
 
 
24 (63.2%) 
13 (81.3%) 
 
 
χ2 (1) 1.71 
 
 
0.191 
 
At least one complete night of missed sleep 
during labour 
Yes (n=30) 
No (n=32) 
 
 
 
13 (43.3%) 
4 (12.5%) 
 
 
 
17 (56.7%) 
28 (87.5%) 
 
 
 
χ2 (1) 7.40 
 
 
 
0.007 
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7.4.2.8 Prophylactic mood stabilising medication in the perinatal period 
 Withdrawal of mood stabilising medication before and during 
pregnancy 
As discussed previously, for reasons which include teratogenicity of medications, many 
women with BD choose to withdraw mood stabilising medication during the perinatal 
period.  Given that the purpose of prophylactic mood stabilisers is primarily to prevent 
manic episodes, the influence of withdrawal of mood stabilising medications (lithium, 
anticonvulsants, typical or atypical antipsychotics) in the six months prior to or during 
pregnancy (that were not recommenced at any time during pregnancy) on risk for PP 
was examined. Of 55 women with BD-I/SA-BD known to be using mood stabilising 
medication in the six months prior to pregnancy, withdrawal of mood stabilising 
medications was not associated with an increased occurrence of PP (26.1%, n=6/23 vs 
21.9%, n=7/32 respectively; p=0.72, OR=1.26, 95% CI 0.36-4.41, Figure 7.3a).  
 
 
 
 
Of women who withdrew all mood stabilising medication (n=23), there was no 
significant difference in the occurrence of PP between women who withdrew mood 
Figure 7.3: Occurrence of PP according to withdrawal of mood stabilising medication during the perinatal 
period in BD-I/SA-BD women in the BDRN pregnancy sample (n=55). 
BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: postpartum psychosis. Bars represent 95% confidence 
intervals. 
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stabilising medications in the six months prior to pregnancy compared to those who 
withdrew mood stabilising medication during pregnancy (23.1%, n=3/13 vs 30.0%, 
n=3/10 respectively; p=1.00, OR=1.43, 95% CI 0.22-9.26, Figure 7.3b). 
 
 Prophylactic mood stabilising medication in the postpartum period 
Figure 7.4 shows the proportion of women who experienced PP among those who did 
and did not use prophylactic medication as a mood stabiliser in the postpartum period 
(see page 120 for full definition). Two women were excluded from this analysis as it was 
not clear whether medications used postpartum were commenced prophylactically or 
as treatment for onset of mood symptoms.  
 
 
 
 
 
 
  
 
 
 
 
 
 
Within the remaining sample (n=80), 25.0% (n=7/28) of women who were not using 
prophylactic medication as a mood stabiliser experienced an episode of PP, compared 
to 21.2% (n=11/52) of those who were. Use of prophylactic mood stabilising medication 
Figure 7.4: Occurrence of PP according to use of any prophylactic medication as a mood 
stabiliser in the postpartum period in BD-I/SA-BD women in the BDRN pregnancy sample 
(n=82).  
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in the postpartum period was not significantly associated with a reduced likelihood of 
developing PP (p=0.69, OR=0.80, 95% CI 0.27-2.38). 
 
 Type of prophylactic mood stabilising medication in the postpartum 
period 
To examine whether use of the three most commonly prescribed medications for 
postpartum prophylaxis of mania was associated with a reduced recurrence of PP, 
further statistical comparisons were made between groups of women who did and did 
not use the following medications: lithium, quetiapine and olanzapine. As highlighted in 
the previous section, two women were excluded from the overall analysis assessing 
postpartum prophylaxis for PP (due to inability to determine whether medication was 
prescribed prophylactically or as treatment). However, of these, one woman could be 
included in the control group for all analyses reported here, given that she had not used 
any of the specified medications during the postpartum period. The second woman was 
excluded only from analyses assessing the use of prophylactic quetiapine in the 
postpartum period (as she had only been using quetiapine, but it was not clear if this 
was commenced prophylactically or as treatment). Figure 7.5 shows the proportion of 
women who experienced PP according to use of each of the three medications. 
 
Women who were using quetiapine (Figure 7.5b) for postpartum prophylaxis of mood 
episodes were not significantly less likely to experience PP compared to women who 
were not using this medication (26.3%, n=5/19 vs 22.6%, n=14/62 respectively; p=0.76, 
OR=1.22, 95% CI 0.38-4.00). As shown in Figure 7.5a and Figure 7.5c, there were trends 
for women who were using lithium or olanzapine to be less likely to experience PP 
compared to women who were not using these medications, however, neither 
difference was statistically significant (18.2%, n=2/11 vs 25.4%, n=18/71; p=1.00, 
OR=0.65, 95% CI 0.13-3.32 and 13.3%, n=2/15 vs 26.9%, n=18/67; p=0.34, OR=0.42, 
95% CI 0.09-2.04 respectively). 
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BD-I: Bipolar I disorder, SA-BD: Schizoaffective disorder bipolar type, PP: postpartum psychosis. Bars represent 95% confidence 
intervals. 
 
 Timing of use of prophylactic mood stabilising medication 
Among women who used medication for postpartum prophylaxis of mood episodes 
(n=52), similar rates of recurrence of PP were observed between women who had 
continued mood stabilising medication from pregnancy into the postpartum period 
(20.0%, n=8/40) and those who had commenced medication following delivery (25.0%, 
n=3/12). There was no significant difference between the two groups (p=0.70, OR=1.33, 
95% CI 0.29-6.09).  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5 Occurrence of PP according to prophylactic use of the most commonly prescribed mood stabilising 
medications in the postpartum period in BD-I/SA-BD women in the BDRN pregnancy sample (n=82) 
 
 195 
Chapter 7 BDRN Pregnancy Study: within pregnancy risk factors 
7.4.2.9 Section summary 
In this section, I presented results of univariate analyses investigating the relationship 
between a range of within-pregnancy factors and PP among women with BD-I/SA-BD in 
the BDRN pregnancy sample. Findings indicated episodes of mania or affective 
psychosis during pregnancy and the loss of at least one complete night of sleep during 
labour to significantly increase risk of PP by 11.67 and 5.35 times respectively (Table 
7.9).  
 
Table 7.9: Summary of within-pregnancy variables significantly associated with the occurrence of PP in 
BD-I/SA-BD women in the BDRN pregnancy sample 
 
BD-I: bipolar I disorder, SA-BD: schizoaffective disorder bipolar type, PP: postpartum psychosis. OR: Odds-ratios, 95% CI: 95% 
confidence intervals. 
 
 
Due to limitations of multiple testing, it is important to consider that these findings may 
be at increased risk of type-I error. If Bonferroni Correction is applied to these analyses 
(p=0.05/51), the observed relationships would no longer reach the adjusted significance 
level of p=0.0009. Nevertheless, given the exploratory nature of this study, this 
significance level was deemed too conservative and thus a p-value of 0.05 was 
considered acceptable. In the following section, I will further examine these potential 
relationships using multivariate logistic regression models, controlling for lifetime 
correlates found to be associated with PP within the BDRN retrospective sample. 
 
 
 
Occurrence of PP 
% (n) 
P-value OR (95% CI) 
DSM-5 episode of mania/affective psychosis in pregnancy 
Mania/affective psychosis (n=11) 
No DSM-5 episode (n=46) 
 
 
63.6% (7) 
13% (6) 
 
0.001 
 
11.67 (2.61-52.21) 
At least one complete night of missed sleep during labour 
Present (n=30) 
Absent (n=32) 
 
43.3% (13) 
12.5% (4) 
 
0.007 
 
5.35 (1.50-19.11) 
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Notably, there were also several trends of within-pregnancy factors influencing risk of 
PP that did not reach statistical significance (Table 7.10). Factors indicated to non-
significantly increase risk of PP included: 
 an unplanned pregnancy 
 occurrence of any adverse life event during pregnancy (and specifically the 
occurrence of a serious illness or injury or a bereavement of a close friend or 
relative) 
 clinically impairing symptoms of anxiety during pregnancy 
 no obstetric complications during pregnancy or delivery (and specifically, no 
symptoms or diagnosis of pre-eclampsia, no pre-term delivery and a non-
assisted delivery) 
 vaginal delivery 
 delivery during the day-time 
 loss of any sleep attributed to labour and delivery  
 the birth of a female baby 
 
The following within-pregnancy factors showed a trend for reducing risk of PP: 
 Use of prophylactic lithium during the postpartum period 
 Use of prophylactic olanzapine during the postpartum period 
 
These factors will not be assessed further in multivariate models.  
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Table 7.10: Within-pregnancy factors demonstrating a trend towards an association with PP in BD-I/SA-BD 
women in the BDRN pregnancy sample 
  
BD-I: bipolar I disorder, SA-BD: schizoaffective disorder bipolar type, PP: postpartum psychosis. OR: Odds-ratios, 95% CI: 95% 
confidence intervals. * Minimum total sample size estimation (based on observed effect size) to achieve 80% power to detect a 
statistical difference using a two-tailed hypothesis with a significance value of p<0.05. a DSM-5 clinically impairing symptoms of 
anxiety during pregnancy. F P-value calculated by Fisher’s Exact Test. X P-value calculated by Pearson’s Chi Square 
 
PP 
% (n) 
P-value 
OR 
(95% CI) 
Power 
(%) 
Sample 
size 
required
* 
Psychosocial variables 
Planned pregnancy 
Planned (n=51) 
                  Unplanned (n=15 
 
23.5% (12) 
40.0% (6) 
 
0.322F 
 
2.17 (0.64-7.33) 
 
20% 
 
n=248 
Adverse life events during pregnancy 
Any adverse life event 
Any event (n=46) 
No event (n=24) 
         
Serious illness or injury 
       Yes (n=6) 
       No (n=62) 
 
Bereavement of close friend/relative 
       Yes (n=13) 
       No (n=54) 
 
28.3% (13) 
16.7% (4) 
 
 
50.0% (3) 
21.0% (13) 
 
 
38.5% (5) 
20.4% (11) 
 
0.283X 
 
 
 
0.137F 
 
 
 
0.274F 
 
1.97 (0.56-6.88) 
 
  
  
3.77 (0.68-20.91) 
 
 
 
2.77 (0.67-8.96) 
 
38% 
 
 
 
32% 
 
 
 
23% 
 
n=404 
 
 
 
n=84 
 
 
 
n=196 
Psychopathology during pregnancy 
Anxiety during pregnancy a 
Present (n=36) 
Absent (n=33) 
 
Non-psychotic depression during pregnancy 
Yes (n=18) 
No (n=46) 
 
27.8% (10) 
15.2% (5) 
 
 
27.8% (5) 
13.0% (6) 
 
0.204X 
 
 
 
0.270 X 
 
2.15 (0.65-7.14) 
 
 
 
2.56 (0.67-9.81) 
 
43% 
 
 
 
31% 
 
n=332 
 
 
 
n=230 
Obstetric factors 
Obstetric complications during pregnancy 
Yes (n=30) 
No (n=47) 
 
Symptoms/diagnosis of pre-eclampsia 
Symptoms/diagnosis (n=13) 
    No symptoms or diagnosis (n=66) 
 
Pre-term delivery (<37 weeks) 
Yes (n=7) 
No (n=70) 
 
Any delivery complications 
     Yes (n=36) 
     No (n=39) 
 
Caesarean section  
Caesarean section (n=28) 
Vaginal delivery (n=50) 
 
Assisted delivery 
Non-assisted delivery (n=38) 
Assisted delivery (n=40) 
 
13.3% (4) 
29.8% (14) 
 
 
7.7% (1) 
27.3% (18) 
 
 
14.3% (1) 
25.7% (18) 
 
 
19.4% (7) 
28.2% (11) 
 
 
17.9% (5) 
28.0% (14) 
 
 
31.6% (12) 
17.5% (7) 
 
0.100 
 
 
 
0.171 
 
 
 
0.674 
 
 
 
0.375 
 
 
 
0.317 
 
 
 
0.148x 
 
2.76 (0.81-9.38) 
 
 
 
4.50 (0.55-37.14) 
 
 
 
2.08 (0.23-18.44) 
 
 
 
1.63 (0.55-4.80) 
 
 
 
1.79 (0.57-5.64) 
 
 
 
2.18 (0.75-6.31) 
 
38% 
 
 
 
26% 
 
 
 
6% 
 
 
 
5.6% 
 
 
 
16% 
 
 
 
30% 
 
n=203 
 
 
 
n=116 
 
 
 
n=384 
 
 
 
n=732 
 
 
 
n=542 
 
 
 
n=290 
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Table 7.10 continued: Within-pregnancy factors demonstrating a trend towards an association with PP in 
BD-I/SA-BD women in the BDRN pregnancy sample 
 
BD-I: bipolar I disorder, SA-BD: schizoaffective disorder bipolar type, PP: postpartum psychosis. OR: Odds-ratios, 95% CI: 95% 
confidence intervals. * Minimum sample size estimation (based on observed effect size) to achieve 80% power to detect a statistical 
difference using a two-tailed hypothesis with a significance value of p<0.05. a DSM-5 clinically impairing symptoms of anxiety during 
pregnancy. F P-value calculated by Fisher’s Exact Test. X P-value calculated by Pearson’s Chi Square 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PP 
% (n) 
P-value OR 
(95% CI) 
 
Power 
(%) 
 
Sample size 
required* 
Sex of baby 
Male (n=36) 
Female (n=41) 
 
 
16.7% (6) 
29.3% (12) 
 
 
0.192x 
 
2.07 (0.69-6.25) 
 
44% 
 
n=348 
Labour/delivery related sleep factors 
Day/night time delivery 
Day time delivery (n=42) 
Night time delivery (n=8) 
 
 
26.2% (11) 
12.5% (1) 
 
 
0.661F 
 
2.48 (0.27-22.54) 
 
2% 
 
n=258 
Any sleep loss during labour 
Yes (n=38) 
No (n=16) 
 
36.8% (14) 
   18.8% (3) 
 
0.191x 
 
2.53 (0.61-10.44) 
 
46% 
 
n=192 
Prophylactic mood stabilising medication in the postpartum period 
Prophylactic lithium  
Prophylactic lithium (n=11) 
No prophylactic lithium (n=71) 
 
 
18.2% (2) 
25.4% (18) 
 
 
1.000F 
 
1.53 (0.30-7.74) 
 
2% 
 
n=1030 
Prophylactic olanzapine 
Prophylactic olanzapine (n=15) 
No prophylactic olanzapine (n=67) 
 
 
13.3% (2) 
26.9% (18) 
 
 
0.340F 
 
2.39 (0.49-11.64) 
 
11% 
 
n=270 
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7.4.3 Regression model of within-pregnancy potential risk factors for 
postpartum psychosis 
The presence or absence of mania or affective psychosis during pregnancy was assessed 
as a predictor of PP in a binary logistic regression model with the presence/absence of 
PP as the outcome variable. The loss of at least one complete night of sleep due to 
labour and delivery was excluded from the model due to the limited number of cases. A 
significance level of p<0.05 was considered an acceptable cut-off for inclusion of within-
pregnancy predictor variables. Potential lifetime predictors found to be significantly 
associated with PP within our BDRN retrospective sample were also included in the 
model as covariates (Table 7.11), with the exception of preconception history of 
psychotic symptoms due to of evidence of multicollinearity (with preconception history 
of PP). An additional regression model was performed to assess potential moderating 
effects of prophylactic mood stabilising medication in the postpartum period on the 
potential relationship between mania and affective psychosis during pregnancy and the 
occurrence of PP (summarised in section 7.4.3.2 and in Table 7.13). 
 
Table 7.11: Lifetime covariates included in the within-pregnancy regression model due to their association with PP in 
the BDRN retrospective sample  
 
 
7.4.3.1 Regression model of within-pregnancy potential risk factors 
controlling for lifetime correlates of PP 
 
The relationship between mania/affective psychosis with onset during pregnancy (with 
no mania/affective psychosis as the control group) and PP was assessed in a regression 
Lifetime covariate 
Relevant citation demonstrating significant relationship 
between lifetime factor and PP 
Preconception lifetime history of PP within 6 weeks Di Florio et al. (2018); Robertson et al. (2005)  
Family history of postpartum mood illness in 1st degree 
relative 
Jones and Craddock (2001) 
Sleep loss as a lifetime preconception self-reported 
trigger of manic episodes    
Lewis et al. (2017) 
Primiparous at conception of current pregnancy Di Florio et al. (2014) 
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model, which also included the following lifetime covariates (meeting recommendations 
of a minimum of 10 cases per independent variable to prevent overfitting of the data, 
Peduzzi et al. 1996): preconception lifetime history of PP (including women who were 
primiparous, coded as no lifetime history of PP to maximise the sample size), primiparity 
at time of conception of the current pregnancy (yes/no), family history of postpartum 
affective illness in a first degree relative (present/absent) and sleep loss as a self-
reported lifetime ever trigger for preconception episodes of mania (present/absent). 
Results of this model are summarised below in Table 7.12. 
 
After controlling for lifetime correlates associated with PP in the BDRN retrospective 
sample, onset of mania or affective psychosis during pregnancy (β=2.803, p=0.002, OR 
16.49, 95% CI 2.76-98.48) significantly predicted PP within six weeks of delivery. This 
model explained 35.1% of the variance of PP (Nagelkerke R Square) and correctly 
classified 82.6% of cases (p=0.002). 
 
Table 7.12: Regression model predicting PP within the BDRN pregnancy sample 
7.4.3.2 Regression model adjusting for prophylactic mood stabilising 
medication in the postpartum period 
After further adjusting for use of prophylactic mood stabilising medication in the 
postpartum period, mania or affective psychosis during pregnancy (β=2.72, p=0.006, OR 
15.24, 95% CI 2.23-104.32) and preconception history of PP significantly predicted the 
 Wald DF p-value OR (95% CI) 
DSM-5 episode of mania/affective psychosis in 
pregnancy 
9.449 1 0.002 16.49 (2.76-98.48) 
Preconception lifetime history of PP within 6 weeks 3.385 1 0.066 5.67 (0.89-35.99) 
Family history of postpartum mood illness 1.612 1 0.204 3.07 (0.54-17.32) 
Primiparous at conception of current pregnancy 0.302 1 0.583 1.61 (0.30-8.71) 
Sleep loss as a trigger for preconception mania 2.040 1 0.153 0.33 (0.07-1.51) 
 
DF: degrees of freedom. OR: odds ratio. 95% CI: 95% confidence intervals 
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occurrence of PP within the current perinatal period (β=2.75, p=0.031, OR 15.58, 95% CI 
1.29-188.18, see Table 7.13). This model explained 38.2% of the variance (Nagelkerke R 
Square) of PP and correctly classified 83.6% of cases (p=0.003). 
 
Table 7.13: Regression model of predictors of PP within the BDRN pregnancy sample after adjustment for 
prophylactic mood stabilising medication in the postpartum period  
7.4.4 Predictors of PP and their relationship to postpartum non-
psychotic depression 
To further examine the specificity of significant predictors of PP, the relationship 
between the occurrence of mania/affective psychosis in pregnancy, preconception 
history of PP and postpartum non-psychotic depression was also assessed. For these 
analyses, outcomes were defined among women with a preconception history of BD-
I/SA-BD as:  
a) No DSM-5 mood episode within three months of delivery (no postpartum 
mood episode ‘No PME’ group, n=47)  
 
b) An episode of non-psychotic depression within three months of delivery 
(PND only group, n=10).  
 
Women who experienced an episode of PP or of postpartum hypomania were excluded 
from these analyses (n=25). A broader temporal definition of the postpartum period 
was used to capture episodes of PND which had a wider distribution of onset. As shown 
 Wald DF p-value OR (95% CI) 
Preconception lifetime history of PP within 6 weeks 4.656 1 0.031 15.58 (1.29-188.78) 
DSM-5 episode of mania/affective psychosis in pregnancy 7.707 1 0.006 15.24 (2.23-104.32) 
Primiparous at conception of current pregnancy 1.591 1 0.207 4.70 (0.42-51.96) 
Family history of postpartum mood illness 2.090 1 0.148 3.66 (0.63-21.27) 
Prophylactic mood stabilising medication in postpartum 0.264 1 0.607 0.67 (0.14-3.16) 
Sleep loss as a lifetime ever trigger of preconception mania 1.094 1 0.296 0.44 (0.09-2.06) 
DF: degrees of freedom. OR: odds ratio. 95% CI: 95% confidence interval 
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in Table 7.14 there was a trend for women who experienced an episode of mania or 
affective psychosis during pregnancy (66.7%, n=2/3) to be more likely to experience an 
episode of PND compared to women who did not experience any DSM-5 mood episode 
during pregnancy (10.8%, n=4/37). However, due to small sample sizes, it was not 
possible to statistically compare this difference. Preconception history of PP (including 
women who were primiparous) was not significantly associated with PND (Fisher’s exact 
test, p=1.000, OR=0.93, 95% CI 0.17-5.06).  
 
Table 7.14: Predictors of PP and their relationship to PND in BD-I/SA-BD women in the BDRN pregnancy 
sample 
 
Numbers differ due to unknown data.BD-I: bipolar I disorder, SA-BD: schizoaffective disorder bipolar type, PND: Postpartum non-
psychotic depression with onset within three months of delivery. No PME: No occurrence of a DSM-5 mood episode with onset 
within three months of delivery, a p-values calculated using Fisher’s Exact Test. b Statistical comparisons could not be conducted due 
to small sample sizes. 
 
 
 
 
 
 
 
 
 
 PND No PME Test statistic p- valuea 
DSM-5 episode of mania/affective psychosis in pregnancy 
Present (n=3) 
                  Absent (n=37) 
 
2 (66.7%) 
4 (10.8%) 
 
1 (33.3%) 
33 (89.2%) 
 
- 
 
-b 
Preconception lifetime history of PP within 6 weeks 
Present (n=12) 
                  Absent (n=45) 
 
2 (16.7%) 
8 (17.8%) 
 
10 (83.3%) 
37 (82.2%) 
 
- 
 
1.000 
 
 203 
Chapter 7 BDRN Pregnancy Study: within pregnancy risk factors 
7.5 Summary of findings 
This study investigated potential within-pregnancy risk factors for the occurrence of PP 
in women with BD-I and SA-BD using a prospective follow-up design. Key findings from 
these analyses are summarised below.  
 
 Univariate analyses revealed episodes of mania or affective psychosis during 
pregnancy and the loss of at least one complete night of sleep during labour to 
be significantly associated with the occurrence of PP. 
 
 In contrast, there was no significant association between within-pregnancy 
psychosocial or obstetric factors and the occurrence of PP.  
 
 Use of prophylactic mood stabilising medications in the postpartum period was 
not significantly associated with a reduced risk of PP.  
 
 Over and above known associations between lifetime factors and PP (identified 
in the BDRN retrospective sample), episodes of mania or affective psychosis with 
onset during pregnancy significantly predicted PP, increasing risk more than 16 
times. After further adjusting for the use of prophylactic mood stabilising 
medication, women who experienced episodes of mania/affective psychosis 
during pregnancy remained at least 15 times more likely to experience PP than 
women who did not experience these episodes during pregnancy.  
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7.6 Discussion 
This chapter aimed to investigate potential within-pregnancy risk factors for PP, over 
and above known associations between lifetime correlates and PP (such as a 
preconception history of PP) in a sample of pregnant women with BD-I/SA-BD using a 
prospective follow-up design. Results of these analyses will be discussed further in this 
section and considered in the context of the existing literature. Strengths and 
limitations of the study and the implications of these findings for clinical practice and 
future research will be presented.  
 
7.6.1 Psychopathology during pregnancy within the current perinatal 
period 
7.6.1.1 DSM-5 recurrence of affective episodes  
In this study, antenatal recurrence of a DSM-5 mood episode, specifically of mania or 
affective psychosis was associated with a more than 15 times increased risk of PP. 
Episodes of mania or affective psychosis during pregnancy remained a significant risk 
factor for PP, even after controlling for the use of prophylactic mood stabilising 
medication within the postpartum period. The relationship between antenatal mood 
episodes and PP appears unique to episodes of mania or affective psychosis, given that 
although a trend was observed, no significant association was found between 
recurrence of non-psychotic depression during pregnancy and of PP.  
 
These findings are consistent with a number of studies indicating high rates of 
postpartum mood episodes among women who experience recurrence during 
pregnancy (Akdeniz et al. 2003; Bergink et al. 2012; Doyle et al. 2012; Freeman et al. 
2002; Viguera et al. 2011), but this study is the first to demonstrate a specific 
association between mania in pregnancy and the occurrence of PP. It could be 
suggested that women who experienced PP had not fully recovered from episodes of 
mania or psychosis occurring during pregnancy, thus reflecting a continuation of illness 
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as opposed to the onset of a new episode in the postpartum period. However, the use 
of a prospective design allowed for the onset and duration of each episode to be more 
accurately determined than in retrospective studies. In addition to each woman’s self-
report of perinatal psychopathology, data were further supplemented by case-note 
review and clinician questionnaires. In particular, clinicians were specifically asked to 
confirm if a postpartum recurrence was a continuation of an episode with onset during 
pregnancy. Using these methods, the clear onset/absence of a DSM-5 mood episode in 
the postpartum period could be determined and independently agreed by consensus in 
nearly all cases. Additionally, postpartum episodes identified as having onset during 
pregnancy or those in which onset could not clearly be established were excluded from 
these analyses.  
 
The association between severe antenatal and postpartum recurrence may also suggest 
that women who experienced episodes within both phases of the perinatal period had a 
more severe course of BD overall, marked by an increased vulnerability to more 
frequent episodes of mania. When examining this further, compared to women who 
remained well during pregnancy, mania or psychosis during pregnancy was significantly 
associated with more frequent lifetime episodes of mania prior to pregnancy, but not of 
depression. Notably however, I also observed trends for episodes of PP to occur more 
frequently among women who experienced non-psychotic depression during 
pregnancy, and for episodes of PND to occur more frequently among women who 
experienced episodes of mania/affective psychosis during pregnancy. This would 
suggest that an increased susceptibility to mania in general is unlikely to explain the 
specific relationship between mania/affective psychosis during pregnancy and 
subsequent PP. 
 
If either factor (i.e. an increased vulnerability to mania or unremitted antenatal mania) 
were accounting for the observed relationship between antenatal mania/psychosis and 
PP, we might expect episodes of mania to occur at similar rates across pregnancy and 
the postpartum period. Yet in this sample, as in others (Di Florio et al. 2013; Munk-
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Olsen et al. 2009; Viguera et al. 2011), episodes of mania/affective psychosis were more 
prevalent following childbirth compared to during pregnancy (Chapter 6, section 6.4). 
Together, this might suggest that the aetiology of PP is distinct from episodes of mania 
occurring within-pregnancy. Regardless of the nature of the relationship, the onset of 
mania or affective psychosis during pregnancy may be an important risk marker of PP in 
women with BD. This finding also further highlights the importance of planning 
pregnancy in BD; not only is the risk of recurrence high antenatally but prevention of 
these episodes may also be crucial for more favourable outcomes postpartum. 
 
7.6.1.2 Anxiety  
This study was the first to investigate the relationship between pathological anxiety 
during pregnancy and risk of PP within BD. Though a significant relationship was not 
found in this study, women reporting clinically impairing symptoms of anxiety during 
pregnancy were more likely to experience PP compared to women who did not have 
such symptoms. These findings are consistent with one other prospective study which 
has also shown anxiety during pregnancy to significantly increase risk of broadly defined 
PP (affective or non-affective) within the first three weeks of delivery (McNeil 1988b). 
Though the relationship between antenatal anxiety and PP was not specifically assessed 
within women with BD, the majority of episodes with early onset (within 3 weeks 
postpartum) were predominantly affective. Given that the same relationship was not 
observed in relation to later onset episodes (which more frequently presented as non-
affective), this would suggest a specific relationship between antenatal anxiety and 
affective PP in particular. 
 
Nonetheless, information regarding anxiety was not gathered for 13 (of 82) women 
recruited during pregnancy to the sample examined within this thesis (due to this 
measure being introduced later in the period of data collection). This analysis was 
therefore underpowered at 43% to detect a statistically significant difference in the 
occurrence of PP according to the presence or absence of pathological anxiety during 
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pregnancy. Based on effect sizes within the current sample, sample size calculations 
indicated at least 332 women would be required in future analyses to achieve sufficient 
power of 80% to detect a between group difference.  
 
7.6.1.3 Sleep factors within the current perinatal period 
 Sleep loss due to labour and delivery 
Within this sample, I observed a trend for episodes of PP to occur more frequently 
among women who self-reported sleep loss (of any duration) during labour compared 
to those who reported no missed sleep during this period.  Furthermore, women who 
reported losing at least one complete night of sleep were significantly more likely to 
develop PP compared to women who did not report this. As this data was not gathered 
for 20 women with BD-I/SA-BD (due to this measure being introduced later in the 
period of data-collection), sample sizes were too small to assess the predictive effect of 
this factor for episodes of PP in multivariate analyses, over and above other known risk 
factors (such as preconception history of PP and FH of postpartum affective illness). 
Nonetheless, these initial findings might suggest that acute sleep loss experienced 
during delivery and the early postpartum is an important triggering factor in the onset 
of PP. If replicated, this finding would also be consistent with evidence indicating sleep 
loss to also be a trigger of non-postpartum manias (Bauer et al. 2006; Leibenluft et al. 
1996; Lewis 2017).  
 
A limitation of this analysis could be that it was difficult for women to distinguish 
between insomnia as a prodromal symptom of mania from sleep lost specifically due to 
labour and delivery, particularly in cases of very early onset PP. This is a common 
limitation of any research which aims to assess the role of self-reported sleep loss in the 
triggering of manic episodes, given that sleep disturbance is likely both a trigger and 
symptom of psychopathology. However, in an attempt to distinguish between the early 
onset of symptoms and sleep loss due to labour/delivery, women were made aware at 
interview that the question referred specifically to sleep lost due to labour and delivery. 
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A small subset of women in the BDRN pregnancy sample (n=7) also participated in an 
actigraphy study during the perinatal period, in which the aim was to assess the causal 
association, if any, between objectively measured sleep in late pregnancy, the 
immediate postpartum period and postpartum psychiatric outcomes (Lewis 2017). Data 
in the current study regarding sleep loss during labour was further validated and 
corroborated by objective data gathered by Lewis (2017) within some women.  
 
Figure 7.6 (adapted from Lewis 2017) shows the number of hours of sleep per night 
across the perinatal period (from late pregnancy to the early postpartum) and 
postpartum psychiatric outcomes in the seven women for whom actigraphy data was 
collected. For example, the objective measure indicated that participant 86 missed two 
complete night’s sleep prior to the day of delivery (i.e. obtained 0 hours sleep for two 
consecutive days) with her delivery being followed by an onset of PP. In almost all 
women (participants 50, 54, 63, 86, 87 and 94), actigraphy data was highly correlated 
with self-reported sleep data from the current study, irrespective of postpartum 
psychiatric outcome. Data was not wholly consistent across measures for only one 
woman (participant 80). In this case, the participant reported missing one complete 
night’s sleep during labour and delivery, while actiwatch data indicated that she slept 
for approximately one hour the night before delivery. However, as noted by Lewis 
(2017), actiwatch data typically measures activity and not sleep, therefore is known to 
overestimate sleep during periods of rest or sitting still. Given that participant 80 self-
reported a complete loss of sleep, it is likely this woman received very little, if any sleep 
during the night indicated. It is also interesting to note that in the two women who 
experienced an episode of PP (Participants 86 and 80), number of hours of sleep 
subsequently increased in the immediate period following delivery and the acute period 
of sleep loss. This would further suggest that women were in fact reporting sleep loss 
attributed to the period of labour and delivery, as opposed to the onset of manic 
symptoms.  
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Figure 7.6: Sleep actigraphy data for the perinatal period in a subset of women in the BDRN prospective 
sample (n=7), adapted from Lewis (2017) 
 
 
Interestingly, I also observed a trend for episodes of PP to occur more frequently among 
women who had given birth during the day time, though no significant association was 
found between length of labour and occurrence of PP. These findings are in contrast to 
those of a previous study (Sharma, Smith and Khan 2004), in which sleep disruption 
during labour was retrospectively compared between a clinical sample of women 
admitted with PP and a healthy parous control group. The authors reported a significant 
association between deliveries occurring at night, increased length of labour and 
episodes of PP, providing indirect evidence to suggest that sleep disruption during 
labour may be a precipitant of PP. Given the high proportion of primiparous women in 
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their sample (57%), the authors further postulated that first pregnancies are likely to 
affect sleep patterns and routines to a greater degree than subsequent pregnancies 
(Sharma and Mazmanian 2003). However, it was not possible to examine this 
hypothesis further within the current study, given the small number of women who 
were primiparous in the BDRN pregnancy sample (n=40).  
 
The discrepancy between findings across studies may be explained by several 
methodological differences. For example, in the study by Sharma, Smith and Khan 
(2004), the case group was comprised of a diagnostically heterogeneous sample of 
women, which in addition to BD, also included women with diagnoses of schizoaffective 
disorder depressed type and unipolar psychotic depression. Furthermore, comparisons 
were made with a healthy parous control group rather than a diagnostically 
homogeneous group of women who were considered at equally high-risk of recurrence. 
Thus, their findings are likely to have limited generalisability to women with BD and may 
instead reflect differences in sleep patterns between parous women with psychiatric 
disorders and parous healthy controls.  
 
Within the current study, the lack of a significant association between night time 
delivery, duration of labour and PP appears inconsistent with the finding that self-
reported sleep loss (of at least one complete night) during labour significantly predicts 
PP. However, time of delivery and duration of labour can only be considered proxy 
measures of sleep disruption and do not necessarily equate to duration of sleep loss or 
indicate if in fact, more acute sleep loss occurred (e.g. complete nights of sleep missed 
during labour/delivery). Acute sleep loss (as opposed to any sleep disruption) may be a 
more important risk factor for PP. This is supported by evidence in the current study 
suggesting that while sleep loss of any duration during labour and delivery was 
associated with an increased risk of PP by more than 2.5 times, this risk more than 
doubled when at least one complete night of sleep was missed during labour (OR=5.35).  
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 Sleep factors related to pregnancy 
In contrast to sleep disruption associated with labour, this study found no association 
between poor self-reported sleep quality in the third trimester of pregnancy and PP. As 
discussed earlier in this thesis, only one published study has previously attempted to 
assess sleep patterns prospectively during pregnancy and the relationship with PP 
(Bilszta, Meyer and Buist 2010).However, given that so few women experienced any 
postpartum recurrence (n=3) the authors were unable to statistically examine the 
specific association between sleep patterns and occurrence of PP. Consequently, the 
current study is the first to prospectively assess the association between sleep quality in 
late pregnancy and occurrence of PP in women with BD.  
 
The finding that poor sleep quality during pregnancy does not appear to increase risk of 
PP in women with BD is novel but should be interpreted carefully in the context of 
several possible limitations. Firstly, it could be argued that subjective measures of sleep, 
especially during pregnancy are not likely to be as reliable as objective measures such as 
actigraphy. However, it has been previously suggested that objective measures of sleep 
(particularly those using actigraphy) are not necessarily more accurate than self-report 
measures when assessing disturbed sleep (Littner et al. 2003). This is especially likely to 
be the case when assessing quality of sleep, given that as discussed above, actigraphy 
data typically gathers information regarding periods of activity or rest, thus only 
indicating number of hours of sleep obtained per period of study. Therefore, for this 
and reasons regarding feasibility, self-report measures of sleep quality were deemed 
the most appropriate measure of this factor. Secondly, sleep patterns and quality are 
known to be highly variable in late pregnancy (Lee 1998). The time at which sleep 
quality was assessed during the third trimester of pregnancy varied in some cases 
(depending on the availability of each participant), it is therefore possible that sleep 
patterns at the start of the third trimester were dissimilar from that in the last week of 
pregnancy. To remedy this limitation, sleep quality would ideally be assessed at multiple 
time points during the third trimester and particularly in the last week of pregnancy. 
However, given the difficulty of predicting the onset of labour, frequent measures of 
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assessment in late pregnancy would be required, reducing feasibility of the study. These 
additional assessments would also likely increase risk of attrition prior to postpartum 
follow-up. A potential compromise for increasing feasibility in future studies may be to 
offer completion of adjunctive online measures of sleep assessments in the late stages 
of pregnancy.  
 
7.6.2 Psychosocial factors within the current pregnancy 
In this study, I did not find a significant association between any of the within-
pregnancy psychosocial factors studied and the subsequent occurrence of PP. To my 
knowledge, this is the first study to prospectively examine women’s perceived 
experience of pregnancy in relation to PP in BD. The lack of association between 
women’s overall subjective experience of pregnancy and PP is however consistent with 
a small study of women with broadly defined PP (i.e. including women who experienced 
affective or non-affective psychoses, McNeil and Blennow, 1988).  
 
Though not significant, I found episodes of PP to occur more frequently among women 
who reported their pregnancy as being unplanned (40%) compared to women who had 
planned their pregnancy (23.5%). This analysis was found to be considerably 
underpowered (at 20%), with sample size estimates indicating at least 248 women with 
BD would be required to achieve 80% power to detect the observed difference between 
groups. Nevertheless, the direction of the trend is consistent with previous reports 
which have found an unplanned pregnancy to increase risk of any postpartum 
recurrence among women with BD (Abdel-Hay, El-Sawy and Badawy 2011; Doyle et al. 
2012) but is inconsistent with one study examining risk factors for PP among a 
diagnostically heterogeneous clinical sample (Marks et al. 1992). Given the paucity of 
research investigating this relationship among women with BD, it remains unclear 
whether this finding may reflect the psychological effects of an unexpected pregnancy 
or the increased likelihood that these women may be more likely to withdraw 
medication suddenly during pregnancy. For example, circumstances related to an 
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unplanned pregnancy (such as pregnancies resulting from reckless behaviour in a manic 
episode or financial pressures) may act as psychological stressors, increasing 
vulnerability of PP. Furthermore, while it was not possible to examine the rate of 
medication withdrawal during pregnancy among women in this sample, rapid 
discontinuation of mood stabilisers (within 14 days) during pregnancy has been 
associated with an increased risk of perinatal recurrence of mood disorder among 
women with BD (Viguera et al. 2000, 2007).  
 
Importantly, few women did not have a partner present during the pregnancy or 
reported their partner as not being emotionally supportive. For this reason, it was not 
possible to meaningfully examine the relationship between these factors and the 
occurrence of PP. While several studies have reported no association between the 
presence of a partner during pregnancy and PP (McNeil 1987; Protheroe 1969; Wisner, 
Peindl and Hanusa 1994) others have reported the opposite (Dean and Kendell 1981; 
Kendell, Chalmers and Platz 1987; Nager, Johansson and Sundquist 2005; Terp and 
Mortensen 1998; Upadhyaya, Sharma and Raval 2014). In the current study, there was a 
trend for women who reported having a partner present and emotionally supportive 
relationships during pregnancy to be more likely to experience PP than women who did 
not report this. This finding is similar to that of a prospective study of women with a 
history of functional psychoses, in which rates of PP were higher among women 
reporting more emotionally supportive relationships during pregnancy (Marks et al. 
1992). This would also be consistent with evidence indicating that women who 
experience PP tend to be high functioning both socially and occupationally (Sit, 
Rothschild and Wisner 2006). Nevertheless, it was not possible to draw conclusions 
from this set of analyses, given that only one woman in the current study did not have a 
partner present during her pregnancy and only two women denied feeling emotionally 
supported by their partner or others.  
 
Alternatively, these observations may reflect a sample bias, in that women recruited to 
his study were on the whole particularly high functioning. This is suggested by a number 
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of factors. Firstly, the rate of single mother pregnancies was low in this sample (1%), 
compared to estimates of 5.2% in the UK general population (Office for National 
Statistics 2017) and the few reports among other prospective studies of pregnant 
women with BD (18%-59%, Driscoll et al. 2017; Viguera et al. 2007). If these women 
were particularly high functioning, they might be expected to experience less difficulty 
in maintaining significant relationships compared to women with BD who are lower 
functioning. Accordingly, most women in the BDRN sample had achieved degree level 
qualifications or higher (62.1%) and had worked in professional occupations (52.4%) at 
some point during their lifetime. Given that women were primarily recruited through 
perinatal services and had reported planning their pregnancy (77%), it is also likely 
these women planned their pregnancy at a time when circumstances were most 
convenient for them (i.e. when in a stable and supportive relationship and at a financial 
advantage).  
 
On the whole, these initial findings do not suggest a significant role of psychosocial 
factors in the aetiology of PP within BD and is consistent with the previous literature. 
This is in contrast to episodes of PND, in which a range of psychosocial factors have 
frequently been reported to significantly increase risk of recurrence (Cantwell and 
Smith 2009; Leigh and Milgrom 2008; O’Hara and Swain 1996). However, as I was 
unable to investigate the influence of partner support and single parenthood on risk of 
PP in this sample, factors which have inconsistently been associated with PP in previous 
literature, their role in the occurrence of PP requires further study.  
 
7.6.3 Adverse life events within the current pregnancy 
Several trends emerged from this study, showing that PP occurred more frequently 
among women who experienced at least one adverse life event during pregnancy and 
specifically, among those who experienced a serious illness or injury or a bereavement 
of a close friend or relative during pregnancy. No significant associations (or trends 
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towards significance) were found between any other specified adverse life event, nor 
the total number of adverse life events experienced and subsequent risk of PP.  
These findings are in contrast to previous literature, which has found no evidence to 
suggest that adverse life events during pregnancy may increase risk of PP (Brockington 
et al. 1990; Dowlatshahi and Paykel 1990; Marks et al. 1992). However, the trends 
observed within this study may be explained by several factors. Specifically, this study is 
the first to examine the relationship between adverse life events during pregnancy and 
PP within women with BD. Previous studies have primarily focused on women with 
broadly defined affective disorder (Marks et al., 1992) or in clinical samples of women 
with PP with no distinction between those with affective and non-affective psychotic 
disorders (Brockington et al. 1990; Dowlatshahi and Paykel 1990). Furthermore, I 
defined life events as being ‘adverse’ on the basis of women’s subjective self-report, 
including only those events that they perceived to have a moderate to severe negative 
impact. In comparison, all three previous studies in this area assessed the degree of 
negative impact objectively (Brockington et al. 1990; Dowlatshahi and Paykel 1990; 
Marks et al. 1992). It is therefore possible that the adverse, psychological impact of 
these events were underestimated, explaining the lack of significant findings or trends 
within their samples. Finally, to ensure I only examined events occurring prior to and 
within close temporal proximity to childbirth, I assessed only those events which had 
occurred during pregnancy. In previous studies, the timeframe during which events 
occurred was either not clear (Brockington et al. 1990) or was considerably broader 
than in the current study (up to one year prior to pregnancy, Dowlatshahi and Paykel, 
1990; Marks et al., 1992). It is plausible that more distally occurring events pose less 
psychological risk for PP than those occurring closer to childbirth.   
 
This suggestion may be supported by findings reported earlier in this thesis, 
demonstrating that adverse life events occurring during childhood do not appear to be 
associated with increased risk of PP in BD (reported in Chapter 3). However, given that 
sample sizes were small (with some events inevitability occurring infrequently during 
pregnancy), it was not possible to examine the specific effect of all individual life events 
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measured. Furthermore, of those that were statistically examined, analyses were largely 
underpowered to detect a difference. According to sample size calculations, to achieve 
80% power, between 84 and 404 women would be required in future studies to detect 
between group differences in adverse life events during pregnancy.  
 
7.6.3.1 Smoking and alcohol use within the current pregnancy 
This study was the first to prospectively examine the relationship between smoking and 
alcohol use during pregnancy and the occurrence of PP within a sample of women with 
BD. The influence of alcohol consumption during pregnancy on risk for PP remains 
unexplored, given that no woman in this study reporting drinking more than the 
recommended number of units per week. However, no significant association was 
found between smoking during pregnancy and the occurrence of PP. This finding is in 
contrast to that previously reported in the BDRN retrospective sample, in which lifetime 
history of smoking was associated with a significantly reduced risk of experiencing PP 
(n=653, Di Florio et al. 2015). It is possible that social desirability effects particularly 
influenced findings within the current study, given that women may be less likely to 
disclose smoking or drinking behaviour when assessed during their pregnancy.  
 
7.6.3.2 Obstetric factors within the current perinatal period 
No significant association was found in this study between any obstetric factor assessed 
(including pregnancy or delivery complications, method of delivery, sex of baby or 
gestation period) and the occurrence of PP. There was a trend for episodes of PP to 
occur more frequently following deliveries of female babies than of male babies (29.3% 
and 16.7% respectively, see page 195 for summary table), though as these analyses 
were found to be underpowered at 44%, this difference did not reach statistical 
significance (sample size estimates suggest 348 women would be required to achieve 
80% power). The observed trend is consistent with the findings of a Indian study in 
which the majority of women (72%) admitted for episodes of PP had given birth to 
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female babies (Agrawal, Bhatia and Malik 1990). In contrast, investigations within a sub-
set of women within our BDRN retrospective sample revealed no association between 
sex of baby and PP (55% of deliveries to male babies, Blackmore et al. (2006).    
 
The finding that complications during pregnancy or delivery were not found to increase 
risk of PP, is consistent with investigations in large case-register studies (Meltzer-Brody 
et al. 2017; Nott 1982; Videbech and Gouliaev 1996) and one prospective study 
(Bergink et al. 2011a). Interestingly, I observed an overall directional trend for episodes 
of PP to occur more frequently among women who did not experience obstetric 
complications during the perinatal period, which may suggest that biological factors 
uniquely associated with giving birth naturally are particularly important in the 
pathophysiology of PP. Consistent with this theory, there was a trend for women who 
reported delivering their baby via normal vaginal delivery to be more likely to 
experience PP (31.6%) compared to women who had delivered their baby by any other 
mode (17.5%). Nevertheless, this finding did not reach statistical significance (post-hoc 
power calculated to be 30%, sample size calculation for 80% power to be n=290). 
Alternatively, women who experience obstetric complications may be more closely 
monitored by health services, receiving more support and being encouraged to rest 
more frequently during pregnancy. It is possible these factors may therefore have had 
an indirect protective effect on risk of PP.   
 
The lack of a significant association between obstetric complications and PP is however 
in contrast to one study conducted within a sub-set of women in the BDRN 
retrospective sample (Blackmore et al. 2006). In this study, obstetric complications were 
compared in 129 women with BD between deliveries affected and unaffected by PP 
within four weeks of childbirth using a within-subjects design.  Due to the small sample 
sizes, the authors were unable to assess the role of individual obstetric complications in 
postpartum recurrence of mood episodes, however they did find the occurrence of any 
obstetric complication during delivery to be significantly associated with increased risk 
of PP. This finding is inconsistent with the current study, despite the same definition of 
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obstetric complications being utilised in both studies. This difference may be explained 
by the retrospective nature of the analysis in the study by Blackmore et al. (2006). 
Specifically, the retrospective assessment of obstetric factors and postpartum outcomes 
may have increased the likelihood of recall bias. Women who experienced PP (many of 
whom were recruited to the study specifically on the basis of having a history of PP) 
may have been more likely to detect or report obstetric complications than those who 
did not experience an adverse psychiatric outcome.  
 
7.6.3.3 Medication use for prophylaxis of postpartum mania within the 
current perinatal period 
The findings of this naturalistic study indicate that risk of PP among women with BD-I 
and SA-BD is high, despite prophylaxis with mood stabilising medications. In this sample, 
use of any mood stabilising medications was not significantly associated with a reduced 
risk of experiencing PP. Further investigation also revealed no significant association 
between the occurrence of PP and specific medications (i.e. lithium or olanzapine), 
timing of use (for example, in both pregnancy and the postpartum period, compared 
with the postpartum period only) or a significant change (i.e. withdrawal) of mood 
stabilising medication during the perinatal period. These findings are consistent with a 
large case-control study of severe affective disorders (Taylor, Stewart and Howard 
2019), in which prophylactic medication use in late pregnancy did not significantly 
reduce risk of severe postpartum recurrence within three months of delivery. However, 
much of the literature to date has reported the opposite. In their meta-analysis of eight 
studies (total n=205), Wesseloo et al (2016) reported the risk of severe postpartum 
recurrence to be lower among women with BD utilising any mood stabilising medication 
in the postpartum period compared to women who were medication free (29% and 
65% respectively). The discrepancy in findings may be attributed to methodological 
differences between studies. Specifically, research included in the meta-analysis were 
primarily descriptive in nature and in contrast to this thesis, had not controlled for 
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factors previously identified as influencing risk for PP (such as primiparity or previous 
history of PP).  
 
Efficacy of lithium (Austin 1992; Bergink et al. 2012; Cohen et al. 1995; Van Gent and 
Verhoeven 1992) and olanzapine (Sharma, Smith and Mazmanian 2006) for prophylaxis 
of PP has been demonstrated in samples of women with BD. Though associations were 
not statistically significant, there was a trend for PP to occur less frequently among 
women using lithium and olanzapine compared to women who were not taking these 
medications (refer to section 7.5). These analyses were found to be underpowered at 
only 2% for lithium and 11% for olanzapine. Given the clinical significance of these 
findings, the prophylactic effect of these medications in particular requires further 
investigation.  Sample size calculations suggest as many as 1030 women with BD would 
be required to achieve 80% when assessing the prophylactic effect of lithium and at 
least 270 women to adequate assess efficacy of olanzapine.  
 
The lack of an overall association between any psychotropic medication use and risk of 
PP was surprising and may be explained by several factors. For example, the definition 
of mood stabilising medications in this study was wider than that used previously, 
including medications (such as antipsychotics) which have little or no demonstrable 
evidence of efficacy for prophylaxis of postpartum recurrence. Of women utilising 
psychotropic medication in the current sample, more than two thirds were using at 
least one atypical antipsychotic (primarily quetiapine). The efficacy of this medication 
for prophylaxis of PP has not yet been examined elsewhere. Moreover, a recent study 
has shown pharmacokinetic changes in pregnancy to affect serum blood levels of 
quetiapine and aripiprazole in particular, reducing bioavailability of these drugs across 
pregnancy. Consequently, higher doses of these medications may be required during 
the perinatal period to achieve the same therapeutic effect. In the BDRN pregnancy 
sample, prophylactic quetiapine was the most commonly used mood stabilsing 
medication.  
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In contrast to randomised controlled trials, it can be difficult in naturalistic studies to 
distinguish between the effects of illness from those of medication. Women with a 
more severe preconception course of illness may have been more likely to remain on 
prophylactic mood stabilising medication during the perinatal period. Personal 
preferences of women and their clinicians were also likely to have influenced decisions 
around psychotropic medication use in the perinatal period. Nevertheless, post-hoc 
comparisons between women using prophylactic mood stabilising medications in the 
postpartum period compared to those without did not reveal significant differences 
between the two groups with regards to markers of a more severe preconception 
course of illness (such as the number of preconception lifetime mood episodes per 
illness year, number of preconception admissions or of psychotic features (see 
Appendix N). Conversely, it could be suggested that the high proportion of women 
recruited through specialist perinatal psychiatric services had an illness that was 
particularly well-managed. However, no significant differences were observed between 
women recruited through specialist perinatal services and those recruited through 
other methods in the rates of postpartum prophylactic medication use (see appendix 
O).  
 
An alternative explanation is that mood stabilising medications may be less effective at 
preventing mania in the postpartum period compared to mania occurring at other 
times. As discussed in the background chapter to this thesis, emerging evidence 
suggests that postpartum mania may be distinct in aetiology from non-puerperal 
episodes. This is reflected by differences in the clinical presentation and course of these 
episodes. Indeed, in our retrospective BDRN sample, we have also found a number of 
key clinical characteristics to significantly differ between postpartum and non-
postpartum manic episodes when using a within-subjects design, with perplexity and 
dysphoria being more frequently present among episodes of postpartum mania (paper 
under review for publication). Consequently, postpartum episodes of mania may 
require a distinct pharmacological approach from that used outside the perinatal 
period, even within the same woman.  
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7.6.4 Strengths and limitations 
There are a number of key strengths of this study. First is the use of a prospective 
follow-up design to assess the perinatal period and predictors of postpartum recurrence 
in a clinically, well defined sample of pregnant women with BD. This is the largest study 
to investigate such a wide range of potential within-pregnancy risk factors for PP in BD 
using this gold-standard method. The use of multiple assessments and follow up 
measures across the perinatal period has a number of benefits compared with a 
retrospective methodology, such as; reducing the possibility of recall bias, allowing for 
directional relationships between risk factors and PP to be established and for perinatal 
mood episodes to be more accurately characterised. Additionally, a combination of 
measures was used to assess postpartum psychiatric outcomes. Had this study relied on 
follow-up interviews alone, severe postpartum recurrences many not have been 
adequately captured, instead being lost to attrition.   
 
A further strength is that in all cases, consensus ratings were made independently by 
the same two members of the research team (myself and CF) for key clinical and 
predictor variables such as prophylactic medication use, preconception main best 
estimate diagnoses and perinatal psychiatric outcomes. In addition, ratings of all key 
clinical data were made independently via a widely used, psychiatric assessment tool 
consistent with DSM criteria. Use of DSM criteria allows for comparability between 
these findings and the wider literature. 
 
Finally, the follow-up period in this study was restricted to the first three postpartum 
months. This period has been shown in population studies to represent the highest-risk 
period for severe recurrence of mood disorder. Using a more narrowly defined 
definition of postpartum onset limits the possibility that episodes unrelated to 
childbirth were included in prevalence rates of psychiatric outcomes and subsequently 
in analyses of potential risk factors for PP.  
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Overall, data from this prospective study are high-quality and provide an important 
contribution to the literature regarding risk prediction of PP in women with BD. The 
naturalistic design of this study also likely captured variability in illness course and 
management that is representative of real-world scenarios encountered by women and 
their clinicians during the perinatal period.  
 
7.6.4.1 Limitations 
Whilst this study has many strengths, it is important to consider the findings in the 
context of several limitations. For example, despite an intense effort to recruit a 
representative sample of women with BD using a combination of both systematic and 
non-systematic methods, approximately two thirds of the sample had a diagnosis of BD-
I disorder. Additionally, just over half (52.4%) of all women recruited to this study were 
identified via specialist perinatal psychiatric services. These women may represent a 
specific sub-group of BD who were more likely to be referred (or to self-refer) to these 
services due to having a more severe illness course or as shown previously, prior history 
of perinatal mood episodes.  
 
In this study, all follow-up interviews were conducted via telephone to increase 
feasibility of the research. Conducting the interview via telephone increased flexibility of 
the assessment for women in the early postpartum period, encouraging participation. 
Interviews could be conducted at any location participants chose (for example, at a 
friend’s or relative’s home whilst the baby was being cared for) and were less intrusive 
than in person interviews. However, despite this benefit, it has been argued that 
compared to face-to-face interviews, telephone interviews may compromise data 
quality. Specifically, rapport between the interviewer and participant may be restricted, 
resulting in increased risk of non-disclosure of emotionally sensitive information (Novick 
2008; Shuy 2003). The potential for this effect is however minimised in the current 
study for several reasons. First, follow-up interviews were conducted after rapport had 
been established during pregnancy. Almost all women were interviewed in person (at 
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home) during pregnancy, typically over a period of two hours. The screening 
assessment and third trimester interview also provided further opportunities for 
relationship building. Second, follow-up data were gathered from clinicians and 
psychiatric case notes, corroborating and supplementing information obtained at 
interview. In addition, no differences have been observed in the quality or quantity of 
information obtained during psychiatric research interviews conducted by telephone 
compared to face-to-face methods (Aneshensel et al. 1982; Crippa et al. 2008; Fenig et 
al. 1993; Simon et al. 1974; Wells et al. 1988).  
 
Another important limitation is the modest sample size of this study, particularly when 
stratifying according to potential risk factors or potential sub-groups of interest. As 
indicated in section 7.5 (page 203), it was not possible to adequately assess a number of 
potential risk factors for PP, given that these analyses would be considerably 
underpowered to detect a statistically significant difference. Emphasis was therefore 
placed on examining trends within the data. It is also of note that relationships found to 
be significant would not survive Bonferroni correction. However, due to the exploratory 
nature of this study, Bonferroni correction was deemed too conservative and a less 
stringent p-value of 0.05 was considered more appropriate. Consequently, findings 
from this study would benefit from replication within a larger sample of women with 
BD. Depending on the factor of interest (and observed effect sizes), sample size 
estimates indicated as many as between 98-1080 women with BD would be required in 
future analyses to achieve sufficient power of 80%.  
 
Due to sample size limitations, it was not possible to examine risk factors for PP 
according to diagnostic subtype of BD, therefore reducing generalisability of findings to 
the wider BD population. Investigating aetiological and triggering factors of PP among 
women with BD-II or BD-NOS is likely to be considered of particular clinical importance, 
given that despite lack of evidence, these women are generally perceived to be at lower 
risk of PP. Similarly, there is evidence to suggest that women who experience episodes 
of mania solely in relation to childbirth may represent a distinct subtype of BD 
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(Wesseloo et al. 2016). It therefore cannot be assumed that aetiological and triggering 
factors for PP among such women are similar to those in women who have a more 
‘typical’ bipolar illness (i.e. women who also experience episodes of mania unrelated to 
childbirth). Narrowly refining samples of women with BD for future studies of PP would 
not only be of clinical benefit, but would also provide further insight into the nosology 
of postpartum psychiatric illnesses. 
 
Despite facing unique challenges when recruiting women with BD to this prospective 
research (for example, the narrow time frame during which women could be recruited 
and women being less likely to take part compared to other times), the sample size 
obtained was that which was feasible within the time frame. Moreover, this study 
remains one of the largest prospective pregnancy studies of BD to date and the first 
such study to be conducted within a UK population. Recruiting larger samples of women 
with BD during pregnancy to prospective or longitudinal research would be highly 
resource intensive and require highly targeted recruitment methods. Women with BD-II 
or BD-NOS may be less likely to be identified by perinatal specialist services, while 
isolated PP cases are uncommon. Recruiting these women would likely be achievable, 
but would rely on continued collaboration with NHS specialist perinatal services and 
also large, national organisations such as Bipolar UK and Action on Postpartum 
Psychosis (APP). 
 
7.6.5 Implications 
7.6.5.1 Clinical practice 
If replicated, the findings of this thesis have potentially important implications for 
clinical practice. Specifically, these data indicate that risk of recurrence of BD is high 
across the perinatal period, despite prophylactic medication use. This finding might 
suggest that in many cases, current pharmacological regimens are suboptimal for 
managing BD across the perinatal period. Further research is therefore needed to 
examine medication factors that may contribute to poorer maternal outcomes across 
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the perinatal period in women who have BD. In particular, focus should be placed on 
investigating the pharmacokinetic changes that may be induced by pregnancy and 
childbirth on psychotropic medications commonly used for prophylaxis of BD. Emerging 
evidence has shown that serum blood levels of lithium and quetiapine can vary 
considerably across pregnancy (Wesseloo et al. 2017a; Westin et al. 2018), reducing 
below optimal therapeutic dose. Thus, the authors have highlighted the need for 
frequent monitoring of blood levels of these medications throughout the perinatal 
period. Nevertheless, data in this area remains limited. Such research is crucial, given 
that as demonstrated in this naturalistic sample, a wide range of medications are 
utilised for prophylaxis of PP, despite having no established evidence base for efficacy. 
Inevitably, large samples of individuals would be required to conduct these analyses. 
One way this could be achieved is through the use of large, naturalistic datasets of 
anonymised clinical records such as that used by the NIHR Maudsley Biomedical 
Research Centre (https://www.maudsleybrc.nihr.ac.uk/facilities/clinical-record-
interactive-search-cris/)   
 
While pharmacotherapy is the first line recommended intervention for prevention of PP 
(National Institute for Health and Clinical Excellence 2014), the findings of this study 
also highlight the importance of exploring the effectiveness of other non-
pharmacological interventions for further managing risk of PP. For example, women in 
this sample who missed more than at least one night of complete sleep across labour 
and delivery were found to be at more than five times increased risk of PP. Where 
possible, strategies to minimise sleep disruption during this period may therefore be 
beneficial, but require further examination.  
 
Finally, an additional approach to enhance perinatal care in women at high-risk of PP 
could involve the provision of further specialist education for midwives and health 
visitors.  Indeed, this is a recommendation that has been outlined in the NHS Long Term 
Plan (NHS England 2019b).  As clinical professionals who are in frequent contact with 
women during pregnancy and the first critical weeks following delivery, midwives and 
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health visitors are instrumental for identifying women at high-risk of PP and also those 
who require urgent psychiatric intervention following childbirth. Data derived from this 
thesis could form the basis of educational programmes regarding risk of PP. For 
example, case-vignettes could be used to demonstrate the phenomenology of episodes 
and provide wider context of severe postpartum mood disorders.  
  
  
7.6.6 Aetiology of postpartum mood episodes 
On the whole, findings from this study are consistent with previous literature indicating 
biological factors related to pregnancy and childbirth to be more important in the 
aetiology of PP than psychological factors. This is generally in contrast to studies of PND, 
which have consistently found psychological factors to be robust predictors of these 
episodes (Cantwell and Smith 2009; Howard et al. 2014). This is also in line with 
emerging literature which has implicated genetic factors (Jones and Craddock 2001), 
immunological factors (Bergink et al. 2015a, 2015b) and sensitivity to hormonal changes 
(Robertson Blackmore et al. 2008) in the pathophysiology of PP. The findings of this 
study, if replicated, may further suggest that episodes of PP and PND are 
heterogeneous forms of mood disorder, with PP in particular having a unique 
relationship to aetiological and triggering factors associated with childbirth. This would 
have important implications for nosology of these episodes and particularly 
classification of postpartum mood disorders, given that currently, neither DSM nor ICD-
10 criteria recognises PP as being distinct from other perinatal episodes. Additionally, 
there are also implications for future research, which should aim to investigate risk 
factors for PND and PP independently in BD, given that these episodes are likely to be 
heterogeneous forms of mood illness.  
 
7.7 Summary  
In summary, the findings of this naturalistic study suggest that women with BD are at 
high risk of recurrence of mood episodes during the perinatal period and particularly of 
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PP within the first few weeks after delivery. The risk of PP within this sample remained 
high, despite the use of prophylactic medications for mood stabilisation in the 
postpartum period. Over and above risk associated with known lifetime predictors (such 
as prior history of PP), episodes of mania or affective psychosis during pregnancy 
significantly increased risk of PP among women with BD-I/SA-BD by more than 15 times. 
Further analysis revealed that prophylactic mood stabilising medication within the 
postpartum period did not significantly reduce this risk. Moreover, additional evidence 
suggests that acute sleep loss (of more than one complete night) associated with labour 
and delivery may act as a final common-pathway in the triggering of PP. Given that no 
clear significant relationship was established between any psychosocial factor and the 
occurrence of PP, this finding suggests biological factors may be especially important in 
the aetiology of PP.  
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8.1 Overview of chapter 
In this chapter, I review the main findings and final conclusions of this thesis, followed 
by a discussion of the potential implications of this work for clinical practice. Key 
limitations of this research will also be discussed, concluding with suggestions for 
further research.  
 
8.2 Main findings 
The primary aim of this thesis was to investigate potential aetiological and triggering 
factors for episodes of PP among women with well-defined BD. Specifically, the three 
main aims of this thesis were to: 
 
1. Investigate potential relationships between history of ACEs, anxiety disorders 
and the lifetime occurrence of PP in a sample of parous women with BD 
(Chapter 3, The BDRN Retrospective Sample). 
 
2. Describe psychotropic medication use and psychiatric outcomes across the 
perinatal period in a sample of pregnant women with BD using a prospective 
follow-up design (Chapter 6, The BDRN Pregnancy Sample) 
 
3. Investigate a wide range of within-pregnancy potential risk factors for PP in a 
sample of pregnant women with BD using a prospective follow-up design 
(Chapter 7, The BDRN Pregnancy Sample).  
 
The main findings of this thesis are reviewed in relation to each aim within the following 
sections.  
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8.2.1 Aim 1 
‘To investigate potential relationships between history of ACEs, anxiety disorders and the 
lifetime occurrence of PP in a sample of parous women with BD’ 
 
In Chapter 3, I examined whether history of ACEs or anxiety disorders was associated 
with PP in a sample of parous women with BD (The BDRN retrospective sample). This 
study was the first to examine these relationships among women with well-defined BD. 
In contrast to studies examining the relationship between these factors and PND, I 
found no evidence to suggest ACEs or lifetime comorbidity of anxiety disorders are 
associated with an increased vulnerability to PP in women with BD.  
 
The lack of evidence for a relationship between ACEs and PP is consistent with one 
small study which also reported no significant relationship between a small range of 
ACEs and broadly defined PP among a diagnostically heterogeneous sample of women 
(Dowlatshahi and Paykel 1990) and the findings of a Danish population study (Meltzer-
Brody et al. 2018). The findings of the current study also support those of the wider 
literature, reporting a lack of association between adverse life events occurring during 
adulthood or within the 12 months prior to pregnancy and the onset of PP. Together, 
these findings suggest that life stressors, or at least more distal life stress (from the 
event of childbirth) do not play an important role in the pathogenesis of PP.  
 
Given that the role of anxiety disorders or life stressors occurring within-pregnancy in 
could not be examined in relation to PP within this sample, these factors were identified 
as areas of further study in prospective research. 
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8.2.2 Aim 2 
‘To describe psychotropic medication use and psychiatric outcomes across the perinatal 
period in a sample of pregnant women with BD using a prospective follow-up design’ 
 
In Chapter 6, I described psychotropic medication use and psychiatric outcomes across 
the perinatal period (to three months postpartum) in women with BD using a 
prospective follow-up design. In this naturalistic study, I found patterns of psychotropic 
medication use to be highly variable across the perinatal period. Most women (61.2%) 
used at least one mood stabilising medication during pregnancy, and almost two thirds 
(64.4%) a prophylactic mood stabilising medication postpartum. 26% of all women 
discontinued all mood stabilising medication prior to or during pregnancy and did not 
recommence these medications within the remaining study period.  
 
Despite frequent use of psychotropic medication, risk of at least one new onset DSM-5 
mood episode remained high during the perinatal period (59.8%). Risk of recurrence 
was comparable during pregnancy (43%) and within the first three postpartum months 
(42.6%). However, compared to pregnancy (11.9%), risk of mania/affective psychosis 
was greatest following childbirth (21%), and occurred more frequently in women with 
BD-I/SA-BD (24.4%) compared to those with BD-II/BD-NOS (5.6%). In contrast, risk of 
postpartum hypomania (8%) was comparable with that of pregnancy (7.9%), while 
depression was less frequent postpartum (14%) compared to pregnancy (22.8%). All 
episodes of PP occurred within six weeks of delivery (76% within the first two weeks), 
while the onset of hypomania and PND was more widely distributed throughout the 
postpartum period.  
 
These findings are consistent with previous literature that has shown the perinatal 
period to be a time of high risk of recurrence of BD (Di Florio et al. 2013) and the early 
postpartum period in particular for episodes of mania/affective psychosis (PP; Wesseloo 
et al. 2016).  Risk of PP remained high despite use of prophylactic mood stabilising 
medication in the postpartum period, suggesting that factors other than medication are 
also likely to influence risk of PP in women with BD. 
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8.2.3 Aim 3 
‘To investigate a wide range of within-pregnancy potential risk factors for PP in a sample 
of pregnant women with BD using a prospective follow-up design’ 
 
In Chapter 7, I reported findings of investigations examining the influence of a range of 
within-pregnancy factors on risk of PP in women with BD using a prospective follow-up 
design. To my knowledge, this prospective study is one of the largest such studies 
conducted to date and the first to be conducted in a UK sample of women with BD.  
 
In univariate analyses, I found the occurrence of mania/affective psychosis during 
pregnancy and loss of more than one complete night’s sleep during labour/delivery to 
significantly increase risk of PP. After adjusting for known lifetime correlates of PP 
(history of mania triggered by sleep loss, prior history of PP, family history of perinatal 
psychiatric illness and primiparity), mania/affective psychosis during pregnancy 
remained a significant predictor of PP (p=<0.01, OR 16.49, 95% CI 2.76-98.48). When 
added to the model, prophylactic mood stabilising medication during the postpartum 
period had little influence in moderating risk of PP (p=0.61, OR 0.67, 95% CI 0.14-3.16).  
 
Given that acute sleep loss across labour/delivery was also associated with PP in 
univariate analysis (but could not be examined further due to limitations in sample size), 
this may suggest that sleep disruption across the peripartum period may also act as a 
final common pathway in the triggering of PP in women with BD. Moreover, despite 
observing several trends within the data, within-pregnancy psychological and 
psychosocial factors did not significantly influence risk of PP, suggesting that in contrast 
to episodes of PND (as demonstrated in the literature), these factors may be less 
important in the pathophysiology of PP. 
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8.2.4 Final conclusions 
In conclusion, the findings of this thesis suggest that risk of PP is high among women 
with BD, despite use of prophylactic mood stabilising medication in the postpartum 
period. Neither history of ACEs nor anxiety disorders were associated with increased 
risk of lifetime PP. However, an episode of mania/affective psychosis with onset during 
pregnancy was found to significantly increase risk of PP, over and above associations 
with known lifetime risk factors. Further evidence suggested that use of prophylactic 
mood stabilising medication had little influence in reducing risk of PP and that sleep loss 
associated with labour and delivery may also act as a final common pathway in the 
triggering of PP. In contrast to studies of PND, no significant associations were found 
between within-pregnancy psychological or psychosocial factors and PP, further 
suggesting that aetiological and triggering factors may be distinct across these 
disorders. 
 
8.3 Implications 
If replicated, the findings of this thesis have potential clinical implications for 
individualising risk prediction and prevention of PP in women with BD and also for 
understanding the aetiology and nosology of PP and related mood disorders. These 
implications are discussed further within this section.  
 
8.3.1 Clinical implications 
The high prevalence of perinatal recurrence observed in the prospective sample further 
highlights the need for all women who have BD to be closely monitored and followed 
throughout pregnancy, as well as the postpartum period. Women with BD should be 
made aware of the risk of recurrence during both stages of the perinatal period and 
advised on the importance of planning pregnancy. Ideally, all women with BD should 
receive care from specialist perinatal psychiatric services from the 
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preconception/planning stage through at least the first three months postpartum. The 
findings of this thesis also suggest that psychological and psychosocial factors may be 
less important when determining individual risk of PP in women with BD.  
 
Given that the risk of PP remains high despite use of prophylactic mood stabilising 
medication, further research is required to examine medication factors and practices 
that may be associated with poorer maternal outcomes. Data also indicates that focus 
should be placed on evaluating the potential effectiveness of non-pharmacological 
interventions for reducing risk of PP. This may for example include strategies to 
minimise the impact of acute sleep disruption where possible across labour and 
delivery. In an effort to ensure women at high risk of PP receive optimal care across all 
healthcare disciplines during the perinatal period, data derived from this thesis could 
also be used to form the basis of education programmes about PP for health visitors 
and midwives. Such healthcare professionals may be instrumental for identifying 
women at high risk of PP and also those who require urgent psychiatric intervention in 
the early postpartum period.  
 
8.3.2 Aetiology and nosology of postpartum mood disorders 
Together with existing literature, the findings of this thesis support evidence to suggest 
that the aetiology of PP is potentially distinct from PND. The lack of strong evidence for 
a role of psychological or social factors in the occurrence of PP is in contrast to studies 
of PND, which have consistently found these factors to be more robust predictors of 
non-psychotic depression following childbirth (Cantwell and Smith 2009; Howard et al. 
2014). If replicated, the findings of this study might suggest that episodes of PP and PND 
are heterogeneous forms of mood disorder, which could have important implications 
for the nosology of these episodes and the classification of postpartum mood disorders 
more generally. 
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8.4 Limitations 
8.4.1 Potential sample biases 
The main limitation of this thesis is the potential for sample bias based on a number of 
recruitment related factors. Firstly, due to a key focus of BDRN being on genetic studies 
of mood disorders, it is possible that women who took part in this research were more 
likely to do so due to having a more biological form of BD or an increased genetic 
vulnerability to BD or PP (for example, as indicated by a strong family history of mood 
disorders).  
 
Secondly, as many women were recruited through perinatal psychiatric services and 
national support charities such as APP (to increase feasibility of the study), it is also 
possible that these women had a more severe form of BD that required increased 
psychiatric monitoring, and more specifically, were a group of women who were 
particularly susceptible to mood disorders triggered by childbirth. However, half of the 
pregnancy sample were found to be primiparous (50.5%) and so did not have a previous 
history of PP. Furthermore, to minimise the influence of any such biases, I adopted a 
range of systematic and non-systematic approaches to recruitment and where relevant, 
conducted post-hoc analyses to assess and/or control for the influence of recruitment 
method and preconception psychiatric history on findings.  
 
Thirdly, despite using a range of methods to recruit women to this research, ethnic 
diversity of the samples remained low. As such, generalisability of the current findings 
to ethnic minority groups is potentially limited. The predominance of White-British 
women in these samples is likely explained by several factors. One contributory factor 
may be the focus of BDRN on genetic studies of mood disorders. Another is that due to 
the nature of the assessments, women were required to be fluent English speaking. The 
ethnic diversity of the sample is also likely to reflect general trends in referral patterns 
and utilisation of perinatal psychiatric services nationally. Specifically, areas of the 
country in which recruitment to this research was most successful (such as the North 
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East of England and South Wales) are predominantly comprised of residents who are 
White British (97.6% and 97.3% respectively; Office for National Statistics 2012). 
Moreover, evidence indicates being from an ethnic minority background as a strong 
predictor of disengagement and non-utilisation of services (O’Brien, Fahmy and Singh 
2009). Thus, to enhance the representativeness of findings from future studies of PP, 
recruitment efforts should focus on areas of the country high in ethnic diversity (such as 
London; Office for National Statistics 2012).  
 
8.4.2 Complications regarding the nosology of postpartum psychosis 
A further limitation of this research is that due to uncertainty regarding the most 
appropriate definition of PP and also the temporal criterion that should be used to 
define the postpartum period, those adopted within this thesis are essentially arbitrary. 
As discussed previously, there is disagreement between standardised diagnostic criteria 
in the temporal definition of the postpartum period (being four weeks in DSM and six 
weeks in ICD criteria), while in clinical practice and other research, a definition of up to 
12 months postpartum is frequently used. However, as a compromise, I chose a 
temporal cut-off of six weeks to define the postpartum period to include both DSM and 
ICD criteria. Furthermore, this is more consistent with literature which indicates the 
early postpartum to be the period of high risk of PP, thus reducing the possibility that I 
included cases of mood disorder that were unrelated to childbirth.  
 
Similarly, the concept of PP and how to most appropriately define the phenotype that 
should be captured within this concept (i.e. what forms of mood illness should be 
included) is not clear. For example, it is uncertain whether episodes of postpartum 
hypomania or PND occurring within close temporal proximity to childbirth should be 
included or excluded within the definition of PP or whether episodes of postpartum 
psychotic depression should be considered distinct from episodes of psychotic or non-
psychotic mania. However, given that evidence primarily suggests that childbirth is most 
closely related to affective psychoses, predominantly those that typically present with 
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manic or mixed features, I narrowly defined PP as any severe episode of mania 
(excluding hypomania) or affective psychosis only, regardless of polarity. This definition 
is also widely used within clinical practice and other research studies, thus ensuring 
these findings could be more directly compared with other literature within this area.  
 
8.5 Further research 
As the investigations presented and discussed within this thesis are novel, further 
independent replication of these findings is required in a larger sample of women with 
BD. Given the considerable heterogeneity in research findings between existing studies 
of PP (likely due to methodological differences), future research should aim to replicate 
these investigations using a similar methodology to that used within this thesis. 
Specifically, future studies should adopt the same definition of PP and temporal cut-off 
used to define the postpartum period, in addition to using a similar standardised 
psychiatric research tool to assess perinatal psychiatric outcomes according to clinical 
diagnostic criteria. This would further enable comparability of findings between studies.  
 
Further research is also needed to assess other within-pregnancy factors that may 
influence risk for PP, but could not be investigated within this thesis. For example, the 
role of neurobiological factors specific within-pregnancy (such as hormonal or 
immunological) in the occurrence of PP has been little studied in samples of women 
with BD, particularly using a prospective methodology. Moreover, it would be of great 
clinical and personal benefit (for women with BD) to examine other medication related 
factors that may explain the lack of association I observed between use of prophylactic 
mood stabilising medications postpartum and risk of PP. Specific areas identified for 
further investigation include assessing the influence of dosage and serum blood levels 
of medications across the perinatal period (to ensure therapeutic dose is being 
achieved). Additionally, due to limitations of sample size, efficacy of commonly used 
psychotropic medications for mood stabilisation could not be examined effectively and 
as such, warrant further study.    
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In order to extend the findings of this thesis further, another area of research would be 
to investigate risk (and potential risk factors) of PP across other subtypes of BD. The 
findings of this study indicate that although risk is low, a small proportion of women 
who have BD-II at conception experience PP and thus, potentially a more severe long-
term course of illness. Being able to predict risk of PP within this group may provide 
early indication of long-term course of BD, but would be particularly beneficial for the 
clinical management of BD-II during the perinatal period. This may be especially 
important, given that risk of PP is often perceived to be low for women with BD-II (by 
women themselves and clinicians), and may result in these women being less likely to 
use medication or be under the care of psychiatric services during the perinatal period.  
 
Similarly, emerging evidence indicates that some women have a distinct, ‘pure 
puerperal’ form of BD, in which episodes of mania/affective psychosis only occur in 
relation to childbirth. It would therefore be of interest to examine potential risk factors 
for PP within this sub-group, as refining the phenotype further may provide additional 
clues to the aetiology and triggering of these episodes. However, to be able to conduct 
these investigations across subtypes of BD, more intensive effort would be required to 
recruit women into future studies, given that a ‘pure puerperal form’ of BD is less 
common and that women with BD-II are less likely to be under the care of perinatal 
psychiatric services during pregnancy. Thus, highlighting the need for targeted 
recruitment of these women via non-systematic methods in particular, which may be 
best achieved through continued close collaboration with national patient support 
charities such as Bipolar UK and APP.   
 
Based on the findings of this thesis and in combination with existing literature, a final 
recommendation for further research is that additional focus should be placed on 
investigating genetic factors that may be involved in the pathogenesis of PP. Despite 
indication that susceptibility to PP may be hereditary in some cases, specific genes are 
yet to be identified. However, collection of genetic material from women with BD and a 
history of PP is ongoing in the BDRN programme of research. It is anticipated that in the 
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future, through international collaboration with other research groups, sample sizes will 
be sufficient to conduct a genome wide association study of PP. Furthermore, given the 
overlap in roles of the endocrine and neurotransmitter function in mood regulation, 
parturition and sleep, the role of sleep disruption in the occurrence of PP should also be 
a prime candidate for further study. Specifically, studies should assess sleep disruption 
using objective methods of assessment (such as with actigraphy), to further distinguish 
between sleep loss as a trigger for PP and the prodromal phase of illness. 
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Appendix A 
Appendix A: Childhood Life Events Questionnaire (CLEQ) 
 
Self / Interviewer rated (please circle) 
Did you experience as a child (up to age 16 years) any of the following life events? 
         If yes, how old were 
      Please circle:   you? 
1. Death of parent    Yes No   _____ 
 
2. Death of a brother/sister   Yes No   _____ 
 
3. Death of a close friend   Yes No   _____ 
 
4. Divorce of parents   Yes No   _____ 
 
5. Marital separation of parents  Yes No   _____ 
 
6. Marriage of parent to step parent Yes No   _____ 
 
7. Serious illness needing  
 hospitalisation    Yes No   _____ 
 
8. Hospitalisation of a parent  Yes No   _____ 
 
9. Acquiring a visible deformity  Yes No   _____ 
 
10. Jail sentence of a parent for a  
 year or more    Yes No   _____ 
 
11. Teenage pregnancy/fatherhood  Yes No   _____ 
 
12. Suspension from school   Yes No   _____ 
 
13. Are there any other significant life events you experienced as a child that are not 
mentioned about?      Yes No  
 
..........................................................................................................................................................................
..........................................................................................................................................................................
................
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Appendix B: Lifetime psychiatric history questionnaire 
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Appendix C: The Brief Life Events Questionnaire (BLEQ) 
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Appendix D: Participant information sheet 
 
 
 
 
 
INFORMATION ABOUT RESEARCH INTO MOOD DISORDERS 
 
INTRODUCTION 
We are a team of psychiatrists and psychologists who work in the Department of Psychological Medicine at 
the University of Worcester and the Department of Psychological Medicine at Cardiff University. We are 
conducting research (funded by the Wellcome Trust and the Stanley Medical Research Institute) into the 
causes of mood disorders and work closely with other research groups both in Europe and the United States. 
We would like to ask you if you would be willing to take part in our research.  Before you decide whether 
or not you would like to take part, please take the time to read the following information carefully.   
 
WHAT IS THE PURPOSE OF THE RESEARCH? 
Mood disorders sometimes run in families but in other cases only one member of a family is affected. 
Unfortunately no-one understands enough about the illnesses to know what causes particular individuals to 
become unwell. The main aim of our research is to look for genes and other factors, such as stressful life 
events, which make some people more likely than others to become ill. We hope that our study will improve 
understanding of mood disorders and help other workers find better treatments in the future.  
 
WHO IS BEING ASKED TO TAKE PART IN THE STUDY? 
Over 6000 individuals have already taken part in our ongoing research into mood disorders. It is important 
for us to see many more people in order that we can get the best possible understanding of the causes of 
mood disorders. We are hoping to recruit individuals who have experienced one or more episodes of high 
mood (often called mania, hypomania or bipolar disorder) at some point in their lives and would be extremely 
grateful if you would be kind enough to help with this study. 
 
WHERE DOES THE STUDY TAKE PLACE? 
If you agree to take part, a member of our research team will arrange a suitable time to visit you in your 
home or at another place convenient for you, or to interview you over the phone. 
 
WHAT DOES TAKING PART INVOLVE? 
Taking part involves: 
 An interview by a trained member of our research team who will spend up to an hour and a half asking 
you about your experiences and the kinds of symptoms you have had in the past. If you are willing we 
would like to audio record part of the interview for consistency and training purposes. 
 Completing a set of questionnaires (which will take around half an hour). 
 In some cases, giving a blood sample from your arm (2 standard blood tubes). 
 
With your permission, we would like to look at your medical records in strict confidence in order to gain 
further information about the kinds of symptoms you have experienced. We only need to see you once but 
may contact you again in the future if we need to collect more information for the research. However, you 
will be free to decline if you do not want to participate further. Once you have agreed to take part in the 
study we will ask you to sign a consent form and will give you a copy to keep along with this information 
sheet. 
 
If you are pregnant, we will also ask you to complete an additional questionnaire about your pregnancy 
(which will take around 10 minutes). With your permission, two months after your expected date of 
delivery we would like to contact your GP and psychiatrist to request information about the pregnancy and 
postnatal period.  Unless your doctors advise us otherwise, we will then arrange an additional telephone  
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interview with you (which will take about 20 minutes) to ask about any symptoms you may have experienced 
in relationship to pregnancy and childbirth.  
You can decline to participate in this part of the study. You do not have to take part when contacted after the 
delivery and this will not affect the care you receive. 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? ARE THERE ANY RISKS? 
 By taking part in the study you will not gain any direct benefit. However, your help will be of great 
value in allowing us to learn more about the causes of mood disorders and we hope this will lead to 
important advances in the treatment and prevention of mood disorders.  
 This study does not include any treatment changes or invasive techniques. Some people experience mild 
discomfort when giving a blood sample and sometimes there is mild bruising afterwards. 
 Most people find talking about their illness beneficial, but some may find it distressing. If at any time 
during the interview you feel distressed, you can ask the interviewer to move onto another question, take 
a break or end the interview. 
 If you have a concern about any aspect of this study, please speak to Dr Katherine Gordon-Smith. Her 
contact details are provided at the end of this information sheet. 
 
DECLINING AND WITHDRAWING FROM THE STUDY  
 You do not have to take part in this study. If you do decide to take part you are still free to withdraw at 
any time and without giving a reason.  
  A decision to withdraw at any time, or a decision not to take part, will not alter the care you receive. 
 If you decide to withdraw from this study, all information and samples you have provided will be 
destroyed and not used further in the research. 
 
DATA CONFIDENTIALITY  
 All interviews and results will be strictly confidential. 
 The interview data, audio recordings of interviews and blood samples will be stored in accordance with 
the General Data Protection Regulation (GDPR). The data will be stored for a minimum of 10 years, but 
probably for longer as this is an ongoing long-term programme of research. 
 The blood sample you provide will be coded and stored safely in a laboratory.  It will be analysed to 
identify genetic variations that might cause some people to develop mood disorders. The results of your 
blood test are for research purposes only and will not be available to anybody on an individual basis. 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
 It is our intention to publish the results of this study in academic journals. Participants will not be 
identifiable in any report or publication. 
 We will keep in touch with you by sending a regular newsletter to let you know how our research is 
progressing and to ask you to let us know about any important changes in your health since we last saw 
you. 
 
FURTHER INFORMATION AND CONTACT DETAILS 
If you have any further questions about this research, please contact the Mood Disorders Research Team and 
ask for Dr Katherine Gordon-Smith (Research Psychologist). Our address appears below, our telephone 
number is 01905 54 2880, and our e-mail address is moodresearch@worc.ac.uk 
                                        
This study was given a favourable ethical opinion for conduct in the NHS (or other) by the West Midlands 
Multi-centre Research Ethics Committee (MREC/97/7/01). 
 
Mood Disorders Research Group, University of Worcester, Henwick Grove, Worcester, WR2 6AJ 
Tel: 01905 54 2880 Fax: 01905 85 5589 Email: moodresearch@worc.ac.uk 
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Appendix E: Participant consent form 
AGREEMENT TO TAKE PART IN THE STUDY OF MOOD DISORDERS 
STUDY ID: _______________ BDRN use only Please initial boxes  
 
1 
I have read the attached information sheet (version 5, dated 03.12.10) on the above 
project and have been given a copy to keep. I have had the opportunity to ask questions 
about the project and understand why the research is being done. 
 
 
 
2 I agree to give a sample of blood for research in the above project. 
 
 
 
3 I agree to part of the interview being audio recorded 
 
 
 
4 
I understand that participation in this project is voluntary and that I am free to withdraw 
from the study without giving a reason and without my medical treatment being 
affected 
 
 
 
5 I give permission for my medical records to be looked at in strict confidence by 
responsible people from the Mood Disorders Research Group 
 
 
 
6 I understand that the tests done as part of this research are not clinically diagnostic and I 
will not be informed of any specific results 
 
 
 
7 I understand that I will not benefit personally from taking part in this research 
 
 
 
8 
I understand that the information and blood sample I have donated for this study will be 
held in a confidential and anonymised form by the research team and may be made 
available to researchers at other centres who are carrying out similar work 
 
 
 
9 I agree that I may be contacted again, in connection with the research, in the future 
 
 
 
10 I know how to contact the research team if I need to 
 
 
 
 If you are pregnant: 
 
 
 
11 I give permission for my GP and psychiatrist to be contacted 2 months after my 
expected delivery date to request information about the pregnancy and postnatal period 
 
 
 
12 
I agree to be contacted 3 months following my expected delivery date to be invited to 
take part in a telephone interview about my pregnancy and the postnatal period. I 
understand that I am free to decline this invitation 
 
 
 
Name   Signed   Date  
Witnessed   Signed   Date  
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Appendix F: Participant information leaflet 
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Appendix G: Participant telephone screen 
Telephone Screen for Prospective Pregnancy Study 
 
Study ID………………………                Initials:          DOB: 
Date of TS:        Due date: 
Thank you very much for your interest in our research into pregnancy and bipolar disorder and 
related mood disorders. The overall aim of the research is to find out more about what makes 
some women more or less likely than others to become unwell in their mood after having a baby.  
 
1. Could I please ask if you are currently pregnant? 
Yes       (If yes go to Q2)      No       (go to Box 1)        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
2. Could I ask how you heard about our research?..................................................................  
 
First of all I’ll just tell you a bit about what taking part involves: 
 
BOX 1 WOMEN WHO ARE NOT PREGNANT BUT REPORT POST NATAL MOOD 
EPISODES 
a) Have you ever experienced an episode of postpartum psychosis, puerperal 
psychosis or any mood episode following childbirth? 
 
Yes          (go to q.b)    No/Unsure          (cut off)  
 
b) Was this a high or low mood? How soon after delivery was this episode?  
........................................................................................................................................ 
........................................................................................................................................ 
c) Were you admitted or received hospital treatment? 
 
Yes           (ask if OK to pass details to Christine)     No/Unsure           (Cut off) 
<CUT OFF> If NO 
I am very sorry but our criteria for the current research project is quite strict and at the 
moment we are only able to interview women who are currently pregnant or have had 
an episode of puerperal psychosis that required hospital treatment.. However, it is 
possible that we may have studies in the future that you could become involved in if 
you are still willing. Would you like to be included on our newsletter mailing list so that 
we can keep you updated with the findings of the research and of any future research 
we are carrying out? 
 
YES        (add details to box 4) No    (End of TS) 
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I usually visit women in their homes during their pregnancy for an interview that lasts about an 
hour and a half. During the interview I will ask about the kinds of mood symptoms you have 
experienced in the past, the types of treatments you have received and questions relating to your 
current pregnancy and any previous pregnancies you may have had. Following the interview, I 
will also leave you with a set of questionnaires to complete and return in your own time. As we 
are interested in identifying genetic factors that make some individuals more susceptible than 
others to mood symptoms, this study does involve providing a small blood sample from your arm 
which I would take when I come to visit you. Then, if you are willing, approximately 3 months after 
your baby is born, I will arrange to contact you by telephone to ask you some questions about 
your delivery and also how you have been since I met with you during your pregnancy. This 
usually lasts around 20 minutes. 
 
3. How does that sound to you? Do you think you may be interested in 
participating?  
 
Yes         (go to Q.4)      No          (Cut off) 
 
 
   <CUT OFF> If NO 
Thank you very much for your interest in our research. Would you like to be included on our  
 newsletter mailing list so that we can keep you updated with the findings of the research? 
 
    Yes           (add details to Box 4) No     (end of TS) 
 
 
We are interested in seeing women who have experienced at least one period of high mood 
(often called mania or hypomania) in their life. Can I ask you a few questions about the mood 
symptoms you have experienced in the past just to make sure you are suitable to take part in 
the study? 
 
4. Have you ever been diagnosed with bipolar disorder by a psychiatrist? 
 
Yes        (go to q.5)               No           (go to box 2)  
 
 
 
 
 
 
 
 
 
5. One of our study inclusion criteria is that individuals are over the age of 18, can I 
just check that you are 18 or older? 
 
 
BOX 2.  NO KNOWN DIAGNOSIS OF BIPOLAR DISORDER 
a) Would you say that you have experiences periods where you have felt very high in mood, or when you have 
felt very energetic or more irritable that usual?  
Yes □ (go to q.b)      No/Unsure □ (cut off) 
b) During the same period did you find that your thoughts were racing □, that you were talking more than usual 
□, that you were more distractible than usual □. Did you feel that you slept less than usual □?  
c) Was this different to how you usually feel?  Yes □ (go to d)      No/Unsure □ (cut off) 
d) How long would you say these periods lasted?............................................................. 
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Yes             (go to Q6)   No          Can I ask the date when you will be 18? 
.......................................... 
 
 
<CUT OFF> If NO AND PARTICIPANT WILL NOT BE 18 DURING PREGNANCY     
Thank you very much for your interest. I am very sorry but we will be unable to interview 
 you for this study as you are under 18. 
 
Our research has been running for many years and we like to check individual’s details with our 
database just to check if they have taken part in our studies previously. 
6. Would you mind if I ask your date of birth? 
DOB...........................................................................  
7. Do you know if any of your family members have participated in this study? 
 
Yes                No        
Details if biological relatives (Initials, DOB, Date participated if known): 
......................................................................................................................................................... 
8. Can I ask how many weeks pregnant you currently are?.............................................. 
 9. When is you expected due date?..................................................................................... 
(If less than 12 weeks): Thank you for agreeing to take part in our pregnancy study. We usually 
feel it is best to interview women when they are at least 12 weeks pregnant. Is ok if I contact you 
in about ? weeks/months time to arrange an interview?  
Date to contact when 12 weeks pregnant.................................................................................. 
 
 
 
 
BOX 2. CONTINUED 
<CUT OFF> If no high or irritable mood OR less than 3 additional symptoms OR episodes 
are not different from usual OR lasting less than 4 days in duration 
I am very sorry but the symptoms you have described during your high moods do not sound as if 
they meet the criteria for our current research project, as our criteria are quite strict. Would you like 
to be included on our newsletter mailing list so that we can keep you updated with the findings of the 
research?         
YES      (add details to box 4) No    (End of TS) 
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BOX 5. RISK ASSESSMENT 
To be completed within two weeks before the interview date.  
There are 2 important issues to consider: 
1. That the potential participant is well enough in their mood to be seen within the 
next 2 weeks. 
2. The level of risk to a lone interviewer conducting the interview at the participant’s 
home. 
 
Would you mind if I just asked you a few questions about how you have been feeling over the 
last month and any treatment you may have received? 
How are you feeling in your mood at the moment? 
.......................................................................................................................................................
.......................................................................................................................................................
.......................................................................................................................................................
.................................................. 
Have you received inpatient hospital treatment or intensive home treatment for your mood 
disorder within the last month?  
YES   (If yes ask if it is OK to call again in one month)         NO   
Are you currently under the care of a CMHT? YES          NO  
Who are you in contact with within the team and how often..................................................... 
If participants are recruited non-systematically: We feel it is important to let an individual’s 
key worker know that they are taking part in the study? Are you happy for me to let your key 
worker know? 
Details (e.g. name and address)................................................................................................ 
……………………………………………………………………………………………………………………………………………… 
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Appendix H: Semi-structured psychiatric research interview 
STUDY NUMBER: _________________ 
PREGNANCY AND POSTPARTUM INTERVIEW 
SUMMARY SHEET 
Interviewer: _________________________  
 
 Date (or 
N/A) 
Comments 
 
INTERVIEW COMPLETED  
 
 
BLOOD PACK GIVEN   
BLOOD SAMPLE RECEIVED   
QUESTIONNAIRES GIVEN   
 
 
QUESTIONNAIRE 2 WK 
REMINDER LETTER 
 
 
 
QUESTIONNAIRE REMINDER 
PHONE CALL 
  
QUESTIONNAIRES RECEIVED   
CASE NOTES REQUESTED (PP 
only see below) 
  
CASE NOTES RECEIVED (PP 
only see below) 
   
 
 
PROSPECTIVE PREGNANCY STUDY ADDITIONAL DATA 
 Date (or 
N/A) 
Comments 
 
ANTENATAL QUESTIONNAIRE 
COMPLETED 
 
 
 
2 MONTH GP LETTER AND 
QUESTIONNAIRE SENT 
  
2 MONTH GP QUESTIONNAIRE 
RECEIVED 
  
2 MONTH PSYCHIATRIST 
LETTER AND QUESTIONNAIRE 
SENT 
  
2 MONTH PSYCHIATRIST 
QUESTIONNAIRE RECEIVED 
  
POSTNATAL TELEPHONE 
INTERVIEW COMPLETED 
 
 
 
CASE NOTES REQUESTED   
CASE NOTES RECEIVED    
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PERSONAL INFORMATION 
 
Initials _________     
 
DOB (DD/MMM-three letters/YY) ___________________________                                         
                                        
INTERVIEW DATE (DD/MMM-three letters/YY)       
________________________________                                  
 
AGE AT INTERVIEW (YEARS)  _____________ 
 
SEX                                1 Male 
2 Female 
9 Unknown 
 
 
 
GP (Surgery name and address)  
 _____________________________________________________________________ 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
 
 
Name and contact details of consultant psychiatrist and/or community mental 
health team R is currently or has previously been in contact with (note how long 
since last seen)  
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PLACE  INTERVIEWED  (CIRCLE ONE)  
  
0 Not interviewed 4 Hospital Ward 
                                    1         Home   5 GP Surgery 
2         QEPH              6 Relative’s home 
                                    3         Psychiatric Clinic 7 Other 
8 Telephone 
9 Unknown 
10 UHW 
 
METHOD OF RECRUITMENT (CIRCLE ONE) 
 
              1 Internet   12 Systematic CMHT 
  2 Media-Press   13 Other Self-help group 
  3 Media-Radio   14 Consultant 
  4 Media-TV               15 Poster/leaflet 
  5 Self-help literature  16 Other 
  6 MDF    17         APP 
  7 Depression Alliance  18         Genesis(DeCC) Controls 
  8 Local MHT Referral               19         Newcastle 
  9 National MHT Referral           20         Systematic GP Surgery 
                         10 Lithium Clinics                                        screen 
                         11 Relatives                                  21        Dublin 
                                                                                     22        F-series 
                                                                                     23        Aberdeen 
 99 UNKNOWN 
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ETHNIC ORIGIN (CIRCLE ONE) 
  
1 South Wales Caucasian 5 Afro-Caribbean 
2 UK/Eire Caucasian  6 Asian 
3 West European Caucasian  7 Mixed race 
4 Other Caucasian  9 Unknown  
 
 
 ORIGIN OF FATHER’S FAMILY (CIRCLE ONE) 
 
1 South Wales Caucasian 5 Afro-Caribbean 
2 UK/Eire Caucasian  6 Asian 
3 West European Caucasian  7 Mixed race 
4 Other Caucasian  9 Unknown 
 
ORIGIN OF MOTHER’S FAMILY (CIRCLE ONE) 
 
1 South Wales Caucasian 5 Afro-Caribbean 
2 UK/Eire Caucasian  6 Asian 
3 West European Caucasian  7 Mixed race 
4 Other Caucasian  9 Unknown 
 
 
 
Ask R to make a mark on the line to show how they feel today: 
 
Most unwell you have ever been                                              Perfectly well 
 
 
CURRENT MENTAL STATE 
How long have you been well for?(circle one) 
1 Currently unwell  5 7-12 months 
2 Less than 1 month  6 More than 1 year 
3 1-3 months   7 More than 5 years 
4 4-6 months   9 Unknown 
 
How long has it been since your last discharge from hospital? (circle one)  
1 Currently in hospital  5 7-12 months 
2 Less than 1 month  6 More than 1 year 
3 1-3 months   7 More than 5 years 
4 4-6 months   8 Not applicable (never been admitted) 
                                                                 9 Unknown 
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Life chart  
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BRIEF HISTORY OF ILLNESS 
 
Age of first symptom of affective/psychotic illness (not necessarily causing clinically 
significant impairment) _______ years or UK 
 
Age of first contact with secondary psychiatric services for affective/psychotic 
disturbance _____ years, UK or NA 
 
Total number of psychiatric admissions including day hospital and intensive home 
treatment (enter 0 if no admissions or UK if unknown)  _____ 
 
Usual Duration of admissions ____ days/weeks (delete one), UK or NA 
 
Longest duration of admissions ____ days/weeks (delete one), UK or NA 
 
Ever Sectioned? (circle one)      
0 Never     12 Majority of all admissions  
11 Once/minority of all admissions  9 Unknown 
 
 
If has experienced perinatal episodes- were any of these episodes the first episode of 
psychiatric illness experienced?                                            Y    N     UK NA 
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OBSTETRIC HISTORY (For all past pregnancies) 
 
PREGNANCY # _________   Date____________ 
 
OUTCOME: 
1 Normal vaginal delivery  3 Stillbirth  5 Termination 
2.1 Elective caesarean section 4 Miscarriage  6 Forceps/Ventouse 
2.2 Emergency caesarean section 
 
GESTATION: ______ wks  MATERNAL AGE AT OUTCOME: ______ yrs 
 
SEX OF BABY: 
 1 Male    5 Twins – male & female    
 2 Female   6 Other _____________   
 3 Twins – both male  7 Unknown    
 4 Twins – both female  
 
Pregnancy planned? Y / N/UK  IVF?  Y / N/UK 
 
 
Rating of psychiatric sequalae (any symptoms occurring within 6 months): 
 
0 No problems   5 “Baby blues” 
1 Mania (including Mixed)  6 Cycloid 
2 Hypomania   7 Other psychotic episode 
3 Psychotic depression  8 Other perinatal episode 
4 Non-psychotic depression  9 Unknown 
 
 
Admitted  Y / N /UK   
 
 
Psychotic symptoms? Description and congruence 
 
   If immediate or as soon as baby born rate 1 week unless day of onset 
Onset: ______ wks clearly stated.  0.3 = 3 days.  Use negative number for onset before term 
   e.g. – 8 weeks = 32 wks. 
 
   Use decimal place for days eg 0.3 = 3 days. 
Duration: ______ wks Use 2nd decimal place for hours eg 0.03 = 3 hours. 
   If  > 9 hours round up to one day. 
 
Medication Timeline: (starting 6 months before conception, to 3 months after delivery) 
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ASK FOLLOWING FOR LIVE DELIVERYS ONLY 
 
PREGNANCY:  
Any complications during pregnancy (maternal or baby medical condition severe enough to warrant 
treatment either as an out patients or hospital admission)? Y / N/UK If yes give details 
 
       
Pre-eclampsia diagnosis Y / N/UK 
Pre-eclampsia symptoms? Y / N/UK If yes give details of symptoms 
Smoke during pregnancy? Y/ N/UK 
 
Overall, was your pregnancy a positive experience for you?  
 
1 Not at all 2 3 Somewhat 4 5 Very much 
    
 
Did you feel you had people you could depend on for emotional support when you got home with 
your baby (other than partner)?  
 
1 Not at all 2 3 Somewhat 4 5 Very much 
    
 
Did you have you a partner in this pregnancy?  Yes          No       
 
If yes, was your relationship with your partner an emotionally supportive one?  
 
1 Not at all 2 3 Somewhat 4 5 Very much 
    
 
DELIVERY:  
 
Labour: Induction Y / N If yes, select method:  IV     Pessary  Other _________  
 Augmentation Y / N If yes, select method:  IV     Pessary  Other _________  
 
Time contractions started ___ Time of delivery ____        Length of labour (hrs) _____    
 
Sleep loss during labour: Y / N/UK Total number of nights missed sleep ___ 
 
Pain relief given: Epidural   Pethidine    
Gas & Air   TENS   Other __________ 
 
Pain score (At worst during labour / delivery): ____________ 1 = mild discomfort, 10 = worst pain 
imaginable 
 
Complications during delivery? (breech, distress, cord accidents): Y / N/UK If yes give details 
 
 
Any problems identified with the baby at birth or following birth? Y / N/UK If yes give details 
 
 
Birth weight ____________   (g or Ib, oz and then convert) 
 
BREASTFEEDING: Y / N  If yes, duration _          wks 
Any episodes in relation to stopping breastfeeding:  Yes          No    Don’t know  
Details (high/low mood? Mixed features? Psychotic symptoms? Anxiety/panic?):  
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SYMPTOMS EXPERIENCED DURING EPISODES OF MANIA/HYPOMANIA 
 
NB: For women who have had a postnatal illness please rate the worst postnatal episode 
independent of polarity, preferentially mania if they have had both depression and mania, however 
there may be exceptions - hypomania vs severe PND.  If the worst postnatal episode is mania/mixed 
please also rate the worst non-puerperal episode of mania/mixed and worst episode of depression.  
If the worst postnatal episode is depression please also rate the worst episode of non-puerperal 
depression and worst episode of mania/mixed.   
 
 Use 0, 1, 2, 8, 9 unless where indicated 
 
Episode to be   Episode to be   Episode to be 
rated WE-NPN________  rated WE-PN________ rated WE-M________ 
 
 
WE- WE-   WE-M 
         NPN PN 
10.001 Expansive (elevated) mood     ___ ___ ___ 
Did you feel intensely happy or elated without reason?  So elated it was unnatural for you 
 
10.02 Irritable mood       ___ ___ ___ 
During that time did you find that you were easily irritated, that any little thing provoked you?  
Did others comment you were too impatient?   
 
Perplexity 
During this episode did you feel confused?  Did you have difficulty getting your thoughts in order?  
Did you understand clearly what was going on?    ___ ___ ___ 
 
 
10.004 Pressing and racing thoughts     ___ ___ ___ 
Did you find thoughts crowding and racing through your mind, speeding up and have too many 
compared to usual?  Describe?  How long did this last? 
 
10.005 Over-talkativeness      ___ ___ ___ 
Did people say you talked too fast/ too much so you weren’t understood?  Could others 
understand you?  Did you feel a pressure to keep talking?  
 
10.006 Distractibility       ___ ___ ___ 
Could you concentrate or keep your attention on one thing so that you could complete the task or 
deal with something properly?  Were you distracted by irrelevant things around you/ 
environmental surroundings? 
 
10.007 Self-reported overactivity     ___ ___ ___ 
Were you more active than usual/normal?  So active that others thought that there was something 
wrong?  Did you have tremendous energy?  Was it unnatural and out of character for you? 
 
 Increased energy      ___ ___ ___ 
Did you find that you have a lot more energy than usual?    
 
10.010 Exaggerated self esteem      ___ ___ ___ 
Did you seem especially efficient or really good at work or in your daily activities- as though 
you had super powers or talents?  Superbly healthy, high intelligence, extraordinary abilities?  
How did you explain this?  How did you opinion compare to others? 
 
 
Appendix H 
287 
WE- WE-   WE-M 
         NPN PN 
 
10.012 Actions based on expansive mood     ___ ___ ___ 
Did you do anything that you wouldn’t have normally?  Was it because of the mood, high spirits 
you were in?  Spend money you didn’t have/ gamble/ reckless driving?  Do anything you 
regretted later or got you into trouble?  Describe? 
 
10.013 Decreased need for sleep      ___ ___ ___ 
 Did you sleep less at night?  Manage with far less sleep without getting tired? 
 
 
10.014 Socially embarrassing behaviour     ___ ___ ___ 
Were you more sociable than usual?  Was it inappropriate, over-familiar or interfering?  
Behaviour that was embarrassing?  Foolish actions out of character?  
 
10.015 Increased sexual drive or activity     ___ ___ ___ 
Did you find that your sex drive or activities changed?  In what way?  Increased sexual activity, 
increased flirting, sexual indiscretions? 
 
Dysphoric Mania 
During episodes of high mood, did you ever also experience (even for brief periods) depressive-type 
symptoms such as low mood, loss of energy, hopelessness or suicidal feelings? ___ ___ ___ 
 
 
EXPANSIVE MOOD AND IDEATION 
 
Duration of longest episode of high mood?______ days/weeks (delete one) or UK   
How many episodes of high mood have you experienced in your life? ______ 
(only include episodes lasting at least 4 days)  
 
Number of episodes of high mood if all episodes of high  ______ 
 mood have lasted less than 4 days   
   
Impairment in Manic Episode: 
Mild/Moderate:    Severe:   
Arguments    Disrupts work or social life more or less completely 
Missed work    Fights 
Annoyed family    Lost job  
Referred for treatment   Police involvement 
Treatment by having    Family split up 
antidepressants discontinued     Received specific treatment (Li or neuroleptic) for mania 
     Psychotic features 
 
1. At what age did these periods of high mood start to cause impairment in your life, for example 
you had to take time off work or school,  you saw your  GP, or  your high mood caused problems 
with family or friends? ______ years or UK 
 
2. Have you ever received treatment for your episodes of high mood either from your GP, a 
psychiatrist or other health professional?    Y   N  UK    
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 Age first received treatment for high mood ______ years or UK 
 
3. Have you ever been admitted to hospital, day hospital or had intensive home treatment for your 
episodes of high mood?                                                       Y   N  UK                                                                                                                                                                                
 IF YES 
Total number of admissions for high mood ______  number or UK 
Age first admitted to hospital for high mood ______years or UK 
Ever been sectioned under the mental health act for high mood Y   N  UK  
Proportion of hypomanic/manic episodes experienced________________________ 
Have any of the following triggered episodes of high mood? 
 
 Ever 
Sleep loss e.g. long haul flights, shift work, 
Specify situation: 
 
Y / N / UK / NA 
Alcohol Y / N / UK / NA 
Menstrual Cycle Y / N / UK / NA 
Contraceptive Pill/Implant Y / N / UK / NA 
Drugs (non-prescription) 
 Specify: 
Y / N / UK / NA 
Medication  
Specify: 
Y / N / UK / NA 
Other 
Specify: 
Y / N / UK / NA 
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SECTION 6: DEPRESSED MOOD AND IDEATION 
 
 
Episode to be   Episode to be                     Episode to be  
rated WE-NPN________  rated WE-PN________                    rated WE-D______ 
 
Use 0,1, 2, 8, 9 unless where indicated 
 
     WE- WE- WE-D 
     NPN PN  
6.001 Depressed mood       ___ ___ ___ 
How would you describe your mood during this period?  Sad, gloomy, despairing, deeply 
depressed?  Mild/ moderate/ severe?  How much of the time were you in reasonable spirits/ 
really low?  When did you last feel your usual self? 
 
7.004 Loss of interests       ___ ___ ___ 
What were your interests before?  Did you lose interest in work, recreation, appearance?  To 
what extent- did you lose interest altogether? 
 
 
6.005 Capacity for enjoyment      ___ ___ ___ 
Was there anything you enjoyed doing that lifted your spirits?  Were you able to positively enjoy 
things, interests, hobbies?  Or were you unable to find pleasure in things you would normally 
enjoy?  
 
6.012 Tedium vitae       ___ ___ ___ 
Did you feel that life was not worth living, or you didn’t care if you wake up?  Ever wish you 
had a fatal disease?  Recurrent death thoughts? 
 
 
6.011 Suicide or self-harm [0-5]     ___ ___ ___ 
 Did you ever think about harming yourself or make an attempt at suicide? 
0=absent, 2=suicidal ideation, 3=suicide attempt unlikely to result in death, 4-attempt likely to 
result in death, 5=multiple attempts likely to result in death 
 
Number of attempts________________ 
Worst attempt___________________________________________________________ 
 
 
Extra question for WE PN episode: Did you have any thoughts about harming your baby? 
      ___  
 
6.009 Morning depression [0-1]     ___ ___ ___ 
 When did it feel worse?  Any time less severe? 
 0= not worse early/ 1= worse early in day 
 
 
6.017 Loss of self-esteem      ___ ___ ___ 
What was your opinion of yourself compared to others?  Did you feel less competent than them?  
Inferior or worthless? 
 
 
6.013 Pathological guilt      ___ ___ ___ 
Did you blame yourself for things you had done?  Feel guilty or ashamed?  What had you done?  
Would you feel the same now?  Out of proportion. 
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     WE-  WE- WE-D 
     NPN PN  
 
6.015 Loss of self confidence with other people    ___ ___ ___ 
How confident did you feel in yourself- in talking to others and managing relationships with 
others?  
 
6.016 Social withdrawal      ___ ___ ___ 
Did you want to stay away from other people?  Would you answer the door or telephone?  Did 
you try to avoid company of others?  Refuse it when offered? 
 
7.002 Loss of concentration      ___ ___ ___ 
Was your concentration as good as usual, did your attention wander?  Could you complete tasks? 
 
7.003 Subjectively inefficient thinking     ___ ___ ___ 
Were you able to think clearly?  Or were simple decisions hard to make?  Thoughts slower?  
Indecisive?  To what extent, severe- hardly begin to think about a problem? 
 
7.005 Subjective feeling of retardation     ___ ___ ___ 
Did you feel as though you were slowed down in your movements?  Talk or move much more 
slower?  Arms and legs feel like lead?  Did everyone else seem faster?   
 
7.006 Loss of energy       ___ ___ ___ 
Did you feel as though you had lost energy or vigour?  Was everything too much trouble?  
Comparative loss of energy to normal functioning? 
 
APPETITE 
Did your appetite change during this episode of illness?   ____ ___ ___ 
 0 = no change 
 1 =  marked loss of appetite 
 2 = increase in appetite 
 
Did you lose any weight at this time? [0/1]     ___ ___ ___ 
 How much? (enter amount) 
 
Did you gain any weight at this time? [0/1]    ___ ___ ___ 
 How much? (enter amount) 
 
SLEEP PROBLEMS 
When well, what is your sleep pattern? (number of hours/ usual times)  ________ hrs 
          ___ to ___ 
 
Did your sleep pattern alter during this episode of depression? [0/1] ___ ___ ___ 
Did you find it difficult to get to sleep? [0/1]       ___        ___      ___ 
How many hours would you lie awake for?       ___     ___     ___hrs 
 
Did you wake during the night? [0/1]         ___     ___     ___ 
 
Did you wake early in the morning? [0/1]         ___     ___     ___ 
How many hours earlier would you wake?        ___     ___    ___hrs 
 
Did you find that you were very sleepy during the daytime even if you had slept through the night? 
[0/1]                 ___     ___     ___ 
 
8.025 Loss of libido associated with depression [0/1]   ___ ___ ___ 
 Was your interest in sex less than usual? 
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3.006 Agitated anxiety (in the context of depression)   ___ ___ ___ 
 Were you so fidgety and restless that you couldn’t sit still? 
 Did you have to keep pacing up and down? 
 [fidgety = mild; restlessness = moderate; pacing = severe] 
 
4.001 General rating of anxiety (in the context of depression)  ___ ___ ___ 
Now I would like to ask you about feelings of anxiety or panic during PERIOD.  When people 
get anxious or panicky they often feel fearful.  They may feel their heart beating fast, or they 
may start shaking or sweating, or feel they can’t get their breath.  Have you had feelings like 
that?  Can you describe it? [0/1] 
 
 
Mixed episodes 
During episodes of depression, did you ever also experience (even for brief periods) manic-type 
symptoms such as elevated mood, increased energy, racing thoughts and increased self esteem? ___
 ___ ___ 
 
 
DEPRESSED MOOD AND IDEATION 
    
1. Duration of longest episode of depression?______ days/weeks (delete one) or UK  
 
2. How many of these episodes have you experienced in your life?  ______ 
(only include episodes lasting at least 2 weeks put UK if unknown or 0 if none)   
 
Go to next page if all episodes of depression have lasted less than two weeks  
3. At what age did these depressions start to cause impairment in your life for example you had to 
take time off work/school, you saw your GP, or your high mood caused problems with family or 
friends?  ______ years or UK 
 
4. Have you ever received treatment for your episodes of depression either from your GP, a 
psychiatrist or other health professional?   Y   N  UK   
     
 Age first received treatment for depression ______ years or UK 
 
5. Have you ever been admitted to hospital for your episodes of depression?  
                                                                                                                          Y   N  UK 
IF YES 
 
Total number of admissions for depression ______ number or UK  
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DEPRESSED MOOD AND IDEATION 
Have any of the following triggered episodes of depressed mood? 
 Ever 
Sleep loss e.g. long haul flights, shift work 
Specify situation: 
Y / N / UK / NA 
Alcohol Y / N / UK / NA 
Menstrual Cycle Y / N / UK / NA 
Contraceptive Pill/Implant Y / N / UK / NA 
Drugs (non-prescription) 
 Specify: 
Y / N / UK / NA 
Medication  
Specify: 
Y / N / UK / NA 
Other 
Specify: 
Y / N / UK / NA 
 
AFFECTIVE SYMPTOMS ADDITIONAL INFORMATION 
 
Have you ever had 4 or more mood episodes (depression or mania) in one year? 
                                 Y    N     UK 
 
Has anyone ever told you that you have rapid cycling  
                                                                                                       Y    N     UK 
 
Suicidal Ideation (LE)  
If R has been asked about suicidal ideation and attempts in the depression section, make 
rating based on the answers to these items  
 
For individuals who were not asked the depression section: 
Have you ever thought that life was not worth living, or you didn’t care if you wake up?  
Have you ever thought about harming yourself or even made an attempt at suicide? 
 
Rate most severe lifetime-ever: 
0 Absent 
1 Tedium vitae 
2 Suicidal ideation 
3 Suicide attempt unlikely to result in death 
4 Suicide attempt likely to result in death 
5 Multiple suicide attempts likely to result in death 
9 Unknown 
NB: Suicidal ideation/attempt does NOT have to be in the 
context of depression to be rated here. 
 
Details: ____________________________________________________ 
 
Polarity of first episode: If age of first impairment is the same for mania and depression, please indicate 
which occurred first 
    Mania  Depression  Unknown N/A  
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HALLUCINATIONS, THOUGHT DISORDER, REPLACEMENT OF WILL & 
DELUSIONS 
 
• Probe question: Hearing noises/voices 
Have you ever heard noises or voices when there was nobody around and no ordinary explanation seemed 
possible? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17.009 Third person Auditory Hallucinations Did you ever hear voices talking about you between 
themselves or did you ever hear a single voice talking about you?   
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PN Mania/mixed 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
Outside mood 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
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17.008 Voice(s) commenting on thoughts or actions Did a voice comment on your thoughts or actions? 
           
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Probe question: Visual Hallucinations  
Have you ever had visions or seen things other people couldn’t see? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
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Other hallucinations (17.022, 17.026, 17.028)  
Have you ever noticed any unusual smells that you couldn’t account for or any unusual sexual sensations 
or noticed any other strange or inexplicable sensations of touch, taste, or temperature, or pain, or floating? 
Or like a crawling sensation under the skin? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Probe Question: Interference with thoughts 
Have you ever felt some outside force or person was interfering with or controlling your thoughts or felt 
that your thoughts were being read? Have you ever experienced a thought in your mind repeating over, 
like an echo?  Has it ever seemed that the thoughts in your mind were not your own, and they seemed to 
come from somewhere else?  How did they get in your mind? Have you ever felt your thoughts were 
somehow public, not private, so that others know what your thinking?  Did you feel the thoughts leaving?  
Have you ever experienced your thoughts actually been taken out or sent out of your mind? 
 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
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Probe Question: Experience of Replacement of Will Have you ever felt some outside force or person 
was controlling your actions? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19.004 Delusions of reference 
Have you ever felt the TV, radio or newspaper were talking about you? or giving messages to you? Have 
people ever seemed to drop hints meant for you, or say things with double meanings? 
 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
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• 19.003 Delusions of being spied upon 
Have people seemed to talk about you, check up on you, or follow you about, or record your movements? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19.007 Delusions of misidentification        
Are there people about who are not what they seem?  Perhaps in disguise?  (strangers are people from the 
past, nursing staff are impostors/or police) 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression
 
 
 
Outside mood 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
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 19.008  Familiar people impersonated (by strangers)     
Did you feel that the appearance of people you know well had changed in ways that suggested someone 
was impersonating them?  
 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 19.012 Delusions of persecution 
Have you ever experienced the feeling that someone or some organisation was trying to harm you? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
 
 
Appendix H 
299 
 19.014 Delusional jealousy       
  
Were you  jealous of your friend or spouse?  What did you do to convince yourself nothing was 
wrong? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19.017 Delusional lover          
Have you believed that someone important was in love with you, even though there was no 
evidence?  Are you loved by someone who does not publicly acknowledge it?  Who is it?  What 
evidence to you have of these advances?  Do you try to make contact?  
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 19.021 Religious delusions 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
PN Mania/mixed 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
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Have you ever been unusually preoccupied with religious ideas for example thoughts about God or the 
Devil? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 10.016/19.029 Delusions of grandiose ability or 10.017/19.030 identity 
Have you ever felt that you or your baby have had special powers? or thought you were somebody 
special? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
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• Delusions of guilt or worthlessness ( 6.018/19.025) 
Have you ever felt responsible for a crime, evil or harm to others? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• (OPCRIT item 57) Delusions of poverty 
Have you ever believed that you have lost all of your money or property? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
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• (OPCRIT item 58) Nihilistic delusions 
Have you ever felt that part of your body had disappeared or was rotting away or was affected by some 
devastating or malignant disorder or did you ever believe that you were dead? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General probe question 
Have you ever had any other unusual or abnormal experiences when your mind has played tricks on you 
that looking back now seems strange or unusual? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
  
AGE FIRST PSYCHOSIS    _________ 
 
DURING (PLEASE CIRCLE ONE): Mania   Depression   At other times    UK 
 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
PN Mania/mixed 
 
 
 
Non PN Mania/mixed 
 
 
 
PN Depression 
 
 
 
Non PN Depression 
 
 
 
Outside mood 
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SECTION 4: PANIC, ANXIETY AND PHOBIAS 
Use scale 1 (0-3) unless stated otherwise 
 
4.001   General rating of anxiety   
When people get anxious or panicky they often feel very fearful. They may feel their heart beating 
fast, or they may start shaking or sweating, or feel they can’t get their breath.  
          _[0/1] 
 
PANIC ATTACKS 
4.020   Frequency of panic attacks with autonomic symptoms  
Have you had any attacks of panic, or sudden attacks of anxiety which very quickly become intolerable? 
 [ number in a 4 week period]  __ 
*Note symptoms in 4.003-4.019* 
4.021   Enduring apprehension of having an attack- after an attack do you worry 
 about its effects or about getting another attack ?      __ 
4.022   Action to prevent or to end panic attack –do you have to do something to end an attack 
, like leaving a bus, or anything to prevent attacks?       
0=absent, 1=action to prevent , 2=action to end, 3 prevent and end    __ 
 
ALL (0/1)       Panic  Generalised 
anxiety 
4.003 can’t get breath and smothering feeling    __   __
  
4.004   heart pounding, missing beats, faster   __   __
  
4.005 dizzy, light-headed, faint, unsteady    __   __
  
4.006  tingly, numbness in face/fingers    __   __
  
4.007  tightness, discomfort or pain in chest    __   __
  
4.008   dry mouth not due to medication or dehydration  __   __
  
4.009   difficulty in swallowing, lump in throat,    __   __
  
4.010   sweating e.g. palms     __   __
  
4.011   trembling or shaking e.g. hands or limbs   __   __
  
4.012   hot or cold sweats or flushes    __   __
  
4.013   unreality, ‘not really here’ like an actor   __   __
  
4.014   churning stomach, nausea, butterflies   __   __
  
4.015   fear of dying      __   __
  
4.016  fear of choking      __   __
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4.17 fear of going crazy, or fear of losing 
emotional control or passing out     __   __
  
4.018   apprehension, jumpiness, or increased startle response  __   __
  
4.019   other e.g. increase urinary frequency    __   __
  
  
Did panic attacks form a prominent part of the WE PN episode (Y, N , UK) ____     
 
 
GENERALISED ANXIETY 
4.023  Free floating  anxiety  
- Have you ever had anxiety periods for longer periods not just in attacks (include only anxiety 
with no apparent reason) 
 0=none, 1=mild occasional anxiety, 2= moderately severe 3= severe anxiety  __ 
 
 4.025  Duration of free floating anxiety –  number of months     __ 
 
PERIOD RATED ___________        
 
*Note symptoms in 4.003-4.019* and also the following all rated (rating scale 1 0-3) 
3.001   Worrying –   did you worry a great deal? did unpleasant thoughts go round and round in your 
mind, could you stop worrying by looking at the TV or reading or thinking about something you enjoy
 __ 
3.002   Feeling of nervous tension- did you often felt on edge or keyed up or mentally strained, 
 everyday problems get on top of you?. Did you Startle too easily?    __ 
3.003   General muscular tension- did you have difficulty relaxing, muscles feel tensed up? __ 
3.005   Localised tension pains- did you have aches and pains, like headache, backache, 
 aching muscles? Exclude migraine        __ 
3.006   Subjective describes restlessness- were you fidgety and restless? 
fidgety=mild  restless=moderate,  pacing=restless      __ 
3.07 Fatigability and exhaustion- were you exhausted and worn out  during the day  
even when you hadn’t  been working very hard       __ 
3.010   Irritability – were you more inpatient or irritable than usual 
1= mild irritability, brief domestic quarrels mood,  2= raised voice, anger, shouting, 
 3=pushing hitting, lost control        __ 
3.012   Depersonalisation and derealisation   Did you feel that things around you 
 or you yourself were unreal        __ 
7.002  Loss of concentration was your concentration as good as usual?   __ 
Did your sleep pattern alter during this episode of anxiety [0/1]     __ 
 
  
Did generalised anxiety form prominent part of the WE PN episode (Y, N , UK) ____     
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FAMILY HISTORY 
 
Draw a family tree of 1ST DEGREE RELATIVES- parents, children, siblings 
Have any of these relatives suffered with their nerves, had a nervous breakdown, seen a psychiatrist, tried 
to harm themselves, committed suicide or had a problem with drugs or alcohol? For female relatives ask 
whether there is any known family history of postnatal illness 
 
NB: REMEMBER TO CHECK THAT RELATIVES ARE BIOLOGICAL RELATIVES 
 
Are you adopted?        Y    N     UK              Are you a twin?            Y    N     UK 
 
 
 
 
 
 
Is there anyone else in the family, such as grandparents, aunts, uncles, nieces or nephew that have 
suffered with their nerves, had a nervous breakdown, seen a psychiatrist tried to harm themselves, 
committed suicide or had a problem with drugs or alcohol? For female relatives ask whether there is any 
known family history of postnatal illness 
 
.......................................................................................................................................................................... 
 
.......................................................................................................................................................................... 
 
 
HIGHEST EDUCATIONAL ATTAINMENT (circle as many as necessary 
 0 None 
               1       11+ 
2       CSE (includes NVQ level 1, GNVQ, GSVO foundation level, other RSA/City  
        & Guilds qualifications, Youth Training Certificate). 
               3      O-Level/GCSE (includes NVQ level 2, GNVQ Intermediate, RSA diploma,  
                      City & Guilds craft) 
              4       A-Level/AS levels/Scottish Highers/HND/BTEC (includes Scottish certificate   
                     of sixth year studies, NVQ levels 3&4, GNVQ Advanced, SCOTVEC, HNC,    
                     RSA Higher/Advanced Diploma, City & Guilds Advanced Craft) 
               5      Degree (includes NVQ level 5) 
6 Post-graduate degree 
9       Unknown 
 
Current Occupation (if individuals are not currently working, check whether they are  unable to work 
due to sickness and whether they are receiving incapacity benefit)   
……………………………………………………………… 
Previous Occupation (please indicate whether they are receiving incapacity benefit 
…………………………………………………………….. 
 
Occupation at time first became unwell (please indicate the individuals occupation at illness onset or if 
they were a full time student or if they were unemployed at that time) 
…………………………………………………………….. 
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ALCOHOL/SMOKING/DRUGS QUESTIONNAIRE 
1. Have you ever been a regular smoker?  (please circle)  YES NO  
 If YES at what age did you begin to smoke?   _____ years  
 
2. ALCOHOL  
a.  Have you ever used alcohol regularly? (please circle)  YES NO
  
IF YES please continue, if NO please go to question 3 on the next page 
 
b.  How old were you when you first used alcohol regularly? ____________(please 
put age or unknown) 
 
c.  At your heaviest ever, how many units of alcohol did you consume on average 
per week (NB 1 unit of alcohol is equal to one small glass of wine, a single measure of 
spirits or half a pint of beer/larger/cider)    
                                                                     ________Number of units per week
            
d. Did you experience any associated problems through alcohol usage at that time 
e.g. psychiatric, medical, financial, relationship, occupational? (please circle)  
YES NO NOT SURE 
 
Brief details if YES ………………………………………………………………………. 
 
e.  During the year before the onset of your illness, how many units of alcohol did 
you consume on average per week? 
     Number of units per week   _____ 
 
f. Did you experience any associated problems through alcohol usage at that time 
e.g. psychiatric, medical, financial, relationship, occupational? (please circle)
   
YES NO NOT SURE
  
Brief details if YES ………………………………………………………………………. 
 
3. DRUGS  
a. Have you ever used cannabis regularly?  (please circle)  
        YES NO NOT SURE 
 
IF YES please continue, if NO please go to question 4 on this page 
 
b. Did you use cannabis regularly in year before the onset of your illness? (please 
circle)  
YES NO NOT SURE 
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c. Did you ever experience any associated problems through cannabis usage e.g. 
psychiatric, medical, financial, relationship, occupational? (please circle)  
YES NO NOT SURE 
 
Brief details if YES 
……………………………………………………………………….. 
 
 
4.NON-PRESCRIPTION DRUGS 
 
a. Have you ever used any other non-prescription/non-over the counter drugs -
such as sedatives, tranquilizers, valium, stimulants, speed, ecstasy, volatile 
substances, glue, solvents, cocaine, opiods, heroin, methadone? (please circle)
  
YES NO NOT SURE 
 
 
If YES please continue if NO end of the questionnaire please go to next questionnaire on 
the next page 
 
b. Which non-prescription drugs have you taken regularly?  
 
……………………………………………………………………………………………. 
 
…………………………………………………………………………………………… 
 
 
c. Did you use any of these regularly during the year before the onset of your 
illness? (please circle)      YES NO NOT 
SURE 
 
         
d. Did you ever experience any associated problems through drug usage e.g. 
psychiatric, medical, financial, relationship, occupational? (please circle) 
        YES NO NOT 
SURE 
 
Brief details if YES 
………………………………………………………………………… 
 
    
…………………………………………………………………………………………… 
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HORMONAL CONTRACEPTION 
 
Hormonal contraception: Yes     No   
            Mini     Combined   Injection   Implant  Mirena coil 
Symptoms worse   Name __________                                   
Symptoms improve  Name ___________                             
No change  
 
Episodes related to Hormonal Contraception:  Yes  No       Don’t know           
 
Details (starting/stopping/changing):  
…………………………………………………………………………………………… 
 
…………………………………………………………………………………………… 
 
MENOPAUSE 
Natural menopause:  Yes        Oophorectomy:  Yes  
Age (range) of Menopause: ____________  
Any episodes in relation to menopause:  Yes          No    Don’t know  
Details (high/low mood? Mixed features? Psychotic symptoms? Anxiety/panic?):  
 
…………………………………………………………………………………………… 
 
…………………………………………………………………………………………… 
 
 
HORMONE REPLACEMENT THERAPY 
HRT:  Yes          No  
Name of HRT medication: ____________  
Any episodes in relation to HRT:  Yes          No    Don’t know  
Details (high/low mood? Mixed features? Psychotic symptoms? Anxiety/panic?):  
 
…………………………………………………………………………………………… 
 
…………………………………………………………………………………………… 
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PREMENSTURAL SYMPTOMS Do you experience some or any of the following 
premenstrual symptoms which start before your period and stop within a few days 
of bleeding? 
 
Symptom Not at 
all 
Mild Moderate Severe 
Anger/irritability     
Anxiety/tension     
Tearful/increased sensitivity to rejection     
Depressed mood/hopelessness     
Decreased interest in work activities     
Decreased interest in home activities     
Decreased interst in social activities     
Difficulty concentrating     
Fatigue/lack of energy     
Overeating/food cravings     
Insomnia     
Hypersomnia (needing more sleep)     
Feeling overwhelmed or out of control     
Physical symptoms: breast tenderness, 
headaches, joint/muscle pain, bloating, 
weight gain 
    
 
 
Have your symptoms, as listed above, interfered with: 
 
 Not at all Mild Moderate Severe 
Your work efficiency or productivity     
Your relationship with coworkers     
Your relationships with your family     
Your social life activities     
Your home responsabilities     
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CLEQ QUESTIONNAIRE 
 
Self / Interviewer rated (please circle) 
 
Did you experience as a child (up to age 16 years) any of the following life events? 
 
         If yes, how old were 
      Please circle:   you? 
1. Death of parent    Yes No   _____ 
 
2. Death of a brother/sister   Yes No   _____ 
 
3. Death of a close friend   Yes No   _____ 
 
4. Divorce of parents   Yes No   _____ 
 
5. Marital separation of parents  Yes No   _____ 
 
6. Marriage of parent to step parent Yes No   _____ 
 
7. Serious illness needing  
 hospitalisation    Yes No   _____ 
 
8. Hospitalisation of a parent  Yes No   _____ 
 
9. Acquiring a visible deformity  Yes No   _____ 
 
10. Jail sentence of a parent for a  
 year or more    Yes No   _____ 
 
11. Teenage pregnancy/fatherhood  Yes No   _____ 
 
12. Suspension from school   Yes No   _____ 
 
13. Are there any other significant life events you experienced as a child that are not 
mentioned about?      Yes No  
 
..........................................................................................................................................................................
..........................................................................................................................................................................
................ 
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Appendix I: Third-trimester pregnancy interview 
 
PROSPECTIVE ANTENATAL QUESTIONNAIRE 
 
TO BE COMPLETED AT THE END OF THE INTERVIEW IF PAST 24 
WEEKS OR AT A LATER DATE VIA TELEPHONE ONCE THE WOMAN 
HAS REACHED 24 WEEKS 
 
STUDY ID __________  INITIALS _________ DOB __________ 
 
Date completed      
 
Questions about your pregnancy: 
What date is your baby due?    
How many weeks pregnant are you?   
 
 
Questions about your feelings about your pregnancy and the support you are 
receiving 
 
Overall, has this pregnancy been a positive experience for you? (please circle one) 
 
1 2 3 4 5 
Not at all Somewhat  Very much 
 
Do you feel you will have people you can depend on for emotional support when you 
go home with your baby?  (other than partner) (please circle one) 
 
1 2 3 4 5 
Not at all Somewhat  Very much 
 
Have you a partner in this pregnancy? (please tick one)  Yes          No 
      
 
If yes, is your relationship with your partner an emotionally supportive one? (please 
circle one) 
 
1 2 3 4 5 
Not at all Somewhat  Very much 
 
 
Pregnancy planned? Y / N/UK  IVF?  Y / N/UK 
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Questions about smoking, drugs and alcohol in pregnancy 
 
In this pregnancy have you smoked cigarettes?   
Yes          No       
 
If YES, on average, how many cigarettes a day have you smoked?  
 
 
In this pregnancy, have you drunk alcohol regularly?   
Yes          No       
 
It YES, how many units of alcohol have you consumed on average per week? (1 unit of 
alcohol is equal to one small glass of wine, a single measure of spirits or half a pint of 
beer/lager/cider) 
 
 
During this pregnancy have you used any of the following substances when they have 
not been prescribed by a doctor?  
Sedatives        Yes          No       
Cannabis   Yes          No       
Speed   Yes          No       
Ecstasy   Yes          No       
Glue   Yes          No       
Solvents  Yes          No       
Cocaine  Yes          No       
Heroin   Yes          No       
Methadone  Yes          No       
Other non prescription/over the counter drugs  
Yes          No      
If yes please give brief details 
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Questions about medications 
What drug treatments (medications) as prescribed by your doctor or over the counter did 
you take in the 6 months before you became pregnant?  
(If you can, please indicate daily doses and say when any changes were made)  
 
 
What drug treatments (medications) as prescribed by your doctor or over the counter  
have you been taking during your pregnancy?  
(If you can, please indicate daily doses and say when any changes were made)  
 
 
 
 
 
 
 
 
 
As prophylaxis  
 
 
 
 
 
 
As treatment  
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PANIC, ANXIETY AND PHOBIAS 
 
4.001   General rating of anxiety   
When people get anxious or panicky they often feel very fearful. They may feel 
their heart beating fast, or they may start shaking or sweating, or feel they can’t 
get their breath. __[0/1] 
 
PANIC ATTACKS 
4.020   Frequency of panic attacks with autonomic symptoms  
Have you had any attacks of panic, or sudden attacks of anxiety which very quickly become intolerable 
during this pregnancy? 
 [ number in a 4 week period]  __ 
*Note symptoms in 4.003-4.019* 
4.021   Enduring apprehension of having an attack- after an attack do you worry 
 about its effects or about getting another attack ?      __ 
4.022   Action to prevent or to end panic attack –do you have to do something to end an attack 
, like leaving a bus, or anything to prevent attacks?       
0=absent, 1=action to prevent , 2=action to end, 3 prevent and end    __ 
 
ALL (0/1)      Panic  Generalised anxiety 
4.003 can’t get breath and smothering feeling    __   __
  
4.004   heart pounding, missing beats, faster   __   __
  
4.005 dizzy, light-headed, faint, unsteady    __   __
  
4.006  tingly, numbness in face/fingers    __   __
  
4.007  tightness, discomfort or pain in chest    __   __
  
4.008   dry mouth not due to medication or dehydration  __   __
  
4.009   difficulty in swallowing, lump in throat,    __   __
  
4.010   sweating e.g. palms     __   __
  
4.011   trembling or shaking e.g. hands or limbs   __   __
  
4.012   hot or cold sweats or flushes    __   __
  
4.013   unreality, ‘not really here’ like an actor   __   __
  
4.014   churning stomach, nausea, butterflies   __   __
  
4.015   fear of dying      __   __
  
4.016  fear of choking      __   __
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4.17 fear of going crazy, or fear of losing 
emotional control or passing out     __   __
  
4.018   apprehension, jumpiness, or increased startle response  __   __
  
4.019   other e.g. increase urinary frequency    __   __
  
  
 
GENERALISED ANXIETY 
4.023  Free floating  anxiety  
- Have you ever had anxiety periods for longer periods during this pregnancy not just in attacks? 
(include only anxiety with no apparent reason) 
 0=none, 1=mild occasional anxiety, 2= moderately severe 3= severe anxiety  __ 
 
 4.025  Duration of free floating anxiety –  number of months     __ 
 
PERIOD RATED ___________        
 
*Note symptoms in 4.003-4.019* and also the following all rated (rating scale 1 0-3) 
3.001   Worrying –   did you worry a great deal? did unpleasant thoughts go round and round in your 
mind, could you stop worrying by looking at the TV or reading or thinking about something you enjoy
 __ 
3.002   Feeling of nervous tension- did you often felt on edge or keyed up or mentally strained, 
 everyday problems get on top of you?. Did you Startle too easily?    __ 
3.003   General muscular tension- did you have difficulty relaxing, muscles feel tensed up? __ 
3.005   Localised tension pains- did you have aches and pains, like headache, backache, 
 aching muscles? Exclude migraine        __ 
3.006   Subjective describes restlessness- were you fidgety and restless? 
fidgety=mild  restless=moderate,  pacing=restless      __ 
3.07 Fatigability and exhaustion- were you exhausted and worn out  during the day  
even when you hadn’t  been working very hard       __ 
3.010   Irritability – were you more inpatient or irritable than usual 
1= mild irritability, brief domestic quarrels mood,  2= raised voice, anger, shouting, 
 3=pushing hitting, lost control        __ 
3.012   Depersonalisation and derealisation   Did you feel that things around you 
 or you yourself were unreal        __ 
7.002  Loss of concentration was your concentration as good as usual?   __ 
Did your sleep pattern alter during this episode of anxiety [0/1]    
 __ 
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Sleep Before Pregnancy: 
The following questions are about what your sleep was like in the last few weeks before you 
became pregnant. Answer each question independently of others and please select the 
answer that best described you. 
 
1. During the first half hour after you woke up in the morning, how did you usually feel? 
□Very tired   □Fairly tired   □Fairly refreshed  □Very refreshed  
 
2. At approximately what time in the evening did you feel tired, and, as a result, in need of 
sleep? (Please circle): 
8:00PM – 9:00PM 9:00PM –10:15PM 10:15PM –12:45AM 12:45AM – 2:00AM 2:00– 3:00 AM 
 
3. At approximately what time of day did you usually feel your best? (Please circle): 
5:00 – 8:00 AM 8:00 – 10:00 AM 10:00 AM -5:00 PM  5:00 – 10:00 PM 10:00PM –5:00AM 
 
4. Approximately what time would you have gotten up if you had been entirely free to plan your 
day?(i.e. if you had no other commitments that day): 
 
5:00 AM – 6:30 AM 6:30 AM – 7:45 AM 7:45 AM – 9:45 AM 
9:45 AM – 11:00 AM 11:00 AM – 12:00 noon 12:00 noon – 5:00 PM 
 
5 One hears about “morning types” and “evening types.” Which one of these types do you consider 
yourself to be? (Please circle): 
 
Definitely a 
morning type 
Rather more a morning type 
than an evening type 
Rather more an evening type 
than a morning type 
Definitely an 
evening type 
 
6. Before you became pregnant, did you have a regular work schedule? If YES, distinguish 
between work days and free days (below). If NO, distinguish between weekdays and 
weekends. Yes          No  
 
On your work days/weekdays: 
a) What time did you usually fall asleep? (NB: this may be different from the time you got 
into bed) _____________ 
b) What time did you usually wake up? (NB: this may be different from the time you got out 
of bed)______________ 
 
On your free days/weekends: 
a) What time did you usually fall asleep? (NB: this may be different from the time you got 
into bed) _____________ 
b) What time did you usually wake up? (NB: this may be different from the time you got out 
of bed)_____________ 
 
7. How many hours of sleep do you think you need (when not pregnant) in order to feel 
refreshed? _______ 
 
Sleep Quality Over the Last Month: 
In the last month, how would you rate your sleep quality overall? 
Very good □   Fairly good □     Fairly bad □     Very bad □ 
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BLEQ (last 6 months)  
 
1. In the last 6 months, did you suffer from a serious illness, injury or an assault?   
       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
2. In the last 6 months, did a serious illness, injury or assault happen to a close relative?  
        Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
3. In the last 6 months, did a parent, spouse (or partner), child, brother or sister of yours die? 
        Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
4. In the last 6 months did a close family friend or relative die, such as an aunt, cousin or grandparent?  
        Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
5. In the last 6 months, did you have a separation due to marital difficulties or break off a steady  
relationship?       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
6. In the last 6 months, did you have a serious problem with a close friend, neighbour or relatives? 
        Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
7. In the last 6 months were you made redundant or sacked from your job?   
      Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
8. In the last 6 months were you seeking work without success for more than one month?     
     Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
9. In the last 6 months did you have a major financial crisis such as losing the equivalent of three  
months income?      Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
10. In the 6 months, did you have problems with the police involving a court appearance?  
        Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
11. In the 6 months, was something you valued lost or stolen?     
        Yes  No 
 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
12. In the last 6 months other than being pregnancy  
any other significant event happened in your life?     
 
        Yes  No 
 
If yes, what was it?      __________________________________________ 
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Appendix J: Postpartum GP questionnaire 
STUDY ID __________ INITIALS __________  DOB __________ 
 
Pregnancy and Childbirth Questionnaire 
 
   
Q 1.  Date of delivery     
Q 2. Pregnancy outcome    Q 3.  Delivery modality  
Live birth     Normal vaginal delivery  
Stillbirth    Elective caesarean section  
Termination     Emergency caesarean section  
Miscarriage     Forceps / Ventouse   
 
Q. 4  Baby health status: 
Healthy   
Minor problem    
Major problem    
 
Please give brief details of any problems: 
 
 
Q 5.  Has she suffered an episode of psychiatric illness in this pregnancy or post-
partum period? 
 
Yes          No       
 
If yes please give brief details: 
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Completed by: 
 
Name 
 
 
Position 
 
 
 
Date  
 
 
 
 
Address 
 
 
E-mail address 
 
 
Telephone number 
 
 
 
 
 
Please send completed questionnaire in the pre-paid envelope provided 
 
 
 
 
Thank you for your time 
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Appendix K: Postpartum psychiatrist questionnaire 
STUDY ID __________ INITIALS __________  DOB __________ 
 
Pregnancy and Childbirth Questionnaire 
 
Q1. Episodes of psychiatric illness during pregnancy 
 
Did she experience an episode of depression during the pregnancy?    
 
Yes          No      Unknown  
 
Did she experience an episode of mania, hypomania or a mixed affective episode 
during the pregnancy?  
 
Yes          No      Unknown  
 
Did she experience another form of psychiatric episode during the pregnancy?       
 
Yes          No      Unknown    
 
If yes please give brief details: 
 
If yes to any of the above, was the onset of the episode; 
 In the first trimester of pregnancy          Yes          No 
 In the second trimester of pregnancy                 Yes          No 
 In the third trimester of pregnancy                     Yes          No 
 A continuation of an episode from before pregnancy       Yes          No  
 
Was she admitted to hospital?             
Yes          No   
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Q 2.   Episodes of psychiatric illness in the postpartum period 
 
Did she experience an episode of depression following this delivery?     
 
Yes          No           
 
Did she experience an episode of mania, hypomania or a mixed affective episode 
following this delivery?  
 
Yes          No   
 
Did she experience another form of psychiatric episode following this delivery?       
 
Yes          No       
 
If yes please give brief details: 
 
 
If yes to any of the above, was the onset of the episode: 
 the continuation of an episode from pregnancy        Yes          No  
  an onset following delivery                                 Yes          No  
 
 
If a postpartum onset, when was the onset in relationship to delivery? 
 
 
days    Or    weeks    following delivery 
 
 
Was she admitted to hospital? 
Yes          No  
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Q 3.  Medication in relationship to the pregnancy 
 
What prescribed medication did she take in the 6 months before pregnancy? 
(Please indicate daily doses and say when any changes were made) 
 
  
 
What prescribed mediation did she take during the pregnancy?  
(Please indicate daily doses and say when any changes were made)  
 
  
 
What prescribed medication did she take in the postpartum period? 
(Please include daily doses and say when any changes made) 
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Completed by: 
 
Name 
 
 
Position 
 
 
Date  
 
 
 
 
Address 
 
 
E-mail address 
 
 
Telephone number 
 
 
 
 
 
 
Please send completed form in the pre-paid envelope provided 
 
 
 
 
Thank you for your time 
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Appendix L: Three month postpartum interview 
 
 
 
PROSPECTIVE POSTNATAL INTERVIEW  
 
TO BE COMPLETED VIA TELEPHONE 3 MONTHS POSTNATALLY AFTER LETTERS SENT 
TO GP AND PSYCHIATRIST 
STUDY ID __________   INITIALS __________ DOB __________ 
   Date of delivery___________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OUTCOME: 
1 Normal vaginal delivery  3 Stillbirth  5 Termination 
2.1 Elective caesarean section 4 Miscarriage  6 Forceps/ Ventouse 
2.2 Emergency caesarean section 
 
 
 
GESTATION: ______ wks  MATERNAL AGE AT DELIVERY: ______ yrs 
 SEX OF BABY: 
 1 Male    5 Twins – male & female    
 2 Female   6 Other _____________   
 3 Twins – both male  7 Unknown    
 4 Twins – both female  
PREGNANCY: 
 
Any complications during pregnancy (maternal or baby medical condition severe enough to warrant 
treatment either as an out patients or hospital admission)? Y / N/UK If yes give details 
 
       
 
 
Pre-eclampsia diagnosis Y / N/UK 
Pre-eclampsia symptoms? Y / N/UK If yes give details of symptoms 
 
DELIVERY:  
 
Labour: Induction Y / N If yes, select method:  IV     Pessary  Other _________  
 Augmentation Y / N If yes, select method:  IV     Pessary  Other _________  
 
 
Time contractions started ___ Time of delivery ____Length of labour (hrs) _____    
 
Sleep loss during labour: Y / N/UK Total number of nights missed sleep ___ 
 
 
Pain relief given:Epidural     Pain score: _______________ 
  Pethidine     (At worst during labour / delivery) 
Gas & Air    1 = mild discomfort 
TENS     10 = worst pain imaginable 
Other   _________________ 
Complications during delivery? (breech, distress, cord accidents): Y / N/UK If yes give details 
 
 
Any problems identified with the baby at birth or following birth? Y / N/UK If yes give details 
 
 
Birth weight (g)___________ Apgar score at birth____  Apgar score at 5 mins__  
BREASTFEEDING: Y / N   Duration  
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During your pregnancy or following childbirth have you experienced any periods of 
depression, high, irritable or mixed mood? Yes  No  Unknown 
 
 
Timeline details of all episodes during perinatal period i.e during pregnancy and 
following delivery  (including time frames, treatments received, if admitted, any 
psychotic symptoms) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First period following delivery? 
If yes, when? 
Did this have any effect on mood? (e.g. trigger 
episode, improve/worsen symptoms?)  
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Worst episode during this pregnancy (RATE SCAN SYMPTOMS FOR THIS 
EPISODE): 
 
0 No problems   5 “Baby blues” 
1 Mania (including Mixed) 6 Cycloid 
2 Hypomania   7 Other psychotic episode 
3 Psychotic depression  8 Other perinatal episode 
4 Non-psychotic depression 9 Unknown 
 
 
If immediate or as soon as baby born rate 1 week unless day of onset 
Onset: ______ wks clearly stated.  0.3 = 3 days.  Use negative number for onset 
before term 
   e.g. – 8 weeks = 32 wks. 
 
 
   Use decimal place for days eg 0.3 = 3 days. 
Duration: ______ wks Use 2nd decimal place for hours eg 0.03 = 3 hours. 
   If  > 9 hours round up to one day. 
 
 
Worst episode following delivery (RATE SCAN SYMPTOMS FOR THIS 
EPISODE): 
0 No problems   5 “Baby blues” 
1 Mania (including Mixed) 6 Cycloid 
2 Hypomania   7 Other psychotic episode 
3 Psychotic depression  8 Other perinatal episode 
4 Non-psychotic depression 9 Unknown 
 
 
  If immediate or as soon as baby born rate 1 week unless day of onset 
Onset: ______ wks clearly stated.  0.3 = 3 days.  Use negative number for onset 
before term 
   e.g. – 8 weeks = 32 wks. 
 
 
   Use decimal place for days eg 0.3 = 3 days. 
Duration: ______ wks Use 2nd decimal place for hours eg 0.03 = 3 hours. 
   If  > 9 hours round up to one day. 
 
 
 
Was the episode following delivery a continuation of the episode during pregnancy? Y, N UK, NA 
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  SYMPTOMS EXPERIENCED DURING MOOD EPISODE 
 
Rate SCAN items for worst episode: if worst episode is depression- start with 
depression section and then ask mania section for that episode also. If worst 
episode is a manic episode, ask the manic section first and then the depression 
section. Ask psychosis questions regardless of polarity 
 
 
Ask following 3 items regardless of polarity 
              Preg         Delivery 
Did you feel particularly anxious, worried or uptight?    ___ ___
  
Did you feel scared?        ___ ___ 
During this episode did you feel confused?  Did you have difficulty getting your thoughts in order?  
Did you understand clearly what was going on?     ___ ___ 
 
DEPRESSION  
Use 0,1, 2, 8, 9 unless where indicated 
      
6.001 Depressed mood       ___ ___ 
How would you describe your mood during this period?  Sad, gloomy, 
despairing, deeply depressed?   
7.004 Loss of interests       ____ ___ 
What were your interests before?  Did you lose interest in work, recreation, 
appearance?  To what extent- did you lose interest altogether? 
 
6.005 Capacity for enjoyment      ___ ___ 
Was there anything you enjoyed doing that lifted your spirits?  Were you able to 
positively enjoy things, interests, hobbies?  Or were you unable to find pleasure 
in things you would normally enjoy?  
 
6.012 Tedium vitae        ___ ___ 
Did you feel that life was not worth living, or you didn’t care if you wake up?  
Ever wish you had a fatal disease?  Recurrent death thoughts? 
 
Following 2 items not to be asked explicitly rate if mentioned 
6.011 Suicide or self-harm [0-5]      ___ ___ 
 Thoughts of harming baby        ___ 
 
6.009 Morning depression [0-1]      ___ ___ 
 When did it feel worse?  Any time less severe? 
 0= not worse early/ 1= worse early in day 
 
6.017 Loss of self-esteem       ___ ___ 
 What was your opinion of yourself compared to others?  Did you feel less 
competent than them?  Inferior or worthless? 
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                     Preg    Delivery 
6.013 Pathological guilt       ___ ___ 
Did you blame yourself for things you had done?  Feel guilty or ashamed?  What 
had you done?  Would you feel the same now?  Out of proportion. 
 
6.015 Loss of self confidence with other people    ___ ___
 How confident did you feel in yourself- in talking to others and managing 
relationships with others?  
 
6.016 Social withdrawal       ___ ___ 
Did you want to stay away from other people?  Would you answer the door or 
telephone?  Did you try to avoid company of others?  Refuse it when offered? 
 
7.002 Loss of concentration      ___ ___ 
Was your concentration as good as usual, did your attention wander?  Could you 
complete tasks? 
 
7.003 Subjectively inefficient thinking     ___ ___ 
Were you able to think clearly?  Or were simple decisions hard to make?  
Thoughts slower?  Indecisive?  To what extent, severe- hardly begin to think 
about a problem? 
 
7.005 Subjective feeling of retardation     ___ ___ 
Did you feel as though you were slowed down in your movements?  Talk or 
move much more slower?  Arms and legs feel like lead?  Did everyone else 
seem faster?   
 
7.006 Loss of energy       ___ ___ 
Did you feel as though you had lost energy or vigour?  Was everything too much 
trouble?  Comparative loss of energy to normal functioning? 
 
4.001 General rating of anxiety (in the context of depression)  ___ __ 
Now I would like to ask you about feelings of anxiety or panic during PERIOD.  
When people get anxious or panicky they often feel fearful.  They may feel their 
heart beating fast, or they may start shaking or sweating, or feel they can’t get 
their breath.  Have you had feelings like that?  Can you describe it? [0/1] 
 
3.006 Agitated anxiety (in the context of depression)   ___ ___ 
 Were you so fidgety and restless that you couldn’t sit still? 
 Did you have to keep pacing up and down? 
 [fidgety = mild; restlessness = moderate; pacing = severe] 
 
Mixed episodes 
During episodes of depression, did you ever also experience (even for brief 
periods) manic-type symptoms such as elevated mood, increased energy, racing 
thoughts and increased self esteem?         
                                                                                                                                 __ ___ 
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MANIA/HYPOMANIA 
                    Preg    Delivery 
10.001 Expansive (elevated) mood      ___ ___ 
Did you feel intensely happy or elated without reason?  So elated it was 
unnatural for you 
 
 
10.03 Irritable mood       ___ ___ 
During that time did you find that you were easily irritated, that any little thing 
provoked you?  Did others comment you were too impatient?   
 
10.004 Pressing and racing thoughts     ___ ___ 
Did you find thoughts crowding and racing through your mind, speeding up and 
have too many compared to usual?  Describe?  How long did this last? 
 
10.005 Over-talkativeness       ___ ___ 
Did people say you talked too fast/ too much so you weren’t understood?  Could 
others understand you?  Did you feel a pressure to keep talking?  
 
10.006 Distractibility       ___ ___ 
Could you concentrate or keep your attention on one thing so that you could 
complete the task or deal with something properly?  Were you distracted by 
irrelevant things around you/ environmental surroundings? 
 
10.007 Self-reported overactivity      ___ ___ 
Were you more active than usual/normal?  So active that others thought that 
there was something wrong?  Did you have tremendous energy?  Was it 
unnatural and out of character for you? 
 
10.010 Exaggerated self esteem      ___ ___ 
Did you seem especially efficient or really good at work or in your daily 
activities- as though you had super powers or talents?  Superbly healthy, high 
intelligence, extraordinary abilities?  How did you explain this?  How did you 
opinion compare to others? 
 
10.012 Actions based on expansive mood     ___ ___ 
Did you do anything that you wouldn’t have normally?  Was it because of the 
mood, high spirits you were in?  Spend money you didn’t have/ gamble/ reckless 
driving?  Do anything you regretted later or got you into trouble?  Describe? 
 
10.013 Decreased need for sleep      ___ ___ 
 Did you sleep less at night?  Manage with far less sleep without getting tired? 
 
10.014 Socially embarrassing behaviour     ____ ___ 
Were you more sociable than usual?  Was it inappropriate, over-familiar or 
interfering?  Behaviour that was embarrassing?  Foolish actions out of 
character?  
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10.015 Increased sexual drive or activity     ___ ___ 
Did you find that your sex drive or activities changed?  In what way?  Increased 
sexual activity, increased flirting, sexual indiscretions? 
 
Dysphoric Mania 
During episodes of high mood, did you ever also experience (even for brief periods) 
depressive-type symptoms such as low mood, loss of energy, hopelessness or suicidal 
feelings? ___ ___   
 
 
 
 
HALLUCINATIONS, THOUGHT DISORDER, REPLACEMENT OF WILL & 
DELUSIONS 
 
• Probe question: Hearing noises/voices 
Have you ever heard noises or voices when there was nobody around and no ordinary 
explanation seemed possible? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
17.009 Third person Auditory Hallucinations Did you ever hear voices talking about 
you between themselves or did you ever hear a single voice talking about you? 
  
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
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17.008 Voice(s) commenting on thoughts or actions Did a voice comment on your 
thoughts or actions? 
           
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
• Probe question: Visual Hallucinations  
Have you ever had visions or seen things other people couldn’t see? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
• Other hallucinations (17.022, 17.026, 17.028)  
Have you ever noticed any unusual smells that you couldn’t account for or any unusual 
sexual sensations or noticed any other strange or inexplicable sensations of touch, taste, 
or temperature, or pain, or floating? Or like a crawling sensation under the skin? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
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• Probe Question: Interference with thoughts 
Have you ever felt some outside force or person was interfering with or controlling your 
thoughts or felt that your thoughts were being read? Have you ever experienced a 
thought in your mind repeating over, like an echo?  Has it ever seemed that the thoughts 
in your mind were not your own, and they seemed to come from somewhere else?  How 
did they get in your mind? Have you ever felt your thoughts were somehow public, not 
private, so that others know what your thinking?  Did you feel the thoughts leaving?  
Have you ever experienced your thoughts actually been taken out or sent out of your 
mind 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
• Probe Question: Experience of Replacement of Will Have you ever felt some 
outside force or person was controlling your actions? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
19.004 Delusions of reference 
Have you ever felt the TV, radio or newspaper were talking about you? or giving 
messages to you? Have people ever seemed to drop hints meant for you, or say things 
with double meanings? 
 
IF YES brief description 
 
 
 
 
 
 
 
• 19.003 Delusions of being spied upon 
During pregnancy 
 
 
Following delivery 
 
 
 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
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Have people seemed to talk about you, check up on you, or follow you about, or record 
your movements? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
19.007 Delusions of misidentification        
Are there people about who are not what they seem?  Perhaps in disguise?  (strangers 
are people from the past, nursing staff are impostors/or police) 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 19.008  Familiar people impersonated (by strangers)   
  
Did you feel that the appearance of people you know well had changed in ways that 
suggested someone was impersonating them?  
 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
During pregnancy 
 
 
Following delivery 
 
 
 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
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• 19.012 Delusions of persecution 
Have you ever experienced the feeling that someone or some organisation was trying to 
harm you? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
19.014 Delusional jealousy         
Were you jealous of your friend or spouse?  What did you do to convince yourself 
nothing was wrong? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
19.017 Delusional lover         
Have you believed that someone important was in love with you, even though 
there was no evidence?  Are you loved by someone who does not publicly 
acknowledge it?  Who is it?  What evidence to you have of these advances?  Do 
you try to make contact?  
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
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• 19.021 Religious delusions 
Have you ever been unusually preoccupied with religious ideas for example thoughts 
about God or the Devil? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
• 
10.016/19.029 Delusions of grandiose ability or 10.017/19.030 identity 
Have you ever felt that you or your baby have had special powers? or thought you were 
somebody special? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
• Delusions of guilt or worthlessness ( 6.018/19.025) 
Have you ever felt responsible for a crime, evil or harm to others? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
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• (OPCRIT item 57) Delusions of poverty 
Have you ever believed that you have lost all of your money or property? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
• (OPCRIT item 58) Nihilistic delusions 
Have you ever felt that part of your body had disappeared or was rotting away or was 
affected by some devastating or malignant disorder or did you ever believe that you 
were dead? 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
General probe question 
Have you ever had any other unusual or abnormal experiences when your mind has 
played tricks on you that looking back now seems strange or unusual? 
 
 
IF YES brief description 
 
 
 
 
 
 
 
 
 
 
 
 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
 
During pregnancy 
 
 
Following delivery 
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SECTION 4:PANIC, ANXIETY AND PHOBIAS 
 
 
4.001   General rating of anxiety in prospective pregnancy  
When people get anxious or panicky they often feel very fearful. They may feel their heart 
beating fast, or they may start shaking or sweating, or feel they can’t get their breath.  
          __[0/1] 
 
PANIC ATTACKS 
4.020   Frequency of panic attacks with autonomic symptoms  
Have you had any attacks of panic, or sudden attacks of anxiety which very quickly become intolerable since we last 
spoke? 
 [ number in a 4 week period]  __ 
*Note symptoms in 4.003-4.019* 
4.021   Enduring apprehension of having an attack- after an attack do you worry 
 about its effects or about getting another attack ?      __ 
4.022   Action to prevent or to end panic attack –do you have to do something to end an attack 
, like leaving a bus, or anything to prevent attacks?       
0=absent, 1=action to prevent , 2=action to end, 3 prevent and end    __ 
 
ALL (0/1)       Panic  Generalised anxiety 
4.003 can’t get breath and smothering feeling    __   __  
4.004   heart pounding, missing beats, faster   __   __  
4.005 dizzy, light-headed, faint, unsteady    __   __  
4.006  tingly, numbness in face/fingers    __   __  
4.007  tightness, discomfort or pain in chest    __   __  
4.008   dry mouth not due to medication or dehydration  __   __  
4.009   difficulty in swallowing, lump in throat,    __   __  
4.010   sweating e.g. palms     __   __  
4.011   trembling or shaking e.g. hands or limbs   __   __  
4.012   hot or cold sweats or flushes    __   __  
4.013   unreality, ‘not really here’ like an actor   __   __  
4.014   churning stomach, nausea, butterflies   __   __  
4.015   fear of dying      __   __  
4.016  fear of choking      __   __  
4.17 fear of going crazy, or fear of losing 
emotional control or passing out     __   __  
4.018   apprehension, jumpiness, or increased startle response  __   __  
4.019   other e.g. increase urinary frequency    __   __  
  
 
Did panic attacks form a prominent part of the WE PN episode (Y, N , UK) ____     
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GENERALISED ANXIETY 
4.023  Free floating  anxiety  
- Have you had anxiety periods for longer periods not just in attacks during pregnancy or 
following childbirth? (include only anxiety with no apparent reason) 
 0=none, 1=mild occasional anxiety, 2= moderately severe 3= severe anxiety  __ 
 
 4.025  Duration of free floating anxiety –  number of months     __ 
 
PERIOD RATED ___________        
 
*Note symptoms in 4.003-4.019* and also the following all rated (rating scale 1 0-3) 
3.001   Worrying –   did you worry a great deal? did unpleasant thoughts go round and round in your 
mind, could you stop worrying by looking at the TV or reading or thinking about something you enjoy
 __ 
3.002   Feeling of nervous tension- did you often felt on edge or keyed up or mentally strained, 
 everyday problems get on top of you?. Did you Startle too easily?    __ 
3.003   General muscular tension- did you have difficulty relaxing, muscles feel tensed up? __ 
3.005   Localised tension pains- did you have aches and pains, like headache, backache, 
 aching muscles? Exclude migraine        __ 
3.006   Subjective describes restlessness- were you fidgety and restless? 
fidgety=mild  restless=moderate,  pacing=restless      __ 
3.08 Fatigability and exhaustion- were you exhausted and worn out  during the day  
even when you hadn’t  been working very hard       __ 
3.010   Irritability – were you more inpatient or irritable than usual 
1= mild irritability, brief domestic quarrels mood,  2= raised voice, anger, shouting, 
 3=pushing hitting, lost control        __ 
3.012   Depersonalisation and derealisation   Did you feel that things around you 
 or you yourself were unreal        __ 
7.002  Loss of concentration was your concentration as good as usual?   __ 
Did your sleep pattern alter during this episode of anxiety [0/1]    
 __ 
 
  
Did generalised anxiety form prominent part of the WE PN episode (Y, N , UK) ____     
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Questions about your feelings about your pregnancy and the support you received 
since we last spoke 
 
Overall, was your  pregnancy a positive experience for you? (please circle one) 
 
1 2 3 4 5 
Not at all Somewhat  Very much 
 
Did you feel you had  people you could depend on for emotional support when you got 
home with your baby? (other than partner) (please circle one) 
 
1 2 3 4 5 
Not at all Somewhat  Very much 
 
Did you have you a partner in this pregnancy? (please tick one)  Yes          
No       
 
If yes, was your relationship with your partner an emotionally supportive one? (please 
circle one) 
 
1 2 3 4 5 
Not at all Somewhat  Very much 
 
 
Question about your sleep during the third trimester of your pregnancy  
1) In the third trimester, how would you rate your sleep quality overall? 
 
Very good  □ Fairly good  □  Fairly bad  □     Very bad □ 
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Baby’s sleep over the two weeks 
Please mark only one (most appropriate choice), for answers with a few options. 
 
1. Sleeping arrangement: 
□ Infant crib in a separate room  □ Infant crib in parents' room 
□ In parents' bed    □ Infant crib in room with sibling  
□ Other, Specify: ______________ 
 
 
2. In what position does your child sleep most of the time? 
□ On his/her belly □ On his/her side  □ On his/her back 
 
3. How much time does your child spend in sleep during the NIGHT (between 7 in 
the evening and 7 in the morning)? Hours: ______ Minutes: _______ 
 
4. How much time does your child spend in sleep during the DAY (between 7 in the 
morning and 7 in the evening)? Hours: ______ Minutes: _______ 
 
5. Average number of night wakings per night: ____________ 
6. How much time during the night does your child spend in wakefulness (from 10 
in the evening to 6 in the morning)? Hours: ______ Minutes: _______ 
7. How long does it take to put your baby to sleep in the evening? ____________ 
 
8. How does your baby fall asleep? 
□ While feeding  □ Being rocked  □ Being held 
□ In bed alone   □ In bed near parent 
9. When does your baby usually fall asleep for the night? ________ 
10. Do you consider your child's sleep as a problem? 
□ A very serious problem  □ A small problem   □Not a problem at all 
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Questions about smoking, drugs and alcohol in pregnancy 
 
Depending on answer to antenatal questionnaire: Since we last spoke did you 
continue to smoke/start smoking cigarettes during your pregnancy? 
Yes          No       
 
If YES, on average, how many cigarettes a day have you smoked since we last spoke?  
 
 
 
Depending on answer to antenatal questionnaire: Since we last spoke did you 
continue to drink alcohol regularly/start drinking alcohol regularly during your 
pregnancy? 
  
Yes          No       
 
It YES, how many units of alcohol have you consumed on average per week since we 
last spoke? (1 unit of alcohol is equal to one small glass of wine, a single measure of 
spirits or half a pint of beer/lager/cider) 
 
 
Depending on answer to antenatal questionnaire: Since we last spoke did you 
continue use any of the following substances/start any of the following substances when 
they have not been prescribed by a doctor during your pregnancy?  
 
Sedatives        Yes          No       
Cannabis   Yes          No       
Speed   Yes          No       
Ecstasy  Yes          No       
Glue   Yes          No       
Solvents  Yes          No       
Cocaine  Yes          No       
Heroin   Yes          No       
Methadone  Yes          No       
Other non prescription/over the counter drugs  
Yes          No      
If yes please give brief details 
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Questions about medications 
What drug treatments (medications) as prescribed by your doctor or over the counter did 
you take during your pregnancy since we last spoke?  
(If you can, please indicate daily doses and say when any changes were made)  
 
 
 
 
What drug treatments (medications) as prescribed by your doctor or over the counter 
have you taken since your pregnancy?  
(If you can, please indicate daily doses and say when any changes were made)  
 
 
 
 
 
 
 
 
 
 
As prophylaxis  
 
 
 
 
 
 
As treatment  
As prophylaxis  
 
 
 
 
 
 
As treatment  
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BLEQ (since last interview)  
 
1. In the last 6 months, did you suffer from a serious illness, injury or an assault?   
       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
2. In the last 6 months, did a serious illness, injury or assault happen to a close relative?   
       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
3. In the last 6 months, did a parent, spouse (or partner), child, brother or sister of yours die?  
       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
4. In the last 6 months did a close family friend or relative die, such as an aunt, cousin or grandparent?   
       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
5. In the last 6 months, did you have a separation due to marital difficulties or break off a steady  
relationship?       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
6. In the last 6 months, did you have a serious problem with a close friend, neighbour or relatives?  
       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
7. In the last 6 months were you made redundant or sacked from your job?    
       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
8. In the last 6 months were you seeking work without success for more than one month?     
     Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
9. In the last 6 months did you have a major financial crisis such as losing the equivalent of three  
months income?      Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
10. In the 6 months, did you have problems with the police involving a court appearance?   
       Yes  No 
 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
11. In the 6 months, was something you valued lost or stolen?      
       Yes  No 
If yes, at the time, how bad was that for you?   Very bad Moderately bad     Not too bad 
 
12. In the last 6 months other than being pregnancy  
any other significant event happened in your life?     
 
        Yes  No 
 
If yes, what was it?      __________________________________________ 
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Appendix N 
Appendix N: Preconception lifetime psychiatric features according to use of 
prophylactic mood stabilising medication in the postpartum period in BD-
I/SA-BD women in the BDRN pregnancy sample 
 
To examine whether preconception severity of BD illness was associated with the use of 
prophylactic mood stabilising medication in the postpartum period (potentially 
confounding the relationship between use of prophylactic mood stabilising medication 
and reduced risk of PP), several key clinical characteristics of BD were compared 
between women who did and did not use prophylactic mood stabilising medication in 
the postpartum period.  
 
Table I: Preconception lifetime clinical characteristics according to use of prophylactic mood stabilising 
medication in the postpartum period in BD-I women in the BDRN pregnancy sample 
 
IQR: Interquartile range. a p-values calculated via Mann-Whitney U test for continuous variables. p-values for categorical variables 
calculated by Chi-Square tests. 
 
 
Mood stabilising 
medication 
(n=28) 
No mood stabilising 
medication 
(n=52) 
Test 
statistica 
p- value 
Age at onset of impairment of BD 
            Median (IQR) 
Range 
 
20 (8) 
11-35 
 
20 (11)  
11-36 
 
U= 595.000 
Z = -.471 
 
 0.637 
 
Preconception lifetime number of episodes 
of mania per illness year 
Median (IQR) 
Range 
 
 
0.37 (0.38) 
0.05-7.37 
 
 
 
0.33 (0.65) 
0.08-1.68 
 
 
U= 591.500, 
Z = -.099 
 
 
0.921 
 
Preconception lifetime number of episodes 
of depression per illness year 
Median (IQR) 
Range 
 
 
0.49 (0.56) 
0.00-4.34 
 
 
0.41 (0.65) 
0-2.64 
 
 
U= 501.000, 
Z = -.896 
 
 
0.370 
 
Preconception lifetime number of 
psychiatric hospital admissions 
Median (IQR) 
            Range 
 
 
1 (3) 
0-9 
 
 
1.5 (3) 
0-5 
 
 
U= 701.000, 
Z = -.137 
 
 
0.891 
Preconception lifetime history of psychotic 
symptoms 
Yes 
No                 
 
 
40 (76.9%) 
12 (23.1%) 
 
 
21 (75.0%) 
7 (25.0%) 
 
 
χ2 (1) .037 
 
 
0.847 
Preconception lifetime history of 
postpartum psychosis (<6 weeks) 
Yes 
            No                  
 
 
13 (25.0%) 
39 (75.0%) 
 
 
8 (28.6%) 
20 (71.4%) 
 
 
χ2 (1) .120 
 
 
0.729 
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As shown in Table I, there were no significant differences between women in the 
medication and no medication groups with regards to age at onset of impairment of BD 
(median age 20 years within both groups, p=0.637), preconception lifetime number of 
episodes of mania (median number of 0.37 and 0.33 respectively, p=0.921) or 
depression per illness year (median number of 0.49 and 0.41 respectively, p=0.370) or 
the number of preconception lifetime number of admissions (median number of 1 and 
1.5 respectively, p=0.891). Furthermore, compared to women not using prophylactic 
mood stabilising medication in the postpartum period, women who did were not 
significantly more likely to have a preconception lifetime history of psychotic symptoms 
(75.0% vs 76.9%, p=0.847) or of PP within 6 weeks of a past delivery (28.6% vs 25.0%, 
p=0.729).  
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Appendix O: Use of prophylactic mood stabilising medication in the 
postpartum period according to method of recruitment in BD-I/SA-BD 
women in the BDRN pregnancy sample 
 
As shown in Table II, women who were recruited to the BDRN Pregnancy Study by 
systematic methods were not significantly more likely to use prophylactic mood 
stabilising medication in the postpartum period compared to women who were 
recruited to the study non-systematically (60.5% and 69% respectively, p=0.425). 
 
Table II: Method of recruitment according to use of prophylactic mood stabilising medication in the 
postpartum period in BD-I women in the BDRN pregnancy sample 
 
a p-value calculated by Chi-Square test. 
 
 
 Systematic 
recruitment 
(n=38) 
Non-systematic 
recruitment 
(n=42) 
Test 
statistica 
p- value 
Prophylactic mood stabilising medication 
postpartum 
Yes 
                   No  
                      
 
 
23 (60.5%) 
15 (39.5%) 
 
 
29 (69.0%) 
13 (31.0%) 
 
 
χ2 (1) .637 
 
 
0.425 
